

## **2023 Incentive Formulary:**

This Incentive Formulary applies to members of an employer/retiree, union, or trust fund health plan

### **For Medicare Part D: 5 Tier Incentive Formulary**

Please click here.

### **For Medicare Part D: Prior Authorization Criteria**

Please click here.

### **For Medicare Part D: Step Therapy Criteria**

Please click here.

For more recent information or other questions, please contact:

Freedom Blue PPO (DE) Customer Service at 1-844-576-1246  
Freedom Blue PPO (PA) Customer Service at 1-800-550-8722  
Freedom Blue PPO (WV) Customer Service at 1-888-459-4020  
Security Blue HMO-POS Customer Service at 1-800-935-2583  
Community Blue Medicare HMO Customer Service at 1-888-234-5397  
Community Blue Medicare PPO Customer Service at 1-888-757-2946  
Community Blue Medicare Plus PPO Customer Service at 1-888-757-2946  
Blue Rx PDP Customer Service at 1-800-290-3914

**Important Message About What You Pay for Vaccines** – Our plan covers most Part D vaccines at no cost to you, even if you haven't paid your deductible (if applicable). Call Member Services for more information.

**Important Message About What You Pay for Insulin** – You won't pay more than \$35 for a one-month supply of each Part D insulin product covered by our plan, no matter what cost-sharing tier it's on, even if you haven't paid your deductible (if applicable).

For TTY users, *711 National Relay Service*, Monday through Sunday, 8 a.m. to 8 p.m.  
Visit [medicare.highmark.com](https://www.medicare.highmark.com).

Formulary ID: 23025 Version: 21

Updated: 12/2023

**Note to existing members:** This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us,” or “our,” it means Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company, Highmark BCBSD or Highmark Health Insurance Company.

When it refers to “plan” or “our plan,” it means 2023 Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP.

This document includes a list of the drugs (formulary) for our plan which is current as of January 1, 2023. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2023, and from time to time during the year.

## **What is the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?**

A formulary is a list of covered drugs selected by our plans in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Our plans will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at one of our plan’s network pharmacies, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

## **Can the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary (drug list) change?**

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

**Changes that can affect you this year:** In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
  - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO or Blue Rx PDP Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost-sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 31-day supply of the drug.
  - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO or Blue Rx PDP Formulary?”

**Changes that will not affect you if you are currently taking the drug.** Generally, if you are taking a drug on our 2023 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2023 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year.

You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of January 1, 2023. To get updated information about the drugs covered by our plans, please contact us. Our contact information appears on the front and back cover pages. In the event of mid-year non-maintenance formulary changes, members will be notified by mail and prospective members will receive an update with this formulary. The most up-to-date formulary is available on our website, [medicare.highmark.com](http://medicare.highmark.com)

## **How do I use the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?**

There are two ways to find your drug within the formulary:

### **Medical Condition**

The formulary begins on page 9. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, “Cardiovascular – Hypertension & Lipids.” If you know what your drug is used for, look for the category name in the list that begins on page number 9. Then look under the category name for your drug.

### **Alphabetical Listing**

If you are not sure what category to look under, you should look for your drug in the Index that begins at the end of this document. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

## **What are generic drugs?**

Our plans cover both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

## **Are there any restrictions on my coverage?**

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plans require you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plans before you fill your prescriptions. If you don't get approval, our plans may not cover the drug.
- **Quantity Limits:** For certain drugs, our plans limit the amount of the drug that is covered. For example, our plans provide 31 tablets, per 31 days, per prescription for 100mg losartan. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, our plans require to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, our plans may not cover Drug B unless you try Drug A first. If Drug A does not work for you, our plans will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 9. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online document(s) that explain(s) our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask our plans to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary?" on page 6 for information about how to request an exception.

## **What if my drug is not on the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?**

If your drug is not included in this formulary (list of covered drugs), you should first contact Customer Service and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Customer Service for a list of similar drugs that are covered by our plan. When you receive the list, show it to your doctor and ask your doctor to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

## How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary?

You can ask our plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at a lower cost-sharing level if this drug is not on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, our plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, our plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions, would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, or utilization restriction exception. **When you request a formulary or utilization restriction exception, you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

## What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 31-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 31-day supply of medication. After your first 31-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

The above transition process will be implemented to accommodate you if you have an immediate need for a non-formulary drug or a drug that requires prior authorization due to a change in your level of care while you are waiting for an exception request to be processed.

## For more information

For more detailed information about your plan's prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about your plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day / 7 days a week. TTY users should call 1-877-486-2048. Or visit <http://www.medicare.gov>.

## Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by your plan. If you have trouble finding your drug in the list, turn to the Index that begins at the end of this document.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., ABELCET) and generic drugs are listed in lowercase italics (e.g., *abacavir*).

The information in the Requirements/Limits column tells you if our plan has any special requirements for coverage of your drug.

*The following is a Formulary Format Example Only:*

Drug Name	Incentive Drug Tier	Requirements/ Limits
Anti - Infectives		
XYZ DRUG	NF	QL- 28





## Table of Contents

Anti - Infectives.....	5
Antineoplastic / Immunosuppressant Drugs.....	17
Autonomic / Cns Drugs, Neurology / Psych.....	26
Cardiovascular, Hypertension / Lipids.....	58
Dermatologicals/Topical Therapy.....	70
Diagnostics / Miscellaneous Agents.....	79
Ear, Nose / Throat Medications.....	82
Endocrine/Diabetes.....	82
Gastroenterology.....	91
Immunology, Vaccines / Biotechnology.....	97
Miscellaneous Supplies.....	101
Musculoskeletal / Rheumatology.....	101
Obstetrics / Gynecology.....	104
Ophthalmology.....	110
Respiratory And Allergy.....	114
Urologicals.....	120
Vitamins, Hematinics / Electrolytes.....	122



## List of Abbreviations

**T1:** Cost-Sharing Tier 1 includes preferred generic drugs. This is the lowest cost-sharing tier.

**T2:** Cost-Sharing Tier 2 includes generic drugs.

**T3:** Cost-Sharing Tier 3 includes preferred brand name drugs and may include some single-sourced drugs (those generic drugs made by a single manufacturer).

**T4:** Cost-Sharing Tier 4 includes non-preferred brand name drugs and may include some single-sourced generic drugs (those generic drugs made by a single manufacturer).

**T5:** Cost-Sharing Tier 5 includes specialty drugs. This is the highest cost-sharing tier.

**LA:** Limited access

**PA:** Prior authorization required

**PA-BvD:** This drug may be covered under Medicare part B or D depending on the circumstance. Information may need to be submitted describing the use and setting of the drug to make the determination.

**PA-NS:** Prior authorization required for new starts only

**QL:** Quantity limit applies. The quantity limit is noted for each drug. For example, if the quantity limit is QL (90 EA per 180 days), the quantity limit would be 90 units per 180-day supply.

**ST:** Step therapy applies

**ST-NS:** Step therapy applies to new starts only

Below is a list of drug name formatting patterns that may appear in the following pages.

## List of Patterns

**lowercase italics:** Generic drugs

**UPPERCASE BOLD:** Brand name drugs

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>Anti - Infectives</b>		
<i>abacavir</i>	T3	
<i>abacavir-lamivudine</i>	T4	
<b>ABELCET</b>	T4	PA-BvD
<i>acyclovir oral capsule</i>	T2	
<i>acyclovir oral suspension 200 mg/5 ml</i>	T2	
<i>acyclovir oral tablet</i>	T2	
<i>acyclovir sodium intravenous solution</i>	T2	PA-BvD
<i>adefovir</i>	T4	
<b>AEMCOLO</b>	T4	QL (12 EA per 3 days)
<i>albendazole</i>	T4	
<i>amantadine hcl oral capsule</i>	T2	QL (124 EA per 31 days)
<i>amantadine hcl oral solution</i>	T2	
<i>amantadine hcl oral tablet</i>	T2	
<b>AMBISOME</b>	T5	PA-BvD
<i>amikacin injection solution 500 mg/2 ml</i>	T2	
<i>amoxicillin oral capsule</i>	T1	
<i>amoxicillin oral suspension for reconstitution</i>	T1	
<i>amoxicillin oral tablet</i>	T1	
<i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i>	T1	
<i>amoxicillin-pot clavulanate</i>	T2	
<i>amphotericin b</i>	T4	PA-BvD
<i>amphotericin b liposome</i>	T5	PA-BvD
<i>ampicillin oral capsule 500 mg</i>	T2	
<i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i>	T2	
<i>ampicillin-sulbactam injection</i>	T2	
<b>ANCOBON</b>	T4	
<b>APTIVUS</b>	T5	
<b>ARIKAYCE</b>	T5	PA
<i>atazanavir</i>	T4	
<i>atovaquone</i>	T5	
<i>atovaquone-proguanil</i>	T2	
<b>AUGMENTIN ES-600</b>	T4	
<b>AUGMENTIN ORAL SUSPENSION FOR RECONSTITUTION 125-31.25 MG/5 ML</b>	T4	
<b>AVYCAZ</b>	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>AZACTAM</b>	T4	
<i>azithromycin</i>	T2	
<i>aztreonam</i>	T2	
<b>BACTRIM</b>	T4	
<b>BACTRIM DS</b>	T4	
<b>BARACLUDE</b>	T5	
<b>BAXDELA INTRAVENOUS</b>	T4	
<b>BAXDELA ORAL</b>	T5	
<i>benznidazole</i>	T4	PA
<b>BETHKIS</b>	T5	PA
<b>BICILLIN C-R</b>	T3	
<b>BICILLIN L-A</b>	T3	
<b>BIKTARVY</b>	T5	QL (31 EA per 31 days)
<b>BILTRICIDE</b>	T4	
<b>CANCIDAS INTRAVENOUS RECON SOLN 50 MG</b>	T4	
<b>CANCIDAS INTRAVENOUS RECON SOLN 70 MG</b>	T5	
<i>casprofungin intravenous recon soln 50 mg</i>	T5	
<i>casprofungin intravenous recon soln 70 mg</i>	T4	
<b>CAYSTON</b>	T5	PA
<i>cefaclor oral capsule</i>	T2	
<i>cefaclor oral suspension for reconstitution 250 mg/5 ml</i>	T2	
<i>cefaclor oral tablet extended release 12 hr</i>	T2	
<i>cefadroxil oral capsule</i>	T2	
<i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i>	T2	
<i>cefadroxil oral tablet</i>	T2	
<i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i>	T2	
<i>cefdinir</i>	T2	
<i>cefepime injection</i>	T2	
<i>cefixime</i>	T2	
<i>cefotetan injection</i>	T2	
<i>cefoxitin</i>	T2	
<i>cefpodoxime</i>	T2	
<i>cefprozil</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>ceftazidime</i>	T2	
<i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i>	T2	
<i>cefuroxime axetil oral tablet</i>	T2	
<i>cefuroxime sodium injection recon soln 750 mg</i>	T2	
<i>cefuroxime sodium intravenous recon soln 1.5 gram</i>	T2	
<i>cephalexin</i>	T2	
<i>chloroquine phosphate oral tablet 250 mg</i>	T2	QL (50 EA per 30 days)
<i>chloroquine phosphate oral tablet 500 mg</i>	T2	QL (25 EA per 30 days)
<b>CIMDUO</b>	T5	QL (31 EA per 31 days)
<b>CIPRO ORAL SUSPENSION,MICROCAPSULE RECON</b>	T3	
<b>CIPRO ORAL TABLET 250 MG, 500 MG</b>	T4	
<i>ciprofloxacin hcl oral</i>	T1	
<i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i>	T2	
<i>clarithromycin</i>	T2	
<b>CLEOCIN HCL</b>	T4	
<b>CLEOCIN INJECTION</b>	T4	
<b>CLEOCIN PEDIATRIC</b>	T4	
<i>clindamycin hcl</i>	T2	
<i>clindamycin in 5 % dextrose</i>	T2	
<b>CLINDAMYCIN PEDIATRIC</b>	T2	
<i>clindamycin phosphate injection</i>	T2	
<i>clindamycin phosphate intravenous</i>	T2	
<i>clotrimazole mucous membrane</i>	T2	
<b>COARTEM</b>	T4	
<i>colistin (colistimethate na)</i>	T4	
<b>COMBIVIR</b>	T5	
<b>COMPLERA</b>	T5	
<b>CRESEMBA ORAL</b>	T5	
<b>CUBICIN RF</b>	T5	
<b>DALVANCE</b>	T5	
<i>dapsone oral</i>	T3	
<i>daptomycin intravenous recon soln 350 mg</i>	T5	
<i>daptomycin intravenous recon soln 500 mg</i>	T4	
<i>darunavir ethanolate</i>	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>DELSTRIGO</b>	T5	QL (31 EA per 31 days)
<i>demeclocycline oral tablet 150 mg</i>	T2	
<i>demeclocycline oral tablet 300 mg</i>	T4	
<b>DESCOVY</b>	T5	QL (31 EA per 31 days)
<i>dicloxacillin</i>	T2	
<b>DIFICID ORAL SUSPENSION FOR RECONSTITUTION</b>	T5	QL (136 ML per 12 days)
<b>DIFICID ORAL TABLET</b>	T5	QL (20 EA per 10 days)
<b>DIFLUCAN ORAL SUSPENSION FOR RECONSTITUTION</b>	T4	
<b>DIFLUCAN ORAL TABLET 100 MG, 150 MG, 200 MG</b>	T4	
<b>DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 120 MG</b>	T4	
<b>DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 60 MG</b>	T5	
<b>DORYX ORAL TABLET,DELAYED RELEASE (DR/EC) 50 MG</b>	T4	
<b>DOVATO</b>	T5	QL (31 EA per 31 days)
<b>DOXY-100</b>	T2	
<i>doxycycline hyclate oral capsule</i>	T2	
<i>doxycycline hyclate oral tablet 100 mg</i>	T2	
<i>doxycycline hyclate oral tablet 150 mg, 50 mg, 75 mg</i>	T4	
<i>doxycycline hyclate oral tablet 20 mg</i>	T1	
<i>doxycycline hyclate oral tablet, delayed release (dr/ec) 100 mg, 200 mg, 50 mg</i>	T2	
<i>doxycycline hyclate oral tablet, delayed release (dr/ec) 150 mg, 75 mg</i>	T1	
<i>doxycycline hyclate oral tablet, delayed release (dr/ec) 80 mg</i>	T4	
<i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i>	T2	
<i>doxycycline monohydrate oral capsule 150 mg, 75 mg</i>	T4	
<i>doxycycline monohydrate oral capsule, ir - delay rel, biphase</i>	T4	
<i>doxycycline monohydrate oral suspension for reconstitution</i>	T2	
<i>doxycycline monohydrate oral tablet</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>E.E.S. 400 ORAL TABLET</b>	T2	
<b>E.E.S. GRANULES</b>	T4	
<b>EDURANT</b>	T5	
<i>efavirenz</i>	T3	
<i>efavirenz-emtricitabin-tenofov</i>	T5	
<i>efavirenz-lamivu-tenofov disop</i>	T5	QL (31 EA per 31 days)
<i>emtricitabine</i>	T3	
<i>emtricitabine-tenofov (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i>	T5	
<i>emtricitabine-tenofov (tdf) oral tablet 200-300 mg</i>	T4	
<b>EMTRIVA ORAL CAPSULE</b>	T4	
<b>EMTRIVA ORAL SOLUTION</b>	T3	
<b>EMVERM</b>	T5	
<i>entecavir</i>	T4	
<b>EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG</b>	T5	PA; QL (28 EA per 28 days)
<b>EPCLUSA ORAL PELLETS IN PACKET 200-50 MG</b>	T5	PA; QL (56 EA per 28 days)
<b>EPCLUSA ORAL TABLET</b>	T5	PA; QL (28 EA per 28 days)
<b>EPIVIR</b>	T4	
<b>EPZICOM</b>	T5	
<b>ERAXIS(WATER DILUENT)</b>	T4	
<i>ertapenem</i>	T4	
<b>ERYPED 200</b>	T4	
<b>ERYPED 400</b>	T4	
<b>ERY-TAB ORAL TABLET,DELAYED RELEASE (DR/EC) 250 MG, 333 MG</b>	T2	
<b>ERY-TAB ORAL TABLET,DELAYED RELEASE (DR/EC) 500 MG</b>	T3	
<b>ERYTHROCIN (AS STEARATE) ORAL TABLET 250 MG</b>	T2	
<b>ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG</b>	T3	
<i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i>	T2	
<i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i>	T5	
<i>erythromycin ethylsuccinate oral tablet</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>erythromycin oral</i>	T2	
<i>ethambutol</i>	T2	
<i>etravirine</i>	T5	
<b>EVOTAZ</b>	T3	
<i>famciclovir</i>	T2	
<b>FIRVANQ</b>	T4	
<b>FLAGYL ORAL CAPSULE</b>	T4	
<i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml</i>	T2	
<i>fluconazole in nacl (iso-osm) intravenous piggyback 400 mg/200 ml</i>	T3	
<i>fluconazole oral suspension for reconstitution</i>	T3	
<i>fluconazole oral tablet</i>	T2	
<i>flucytosine</i>	T5	
<i>fosamprenavir</i>	T3	
<i>fosfomycin tromethamine</i>	T4	
<b>FUZEON SUBCUTANEOUS RECON SOLN</b>	T5	
<i>gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml</i>	T2	
<i>gentamicin injection solution 40 mg/ml</i>	T1	
<b>GENVOYA</b>	T5	
<i>griseofulvin microsize</i>	T2	
<i>griseofulvin ultramicrosize</i>	T2	
<b>HARVONI ORAL PELLETS IN PACKET</b>	T5	PA; QL (28 EA per 28 days)
<b>HARVONI ORAL TABLET 90-400 MG</b>	T5	PA; QL (28 EA per 28 days)
<b>HIPREX</b>	T4	
<b>HUMATIN</b>	T4	
<i>hydroxychloroquine oral tablet 100 mg</i>	T4	QL (93 EA per 31 days)
<i>hydroxychloroquine oral tablet 200 mg</i>	T2	QL (93 EA per 31 days)
<i>hydroxychloroquine oral tablet 300 mg</i>	T4	QL (62 EA per 31 days)
<i>hydroxychloroquine oral tablet 400 mg</i>	T4	QL (31 EA per 31 days)
<i>imipenem-cilastatin</i>	T2	
<b>IMPAVIDO</b>	T5	
<b>INTELENCE ORAL TABLET 100 MG, 200 MG</b>	T5	
<b>INTELENCE ORAL TABLET 25 MG</b>	T4	
<b>INVANZ INJECTION</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ISENTRESS HD</b>	T5	
<b>ISENTRESS ORAL POWDER IN PACKET</b>	T5	
<b>ISENTRESS ORAL TABLET</b>	T5	
<b>ISENTRESS ORAL TABLET,CHEWABLE 100 MG</b>	T5	
<b>ISENTRESS ORAL TABLET,CHEWABLE 25 MG</b>	T3	
<i>isoniazid oral solution</i>	T2	
<i>isoniazid oral tablet</i>	T1	
<i>itraconazole oral capsule</i>	T2	PA
<i>itraconazole oral solution</i>	T4	PA
<i>ivermectin oral</i>	T2	PA
<b>JULUCA</b>	T5	
<b>KALETRA ORAL SOLUTION</b>	T5	
<b>KALETRA ORAL TABLET 100-25 MG</b>	T4	
<b>KALETRA ORAL TABLET 200-50 MG</b>	T5	
<i>ketoconazole oral</i>	T2	
<b>KITABIS PAK</b>	T4	PA
<b>KRINTAFEL</b>	T4	
<i>lamivudine</i>	T2	
<i>lamivudine-zidovudine</i>	T2	
<b>LAMPIT</b>	T4	PA
<i>ledipasvir-sofosbuvir</i>	T5	PA; QL (28 EA per 28 days)
<i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i>	T2	
<i>levofloxacin oral</i>	T2	
<b>LEXIVA ORAL SUSPENSION</b>	T3	
<b>LEXIVA ORAL TABLET</b>	T5	
<i>linezolid</i>	T4	
<i>linezolid in dextrose 5%</i>	T4	
<b>LIVTENCITY</b>	T5	PA; QL (124 EA per 31 days)
<i>lopinavir-ritonavir oral solution</i>	T4	
<i>lopinavir-ritonavir oral tablet 100-25 mg</i>	T3	
<i>lopinavir-ritonavir oral tablet 200-50 mg</i>	T5	
<b>MACROBID</b>	T4	QL (90 EA per 365 days)
<b>MACRODANTIN ORAL CAPSULE 100 MG</b>	T4	QL (90 EA per 365 days)
<b>MACRODANTIN ORAL CAPSULE 25 MG</b>	T4	QL (360 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>MACRODANTIN ORAL CAPSULE 50 MG</b>	T4	QL (180 EA per 365 days)
<b>MALARONE</b>	T4	
<b>MALARONE PEDIATRIC</b>	T4	
<i>maraviroc</i>	T5	
<b>MAVYRET ORAL PELLETS IN PACKET</b>	T5	PA; QL (140 EA per 28 days)
<b>MAVYRET ORAL TABLET</b>	T5	PA; QL (84 EA per 28 days)
<i>mefloquine</i>	T2	
<b>MEPRON</b>	T5	
<i>meropenem intravenous recon soln 1 gram, 500 mg</i>	T2	
<i>methenamine hippurate</i>	T2	
<i>metronidazole in nacl (iso-os)</i>	T2	
<i>metronidazole oral capsule</i>	T2	
<i>metronidazole oral tablet</i>	T1	
<i>micafungin</i>	T5	
<i>minocycline oral capsule</i>	T2	
<i>minocycline oral tablet</i>	T2	
<i>minocycline oral tablet extended release 24 hr 105 mg, 115 mg, 135 mg, 45 mg, 65 mg, 80 mg, 90 mg</i>	T2	
<i>minocycline oral tablet extended release 24 hr 55 mg</i>	T4	
<b>MINOLIRA ER</b>	T4	
<i>moxifloxacin oral</i>	T3	
<i>moxifloxacin-sod.chloride(iso)</i>	T4	
<b>MYAMBUTOL ORAL TABLET 400 MG</b>	T4	
<b>MYCAMINE INTRAVENOUS RECON SOLN 50 MG</b>	T5	
<b>MYCOBUTIN</b>	T4	
<i>nafcillin injection recon soln 1 gram</i>	T2	
<i>nafcillin injection recon soln 10 gram</i>	T5	
<i>nafcillin injection recon soln 2 gram</i>	T4	
<b>NEBUPENT</b>	T4	PA-BvD; QL (1 EA per 28 days)
<i>neomycin</i>	T2	
<i>nevirapine oral suspension</i>	T2	
<i>nevirapine oral tablet</i>	T2	
<i>nevirapine oral tablet extended release 24 hr 400 mg</i>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>nitazoxanide</i>	T5	
<i>nitrofurantoin macrocrystal oral capsule 100 mg</i>	T2	QL (90 EA per 365 days)
<i>nitrofurantoin macrocrystal oral capsule 25 mg</i>	T2	QL (360 EA per 365 days)
<i>nitrofurantoin macrocrystal oral capsule 50 mg</i>	T2	QL (180 EA per 365 days)
<i>nitrofurantoin monohyd/m-cryst</i>	T2	QL (90 EA per 365 days)
<i>nitrofurantoin oral suspension 25 mg/5 ml</i>	T5	QL (1800 ML per 365 days)
<b>NORVIR ORAL POWDER IN PACKET</b>	T3	
<b>NORVIR ORAL TABLET</b>	T4	
<b>NOXAFIL ORAL SUSP,DELAYED RELEASE FOR RECON</b>	T5	QL (32 EA per 31 days)
<b>NOXAFIL ORAL SUSPENSION</b>	T5	
<b>NOXAFIL ORAL TABLET,DELAYED RELEASE (DR/EC)</b>	T5	
<b>NUZYRA</b>	T5	
<i>nystatin oral</i>	T2	
<b>ODEFSEY</b>	T5	QL (31 EA per 31 days)
<i>ofloxacin oral tablet 300 mg, 400 mg</i>	T2	
<b>ORACEA</b>	T4	
<i>oseltamivir oral capsule 30 mg</i>	T2	QL (170 EA per 365 days)
<i>oseltamivir oral capsule 45 mg, 75 mg</i>	T2	QL (90 EA per 365 days)
<i>oseltamivir oral suspension for reconstitution</i>	T3	QL (1080 ML per 365 days)
<i>oxacillin in dextrose(iso-osm)</i>	T2	
<i>oxacillin injection recon soln 1 gram, 2 gram</i>	T2	
<i>oxacillin injection recon soln 10 gram</i>	T4	
<i>paromomycin</i>	T2	
<i>penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml</i>	T4	
<i>penicillin g potassium injection recon soln 20 million unit</i>	T2	
<i>penicillin g sodium</i>	T5	
<i>penicillin v potassium</i>	T1	
<b>PENTAM</b>	T4	
<i>pentamidine inhalation</i>	T4	PA-BvD; QL (1 EA per 28 days)
<i>pentamidine injection</i>	T4	
<b>PIFELTRO</b>	T5	QL (62 EA per 31 days)
<i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i>	T2	
<b>PLAQUENIL</b>	T4	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>polymyxin b sulfate</i>	T2	
<i>posaconazole oral</i>	T5	
<i>praziquantel</i>	T4	
<i>pretomanid</i>	T4	PA; QL (31 EA per 31 days)
<b>PREVYMIS ORAL</b>	T5	QL (31 EA per 31 days)
<b>PREZCOBIX</b>	T5	
<b>PREZISTA ORAL SUSPENSION</b>	T5	
<b>PREZISTA ORAL TABLET 150 MG, 600 MG, 75 MG, 800 MG</b>	T5	
<b>PRIFTIN</b>	T4	
<i>primaquine</i>	T3	
<b>PRIMAXIN IV INTRAVENOUS RECON SOLN 500 MG</b>	T4	
<i>pyrazinamide</i>	T2	
<i>pyrimethamine</i>	T5	PA
<b>QUALAQUIN</b>	T4	PA; QL (42 EA per 28 days)
<i>quinine sulfate</i>	T3	PA; QL (42 EA per 28 days)
<b>RELENZA DISKHALER</b>	T3	
<b>RETROVIR ORAL CAPSULE</b>	T4	
<b>RETROVIR ORAL SYRUP</b>	T4	
<b>REYATAZ ORAL CAPSULE 200 MG</b>	T5	
<b>REYATAZ ORAL CAPSULE 300 MG</b>	T3	
<b>REYATAZ ORAL POWDER IN PACKET</b>	T4	
<i>ribavirin oral capsule</i>	T2	
<i>ribavirin oral tablet 200 mg</i>	T2	
<i>rifabutin</i>	T2	
<i>rifampin</i>	T2	
<i>rimantadine</i>	T2	
<i>ritonavir</i>	T3	
<b>RUKOBIA</b>	T5	QL (62 EA per 31 days)
<b>SELZENTRY ORAL SOLUTION</b>	T5	
<b>SELZENTRY ORAL TABLET 150 MG, 300 MG, 75 MG</b>	T5	
<b>SELZENTRY ORAL TABLET 25 MG</b>	T4	
<b>SEYSARA</b>	T5	
<b>SIRTURO</b>	T5	
<b>SITAVIG</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>SIVEXTRO INTRAVENOUS</b>	T5	
<b>SIVEXTRO ORAL</b>	T5	QL (6 EA per 31 days)
<i>sofosbuvir-velpatasvir</i>	T5	PA; QL (28 EA per 28 days)
<b>SOLODYN ORAL TABLET EXTENDED RELEASE 24 HR 105 MG, 115 MG, 55 MG, 65 MG, 80 MG</b>	T4	
<b>SOLOSEC</b>	T4	
<b>SOVALDI</b>	T5	PA; QL (28 EA per 28 days)
<b>SPORANOX ORAL CAPSULE</b>	T5	PA
<b>SPORANOX ORAL SOLUTION</b>	T4	PA
<i>streptomycin</i>	T5	
<b>STRIBILD</b>	T5	
<b>STROMEKTOL</b>	T4	PA
<i>sulfadiazine</i>	T2	
<i>sulfamethoxazole-trimethoprim oral</i>	T1	
<b>SUNLENCA ORAL</b>	T5	
<b>SUPRAX ORAL CAPSULE</b>	T4	
<b>SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 200 MG/5 ML</b>	T4	
<b>SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 500 MG/5 ML</b>	T3	
<b>SUPRAX ORAL TABLET,CHEWABLE</b>	T3	
<b>SYMFI</b>	T5	QL (31 EA per 31 days)
<b>SYMFI LO</b>	T5	QL (31 EA per 31 days)
<b>SYMTUZA</b>	T5	QL (31 EA per 31 days)
<b>TAMIFLU ORAL CAPSULE 30 MG</b>	T3	QL (170 EA per 365 days)
<b>TAMIFLU ORAL CAPSULE 45 MG, 75 MG</b>	T3	QL (90 EA per 365 days)
<b>TAMIFLU ORAL SUSPENSION FOR RECONSTITUTION</b>	T3	QL (1080 ML per 365 days)
<b>TARGADOX</b>	T4	
<b>TAZICEF INJECTION</b>	T4	
<b>TEFLARO</b>	T5	
<i>tenofovir disoproxil fumarate</i>	T3	
<i>terbinafine hcl oral</i>	T1	QL (90 EA per 180 days)
<i>tetracycline</i>	T2	
<i>tigecycline</i>	T5	
<i>tinidazole</i>	T2	
<b>TIVICAY ORAL TABLET 10 MG</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TIVICAY ORAL TABLET 25 MG, 50 MG</b>	T5	
<b>TIVICAY PD</b>	T4	
<b>TOBI</b>	T4	PA
<b>TOBI PODHALER</b>	T5	PA; QL (224 EA per 56 days)
<i>tobramycin in 0.225 % nacl</i>	T5	PA
<i>tobramycin inhalation</i>	T4	PA
<i>tobramycin sulfate injection solution</i>	T1	
<b>TOLSURA</b>	T5	PA; QL (130 EA per 31 days)
<b>TRECTOR</b>	T4	
<i>trimethoprim</i>	T2	
<b>TRIUMEQ</b>	T5	
<b>TRIUMEQ PD</b>	T5	QL (186 EA per 31 days)
<b>TRIZIVIR</b>	T5	
<b>TRUVADA</b>	T5	
<b>TYBOST</b>	T3	
<b>TYGACIL</b>	T5	
<b>UNASYN INJECTION RECON SOLN 15 GRAM, 3 GRAM</b>	T4	
<b>VABOMERE</b>	T4	
<i>valacyclovir</i>	T2	
<b>VALCYTE ORAL RECON SOLN</b>	T4	
<b>VALCYTE ORAL TABLET</b>	T5	
<i>valganciclovir oral recon soln</i>	T5	
<i>valganciclovir oral tablet</i>	T3	
<b>VALTREX</b>	T4	
<b>VANCOCIN ORAL CAPSULE 125 MG</b>	T4	PA; QL (124 EA per 31 days)
<b>VANCOCIN ORAL CAPSULE 250 MG</b>	T5	PA; QL (248 EA per 31 days)
<i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg</i>	T2	
<i>vancomycin oral capsule 125 mg</i>	T4	PA; QL (124 EA per 31 days)
<i>vancomycin oral capsule 250 mg</i>	T4	PA; QL (248 EA per 31 days)
<i>vancomycin oral recon soln</i>	T4	
<b>VEMLIDY</b>	T5	QL (31 EA per 31 days)
<b>VFEND IV</b>	T4	PA
<b>VFEND ORAL SUSPENSION FOR RECONSTITUTION</b>	T5	
<b>VFEND ORAL TABLET</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>VIBRAMYCIN (CALCIUM)</b>	T4	
<b>VIBRAMYCIN (MONO)</b>	T4	
<b>VIBRAMYCIN ORAL CAPSULE 100 MG</b>	T4	
<b>VIRACEPT ORAL TABLET</b>	T5	
<b>VIREAD</b>	T5	
<b>VIVJOA</b>	T4	PA; QL (18 EA per 84 days)
<i>voriconazole intravenous</i>	T5	PA
<i>voriconazole oral suspension for reconstitution</i>	T5	
<i>voriconazole oral tablet</i>	T4	
<b>VOSEVI</b>	T5	PA; QL (28 EA per 28 days)
<b>XENLETA ORAL</b>	T5	
<b>XIFAXAN ORAL TABLET 200 MG</b>	T5	QL (27 EA per 365 days)
<b>XIFAXAN ORAL TABLET 550 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>XIMINO</b>	T4	
<b>XOFLUZA ORAL TABLET 40 MG, 80 MG</b>	T3	QL (9 EA per 365 days)
<b>ZEMDRI</b>	T5	
<b>ZEPATIER</b>	T5	PA; QL (28 EA per 28 days)
<b>ZERBAXA</b>	T5	
<b>ZIAGEN ORAL SOLUTION</b>	T3	
<b>ZIAGEN ORAL TABLET</b>	T4	
<i>zidovudine</i>	T2	
<b>ZITHROMAX INTRAVENOUS</b>	T4	
<b>ZITHROMAX ORAL PACKET</b>	T4	
<b>ZITHROMAX ORAL SUSPENSION FOR RECONSTITUTION</b>	T4	
<b>ZITHROMAX ORAL TABLET 250 MG, 500 MG</b>	T4	
<b>ZITHROMAX TRI-PAK</b>	T4	
<b>ZITHROMAX Z-PAK</b>	T4	
<b>ZOSYN IN DEXTROSE (ISO-OSM) INTRAVENOUS PIGGYBACK 2.25 GRAM/50 ML</b>	T3	
<b>ZYVOX INTRAVENOUS PIGGYBACK 600 MG/300 ML</b>	T4	
<b>ZYVOX ORAL</b>	T5	
<b>Antineoplastic / Immunosuppressant Drugs</b>		
<i>abiraterone oral tablet 250 mg</i>	T5	PA-NS; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>abiraterone oral tablet 500 mg</i>	T5	PA-NS; QL (62 EA per 31 days)
<b>AFINITOR</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 5 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 3 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>ALECENSA</b>	T5	PA-NS; QL (248 EA per 31 days)
<b>ALUNBRIG ORAL TABLET 180 MG, 90 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>ALUNBRIG ORAL TABLET 30 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>ALUNBRIG ORAL TABLETS,DOSE PACK</b>	T5	PA-NS; QL (60 EA per 365 days)
<i>anastrozole</i>	T2	
<b>ARIMIDEX</b>	T5	
<b>AROMASIN</b>	T5	
<b>ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG</b>	T3	PA-BvD
<b>ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG</b>	T4	PA-BvD
<b>AYVAKIT</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>AZASAN</b>	T4	PA-BvD
<i>azathioprine oral tablet 100 mg, 75 mg</i>	T4	PA-BvD
<i>azathioprine oral tablet 50 mg</i>	T2	PA-BvD
<b>BALVERSA</b>	T5	PA-NS
<i>bexarotene oral</i>	T5	PA-NS
<i>bexarotene topical</i>	T5	PA-NS; QL (60 GM per 28 days)
<i>bicalutamide</i>	T2	
<b>BOSULIF ORAL TABLET 100 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>BOSULIF ORAL TABLET 400 MG, 500 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>BRAFTOVI ORAL CAPSULE 75 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>BRUKINSA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>CABOMETYX</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>CALQUENCE</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>CALQUENCE (ACALABRUTINIB MAL)</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>CAPRELSA ORAL TABLET 100 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>CAPRELSA ORAL TABLET 300 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>CASODEX</b>	T4	
<b>CELLCEPT ORAL CAPSULE</b>	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>CELLCEPT ORAL SUSPENSION FOR RECONSTITUTION</b>	T4	PA-BvD
<b>CELLCEPT ORAL TABLET</b>	T5	PA-BvD
<b>COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1)</b>	T5	PA-NS; QL (56 EA per 28 days)
<b>COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3)</b>	T5	PA-NS; QL (112 EA per 28 days)
<b>COMETRIQ ORAL CAPSULE 60 MG/DAY (20 MG X 3/DAY)</b>	T5	PA-NS; QL (84 EA per 28 days)
<b>COPIKTRA</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>COTELLIC</b>	T5	PA-NS; LA; QL (63 EA per 28 days)
<i>cyclophosphamide oral</i>	T3	PA-BvD
<i>cyclosporine modified</i>	T2	PA-BvD
<i>cyclosporine oral capsule</i>	T2	PA-BvD
<b>DAURISMO ORAL TABLET 100 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>DAURISMO ORAL TABLET 25 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>DROXIA</b>	T4	
<b>ELIGARD</b>	T4	
<b>ELIGARD (3 MONTH)</b>	T4	
<b>ELIGARD (4 MONTH)</b>	T4	
<b>ELIGARD (6 MONTH)</b>	T4	
<b>EMCYT</b>	T3	
<b>ENSPRYNG</b>	T5	PA; QL (1 ML per 28 days)
<b>ENVARUSUS XR</b>	T4	PA-BvD
<b>ERIVEDGE</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>ERLEADA ORAL TABLET 240 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>ERLEADA ORAL TABLET 60 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<i>erlotinib</i>	T5	PA-NS; QL (31 EA per 31 days)
<i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 7.5 mg</i>	T5	PA-NS; QL (31 EA per 31 days)
<i>everolimus (antineoplastic) oral tablet 5 mg</i>	T5	PA-NS; QL (62 EA per 31 days)
<i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg</i>	T5	PA-NS; QL (62 EA per 31 days)
<i>everolimus (antineoplastic) oral tablet for suspension 3 mg</i>	T5	PA-NS; QL (93 EA per 31 days)
<i>everolimus (immunosuppressive)</i>	T5	PA-BvD
<i>exemestane</i>	T2	
<b>EXKIVITY</b>	T5	PA-NS; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>FARESTON</b>	T4	
<b>FEMARA</b>	T4	
<b>FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG</b>	T5	
<b>FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG</b>	T4	
<b>FOTIVDA</b>	T5	PA-NS; QL (21 EA per 28 days)
<b>GAVRETO</b>	T5	PA-NS; QL (124 EA per 31 days)
<i>gefitinib</i>	T5	PA-NS; QL (31 EA per 31 days)
<b>GENGRAF</b>	T2	PA-BvD
<b>GILOTRIF</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>GLEEVEC ORAL TABLET 100 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>GLEEVEC ORAL TABLET 400 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>GLEOSTINE ORAL CAPSULE 10 MG, 40 MG</b>	T4	PA-NS
<b>GLEOSTINE ORAL CAPSULE 100 MG</b>	T5	PA-NS
<b>HYDREA</b>	T4	
<i>hydroxyurea</i>	T2	
<b>IBRANCE</b>	T5	PA-NS; QL (21 EA per 28 days)
<b>ICLUSIG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>IDHIFA ORAL TABLET 100 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>IDHIFA ORAL TABLET 50 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<i>imatinib oral tablet 100 mg</i>	T5	PA-NS; QL (93 EA per 31 days)
<i>imatinib oral tablet 400 mg</i>	T5	PA-NS; QL (62 EA per 31 days)
<b>IMBRUVICA ORAL CAPSULE 140 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>IMBRUVICA ORAL CAPSULE 70 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>IMBRUVICA ORAL SUSPENSION</b>	T5	PA-NS; QL (216 ML per 25 days)
<b>IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>IMURAN</b>	T4	PA-BvD
<b>INLYTA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>INQOVI</b>	T5	PA-NS; QL (5 EA per 28 days)
<b>INREBIC</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>IRESSA</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>JAKAFI</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>JAYPIRCA ORAL TABLET 100 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>JAYPIRCA ORAL TABLET 50 MG</b>	T5	PA-NS; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG</b>	T5	PA-NS; QL (49 EA per 28 days)
<b>KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG</b>	T5	PA-NS; QL (70 EA per 28 days)
<b>KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG</b>	T5	PA-NS; QL (91 EA per 28 days)
<b>KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1)</b>	T5	PA-NS; QL (21 EA per 28 days)
<b>KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2)</b>	T5	PA-NS; QL (42 EA per 28 days)
<b>KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3)</b>	T5	PA-NS; QL (63 EA per 28 days)
<b>KLISYRI</b>	T4	PA
<b>KOSELUGO ORAL CAPSULE 10 MG</b>	T5	PA-NS; QL (279 EA per 31 days)
<b>KOSELUGO ORAL CAPSULE 25 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>KRAZATI</b>	T5	PA-NS; QL (186 EA per 31 days)
<i>lapatinib</i>	T5	PA-NS; QL (186 EA per 31 days)
<i>lenalidomide</i>	T5	PA-NS; QL (21 EA per 28 days)
<b>LENVIMA</b>	T5	PA-NS
<i>letrozole</i>	T2	
<i>leucovorin calcium oral</i>	T2	
<b>LEUKERAN</b>	T4	
<i>leuprolide (3 month)</i>	T4	ST
<i>leuprolide subcutaneous kit</i>	T2	
<b>LONSURF</b>	T5	PA-NS
<b>LORBRENA ORAL TABLET 100 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>LORBRENA ORAL TABLET 25 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>LUMAKRAS ORAL TABLET 120 MG</b>	T5	PA-NS; QL (248 EA per 31 days)
<b>LUMAKRAS ORAL TABLET 320 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>LUPKYNIS</b>	T5	PA; QL (186 EA per 31 days)
<b>LUPRON DEPOT</b>	T5	ST
<b>LUPRON DEPOT (3 MONTH)</b>	T5	ST
<b>LUPRON DEPOT (4 MONTH)</b>	T5	ST
<b>LUPRON DEPOT (6 MONTH)</b>	T5	ST
<b>LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG</b>	T5	PA
<b>LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)</b>	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT</b>	T5	PA
<b>LYNPARZA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>LYSODREN</b>	T3	
<b>LYTGOBI ORAL TABLET 4 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>LYTGOBI ORAL TABLET 4 MG (4X 4 MG TB)</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>LYTGOBI ORAL TABLET 4 MG (5X 4 MG TB)</b>	T5	PA-NS; QL (155 EA per 31 days)
<b>MATULANE</b>	T5	
<i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i>	T2	PA
<i>megestrol oral tablet</i>	T2	PA-NS
<b>MEKINIST ORAL RECON SOLN</b>	T5	PA-NS; QL (1260 ML per 31 days)
<b>MEKINIST ORAL TABLET 0.5 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>MEKINIST ORAL TABLET 2 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>MEKTOVI</b>	T5	PA-NS; QL (186 EA per 31 days)
<i>mercaptopurine</i>	T2	
<b>MESNEX ORAL</b>	T3	
<i>methotrexate sodium (pf) injection solution</i>	T2	PA-BvD
<i>methotrexate sodium injection</i>	T2	PA-BvD
<i>methotrexate sodium oral</i>	T1	PA-BvD
<b>MYCAPSSA</b>	T5	PA; QL (124 EA per 31 days)
<i>mycophenolate mofetil oral capsule</i>	T2	PA-BvD
<i>mycophenolate mofetil oral suspension for reconstitution</i>	T5	PA-BvD
<i>mycophenolate mofetil oral tablet</i>	T2	PA-BvD
<i>mycophenolate sodium</i>	T2	PA-BvD
<b>MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 180 MG</b>	T3	PA-BvD
<b>MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 360 MG</b>	T5	PA-BvD
<b>NEORAL</b>	T3	PA-BvD
<b>NERLYNX</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>NEXAVAR</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>NILANDRON</b>	T5	
<i>nilutamide</i>	T5	
<b>NINLARO</b>	T5	PA-NS; QL (3 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>NUBEQA</b>	T5	PA-NS; QL (124 EA per 31 days)
<i>octreotide acetate injection solution 1,000 mcg/ml</i>	T3	PA
<i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml</i>	T2	PA
<i>octreotide acetate injection solution 200 mcg/ml</i>	T4	PA
<i>octreotide acetate injection solution 500 mcg/ml</i>	T5	PA
<b>ODOMZO</b>	T5	PA-NS; LA; QL (31 EA per 31 days)
<b>ONUREG</b>	T5	PA-NS; QL (14 EA per 28 days)
<b>ORGOVYX</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>ORSERDU ORAL TABLET 345 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>ORSERDU ORAL TABLET 86 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>PEMAZYRE</b>	T5	PA-NS; QL (14 EA per 21 days)
<b>PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1)</b>	T5	PA-NS; QL (28 EA per 28 days)
<b>PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)</b>	T5	PA-NS; QL (56 EA per 28 days)
<b>POMALYST</b>	T5	PA-NS; QL (21 EA per 28 days)
<b>PROGRAF ORAL</b>	T4	PA-BvD
<b>PURIXAN</b>	T4	
<b>QINLOCK</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>RAPAMUNE ORAL SOLUTION</b>	T5	PA-BvD
<b>RAPAMUNE ORAL TABLET 0.5 MG</b>	T4	PA-BvD
<b>RAPAMUNE ORAL TABLET 1 MG, 2 MG</b>	T5	PA-BvD
<b>RETEVMO ORAL CAPSULE 40 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>RETEVMO ORAL CAPSULE 80 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>REVLIMID</b>	T5	PA-NS; QL (21 EA per 28 days)
<b>REZLIDHIA</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>REZUROCK</b>	T5	PA; QL (62 EA per 31 days)
<b>ROZLYTREK ORAL CAPSULE 100 MG</b>	T5	PA-NS; QL (155 EA per 31 days)
<b>ROZLYTREK ORAL CAPSULE 200 MG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>RUBRACA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>RYDAPT</b>	T5	PA-NS; QL (248 EA per 31 days)
<b>SANDIMMUNE ORAL CAPSULE 100 MG</b>	T5	PA-BvD
<b>SANDIMMUNE ORAL CAPSULE 25 MG</b>	T3	PA-BvD
<b>SANDIMMUNE ORAL SOLUTION</b>	T3	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML</b>	T4	PA
<b>SCEMBLIX ORAL TABLET 20 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>SCEMBLIX ORAL TABLET 40 MG</b>	T5	PA-NS; QL (310 EA per 31 days)
<b>SIGNIFOR</b>	T5	PA
<b>SIKLOS ORAL TABLET 1,000 MG</b>	T5	
<b>SIKLOS ORAL TABLET 100 MG</b>	T4	
<i>sirolimus</i>	T2	PA-BvD
<b>SOLTAMOX</b>	T5	
<i>sorafenib</i>	T5	PA-NS; QL (124 EA per 31 days)
<b>SPRYCEL</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>STIVARGA</b>	T5	PA-NS; QL (84 EA per 28 days)
<i>sunitinib malate</i>	T5	PA-NS; QL (31 EA per 31 days)
<b>SUTENT</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>SYNRIBO</b>	T5	
<b>TABLOID</b>	T3	
<b>TABRECTA</b>	T5	PA-NS; QL (124 EA per 31 days)
<i>tacrolimus oral</i>	T2	PA-BvD
<b>TAFINLAR ORAL CAPSULE</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>TAFINLAR ORAL TABLET FOR SUSPENSION</b>	T5	PA-NS; QL (930 EA per 31 days)
<b>TAGRISSO</b>	T5	PA-NS; LA; QL (31 EA per 31 days)
<b>TALZENNA</b>	T5	PA-NS; QL (31 EA per 31 days)
<i>tamoxifen</i>	T1	
<b>TARGRETIN ORAL</b>	T5	PA-NS
<b>TARGRETIN TOPICAL</b>	T5	PA-NS; QL (60 GM per 28 days)
<b>TASIGNA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>TAZVERIK</b>	T5	PA-NS; QL (248 EA per 31 days)
<b>TEPMETKO</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>THALOMID ORAL CAPSULE 100 MG, 150 MG, 50 MG</b>	T5	PA-NS; QL (28 EA per 28 days)
<b>THALOMID ORAL CAPSULE 200 MG</b>	T5	PA-NS; QL (56 EA per 28 days)
<b>TIBSOVO</b>	T5	PA-NS; QL (62 EA per 31 days)
<i>toremifene</i>	T5	
<b>TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION</b>	T5	ST
<i>tretinoin (antineoplastic)</i>	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TREXALL</b>	T3	PA-BvD
<b>TUKYSA ORAL TABLET 150 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>TUKYSA ORAL TABLET 50 MG</b>	T5	PA-NS; QL (248 EA per 31 days)
<b>TURALIO ORAL CAPSULE 125 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>TYKERB</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>VANFLYTA</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>VENCLEXTA ORAL TABLET 10 MG</b>	T4	PA-NS; QL (62 EA per 31 days)
<b>VENCLEXTA ORAL TABLET 100 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>VENCLEXTA ORAL TABLET 50 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>VENCLEXTA STARTING PACK</b>	T5	PA-NS; QL (84 EA per 365 days)
<b>VERZENIO</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>VIJOICE ORAL TABLET 125 MG, 50 MG</b>	T5	PA-NS; QL (28 EA per 28 days)
<b>VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1)</b>	T5	PA-NS; QL (56 EA per 28 days)
<b>VITRAKVI ORAL CAPSULE 100 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>VITRAKVI ORAL CAPSULE 25 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>VITRAKVI ORAL SOLUTION</b>	T5	PA-NS; QL (310 ML per 31 days)
<b>VIZIMPRO</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>VONJO</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>VOTRIENT</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>WELIREG</b>	T5	PA-NS; QL (93 EA per 31 days)
<b>XALKORI</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>XATMEP</b>	T4	PA-BvD
<b>XERMELO</b>	T5	PA; QL (93 EA per 31 days)
<b>XGEVA</b>	T5	PA-NS
<b>XOSPATA</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2)</b>	T5	PA-NS; QL (8 EA per 28 days)
<b>XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1)</b>	T5	PA-NS; QL (4 EA per 28 days)
<b>XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK)</b>	T5	PA-NS; QL (24 EA per 28 days)
<b>XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK)</b>	T5	PA-NS; QL (32 EA per 28 days)
<b>XTANDI ORAL CAPSULE</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>XTANDI ORAL TABLET 40 MG</b>	T5	PA-NS; QL (124 EA per 31 days)
<b>XTANDI ORAL TABLET 80 MG</b>	T5	PA-NS; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
YONSA	T5	PA-NS; QL (124 EA per 31 days)
ZEJULA ORAL CAPSULE	T5	PA-NS; QL (93 EA per 31 days)
ZEJULA ORAL TABLET	T5	PA-NS; QL (31 EA per 31 days)
ZELBORAF	T5	PA-NS; QL (248 EA per 31 days)
ZOLINZA	T5	PA-NS
ZORTRESS	T5	PA-BvD
ZYDELIG	T5	PA-NS; QL (62 EA per 31 days)
ZYKADIA	T5	PA-NS; QL (93 EA per 31 days)
ZYTIGA ORAL TABLET 250 MG	T5	PA-NS; QL (124 EA per 31 days)
ZYTIGA ORAL TABLET 500 MG	T5	PA-NS; QL (62 EA per 31 days)
<b>Autonomic / Cns Drugs, Neurology / Psych</b>		
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML	T5	QL (2.4 ML per 56 days)
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML	T5	QL (3.2 ML per 56 days)
ABILIFY MAINTENA	T5	QL (1 EA per 28 days)
ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG	T5	PA-NS
ABILIFY MYCITE STARTER KIT ORAL TABLET WITH SENSOR, STRIP, POD 10 MG	T5	PA-NS
ABILIFY ORAL TABLET	T5	PA-NS
<i>acetaminophen-cafff-dihydrocod oral capsule</i>	T4	PA; QL (372 EA per 31 days)
<i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i>	T1	PA; QL (5167 ML per 31 days)
<i>acetaminophen-codeine oral tablet</i>	T2	PA; QL (403 EA per 31 days)
ADDERALL ORAL TABLET 20 MG	T4	ST; QL (93 EA per 31 days)
ADDERALL ORAL TABLET 5 MG, 7.5 MG	T4	ST; QL (62 EA per 31 days)
ADDERALL XR	T4	ST; QL (31 EA per 31 days)
ADLARITY	T4	PA; QL (4 EA per 28 days)
ADZENYS XR-ODT	T4	ST; QL (31 EA per 31 days)
AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML	T3	PA; QL (1 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML</b>	T3	PA; QL (2 ML per 28 days)
<b>AJOVY AUTOINJECTOR</b>	T3	PA; QL (1.5 ML per 28 days)
<b>AJOVY SYRINGE</b>	T3	PA; QL (1.5 ML per 28 days)
<b>ALLZITAL</b>	T4	QL (372 EA per 31 days)
<i>almotriptan malate oral tablet 12.5 mg</i>	T2	QL (8 EA per 28 days)
<i>almotriptan malate oral tablet 6.25 mg</i>	T2	QL (16 EA per 28 days)
<b>ALPRAZOLAM INTENSOL</b>	T2	PA
<i>alprazolam oral tablet 0.25 mg, 0.5 mg</i>	T2	PA; QL (93 EA per 31 days)
<i>alprazolam oral tablet 1 mg, 2 mg</i>	T2	PA; QL (155 EA per 31 days)
<i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg</i>	T2	PA; QL (31 EA per 31 days)
<i>alprazolam oral tablet extended release 24 hr 2 mg</i>	T2	PA; QL (155 EA per 31 days)
<i>alprazolam oral tablet extended release 24 hr 3 mg</i>	T2	PA; QL (93 EA per 31 days)
<i>alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg</i>	T2	PA; QL (93 EA per 31 days)
<i>alprazolam oral tablet, disintegrating 1 mg, 2 mg</i>	T2	PA; QL (155 EA per 31 days)
<b>AMBIEN</b>	T4	PA; QL (31 EA per 31 days)
<b>AMBIEN CR</b>	T4	PA; QL (31 EA per 31 days)
<i>amitriptyline</i>	T2	PA-NS
<i>amitriptyline-chlordiazepoxide</i>	T2	PA-NS
<i>amoxapine</i>	T1	
<i>amphetamine sulfate</i>	T4	PA
<b>AMPYRA</b>	T5	PA; QL (62 EA per 31 days)
<b>AMRIX</b>	T4	QL (31 EA per 31 days)
<b>ANAFRANIL</b>	T4	PA-NS
<b>ALENZIN ORAL TABLET EXTENDED RELEASE 24 HR 174 MG</b>	T4	QL (31 EA per 31 days)
<b>ALENZIN ORAL TABLET EXTENDED RELEASE 24 HR 348 MG, 522 MG</b>	T5	QL (31 EA per 31 days)
<b>APOKYN</b>	T5	PA; QL (60 ML per 30 days)
<i>apomorphine</i>	T5	PA; QL (60 ML per 30 days)
<b>APTENSIO XR</b>	T4	ST; QL (31 EA per 31 days)
<b>APTIOM ORAL TABLET 200 MG</b>	T5	QL (186 EA per 31 days)
<b>APTIOM ORAL TABLET 400 MG</b>	T5	QL (93 EA per 31 days)
<b>APTIOM ORAL TABLET 600 MG, 800 MG</b>	T5	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ARICEPT</b>	T4	
<i>aripiprazole oral solution</i>	T3	PA-NS
<i>aripiprazole oral tablet</i>	T3	PA-NS
<i>aripiprazole oral tablet, disintegrating</i>	T5	PA-NS
<b>ARISTADA INITIO</b>	T5	QL (4.8 ML per 365 days)
<b>ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 1,064 MG/3.9 ML</b>	T5	QL (3.9 ML per 28 days)
<b>ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 441 MG/1.6 ML</b>	T5	QL (1.6 ML per 28 days)
<b>ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 662 MG/2.4 ML</b>	T5	QL (2.4 ML per 28 days)
<b>ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 882 MG/3.2 ML</b>	T5	QL (3.2 ML per 28 days)
<i>armodafinil</i>	T4	PA; QL (31 EA per 31 days)
<b>ARTHROTEC 50</b>	T4	
<b>ARTHROTEC 75</b>	T4	
<b>ASCOMP WITH CODEINE</b>	T2	PA; QL (372 EA per 31 days)
<i>asenapine maleate</i>	T4	QL (62 EA per 31 days)
<b>ATIVAN ORAL TABLET 0.5 MG</b>	T5	QL (124 EA per 31 days)
<b>ATIVAN ORAL TABLET 1 MG</b>	T5	QL (186 EA per 31 days)
<b>ATIVAN ORAL TABLET 2 MG</b>	T5	QL (155 EA per 31 days)
<i>atomoxetine oral capsule 10 mg, 25 mg, 40 mg</i>	T4	QL (62 EA per 31 days)
<i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i>	T4	QL (31 EA per 31 days)
<i>atomoxetine oral capsule 18 mg</i>	T4	QL (124 EA per 31 days)
<b>AUBAGIO</b>	T5	PA; QL (31 EA per 31 days)
<b>AUSTEDO ORAL TABLET 12 MG, 6 MG</b>	T5	PA; QL (124 EA per 31 days)
<b>AUSTEDO ORAL TABLET 9 MG</b>	T5	PA; QL (155 EA per 31 days)
<b>AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG</b>	T5	PA; QL (93 EA per 31 days)
<b>AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 24 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG</b>	T5	PA; QL (217 EA per 31 days)
<b>AUSTEDO XR TITRATION KT(WK1-4)</b>	T5	PA; QL (84 EA per 365 days)
<b>AUVELITY</b>	T4	PA-NS; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>AZILECT ORAL TABLET 0.5 MG</b>	T4	
<b>AZILECT ORAL TABLET 1 MG</b>	T5	
<b>AZSTARYS</b>	T4	ST; QL (31 EA per 31 days)
<i>baclofen oral suspension</i>	T4	PA; QL (496 ML per 31 days)
<i>baclofen oral tablet 10 mg</i>	T1	
<i>baclofen oral tablet 20 mg, 5 mg</i>	T2	
<b>BAFIERTAM</b>	T5	PA; QL (124 EA per 31 days)
<b>BANZEL</b>	T5	PA-NS
<b>BELBUCA BUCCAL FILM 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG</b>	T4	PA; QL (62 EA per 31 days)
<b>BELBUCA BUCCAL FILM 750 MCG, 900 MCG</b>	T5	PA; QL (62 EA per 31 days)
<b>BELSOMRA</b>	T4	ST; QL (31 EA per 31 days)
<i>benztropine oral</i>	T2	PA
<b>BRIVIACT ORAL SOLUTION</b>	T5	QL (620 ML per 31 days)
<b>BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 75 MG</b>	T5	QL (62 EA per 31 days)
<b>BRIVIACT ORAL TABLET 50 MG</b>	T4	QL (62 EA per 31 days)
<i>bromocriptine</i>	T2	
<b>BUPAP</b>	T4	QL (403 EA per 31 days)
<i>buprenorphine</i>	T4	PA; QL (4 EA per 28 days)
<i>buprenorphine hcl sublingual tablet 2 mg</i>	T2	QL (93 EA per 31 days)
<i>buprenorphine hcl sublingual tablet 8 mg</i>	T2	QL (62 EA per 31 days)
<i>buprenorphine-naloxone sublingual film 12-3 mg, 4-1 mg, 8-2 mg</i>	T2	QL (62 EA per 31 days)
<i>buprenorphine-naloxone sublingual film 2-0.5 mg</i>	T2	QL (93 EA per 31 days)
<i>buprenorphine-naloxone sublingual tablet</i>	T4	QL (93 EA per 31 days)
<i>bupropion hcl oral tablet</i>	T2	
<i>bupropion hcl oral tablet extended release 24 hr 150 mg</i>	T2	QL (93 EA per 31 days)
<i>bupropion hcl oral tablet extended release 24 hr 300 mg</i>	T2	QL (31 EA per 31 days)
<i>bupropion hcl oral tablet extended release 24 hr 450 mg</i>	T4	QL (31 EA per 31 days)
<i>bupropion hcl oral tablet sustained-release 12 hr</i>	T2	QL (62 EA per 31 days)
<i>bupirone</i>	T2	
<i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg</i>	T2	PA; QL (403 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i>	T2	PA; QL (372 EA per 31 days)
<i>butalbital-acetaminophen oral capsule</i>	T2	QL (403 EA per 31 days)
<i>butalbital-acetaminophen oral tablet 50-300 mg</i>	T2	QL (403 EA per 31 days)
<i>butalbital-acetaminophen oral tablet 50-325 mg</i>	T2	QL (372 EA per 31 days)
<i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg</i>	T2	QL (403 EA per 31 days)
<i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i>	T2	QL (372 EA per 31 days)
<i>butalbital-acetaminophen-caff oral tablet</i>	T2	QL (372 EA per 31 days)
<i>butalbital-aspirin-caffeine oral capsule</i>	T2	
<i>butorphanol nasal</i>	T2	QL (5 ML per 28 days)
<b>BUTRANS TRANSDERMAL PATCH WEEKLY 10 MCG/HOUR, 15 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR</b>	T4	PA; QL (4 EA per 28 days)
<b>BUTRANS TRANSDERMAL PATCH WEEKLY 20 MCG/HOUR</b>	T5	PA; QL (4 EA per 28 days)
<b>CAMBIA</b>	T5	
<b>CAPLYTA</b>	T5	PA-NS; QL (31 EA per 31 days)
<i>carbamazepine oral capsule, er multiphase 12 hr</i>	T2	
<i>carbamazepine oral suspension 100 mg/5 ml</i>	T1	
<i>carbamazepine oral tablet</i>	T1	
<i>carbamazepine oral tablet extended release 12 hr</i>	T2	
<i>carbamazepine oral tablet, chewable</i>	T1	
<b>CARBATROL</b>	T4	
<i>carbidopa</i>	T4	
<i>carbidopa-levodopa</i>	T2	
<i>carbidopa-levodopa-entacapone</i>	T2	
<i>carisoprodol</i>	T2	PA
<b>CELEBREX</b>	T4	ST; QL (62 EA per 31 days)
<i>celecoxib</i>	T2	ST; QL (62 EA per 31 days)
<b>CELEXA ORAL TABLET</b>	T4	
<b>CELONTIN ORAL CAPSULE 300 MG</b>	T4	
<i>chlordiazepoxide hcl</i>	T2	
<i>chlorpromazine oral</i>	T2	
<i>chlorzoxazone oral tablet 250 mg</i>	T5	PA
<i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i>	T2	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>citalopram oral capsule</i>	T4	PA-NS; QL (31 EA per 31 days)
<i>citalopram oral solution</i>	T1	
<i>citalopram oral tablet</i>	T1	
<i>clobazam oral suspension</i>	T4	PA-NS; QL (496 ML per 31 days)
<i>clobazam oral tablet</i>	T3	PA-NS; QL (62 EA per 31 days)
<i>clomipramine</i>	T2	PA-NS
<i>clonazepam oral tablet 0.5 mg</i>	T2	QL (93 EA per 31 days)
<i>clonazepam oral tablet 1 mg</i>	T2	QL (124 EA per 31 days)
<i>clonazepam oral tablet 2 mg</i>	T2	QL (310 EA per 31 days)
<i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg</i>	T2	QL (93 EA per 31 days)
<i>clonazepam oral tablet, disintegrating 1 mg</i>	T2	QL (124 EA per 31 days)
<i>clonazepam oral tablet, disintegrating 2 mg</i>	T2	QL (310 EA per 31 days)
<i>clonidine hcl oral tablet extended release 12 hr</i>	T2	PA
<i>clorazepate dipotassium oral tablet 15 mg</i>	T2	QL (186 EA per 31 days)
<i>clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg</i>	T2	QL (93 EA per 31 days)
<i>clozapine oral tablet 100 mg, 25 mg</i>	T2	QL (279 EA per 31 days)
<i>clozapine oral tablet 200 mg</i>	T2	QL (124 EA per 31 days)
<i>clozapine oral tablet 50 mg</i>	T2	QL (93 EA per 31 days)
<i>clozapine oral tablet, disintegrating 100 mg, 25 mg</i>	T2	QL (279 EA per 31 days)
<i>clozapine oral tablet, disintegrating 12.5 mg</i>	T2	QL (93 EA per 31 days)
<i>clozapine oral tablet, disintegrating 150 mg</i>	T4	QL (186 EA per 31 days)
<i>clozapine oral tablet, disintegrating 200 mg</i>	T4	QL (124 EA per 31 days)
<b>CLOZARIL ORAL TABLET 100 MG, 25 MG</b>	T4	QL (279 EA per 31 days)
<b>CLOZARIL ORAL TABLET 200 MG</b>	T4	QL (124 EA per 31 days)
<b>CLOZARIL ORAL TABLET 50 MG</b>	T4	QL (93 EA per 31 days)
<i>codeine sulfate</i>	T2	PA; QL (186 EA per 31 days)
<i>codeine-butalbital-asa-caff</i>	T2	PA; QL (372 EA per 31 days)
<b>COMTAN</b>	T4	
<b>CONCERTA</b>	T4	ST; QL (31 EA per 31 days)
<b>CONZIP</b>	T4	PA; QL (30 EA per 30 days)
<b>COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML</b>	T5	QL (31 ML per 31 days)
<b>COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML</b>	T5	QL (12 ML per 28 days)
<b>COTEMPLA XR-ODT</b>	T4	ST; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>cyclobenzaprine oral capsule,extended release 24hr</i>	T4	QL (31 EA per 31 days)
<i>cyclobenzaprine oral tablet 10 mg, 7.5 mg</i>	T2	QL (93 EA per 31 days)
<i>cyclobenzaprine oral tablet 5 mg</i>	T2	QL (155 EA per 31 days)
<b>CYMBALTA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 20 MG, 60 MG</b>	T4	QL (62 EA per 31 days)
<b>CYMBALTA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 30 MG</b>	T4	QL (31 EA per 31 days)
<i>dalfampridine</i>	T5	PA; QL (62 EA per 31 days)
<b>DANTRIUM ORAL CAPSULE 25 MG</b>	T4	
<i>dantrolene oral</i>	T2	
<b>DAYBUE</b>	T5	PA; QL (3600 ML per 30 days)
<b>DAYPRO</b>	T4	
<b>DAYTRANA</b>	T4	PA; QL (30 EA per 30 days)
<b>DAYVIGO</b>	T4	ST; QL (31 EA per 31 days)
<b>DEMEROL (PF) INJECTION SYRINGE 25 MG/ML</b>	T4	PA; QL (824 ML per 31 days)
<b>DEMEROL INJECTION SOLUTION 50 MG/ML</b>	T4	PA; QL (412 ML per 31 days)
<b>DEPAKOTE</b>	T4	
<b>DEPAKOTE ER</b>	T4	
<b>DEPAKOTE SPRINKLES</b>	T4	
<i>desipramine</i>	T2	
<i>desvenlafaxine oral tablet extended release 24 hr 100 mg</i>	T4	QL (124 EA per 31 days)
<i>desvenlafaxine oral tablet extended release 24 hr 50 mg</i>	T4	QL (31 EA per 31 days)
<i>desvenlafaxine succinate</i>	T3	QL (31 EA per 31 days)
<b>DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 10 MG</b>	T4	ST; QL (155 EA per 31 days)
<b>DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 15 MG</b>	T5	ST; QL (124 EA per 31 days)
<i>dexmethylphenidate oral capsule,er biphasic 50-50</i>	T2	QL (31 EA per 31 days)
<i>dexmethylphenidate oral tablet 10 mg</i>	T2	QL (62 EA per 31 days)
<i>dexmethylphenidate oral tablet 2.5 mg, 5 mg</i>	T2	QL (93 EA per 31 days)
<i>dextroamphetamine sulfate oral capsule, extended release 10 mg</i>	T2	QL (155 EA per 31 days)
<i>dextroamphetamine sulfate oral capsule, extended release 15 mg</i>	T2	QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>dextroamphetamine sulfate oral capsule, extended release 5 mg</i>	T2	QL (186 EA per 31 days)
<i>dextroamphetamine sulfate oral solution</i>	T3	
<i>dextroamphetamine sulfate oral tablet 10 mg</i>	T2	QL (186 EA per 31 days)
<i>dextroamphetamine sulfate oral tablet 15 mg, 20 mg, 30 mg</i>	T4	QL (62 EA per 31 days)
<i>dextroamphetamine sulfate oral tablet 5 mg</i>	T2	QL (341 EA per 31 days)
<i>dextroamphetamine-amphetamine oral capsule, extended release 24hr</i>	T2	QL (31 EA per 31 days)
<i>dextroamphetamine-amphetamine oral tablet 10 mg, 30 mg</i>	T2	QL (62 EA per 31 days)
<i>dextroamphetamine-amphetamine oral tablet 12.5 mg, 15 mg, 5 mg, 7.5 mg</i>	T1	QL (62 EA per 31 days)
<i>dextroamphetamine-amphetamine oral tablet 20 mg</i>	T2	QL (93 EA per 31 days)
<b>DHIVY</b>	T4	ST
<b>DIACOMIT ORAL CAPSULE 250 MG</b>	T5	PA-NS; QL (341 EA per 31 days)
<b>DIACOMIT ORAL CAPSULE 500 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>DIACOMIT ORAL POWDER IN PACKET 250 MG</b>	T5	PA-NS; QL (341 EA per 31 days)
<b>DIACOMIT ORAL POWDER IN PACKET 500 MG</b>	T5	PA-NS; QL (186 EA per 31 days)
<b>DIASTAT</b>	T4	
<b>DIASTAT ACUDIAL</b>	T4	
<b>DIAZEPAM INTENSOL</b>	T2	QL (248 ML per 31 days)
<i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i>	T2	QL (1500 ML per 31 days)
<i>diazepam oral tablet</i>	T2	QL (124 EA per 31 days)
<i>diazepam rectal</i>	T4	
<i>diclofenac epolamine</i>	T4	PA; QL (62 EA per 31 days)
<i>diclofenac potassium oral capsule</i>	T5	
<i>diclofenac potassium oral powder in packet</i>	T4	
<i>diclofenac potassium oral tablet 25 mg</i>	T5	
<i>diclofenac potassium oral tablet 50 mg</i>	T1	
<i>diclofenac sodium oral</i>	T1	
<i>diclofenac sodium topical drops</i>	T2	QL (450 ML per 28 days)
<i>diclofenac sodium topical gel 1 %</i>	T3	QL (900 GM per 28 days)
<i>diclofenac sodium topical solution in metered-dose pump</i>	T5	QL (224 GM per 28 days)
<i>diclofenac-misoprostol</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>diflunisal</i>	T2	
<i>dihydroergotamine nasal</i>	T5	PA; QL (8 ML per 31 days)
<b>DILANTIN</b>	T4	
<b>DILANTIN EXTENDED</b>	T4	
<b>DILANTIN INFATABS</b>	T4	
<b>DILANTIN-125</b>	T4	
<b>DILAUDID ORAL LIQUID</b>	T4	PA; QL (1550 ML per 31 days)
<b>DILAUDID ORAL TABLET 2 MG</b>	T4	PA; QL (186 EA per 31 days)
<b>DILAUDID ORAL TABLET 4 MG, 8 MG</b>	T5	PA; QL (186 EA per 31 days)
<i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i>	T5	PA; QL (120 EA per 365 days)
<i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 240 mg</i>	T5	PA; QL (62 EA per 31 days)
<i>divalproex oral capsule, delayed rel sprinkle</i>	T2	
<i>divalproex oral tablet extended release 24 hr 250 mg</i>	T2	
<i>divalproex oral tablet extended release 24 hr 500 mg</i>	T3	
<i>divalproex oral tablet, delayed release (dr/ec)</i>	T2	
<i>donepezil oral tablet 10 mg, 5 mg</i>	T2	
<i>donepezil oral tablet 23 mg</i>	T2	QL (31 EA per 31 days)
<i>donepezil oral tablet, disintegrating</i>	T2	
<i>doxepin oral capsule</i>	T2	PA-NS
<i>doxepin oral concentrate</i>	T2	PA-NS
<i>doxepin oral tablet</i>	T2	PA
<b>DUEXIS</b>	T5	PA; QL (93 EA per 31 days)
<i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 60 mg</i>	T2	QL (62 EA per 31 days)
<i>duloxetine oral capsule, delayed release(dr/ec) 30 mg</i>	T2	QL (31 EA per 31 days)
<i>duloxetine oral capsule, delayed release(dr/ec) 40 mg</i>	T3	QL (31 EA per 31 days)
<b>DUOPA</b>	T5	PA-BvD
<b>DYANAVEL XR ORAL SUSPEN, IR - ER, BIPHASIC 24HR</b>	T4	ST; QL (248 ML per 31 days)
<b>DYANAVEL XR ORAL TABLET, IR - ER, BIPHASIC 24HR</b>	T4	ST; QL (31 EA per 31 days)
<b>EDLUAR</b>	T4	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG, 37.5 MG</b>	T4	QL (31 EA per 31 days)
<b>EFFEXOR XR ORAL CAPSULE,EXTENDED RELEASE 24HR 75 MG</b>	T4	QL (93 EA per 31 days)
<i>eletriptan oral tablet 20 mg</i>	T4	QL (12 EA per 28 days)
<i>eletriptan oral tablet 40 mg</i>	T4	QL (6 EA per 28 days)
<b>EMGALITY PEN</b>	T3	PA; QL (1 ML per 28 days)
<b>EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML</b>	T3	PA; QL (1 ML per 28 days)
<b>EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3)</b>	T5	PA; QL (3 ML per 28 days)
<b>EMSAM</b>	T5	QL (30 EA per 30 days)
<b>ENDOCET</b>	T2	PA; QL (372 EA per 31 days)
<i>entacapone</i>	T2	
<b>EPIDIOLEX</b>	T5	PA-NS
<b>EPITOL</b>	T1	
<b>EPRONTIA</b>	T4	PA-NS; QL (496 ML per 31 days)
<b>EQUETRO</b>	T4	
<i>ergoloid</i>	T2	PA
<i>ergotamine-caffeine</i>	T2	PA
<i>escitalopram oxalate oral solution</i>	T4	QL (620 ML per 31 days)
<i>escitalopram oxalate oral tablet 10 mg</i>	T2	QL (45 EA per 30 days)
<i>escitalopram oxalate oral tablet 20 mg, 5 mg</i>	T2	QL (30 EA per 30 days)
<b>ESGIC ORAL TABLET</b>	T4	QL (372 EA per 31 days)
<i>estazolam</i>	T2	
<i>eszopiclone</i>	T2	PA; QL (31 EA per 31 days)
<i>ethosuximide oral capsule</i>	T3	
<i>ethosuximide oral solution</i>	T2	
<i>etodolac</i>	T2	
<b>EVEKEO</b>	T4	PA
<b>EVEKEO ODT</b>	T4	ST
<b>EVRYSDI</b>	T5	PA; QL (240 ML per 31 days)
<b>EXELON PATCH</b>	T4	QL (30 EA per 30 days)
<b>FANAPT ORAL TABLET 1 MG</b>	T4	QL (62 EA per 31 days)
<b>FANAPT ORAL TABLET 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG</b>	T5	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>FANAPT ORAL TABLETS,DOSE PACK</b>	T4	QL (16 EA per 365 days)
<i>felbamate</i>	T2	
<b>FELBATOL ORAL TABLET</b>	T4	
<b>FELDENE</b>	T4	
<i>fenoprofen oral capsule 400 mg</i>	T4	
<i>fenoprofen oral tablet</i>	T2	
<i>fentanyl citrate buccal lozenge on a handle 1,200 mcg</i>	T5	PA; QL (40 EA per 31 days)
<i>fentanyl citrate buccal lozenge on a handle 1,600 mcg</i>	T5	PA; QL (30 EA per 31 days)
<i>fentanyl citrate buccal lozenge on a handle 200 mcg</i>	T4	PA; QL (124 EA per 31 days)
<i>fentanyl citrate buccal lozenge on a handle 400 mcg</i>	T5	PA; QL (119 EA per 31 days)
<i>fentanyl citrate buccal lozenge on a handle 600 mcg</i>	T5	PA; QL (79 EA per 31 days)
<i>fentanyl citrate buccal lozenge on a handle 800 mcg</i>	T5	PA; QL (59 EA per 31 days)
<i>fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg</i>	T5	PA; QL (124 EA per 31 days)
<i>fentanyl citrate buccal tablet, effervescent 400 mcg</i>	T5	PA; QL (119 EA per 31 days)
<i>fentanyl citrate buccal tablet, effervescent 600 mcg</i>	T5	PA; QL (79 EA per 31 days)
<i>fentanyl citrate buccal tablet, effervescent 800 mcg</i>	T5	PA; QL (59 EA per 31 days)
<i>fentanyl transdermal patch 72 hour 100 mcg/hr</i>	T3	PA; QL (10 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 12 mcg/hr</i>	T3	PA; QL (20 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 25 mcg/hr</i>	T2	PA; QL (20 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 37.5 mcg/hour</i>	T4	PA; QL (20 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 50 mcg/hr</i>	T2	PA; QL (17 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 62.5 mcg/hour</i>	T4	PA; QL (15 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 75 mcg/hr</i>	T3	PA; QL (12 EA per 30 days)
<i>fentanyl transdermal patch 72 hour 87.5 mcg/hour</i>	T5	PA; QL (11 EA per 30 days)
<b>FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG</b>	T5	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>FENTORA BUCCAL TABLET, EFFERVESCENT 400 MCG</b>	T5	PA; QL (119 EA per 31 days)
<b>FENTORA BUCCAL TABLET, EFFERVESCENT 600 MCG</b>	T5	PA; QL (79 EA per 31 days)
<b>FENTORA BUCCAL TABLET, EFFERVESCENT 800 MCG</b>	T5	PA; QL (59 EA per 31 days)
<b>FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK</b>	T4	PA-NS; QL (56 EA per 365 days)
<b>FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG</b>	T4	PA-NS; QL (31 EA per 31 days)
<b>FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG</b>	T4	PA-NS; QL (93 EA per 31 days)
<b>FEXMID</b>	T4	QL (124 EA per 31 days)
<i>fingolimod</i>	T5	PA; QL (31 EA per 31 days)
<b>FINTEPLA</b>	T5	PA-NS; QL (360 ML per 30 days)
<b>FIORICET</b>	T4	QL (403 EA per 31 days)
<b>FIORICET WITH CODEINE</b>	T4	PA; QL (403 EA per 31 days)
<b>FIRDAPSE</b>	T5	PA; QL (248 EA per 31 days)
<b>FLECTOR</b>	T4	PA; QL (62 EA per 31 days)
<b>FLEQSUVY</b>	T4	PA; QL (496 ML per 31 days)
<i>fluoxetine (pmd)</i>	T1	
<i>fluoxetine oral capsule</i>	T1	
<i>fluoxetine oral capsule,delayed release(dr/ec)</i>	T2	
<i>fluoxetine oral solution</i>	T1	
<i>fluoxetine oral tablet 10 mg, 20 mg</i>	T1	
<i>fluoxetine oral tablet 60 mg</i>	T4	
<i>fluphenazine decanoate</i>	T2	
<i>fluphenazine hcl injection</i>	T2	
<i>fluphenazine hcl oral concentrate</i>	T2	
<i>fluphenazine hcl oral elixir</i>	T1	
<i>fluphenazine hcl oral tablet</i>	T1	
<i>flurbiprofen oral tablet 100 mg</i>	T2	
<i>fluvoxamine</i>	T2	
<b>FOCALIN ORAL TABLET 10 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>FOCALIN ORAL TABLET 2.5 MG, 5 MG</b>	T4	ST; QL (93 EA per 31 days)
<b>FOCALIN XR</b>	T4	ST; QL (31 EA per 31 days)
<b>FORFIVO XL</b>	T4	QL (31 EA per 31 days)
<b>FROVA</b>	T4	QL (12 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>frovatriptan</i>	T3	QL (12 EA per 28 days)
<b>FYCOMPA ORAL SUSPENSION</b>	T5	QL (744 ML per 31 days)
<b>FYCOMPA ORAL TABLET</b>	T5	QL (31 EA per 31 days)
<i>gabapentin oral capsule 100 mg, 400 mg</i>	T2	PA-NS; QL (270 EA per 30 days)
<i>gabapentin oral capsule 300 mg</i>	T2	PA-NS; QL (360 EA per 30 days)
<i>gabapentin oral solution 250 mg/5 ml</i>	T2	PA-NS; QL (2160 ML per 30 days)
<i>gabapentin oral tablet 600 mg</i>	T2	PA-NS; QL (180 EA per 30 days)
<i>gabapentin oral tablet 800 mg</i>	T2	PA-NS; QL (120 EA per 30 days)
<i>galantamine</i>	T2	
<b>GEODON INTRAMUSCULAR</b>	T4	
<b>GEODON ORAL</b>	T4	QL (62 EA per 31 days)
<b>GILENYA</b>	T5	PA; QL (31 EA per 31 days)
<i>glatiramer subcutaneous syringe 20 mg/ml</i>	T5	QL (31 ML per 31 days)
<i>glatiramer subcutaneous syringe 40 mg/ml</i>	T5	QL (12 ML per 28 days)
<b>GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML</b>	T5	QL (31 ML per 31 days)
<b>GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML</b>	T5	QL (12 ML per 28 days)
<b>GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 68.5 MG</b>	T5	PA; QL (124 EA per 31 days)
<b>GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG</b>	T4	PA; QL (155 EA per 31 days)
<b>GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 450 MG</b>	T4	PA; QL (31 EA per 31 days)
<b>GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 600 MG</b>	T5	PA; QL (93 EA per 31 days)
<b>GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 750 MG, 900 MG</b>	T4	PA; QL (62 EA per 31 days)
<i>guanfacine oral tablet extended release 24 hr</i>	T2	PA
<b>HALCION ORAL TABLET 0.25 MG</b>	T4	PA
<b>HALDOL DECANOATE</b>	T4	
<i>haloperidol</i>	T1	
<i>haloperidol decanoate</i>	T2	
<i>haloperidol lactate injection</i>	T1	
<i>haloperidol lactate oral</i>	T2	
<b>HETLIOZ</b>	T5	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>HETLIOZ LQ</b>	T5	PA; QL (158 ML per 31 days)
<b>HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG</b>	T4	PA; QL (90 EA per 30 days)
<b>HORIZANT ORAL TABLET EXTENDED RELEASE 600 MG</b>	T4	PA; QL (60 EA per 30 days)
<i>hydrocodone bitartrate oral capsule, oral only, er 12hr</i>	T4	PA; QL (100 EA per 31 days)
<i>hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 100 mg, 120 mg</i>	T5	PA; QL (31 EA per 31 days)
<i>hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</i>	T4	PA; QL (31 EA per 31 days)
<i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i>	T2	PA; QL (5723 ML per 31 days)
<i>hydrocodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg</i>	T2	PA; QL (403 EA per 31 days)
<i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i>	T2	PA; QL (372 EA per 31 days)
<i>hydrocodone-ibuprofen</i>	T2	PA; QL (155 EA per 31 days)
<i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i>	T2	PA; QL (124 ML per 31 days)
<i>hydromorphone oral liquid</i>	T2	PA; QL (1550 ML per 31 days)
<i>hydromorphone oral tablet</i>	T2	PA; QL (186 EA per 31 days)
<i>hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 8 mg</i>	T2	PA; QL (62 EA per 31 days)
<i>hydromorphone oral tablet extended release 24 hr 32 mg</i>	T2	PA; QL (48 EA per 31 days)
<b>HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 100 MG, 120 MG, 60 MG, 80 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>HYSINGLA ER ORAL TABLET,ORAL ONLY,EXT.REL.24 HR 20 MG, 30 MG, 40 MG</b>	T4	PA; QL (31 EA per 31 days)
<b>IBU ORAL TABLET 600 MG, 800 MG</b>	T1	
<i>ibuprofen oral suspension</i>	T1	
<i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i>	T1	
<i>ibuprofen-famotidine</i>	T4	PA; QL (93 EA per 31 days)
<i>imipramine hcl</i>	T2	PA-NS
<i>imipramine pamoate</i>	T2	PA-NS
<b>IMITREX NASAL SPRAY,NON-AEROSOL 20 MG/ACTUATION</b>	T4	QL (8 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>IMITREX NASAL SPRAY, NON-AEROSOL 5 MG/ACTUATION</b>	T4	QL (32 EA per 28 days)
<b>IMITREX ORAL TABLET 100 MG</b>	T4	QL (9 EA per 28 days)
<b>IMITREX ORAL TABLET 25 MG</b>	T4	QL (36 EA per 28 days)
<b>IMITREX ORAL TABLET 50 MG</b>	T4	QL (18 EA per 28 days)
<b>IMITREX STATDOSE PEN SUBCUTANEOUS PEN INJECTOR 4 MG/0.5 ML</b>	T4	QL (6 ML per 28 days)
<b>IMITREX STATDOSE REFILL SUBCUTANEOUS CARTRIDGE 6 MG/0.5 ML</b>	T5	QL (4 ML per 28 days)
<b>INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE</b>	T5	PA; QL (300 EA per 30 days)
<b>INDOCIN</b>	T4	
<i>indomethacin oral</i>	T1	
<i>indomethacin rectal suppository 50 mg</i>	T5	
<b>INGREZZA INITIATION PACK</b>	T5	PA; QL (56 EA per 365 days)
<b>INGREZZA ORAL CAPSULE 40 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>INGREZZA ORAL CAPSULE 60 MG, 80 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>INTUNIV ER</b>	T4	PA
<b>INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML</b>	T5	QL (3.5 ML per 180 days)
<b>INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML</b>	T5	QL (5 ML per 180 days)
<b>INVEGA ORAL TABLET EXTENDED RELEASE 24HR 3 MG</b>	T4	QL (31 EA per 31 days)
<b>INVEGA ORAL TABLET EXTENDED RELEASE 24HR 6 MG</b>	T4	QL (62 EA per 31 days)
<b>INVEGA ORAL TABLET EXTENDED RELEASE 24HR 9 MG</b>	T5	QL (31 EA per 31 days)
<b>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML</b>	T5	QL (0.75 ML per 28 days)
<b>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML</b>	T5	QL (1 ML per 28 days)
<b>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML</b>	T5	QL (1.5 ML per 28 days)
<b>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML</b>	T4	QL (0.25 ML per 28 days)
<b>INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML</b>	T5	QL (0.5 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML</b>	T5	QL (0.88 ML per 84 days)
<b>INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML</b>	T5	QL (1.32 ML per 84 days)
<b>INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML</b>	T5	QL (1.75 ML per 84 days)
<b>INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML</b>	T5	QL (2.63 ML per 84 days)
<b>JORNAY PM</b>	T4	ST; QL (31 EA per 31 days)
<b>KAPVAY</b>	T4	PA
<b>KEPPRA ORAL SOLUTION</b>	T5	
<b>KEPPRA ORAL TABLET 1,000 MG</b>	T5	
<b>KEPPRA ORAL TABLET 250 MG, 500 MG, 750 MG</b>	T4	
<b>KEPPRA XR</b>	T4	
<b>KESIMPTA PEN</b>	T5	PA; QL (0.4 ML per 28 days)
<i>ketoprofen oral capsule 25 mg, 50 mg</i>	T2	
<i>ketoprofen oral capsule, ext rel. pellets 24 hr 200 mg</i>	T2	
<i>ketorolac nasal</i>	T5	QL (5 EA per 31 days)
<i>ketorolac oral</i>	T2	
<b>KEVEYIS</b>	T5	PA; QL (124 EA per 31 days)
<b>KLONOPIN ORAL TABLET 0.5 MG</b>	T4	QL (93 EA per 31 days)
<b>KLONOPIN ORAL TABLET 1 MG</b>	T4	QL (124 EA per 31 days)
<b>KLONOPIN ORAL TABLET 2 MG</b>	T4	QL (310 EA per 31 days)
<b>KLOXXADO</b>	T3	
<i>lacosamide oral</i>	T4	
<b>LAMICTAL ODT</b>	T4	
<b>LAMICTAL ORAL TABLET 100 MG, 150 MG</b>	T5	
<b>LAMICTAL ORAL TABLET 200 MG, 25 MG</b>	T4	
<b>LAMICTAL ORAL TABLET, CHEWABLE DISPERSIBLE 25 MG, 5 MG</b>	T4	
<b>LAMICTAL STARTER (BLUE) KIT</b>	T4	
<b>LAMICTAL STARTER (GREEN) KIT</b>	T4	
<b>LAMICTAL STARTER (ORANGE) KIT</b>	T4	
<b>LAMICTAL XR</b>	T4	
<b>LAMICTAL XR STARTER (BLUE)</b>	T4	
<b>LAMICTAL XR STARTER (GREEN)</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LAMICTAL XR STARTER (ORANGE)</b>	T4	
<i>lamotrigine oral tablet</i>	T2	
<i>lamotrigine oral tablet disintegrating, dose pk 25 mg (21) -50 mg (7), 50 mg (42) -100 mg (14)</i>	T4	
<i>lamotrigine oral tablet disintegrating, dose pk 25 mg(14)-50 mg (14)-100 mg (7)</i>	T2	
<i>lamotrigine oral tablet extended release 24hr</i>	T2	
<i>lamotrigine oral tablet, chewable dispersible</i>	T2	
<i>lamotrigine oral tablet,disintegrating</i>	T2	
<i>lamotrigine oral tablets,dose pack 25 mg (35), 25 mg (42) -100 mg (7)</i>	T2	
<i>lamotrigine oral tablets,dose pack 25 mg (84) - 100 mg (14)</i>	T4	
<b>LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>LATUDA ORAL TABLET 80 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<i>levetiracetam oral solution 100 mg/ml</i>	T2	
<i>levetiracetam oral tablet</i>	T2	
<i>levetiracetam oral tablet extended release 24 hr</i>	T2	
<i>levorphanol tartrate</i>	T5	PA; QL (186 EA per 31 days)
<b>LEXAPRO ORAL TABLET 10 MG</b>	T4	QL (45 EA per 30 days)
<b>LEXAPRO ORAL TABLET 20 MG, 5 MG</b>	T4	QL (30 EA per 30 days)
<b>LICART</b>	T4	PA; QL (31 EA per 31 days)
<i>lisdexamfetamine oral capsule</i>	T4	ST; QL (31 EA per 31 days)
<i>lithium carbonate</i>	T1	
<i>lithium citrate oral solution 8 meq/5 ml</i>	T1	
<b>LITHOBID</b>	T4	
<b>LODINE ORAL TABLET</b>	T4	
<b>LODOSYN</b>	T4	
<b>LOFENA</b>	T5	
<b>LORAZEPAM INTENSOL</b>	T2	QL (155 ML per 31 days)
<i>lorazepam oral tablet 0.5 mg</i>	T2	QL (124 EA per 31 days)
<i>lorazepam oral tablet 1 mg</i>	T2	QL (186 EA per 31 days)
<i>lorazepam oral tablet 2 mg</i>	T2	QL (155 EA per 31 days)
<b>LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1 MG, 3 MG</b>	T4	QL (93 EA per 31 days)
<b>LOREEV XR ORAL CAPSULE,EXTENDED RELEASE 24HR 1.5 MG, 2 MG</b>	T4	QL (155 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LORZONE</b>	T4	PA
<i>loxapine succinate</i>	T2	
<b>LUCEMYRA</b>	T5	
<b>LUMRYZ</b>	T5	PA; QL (31 EA per 31 days)
<b>LUNESTA</b>	T4	PA; QL (31 EA per 31 days)
<i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i>	T5	PA-NS; QL (31 EA per 31 days)
<i>lurasidone oral tablet 80 mg</i>	T5	PA-NS; QL (62 EA per 31 days)
<b>LYBALVI</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>LYRICA CR</b>	T4	PA; QL (31 EA per 31 days)
<b>LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG</b>	T4	PA-NS; QL (93 EA per 31 days)
<b>LYRICA ORAL CAPSULE 225 MG, 300 MG</b>	T4	PA-NS; QL (62 EA per 31 days)
<b>LYRICA ORAL SOLUTION</b>	T4	PA-NS; QL (930 ML per 31 days)
<b>LYVISPAH</b>	T4	PA; QL (124 EA per 31 days)
<b>MARPLAN</b>	T3	
<b>MAVENCLAD (10 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (4 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (5 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (6 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (7 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (8 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAVENCLAD (9 TABLET PACK)</b>	T5	PA; QL (40 EA per 365 days)
<b>MAXALT ORAL TABLET 10 MG</b>	T4	QL (12 EA per 28 days)
<b>MAXALT-MLT ORAL TABLET,DISINTEGRATING 10 MG</b>	T4	QL (12 EA per 28 days)
<b>MAYZENT ORAL TABLET 0.25 MG</b>	T5	PA; QL (155 EA per 31 days)
<b>MAYZENT ORAL TABLET 1 MG, 2 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>MAYZENT STARTER(FOR 1MG MAINT)</b>	T4	PA; QL (14 EA per 365 days)
<b>MAYZENT STARTER(FOR 2MG MAINT)</b>	T5	PA; QL (24 EA per 365 days)
<i>meclofenamate</i>	T2	
<i>mefenamic acid</i>	T4	
<i>meloxicam oral tablet</i>	T1	
<i>meloxicam submicronized</i>	T4	PA; QL (31 EA per 31 days)
<i>memantine oral capsule,sprinkle,er 24hr</i>	T3	
<i>memantine oral solution</i>	T3	
<i>memantine oral tablet</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>memantine oral tablets,dose pack</i>	T4	
<i>meperidine (pf) injection solution 100 mg/ml</i>	T2	PA; QL (200 ML per 31 days)
<i>meperidine (pf) injection solution 25 mg/ml</i>	T2	PA; QL (800 ML per 31 days)
<i>meperidine (pf) injection solution 50 mg/ml</i>	T2	PA; QL (400 ML per 31 days)
<i>meperidine oral solution</i>	T2	PA; QL (6200 ML per 31 days)
<i>meperidine oral tablet 50 mg</i>	T2	PA; QL (1240 EA per 31 days)
<i>meprobamate oral tablet 200 mg</i>	T2	QL (341 EA per 31 days)
<i>meprobamate oral tablet 400 mg</i>	T2	QL (186 EA per 31 days)
<b>MESTINON ORAL SYRUP</b>	T4	
<b>MESTINON ORAL TABLET</b>	T5	
<b>MESTINON TIMESPAN</b>	T5	
<i>metaxalone</i>	T2	PA
<i>methadone oral solution 10 mg/5 ml</i>	T2	PA; QL (1033 ML per 31 days)
<i>methadone oral solution 5 mg/5 ml</i>	T2	PA; QL (2066 ML per 31 days)
<i>methadone oral tablet 10 mg</i>	T2	PA; QL (206 EA per 31 days)
<i>methadone oral tablet 5 mg</i>	T2	PA; QL (248 EA per 31 days)
<i>methamphetamine</i>	T5	PA
<i>methocarbamol oral tablet 1,000 mg</i>	T5	
<i>methocarbamol oral tablet 500 mg, 750 mg</i>	T2	
<i>methsuximide</i>	T4	
<b>METHYLIN ORAL SOLUTION</b>	T4	ST
<i>methylphenidate hcl oral cap,er sprinkle,biphasic 40-60</i>	T4	QL (31 EA per 31 days)
<i>methylphenidate hcl oral capsule, er biphasic 30-70</i>	T2	QL (31 EA per 31 days)
<i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg</i>	T2	QL (186 EA per 31 days)
<i>methylphenidate hcl oral capsule,er biphasic 50-50 20 mg</i>	T2	QL (93 EA per 31 days)
<i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg, 40 mg</i>	T2	QL (62 EA per 31 days)
<i>methylphenidate hcl oral capsule,er biphasic 50-50 60 mg</i>	T2	QL (31 EA per 31 days)
<i>methylphenidate hcl oral solution</i>	T2	
<i>methylphenidate hcl oral tablet</i>	T2	QL (93 EA per 31 days)
<i>methylphenidate hcl oral tablet extended release 10 mg</i>	T2	QL (186 EA per 31 days)
<i>methylphenidate hcl oral tablet extended release 20 mg</i>	T2	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating), 36 mg, 36 mg (bx rating), 54 mg, 54 mg (bx rating)</i>	T2	QL (31 EA per 31 days)
<i>methylphenidate hcl oral tablet extended release 24hr 45 mg, 63 mg, 72 mg</i>	T4	ST; QL (31 EA per 31 days)
<i>methylphenidate hcl oral tablet, chewable 10 mg</i>	T2	QL (186 EA per 31 days)
<i>methylphenidate hcl oral tablet, chewable 2.5 mg, 5 mg</i>	T2	QL (93 EA per 31 days)
<b>MIGERGOT</b>	T5	
<b>MIGRANAL</b>	T4	PA; QL (8 ML per 31 days)
<b>MIRAPEX ER</b>	T4	
<i>mirtazapine</i>	T2	
<i>modafinil</i>	T2	PA; QL (31 EA per 31 days)
<i>molindone</i>	T4	
<i>morphine concentrate oral solution</i>	T2	PA; QL (310 ML per 31 days)
<i>morphine oral capsule, er multiphase 24 hr 120 mg</i>	T2	PA; QL (51 EA per 31 days)
<i>morphine oral capsule, er multiphase 24 hr 30 mg, 45 mg, 60 mg, 75 mg, 90 mg</i>	T2	PA; QL (62 EA per 31 days)
<i>morphine oral capsule, extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg</i>	T2	PA; QL (62 EA per 31 days)
<i>morphine oral solution 10 mg/5 ml</i>	T2	PA; QL (2800 ML per 31 days)
<i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i>	T2	PA; QL (1400 ML per 31 days)
<i>morphine oral tablet</i>	T2	PA; QL (186 EA per 31 days)
<i>morphine oral tablet extended release 100 mg</i>	T2	PA; QL (62 EA per 31 days)
<i>morphine oral tablet extended release 15 mg, 30 mg, 60 mg</i>	T2	PA; QL (100 EA per 31 days)
<i>morphine oral tablet extended release 200 mg</i>	T2	PA; QL (31 EA per 31 days)
<b>MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG</b>	T4	PA; QL (100 EA per 31 days)
<b>MS CONTIN ORAL TABLET EXTENDED RELEASE 200 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>MS CONTIN ORAL TABLET EXTENDED RELEASE 60 MG</b>	T5	PA; QL (100 EA per 31 days)
<b>MYDAYIS</b>	T4	ST; QL (31 EA per 31 days)
<b>MYSOLINE</b>	T5	
<i>nabumetone</i>	T1	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>NALFON ORAL CAPSULE 400 MG</b>	T4	
<b>NALFON ORAL TABLET</b>	T4	
<b>NALOCET</b>	T4	PA; QL (403 EA per 31 days)
<i>naloxone injection solution</i>	T2	
<i>naloxone injection syringe</i>	T2	
<i>naloxone nasal</i>	T3	
<i>naltrexone</i>	T2	
<b>NAMENDA ORAL TABLET</b>	T4	PA
<b>NAMENDA TITRATION PAK</b>	T4	PA
<b>NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG, 21 MG, 28 MG</b>	T4	PA
<b>NAMZARIC</b>	T4	PA
<b>NAPRELAN CR</b>	T4	
<i>naproxen oral suspension</i>	T1	
<i>naproxen oral tablet</i>	T1	
<i>naproxen oral tablet, delayed release (dr/ec)</i>	T2	
<i>naproxen sodium oral tablet 275 mg, 550 mg</i>	T1	
<i>naproxen sodium oral tablet, er multiphase 24 hr 375 mg, 750 mg</i>	T4	
<i>naproxen sodium oral tablet, er multiphase 24 hr 500 mg</i>	T5	
<i>naproxen-esomeprazole</i>	T5	PA; QL (62 EA per 31 days)
<i>naratriptan oral tablet 1 mg</i>	T2	QL (20 EA per 28 days)
<i>naratriptan oral tablet 2.5 mg</i>	T2	QL (9 EA per 28 days)
<b>NARCAN</b>	T3	
<b>NARDIL</b>	T4	
<b>NAYZILAM</b>	T4	PA-NS; QL (10 EA per 30 days)
<i>nefazodone</i>	T2	
<b>NEUPRO</b>	T4	
<b>NEURONTIN ORAL CAPSULE 100 MG, 400 MG</b>	T4	PA-NS; QL (270 EA per 30 days)
<b>NEURONTIN ORAL CAPSULE 300 MG</b>	T4	PA-NS; QL (360 EA per 30 days)
<b>NEURONTIN ORAL SOLUTION</b>	T4	PA-NS; QL (2160 ML per 30 days)
<b>NEURONTIN ORAL TABLET 600 MG</b>	T5	PA-NS; QL (180 EA per 30 days)
<b>NEURONTIN ORAL TABLET 800 MG</b>	T4	PA-NS; QL (120 EA per 30 days)
<b>NORGESIC</b>	T4	PA; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>NORGESIC FORTE</b>	T4	PA; QL (124 EA per 31 days)
<b>NORPRAMIN ORAL TABLET 10 MG, 25 MG</b>	T4	
<i>nortriptyline</i>	T2	
<b>NOURIANZ</b>	T5	PA; QL (31 EA per 31 days)
<b>NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 100 MG, 200 MG, 250 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>NUCYNTA ER ORAL TABLET EXTENDED RELEASE 12 HR 150 MG, 50 MG</b>	T4	PA; QL (62 EA per 31 days)
<b>NUCYNTA ORAL TABLET 100 MG</b>	T5	PA; QL (186 EA per 31 days)
<b>NUCYNTA ORAL TABLET 50 MG, 75 MG</b>	T4	PA; QL (186 EA per 31 days)
<b>NUEDEXTA</b>	T3	PA; QL (62 EA per 31 days)
<b>NUPLAZID</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>NURTEC ODT</b>	T5	PA; QL (18 EA per 28 days)
<b>NUVIGIL ORAL TABLET 150 MG, 200 MG, 250 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>NUVIGIL ORAL TABLET 50 MG</b>	T4	PA; QL (31 EA per 31 days)
<i>olanzapine intramuscular</i>	T2	
<i>olanzapine oral</i>	T2	QL (31 EA per 31 days)
<i>olanzapine-fluoxetine</i>	T2	
<b>ONFI ORAL SUSPENSION</b>	T4	PA-NS; QL (496 ML per 31 days)
<b>ONFI ORAL TABLET</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>ONGENTYS</b>	T4	PA; QL (31 EA per 31 days)
<b>ONZETRA XSAIL</b>	T5	QL (16 EA per 28 days)
<i>orphenadrine citrate oral</i>	T2	PA
<i>orphenadrine-asa-caffeine oral tablet 25-385-30 mg</i>	T4	PA; QL (124 EA per 31 days)
<b>OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 193 MG</b>	T4	PA; QL (31 EA per 31 days)
<i>oxaprozin</i>	T2	
<i>oxazepam</i>	T2	
<i>oxcarbazepine</i>	T2	
<b>OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG</b>	T4	
<b>OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 600 MG</b>	T5	
<i>oxycodone oral capsule</i>	T2	PA; QL (186 EA per 31 days)
<i>oxycodone oral concentrate</i>	T2	PA; QL (180 ML per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>oxycodone oral solution</i>	T2	PA; QL (4133 ML per 31 days)
<i>oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i>	T2	PA; QL (186 EA per 31 days)
<i>oxycodone oral tablet 30 mg</i>	T3	PA; QL (138 EA per 31 days)
<i>oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg</i>	T4	PA; QL (100 EA per 31 days)
<i>oxycodone-acetaminophen oral solution 5-325 mg/5 ml</i>	T4	PA; QL (1907 ML per 31 days)
<i>oxycodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg</i>	T4	PA; QL (403 EA per 31 days)
<i>oxycodone-acetaminophen oral tablet 10-325 mg</i>	T3	PA; QL (372 EA per 31 days)
<i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg, 7.5-325 mg</i>	T2	PA; QL (372 EA per 31 days)
<b>OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG</b>	T4	PA; QL (100 EA per 31 days)
<b>OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 40 MG</b>	T5	PA; QL (100 EA per 31 days)
<b>OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 60 MG</b>	T5	PA; QL (69 EA per 31 days)
<b>OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 80 MG</b>	T5	PA; QL (62 EA per 31 days)
<i>oxymorphone oral tablet</i>	T2	PA; QL (186 EA per 31 days)
<i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i>	T2	PA; QL (100 EA per 31 days)
<i>oxymorphone oral tablet extended release 12 hr 30 mg</i>	T2	PA; QL (69 EA per 31 days)
<i>oxymorphone oral tablet extended release 12 hr 40 mg</i>	T5	PA; QL (51 EA per 31 days)
<i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i>	T4	QL (31 EA per 31 days)
<i>paliperidone oral tablet extended release 24hr 6 mg</i>	T4	QL (62 EA per 31 days)
<b>PAMELOR</b>	T4	
<b>PARLODEL</b>	T4	
<b>PARNATE</b>	T4	
<i>paroxetine hcl oral suspension</i>	T4	
<i>paroxetine hcl oral tablet</i>	T1	
<i>paroxetine hcl oral tablet extended release 24 hr</i>	T2	
<i>paroxetine mesylate(menop.sym)</i>	T4	
<b>PAXIL</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>PAXIL CR</b>	T4	
<b>PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP</b>	T5	QL (224 GM per 28 days)
<i>pentazocine-naloxone</i>	T2	QL (335 EA per 31 days)
<b>PERCOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG</b>	T5	PA; QL (372 EA per 31 days)
<b>PERCOCET ORAL TABLET 2.5-325 MG</b>	T4	PA; QL (372 EA per 31 days)
<i>perphenazine</i>	T2	
<i>perphenazine-amitriptyline</i>	T2	PA-NS
<b>PERSERIS</b>	T5	QL (1 EA per 28 days)
<i>phenelzine</i>	T2	
<i>phenobarbital</i>	T2	PA-NS
<b>PHENYTEK</b>	T4	
<i>phenytoin oral suspension 125 mg/5 ml</i>	T2	
<i>phenytoin oral tablet, chewable</i>	T2	
<i>phenytoin sodium extended</i>	T2	
<i>pimozide</i>	T2	
<i>piroxicam</i>	T2	
<b>PONVORY</b>	T5	PA; QL (31 EA per 31 days)
<b>PONVORY 14-DAY STARTER PACK</b>	T5	PA; QL (28 EA per 365 days)
<i>pramipexole</i>	T2	
<i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i>	T2	PA-NS; QL (93 EA per 31 days)
<i>pregabalin oral capsule 225 mg, 300 mg</i>	T2	PA-NS; QL (62 EA per 31 days)
<i>pregabalin oral solution</i>	T2	PA-NS; QL (930 ML per 31 days)
<i>pregabalin oral tablet extended release 24 hr</i>	T4	PA; QL (31 EA per 31 days)
<i>primidone oral tablet 125 mg</i>	T4	
<i>primidone oral tablet 250 mg, 50 mg</i>	T2	
<b>PRISTIQ</b>	T4	QL (31 EA per 31 days)
<b>PROCENTRA</b>	T3	
<b>PROLATE ORAL SOLUTION</b>	T4	PA; QL (5167 ML per 31 days)
<b>PROLATE ORAL TABLET</b>	T4	PA; QL (403 EA per 31 days)
<i>protriptyline</i>	T2	
<b>PROVIGIL</b>	T5	PA; QL (31 EA per 31 days)
<b>PROZAC ORAL CAPSULE</b>	T4	
<i>pyridostigmine bromide oral syrup</i>	T2	
<i>pyridostigmine bromide oral tablet 30 mg</i>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>pyridostigmine bromide oral tablet 60 mg</i>	T2	
<i>pyridostigmine bromide oral tablet extended release</i>	T2	
<b>QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 200 MG</b>	T4	PA; QL (93 EA per 31 days)
<b>QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG</b>	T4	PA; QL (62 EA per 31 days)
<b>QUDEXY XR ORAL CAPSULE,SPRINKLE,ER 24HR 100 MG, 150 MG, 25 MG, 50 MG</b>	T4	
<b>QUDEXY XR ORAL CAPSULE,SPRINKLE,ER 24HR 200 MG</b>	T5	
<i>quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg</i>	T2	QL (62 EA per 31 days)
<i>quetiapine oral tablet 150 mg</i>	T3	QL (62 EA per 31 days)
<i>quetiapine oral tablet 25 mg</i>	T1	QL (62 EA per 31 days)
<i>quetiapine oral tablet extended release 24 hr</i>	T3	QL (62 EA per 31 days)
<b>QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 20 MG, 40 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 30 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>QUILLIVANT XR</b>	T4	ST; QL (360 ML per 30 days)
<b>QULIPTA</b>	T5	PA; QL (31 EA per 31 days)
<b>QUVIVIQ</b>	T4	ST; QL (31 EA per 31 days)
<b>RADICAVA ORS STARTER KIT SUSP</b>	T5	PA; QL (70 ML per 28 days)
<i>ramelteon</i>	T4	QL (31 EA per 31 days)
<i>rasagiline</i>	T3	
<b>RELAFEN DS</b>	T5	
<b>RELEXXII ORAL TABLET EXTENDED RELEASE 24HR 45 MG, 63 MG, 72 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>RELPAX ORAL TABLET 20 MG</b>	T4	QL (12 EA per 28 days)
<b>RELPAX ORAL TABLET 40 MG</b>	T4	QL (6 EA per 28 days)
<b>RELYVRIO</b>	T5	PA; QL (62 EA per 31 days)
<b>REMERON ORAL TABLET 15 MG, 30 MG</b>	T4	
<b>REMERON SOLTAB</b>	T4	
<b>RESTORIL ORAL CAPSULE 15 MG, 22.5 MG, 7.5 MG</b>	T4	QL (31 EA per 31 days)
<b>RESTORIL ORAL CAPSULE 30 MG</b>	T5	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>REXULTI ORAL TABLET</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>REYVOW ORAL TABLET 100 MG</b>	T4	QL (8 EA per 28 days)
<b>REYVOW ORAL TABLET 50 MG</b>	T4	QL (4 EA per 28 days)
<b>RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML</b>	T4	QL (2 EA per 28 days)
<b>RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 37.5 MG/2 ML, 50 MG/2 ML</b>	T5	QL (2 EA per 28 days)
<b>RISPERDAL ORAL SOLUTION</b>	T4	QL (496 ML per 31 days)
<b>RISPERDAL ORAL TABLET 0.5 MG, 1 MG, 2 MG</b>	T4	QL (31 EA per 31 days)
<b>RISPERDAL ORAL TABLET 3 MG</b>	T4	QL (93 EA per 31 days)
<b>RISPERDAL ORAL TABLET 4 MG</b>	T4	QL (124 EA per 31 days)
<i>risperidone oral solution</i>	T1	QL (496 ML per 31 days)
<i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i>	T1	QL (31 EA per 31 days)
<i>risperidone oral tablet 3 mg</i>	T1	QL (93 EA per 31 days)
<i>risperidone oral tablet 4 mg</i>	T1	QL (124 EA per 31 days)
<i>risperidone oral tablet,disintegrating 0.25 mg</i>	T2	QL (31 EA per 31 days)
<i>risperidone oral tablet,disintegrating 0.5 mg, 1 mg, 2 mg</i>	T1	QL (31 EA per 31 days)
<i>risperidone oral tablet,disintegrating 3 mg</i>	T1	QL (93 EA per 31 days)
<i>risperidone oral tablet,disintegrating 4 mg</i>	T1	QL (124 EA per 31 days)
<b>RITALIN</b>	T4	ST; QL (93 EA per 31 days)
<b>RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 10 MG</b>	T4	ST; QL (186 EA per 31 days)
<b>RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 20 MG, 40 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 30 MG</b>	T4	ST; QL (62 EA per 31 days)
<i>rivastigmine</i>	T2	QL (30 EA per 30 days)
<i>rivastigmine tartrate</i>	T2	
<i>rizatriptan oral tablet 10 mg</i>	T2	QL (12 EA per 28 days)
<i>rizatriptan oral tablet 5 mg</i>	T2	QL (24 EA per 28 days)
<i>rizatriptan oral tablet,disintegrating 10 mg</i>	T2	QL (12 EA per 28 days)
<i>rizatriptan oral tablet,disintegrating 5 mg</i>	T2	QL (24 EA per 28 days)
<i>ropinirole</i>	T2	
<b>ROWEEPRA ORAL TABLET 500 MG</b>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ROXICODONE ORAL TABLET 15 MG</b>	T4	PA; QL (186 EA per 31 days)
<b>ROXICODONE ORAL TABLET 30 MG</b>	T4	PA; QL (138 EA per 31 days)
<b>ROXYBOND</b>	T5	PA; QL (186 EA per 31 days)
<b>ROZEREM</b>	T4	QL (31 EA per 31 days)
<i>rufinamide oral suspension</i>	T5	PA-NS
<i>rufinamide oral tablet 200 mg</i>	T4	PA-NS
<i>rufinamide oral tablet 400 mg</i>	T5	PA-NS
<b>RYTARY</b>	T3	ST
<b>SABRIL</b>	T5	PA-NS
<b>SAPHRIS</b>	T4	QL (62 EA per 31 days)
<b>SECUADO</b>	T5	QL (31 EA per 31 days)
<b>SEGLENTIS</b>	T4	PA; QL (124 EA per 31 days)
<i>selegiline hcl</i>	T2	
<b>SEROQUEL</b>	T4	QL (62 EA per 31 days)
<b>SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR</b>	T4	QL (62 EA per 31 days)
<i>sertraline oral capsule</i>	T4	PA-NS; QL (31 EA per 31 days)
<i>sertraline oral concentrate</i>	T1	
<i>sertraline oral tablet</i>	T1	
<b>SILENOR</b>	T4	PA
<b>SINEMET ORAL TABLET 10-100 MG, 25-100 MG</b>	T4	
<b>SKYCLARYS</b>	T5	PA; QL (93 EA per 31 days)
<i>sodium oxybate</i>	T5	PA; QL (540 ML per 30 days)
<b>SOMA ORAL TABLET 250 MG</b>	T4	PA
<b>SOMA ORAL TABLET 350 MG</b>	T5	PA
<b>SPRITAM</b>	T4	
<b>SPRIX</b>	T5	QL (5 EA per 31 days)
<b>STALEVO 100</b>	T4	
<b>STALEVO 125</b>	T4	
<b>STALEVO 150</b>	T4	
<b>STALEVO 200</b>	T4	
<b>STALEVO 50</b>	T4	
<b>STALEVO 75</b>	T4	
<b>STRATTERA ORAL CAPSULE 10 MG, 25 MG, 40 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>STRATTERA ORAL CAPSULE 100 MG, 60 MG, 80 MG</b>	T4	ST; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>STRATTERA ORAL CAPSULE 18 MG</b>	T4	ST; QL (124 EA per 31 days)
<b>SUBOXONE SUBLINGUAL FILM 12-3 MG, 4-1 MG, 8-2 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>SUBOXONE SUBLINGUAL FILM 2-0.5 MG</b>	T4	ST; QL (93 EA per 31 days)
<b>SUBVENITE</b>	T2	
<b>SUBVENITE STARTER (BLUE) KIT</b>	T4	
<b>SUBVENITE STARTER (GREEN) KIT</b>	T4	
<b>SUBVENITE STARTER (ORANGE) KIT</b>	T4	
<i>sulindac</i>	T2	
<i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i>	T2	QL (8 EA per 28 days)
<i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i>	T2	QL (32 EA per 28 days)
<i>sumatriptan succinate oral tablet 100 mg</i>	T2	QL (9 EA per 28 days)
<i>sumatriptan succinate oral tablet 25 mg</i>	T2	QL (36 EA per 28 days)
<i>sumatriptan succinate oral tablet 50 mg</i>	T2	QL (18 EA per 28 days)
<i>sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml</i>	T2	QL (6 ML per 28 days)
<i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i>	T2	QL (4 ML per 28 days)
<i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i>	T2	QL (6 ML per 28 days)
<i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i>	T2	QL (4 ML per 28 days)
<i>sumatriptan succinate subcutaneous solution</i>	T2	QL (4 ML per 28 days)
<i>sumatriptan-naproxen</i>	T4	QL (9 EA per 28 days)
<b>SUNOSI</b>	T4	PA; QL (31 EA per 31 days)
<b>SYMBYAX ORAL CAPSULE 3-25 MG, 6-25 MG</b>	T4	
<b>SYMPAZAN ORAL FILM 10 MG, 20 MG</b>	T5	PA-NS; QL (62 EA per 31 days)
<b>SYMPAZAN ORAL FILM 5 MG</b>	T4	PA-NS; QL (62 EA per 31 days)
<b>TASCENSO ODT</b>	T5	PA; QL (31 EA per 31 days)
<i>tasimelteon</i>	T5	PA; QL (31 EA per 31 days)
<b>TASMAR ORAL TABLET 100 MG</b>	T5	
<b>TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46)</b>	T5	PA; QL (120 EA per 365 days)
<b>TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 240 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>TEGRETOL ORAL SUSPENSION</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TEGRETOL ORAL TABLET</b>	T4	
<b>TEGRETOL XR</b>	T4	
<b>TEGSEDI</b>	T5	PA; QL (6 ML per 28 days)
<i>temazepam</i>	T2	QL (31 EA per 31 days)
<b>TENCON</b>	T2	QL (372 EA per 31 days)
<i>teriflunomide</i>	T5	PA; QL (31 EA per 31 days)
<i>tetrabenazine oral tablet 12.5 mg</i>	T5	PA; QL (93 EA per 31 days)
<i>tetrabenazine oral tablet 25 mg</i>	T5	PA; QL (124 EA per 31 days)
<i>thioridazine</i>	T2	
<i>thiothixene</i>	T1	
<i>tiagabine</i>	T2	
<i>tizanidine</i>	T2	
<i>tolcapone</i>	T5	
<b>TOPAMAX</b>	T4	
<i>topiramate oral capsule, sprinkle</i>	T2	
<i>topiramate oral capsule, extended release 24hr</i>	T4	
<i>topiramate oral capsule, sprinkle, er 24hr</i>	T4	
<i>topiramate oral tablet</i>	T2	
<b>TOSYMRA</b>	T4	QL (12 EA per 28 days)
<i>tramadol oral capsule, er biphasic 24 hr 17-83</i>	T4	PA; QL (30 EA per 30 days)
<i>tramadol oral capsule, er biphasic 24 hr 25-75 100 mg, 200 mg</i>	T4	PA; QL (30 EA per 30 days)
<i>tramadol oral solution</i>	T4	PA; QL (2480 ML per 31 days)
<i>tramadol oral tablet 100 mg</i>	T4	PA; QL (124 EA per 31 days)
<i>tramadol oral tablet 50 mg</i>	T1	PA; QL (240 EA per 30 days)
<i>tramadol oral tablet extended release 24 hr</i>	T2	PA; QL (30 EA per 30 days)
<i>tramadol oral tablet, er multiphasic 24 hr</i>	T2	PA; QL (30 EA per 30 days)
<i>tramadol-acetaminophen</i>	T2	PA; QL (372 EA per 31 days)
<i>tranylcypramine</i>	T2	
<i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i>	T1	
<i>trazodone oral tablet 300 mg</i>	T2	
<b>TREXIMET</b>	T5	QL (9 EA per 28 days)
<b>TREZIX</b>	T4	PA; QL (372 EA per 31 days)
<i>triazolam</i>	T2	PA
<i>trifluoperazine</i>	T2	
<i>trihexyphenidyl</i>	T2	
<b>TRILEPTAL</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>trimipramine</i>	T3	PA-NS
<b>TRINTELLIX</b>	T3	
<b>TROKENDI XR</b>	T4	
<b>TRUDHESA</b>	T4	PA; QL (12 ML per 28 days)
<b>UBRELVY ORAL TABLET 100 MG</b>	T5	PA; QL (17 EA per 28 days)
<b>UBRELVY ORAL TABLET 50 MG</b>	T5	PA; QL (34 EA per 28 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML</b>	T5	QL (0.28 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML</b>	T5	QL (0.35 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML</b>	T5	QL (0.42 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML</b>	T5	QL (0.56 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML</b>	T5	QL (0.7 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML</b>	T5	QL (0.14 ML per 30 days)
<b>UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML</b>	T5	QL (0.21 ML per 30 days)
<b>VALIUM</b>	T4	QL (124 EA per 31 days)
<i>valproic acid</i>	T2	
<i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i>	T2	
<b>VALTOCO</b>	T4	PA-NS; QL (10 EA per 30 days)
<i>venlafaxine besylate</i>	T4	PA-NS; QL (62 EA per 31 days)
<i>venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg</i>	T2	QL (31 EA per 31 days)
<i>venlafaxine oral capsule,extended release 24hr 75 mg</i>	T2	QL (93 EA per 31 days)
<i>venlafaxine oral tablet</i>	T2	
<i>venlafaxine oral tablet extended release 24hr 150 mg, 37.5 mg, 75 mg</i>	T2	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>venlafaxine oral tablet extended release 24hr 225 mg</i>	T4	QL (31 EA per 31 days)
<b>VERSACLOZ</b>	T4	QL (558 ML per 31 days)
<i>vigabatrin</i>	T5	PA-NS
<b>VIGADRONE</b>	T5	PA-NS
<b>VIIBRYD ORAL TABLET</b>	T4	QL (31 EA per 31 days)
<b>VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23)</b>	T3	QL (60 EA per 365 days)
<i>vilazodone</i>	T3	QL (31 EA per 31 days)
<b>VIMOVO</b>	T5	PA; QL (62 EA per 31 days)
<b>VIMPAT ORAL SOLUTION</b>	T4	
<b>VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG</b>	T5	
<b>VIMPAT ORAL TABLET 50 MG</b>	T4	
<b>VIVITROL</b>	T5	
<b>VRAYLAR ORAL CAPSULE</b>	T5	PA-NS; QL (31 EA per 31 days)
<b>VRAYLAR ORAL CAPSULE,DOSE PACK</b>	T4	PA-NS; QL (14 EA per 365 days)
<b>VUMERITY</b>	T5	PA; QL (124 EA per 31 days)
<b>VYVANSE</b>	T4	ST; QL (31 EA per 31 days)
<b>WAKIX</b>	T5	PA; QL (62 EA per 31 days)
<b>WELLBUTRIN SR</b>	T4	QL (62 EA per 31 days)
<b>WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 150 MG</b>	T4	QL (93 EA per 31 days)
<b>WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 300 MG</b>	T4	QL (31 EA per 31 days)
<b>XANAX ORAL TABLET 0.25 MG, 0.5 MG</b>	T4	PA; QL (93 EA per 31 days)
<b>XANAX ORAL TABLET 1 MG, 2 MG</b>	T4	PA; QL (155 EA per 31 days)
<b>XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG</b>	T4	PA; QL (31 EA per 31 days)
<b>XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 2 MG</b>	T4	PA; QL (155 EA per 31 days)
<b>XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 3 MG</b>	T4	PA; QL (93 EA per 31 days)
<b>XCOPRI</b>	T5	PA-NS
<b>XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1)</b>	T5	PA-NS
<b>XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14)</b>	T4	PA-NS

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14)</b>	T5	PA-NS
<b>XELSTRYM</b>	T4	ST; QL (30 EA per 30 days)
<b>XENAZINE ORAL TABLET 12.5 MG</b>	T5	PA; QL (93 EA per 31 days)
<b>XENAZINE ORAL TABLET 25 MG</b>	T5	PA; QL (124 EA per 31 days)
<b>XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 27 MG, 9 MG</b>	T4	PA; QL (62 EA per 31 days)
<b>XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>XYREM</b>	T5	PA; QL (540 ML per 30 days)
<b>XYWAV</b>	T5	PA; QL (540 ML per 30 days)
<i>zaleplon oral capsule 10 mg</i>	T2	PA; QL (62 EA per 31 days)
<i>zaleplon oral capsule 5 mg</i>	T2	PA; QL (93 EA per 31 days)
<b>ZANAFLEX</b>	T4	
<b>ZARONTIN</b>	T4	
<b>ZAVZPRET</b>	T5	PA; QL (8 EA per 30 days)
<b>ZELAPAR</b>	T5	
<b>ZEMBRACE SYMTOUCH</b>	T5	QL (8 ML per 28 days)
<b>ZENZEDI</b>	T4	QL (62 EA per 31 days)
<b>ZEPOSIA</b>	T5	PA; QL (31 EA per 31 days)
<b>ZEPOSIA STARTER KIT (28-DAY)</b>	T5	PA; QL (56 EA per 365 days)
<b>ZEPOSIA STARTER PACK (7-DAY)</b>	T5	PA; QL (14 EA per 365 days)
<b>ZIMHI</b>	T4	
<i>ziprasidone hcl</i>	T2	QL (62 EA per 31 days)
<i>ziprasidone mesylate</i>	T2	
<b>ZIPSOR</b>	T5	
<i>zolmitriptan nasal spray,non-aerosol 5 mg</i>	T4	QL (8 EA per 28 days)
<i>zolmitriptan oral tablet 2.5 mg</i>	T2	QL (16 EA per 28 days)
<i>zolmitriptan oral tablet 5 mg</i>	T2	QL (8 EA per 28 days)
<i>zolmitriptan oral tablet,disintegrating 2.5 mg</i>	T2	QL (16 EA per 28 days)
<i>zolmitriptan oral tablet,disintegrating 5 mg</i>	T2	QL (8 EA per 28 days)
<b>ZOLOFT</b>	T4	
<i>zolpidem oral capsule</i>	T4	PA; QL (31 EA per 31 days)
<i>zolpidem oral tablet</i>	T2	PA; QL (31 EA per 31 days)
<i>zolpidem oral tablet,ext release multiphase</i>	T2	PA; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>zolpidem sublingual</i>	T3	PA; QL (31 EA per 31 days)
<b>ZOMIG NASAL SPRAY, NON-AEROSOL 2.5 MG</b>	T4	QL (16 EA per 28 days)
<b>ZOMIG NASAL SPRAY, NON-AEROSOL 5 MG</b>	T4	QL (8 EA per 28 days)
<b>ZOMIG ORAL TABLET 2.5 MG</b>	T4	QL (16 EA per 28 days)
<b>ZOMIG ORAL TABLET 5 MG</b>	T4	QL (8 EA per 28 days)
<b>ZONEGRAN ORAL CAPSULE 100 MG, 25 MG</b>	T5	
<b>ZONISADE</b>	T5	PA-NS; QL (930 ML per 31 days)
<i>zonisamide</i>	T2	
<b>ZTALMY</b>	T5	PA-NS; QL (1100 ML per 30 days)
<b>ZUBSOLV SUBLINGUAL TABLET 0.7-0.18 MG, 2.9-0.71 MG, 8.6-2.1 MG</b>	T3	QL (62 EA per 31 days)
<b>ZUBSOLV SUBLINGUAL TABLET 1.4-0.36 MG</b>	T3	QL (93 EA per 31 days)
<b>ZUBSOLV SUBLINGUAL TABLET 11.4-2.9 MG, 5.7-1.4 MG</b>	T3	QL (31 EA per 31 days)
<b>ZYPREXA INTRAMUSCULAR</b>	T4	
<b>ZYPREXA ORAL</b>	T4	QL (31 EA per 31 days)
<b>ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG</b>	T5	QL (2 EA per 28 days)
<b>ZYPREXA ZYDIS</b>	T4	QL (31 EA per 31 days)
<b>Cardiovascular, Hypertension / Lipids</b>		
<i>acebutolol</i>	T1	
<b>ALDACTONE</b>	T4	
<i>aliskiren</i>	T4	
<b>ALTACE ORAL CAPSULE 1.25 MG</b>	T4	QL (62 EA per 31 days)
<b>ALTACE ORAL CAPSULE 10 MG</b>	T4	QL (93 EA per 31 days)
<b>ALTACE ORAL CAPSULE 2.5 MG, 5 MG</b>	T4	
<b>ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HR 20 MG, 60 MG</b>	T4	
<b>ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HR 40 MG</b>	T5	
<i>amiloride</i>	T1	
<i>amiloride-hydrochlorothiazide</i>	T1	
<i>amiodarone oral</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>amlodipine</i>	T1	
<i>amlodipine-atorvastatin</i>	T2	
<i>amlodipine-benazepril</i>	T1	
<i>amlodipine-olmesartan</i>	T3	QL (31 EA per 31 days)
<i>amlodipine-valsartan</i>	T2	
<i>amlodipine-valsartan-hcthiazyd</i>	T4	
<b>ANTARA ORAL CAPSULE 90 MG</b>	T4	
<b>ARIXTRA SUBCUTANEOUS SYRINGE 10 MG/0.8 ML, 5 MG/0.4 ML, 7.5 MG/0.6 ML</b>	T5	
<b>ARIXTRA SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML</b>	T4	
<i>aspirin-dipyridamole</i>	T2	
<b>ASPRUZYO SPRINKLE</b>	T4	PA; QL (60 EA per 30 days)
<b>ATACAND</b>	T4	
<b>ATACAND HCT</b>	T4	
<i>atenolol</i>	T1	
<i>atenolol-chlorthalidone</i>	T1	
<b>ATORVALIQ</b>	T4	PA; QL (600 ML per 30 days)
<i>atorvastatin</i>	T1	
<b>AVALIDE</b>	T4	QL (31 EA per 31 days)
<b>AVAPRO</b>	T4	QL (31 EA per 31 days)
<b>AZOR</b>	T4	QL (31 EA per 31 days)
<i>benazepril</i>	T1	
<i>benazepril-hydrochlorothiazide</i>	T1	
<b>BENICAR HCT</b>	T4	QL (31 EA per 31 days)
<b>BENICAR ORAL TABLET 20 MG, 40 MG</b>	T4	QL (31 EA per 31 days)
<b>BENICAR ORAL TABLET 5 MG</b>	T4	QL (93 EA per 31 days)
<b>BETAPACE AF</b>	T4	
<i>betaxolol oral</i>	T1	
<b>BIDIL</b>	T4	
<i>bisoprolol fumarate</i>	T1	
<i>bisoprolol-hydrochlorothiazide</i>	T1	
<b>BRILINTA</b>	T3	
<i>bumetanide</i>	T1	
<b>BYSTOLIC ORAL TABLET 10 MG, 2.5 MG</b>	T4	QL (93 EA per 31 days)
<b>BYSTOLIC ORAL TABLET 20 MG</b>	T4	QL (62 EA per 31 days)
<b>BYSTOLIC ORAL TABLET 5 MG</b>	T4	QL (217 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>CABLIVI INJECTION KIT</b>	T5	PA; QL (31 EA per 31 days)
<b>CADUET</b>	T4	
<b>CAMZYOS</b>	T5	PA; QL (31 EA per 31 days)
<i>candesartan</i>	T1	
<i>candesartan-hydrochlorothiazid</i>	T1	
<i>captopril</i>	T1	
<b>CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 120 MG, 360 MG</b>	T5	
<b>CARDIZEM CD ORAL CAPSULE,EXTENDED RELEASE 24HR 180 MG, 240 MG, 300 MG</b>	T4	
<b>CARDIZEM LA</b>	T4	
<b>CARDIZEM ORAL TABLET 120 MG, 30 MG</b>	T4	
<b>CARDIZEM ORAL TABLET 60 MG</b>	T5	
<b>CARDURA</b>	T4	
<b>CARDURA XL</b>	T4	
<b>CAROSPIR</b>	T4	
<b>CARTIA XT</b>	T1	
<i>carvedilol</i>	T1	
<i>carvedilol phosphate</i>	T4	
<b>CATAPRES-TTS-1</b>	T4	
<b>CATAPRES-TTS-2</b>	T4	
<b>CATAPRES-TTS-3</b>	T4	
<i>chlorthalidone oral tablet 25 mg, 50 mg</i>	T1	
<i>cholestyramine (with sugar) oral powder in packet</i>	T2	
<b>CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET</b>	T2	
<i>cilostazol</i>	T2	
<i>clonidine</i>	T2	
<i>clonidine hcl oral tablet</i>	T1	
<i>clopidogrel oral tablet 75 mg</i>	T1	
<i>colesevelam</i>	T3	
<b>COLESTID ORAL TABLET</b>	T4	
<i>colestipol oral packet</i>	T2	
<i>colestipol oral tablet</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>CONJUPRI</b>	T4	ST; QL (31 EA per 31 days)
<b>COREG CR</b>	T4	
<b>COREG ORAL TABLET 25 MG</b>	T4	
<b>CORGARD ORAL TABLET 20 MG, 40 MG</b>	T4	
<b>CORLANOR ORAL SOLUTION</b>	T4	PA; QL (420 ML per 28 days)
<b>CORLANOR ORAL TABLET 5 MG</b>	T4	PA; QL (93 EA per 31 days)
<b>CORLANOR ORAL TABLET 7.5 MG</b>	T4	PA; QL (62 EA per 31 days)
<b>COZAAR ORAL TABLET 100 MG</b>	T4	QL (31 EA per 31 days)
<b>COZAAR ORAL TABLET 25 MG</b>	T4	QL (93 EA per 31 days)
<b>COZAAR ORAL TABLET 50 MG</b>	T4	QL (62 EA per 31 days)
<b>CRESTOR</b>	T4	
<i>dabigatran etexilate</i>	T4	QL (62 EA per 31 days)
<b>DEMSER</b>	T4	
<b>DIBENZYLINE</b>	T5	PA
<i>digoxin oral solution</i>	T2	QL (155 ML per 31 days)
<i>digoxin oral tablet 125 mcg (0.125 mg)</i>	T1	QL (62 EA per 31 days)
<i>digoxin oral tablet 250 mcg (0.25 mg)</i>	T2	QL (31 EA per 31 days)
<i>digoxin oral tablet 62.5 mcg (0.0625 mg)</i>	T4	QL (124 EA per 31 days)
<i>diltiazem hcl oral capsule,extended release 12 hr</i>	T1	
<i>diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg</i>	T1	
<i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i>	T1	
<i>diltiazem hcl oral tablet</i>	T1	
<i>diltiazem hcl oral tablet extended release 24 hr 120 mg</i>	T4	
<i>diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i>	T1	
<b>DILT-XR</b>	T1	
<b>DIOVAN HCT</b>	T4	QL (31 EA per 31 days)
<b>DIOVAN ORAL TABLET 160 MG, 40 MG, 80 MG</b>	T4	QL (62 EA per 31 days)
<b>DIOVAN ORAL TABLET 320 MG</b>	T4	QL (31 EA per 31 days)
<i>dipyridamole oral</i>	T2	
<i>disopyramide phosphate oral capsule</i>	T2	
<b>DIURIL</b>	T4	
<i>dofetilide</i>	T3	
<b>DOPTELET (10 TAB PACK)</b>	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>DOPTELET (15 TAB PACK)</b>	T5	PA
<b>DOPTELET (30 TAB PACK)</b>	T5	PA
<i>doxazosin</i>	T1	
<b>DYRENIUM</b>	T4	
<b>EDARBI</b>	T4	
<b>EDARBYCLOR</b>	T4	
<b>EDECIN</b>	T3	
<b>EFFIENT</b>	T4	
<b>ELIQUIS DVT-PE TREAT 30D START</b>	T3	QL (74 EA per 30 days)
<b>ELIQUIS ORAL TABLET 2.5 MG</b>	T3	QL (60 EA per 30 days)
<b>ELIQUIS ORAL TABLET 5 MG</b>	T3	QL (74 EA per 30 days)
<i>enalapril maleate oral solution</i>	T4	
<i>enalapril maleate oral tablet</i>	T1	
<i>enalapril-hydrochlorothiazide</i>	T1	
<i>enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml</i>	T4	
<i>enoxaparin subcutaneous syringe 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml</i>	T2	
<b>ENTRESTO ORAL TABLET 24-26 MG</b>	T3	QL (186 EA per 31 days)
<b>ENTRESTO ORAL TABLET 49-51 MG</b>	T3	QL (93 EA per 31 days)
<b>ENTRESTO ORAL TABLET 97-103 MG</b>	T3	QL (62 EA per 31 days)
<i>eplerenone</i>	T2	
<i>ethacrynic acid</i>	T2	
<b>EXFORGE</b>	T4	
<b>EXFORGE HCT</b>	T4	
<b>EZALLOR SPRINKLE</b>	T4	
<i>ezetimibe</i>	T2	
<i>ezetimibe-simvastatin</i>	T3	
<i>felodipine</i>	T2	
<i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i>	T2	
<i>fenofibrate micronized oral capsule 90 mg</i>	T4	
<i>fenofibrate nanocrystallized</i>	T2	
<i>fenofibrate oral capsule</i>	T4	
<i>fenofibrate oral tablet 120 mg, 40 mg</i>	T4	
<i>fenofibrate oral tablet 160 mg, 54 mg</i>	T2	
<i>fenofibric acid (choline)</i>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>FENOGLIDE</b>	T4	
<b>FILSPARI</b>	T5	PA; QL (31 EA per 31 days)
<i>flecainide</i>	T2	
<b>FLOLIPID</b>	T4	
<i>fluvastatin oral capsule</i>	T1	
<i>fluvastatin oral tablet extended release 24 hr</i>	T3	
<i>fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml</i>	T5	
<i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i>	T2	
<i>fosinopril</i>	T1	
<i>fosinopril-hydrochlorothiazide</i>	T1	
<b>FRAGMIN SUBCUTANEOUS SOLUTION 25,000 ANTI-XA UNIT/ML</b>	T5	
<b>FRAGMIN SUBCUTANEOUS SYRINGE 10,000 ANTI-XA UNIT/ML, 12,500 ANTI-XA UNIT/0.5 ML, 18,000 ANTI-XA UNIT/0.72 ML, 7,500 ANTI-XA UNIT/0.3 ML</b>	T5	
<b>FRAGMIN SUBCUTANEOUS SYRINGE 15,000 ANTI-XA UNIT/0.6 ML, 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML</b>	T3	
<b>FUROSCIX</b>	T5	PA; QL (8 EA per 30 days)
<i>furosemide injection solution</i>	T2	
<i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i>	T2	
<i>furosemide oral tablet</i>	T1	
<i>gemfibrozil</i>	T1	
<i>guanfacine oral tablet</i>	T2	
<i>heparin (porcine) injection solution</i>	T2	
<i>hydralazine oral</i>	T1	
<i>hydrochlorothiazide</i>	T1	
<b>HYZAAR</b>	T4	
<i>icosapent ethyl oral capsule 0.5 gram</i>	T4	QL (248 EA per 31 days)
<i>icosapent ethyl oral capsule 1 gram</i>	T4	QL (124 EA per 31 days)
<i>indapamide</i>	T1	
<b>INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 60 MG</b>	T4	
<b>INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 160 MG, 80 MG</b>	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>INNOPRAN XL</b>	T4	
<b>INSPRA</b>	T4	
<i>irbesartan</i>	T1	QL (31 EA per 31 days)
<i>irbesartan-hydrochlorothiazide</i>	T2	QL (31 EA per 31 days)
<b>ISORDIL</b>	T4	
<b>ISORDIL TITRADOSE ORAL TABLET 5 MG</b>	T4	
<i>isosorbide dinitrate oral tablet</i>	T2	
<i>isosorbide mononitrate</i>	T1	
<i>isosorbide-hydralazine</i>	T4	
<i>isradipine</i>	T2	
<b>JANTOVEN</b>	T1	
<b>JUXTAPID</b>	T5	PA
<b>KATERZIA</b>	T4	PA
<b>KERENDIA</b>	T4	PA; QL (31 EA per 31 days)
<i>labetalol oral</i>	T1	
<b>LANOXIN ORAL TABLET 125 MCG (0.125 MG)</b>	T4	QL (62 EA per 31 days)
<b>LANOXIN ORAL TABLET 250 MCG (0.25 MG)</b>	T4	QL (31 EA per 31 days)
<b>LANOXIN ORAL TABLET 62.5 MCG (0.0625 MG)</b>	T4	QL (124 EA per 31 days)
<b>LASIX</b>	T4	
<b>LESCOL XL</b>	T4	
<i>levamlodipine</i>	T4	ST; QL (31 EA per 31 days)
<b>LIPITOR</b>	T4	
<b>LIPOFEN</b>	T4	
<i>lisinopril</i>	T1	
<i>lisinopril-hydrochlorothiazide</i>	T1	
<b>LIVALO</b>	T3	
<b>LODOCO</b>	T4	PA; QL (31 EA per 31 days)
<b>LOPID</b>	T4	
<b>LOPRESSOR ORAL</b>	T4	
<i>losartan oral tablet 100 mg</i>	T1	QL (31 EA per 31 days)
<i>losartan oral tablet 25 mg</i>	T1	QL (93 EA per 31 days)
<i>losartan oral tablet 50 mg</i>	T1	QL (62 EA per 31 days)
<i>losartan-hydrochlorothiazide</i>	T1	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LOTENSIN ORAL TABLET 10 MG, 20 MG, 40 MG</b>	T4	
<b>LOTREL ORAL CAPSULE 10-20 MG, 10-40 MG, 5-10 MG, 5-20 MG</b>	T4	
<i>lovastatin</i>	T1	
<b>LOVAZA</b>	T3	PA; QL (124 EA per 31 days)
<b>LOVENOX SUBCUTANEOUS SYRINGE 100 MG/ML</b>	T5	
<b>LOVENOX SUBCUTANEOUS SYRINGE 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML</b>	T4	
<b>MATZIM LA</b>	T1	
<b>MAXZIDE</b>	T4	
<b>MAXZIDE-25MG</b>	T4	
<i>metolazone</i>	T2	
<i>metoprolol succinate</i>	T1	
<i>metoprolol ta-hydrochlorothiaz</i>	T1	
<i>metoprolol tartrate oral</i>	T1	
<i>metyrosine</i>	T3	
<i>mexiletine</i>	T2	
<b>MICARDIS</b>	T4	
<b>MICARDIS HCT</b>	T4	
<b>MINIPRESS</b>	T4	
<i>minoxidil oral</i>	T2	
<i>moexipril</i>	T1	
<b>MULPLETA</b>	T5	PA
<b>MULTAQ</b>	T4	
<i>nadolol</i>	T1	
<i>nebivolol oral tablet 10 mg, 2.5 mg</i>	T4	QL (93 EA per 31 days)
<i>nebivolol oral tablet 20 mg</i>	T4	QL (62 EA per 31 days)
<i>nebivolol oral tablet 5 mg</i>	T4	QL (217 EA per 31 days)
<b>NEXLETOL</b>	T4	PA; QL (31 EA per 31 days)
<b>NEXLIZET</b>	T4	PA; QL (31 EA per 31 days)
<i>niacin oral tablet 500 mg</i>	T5	
<i>niacin oral tablet extended release 24 hr 1,000 mg, 750 mg</i>	T3	
<i>niacin oral tablet extended release 24 hr 500 mg</i>	T3	QL (31 EA per 31 days)
<b>NIACOR</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>nicardipine oral</i>	T2	
<i>nifedipine</i>	T2	
<i>nimodipine</i>	T2	
<i>nisoldipine</i>	T2	
<b>NITRO-BID</b>	T2	
<b>NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.1 MG/HR, 0.2 MG/HR, 0.3 MG/HR, 0.4 MG/HR, 0.6 MG/HR</b>	T3	
<b>NITRO-DUR TRANSDERMAL PATCH 24 HOUR 0.8 MG/HR</b>	T5	
<i>nitroglycerin sublingual</i>	T2	
<i>nitroglycerin transdermal patch 24 hour</i>	T2	
<i>nitroglycerin translingual</i>	T2	
<b>NITROLINGUAL</b>	T4	
<b>NITROSTAT</b>	T4	
<b>NORLIQVA</b>	T4	PA; QL (300 ML per 30 days)
<b>NORPACE</b>	T4	
<b>NORPACE CR</b>	T4	
<b>NORVASC</b>	T4	
<b>NYMALIZE ORAL SYRINGE 60 MG/10 ML</b>	T4	
<i>olmesartan oral tablet 20 mg, 40 mg</i>	T2	QL (31 EA per 31 days)
<i>olmesartan oral tablet 5 mg</i>	T2	QL (93 EA per 31 days)
<i>olmesartan-amlodipin-hcthiazyd</i>	T3	
<i>olmesartan-hydrochlorothiazide</i>	T2	QL (31 EA per 31 days)
<i>omega-3 acid ethyl esters</i>	T3	QL (124 EA per 31 days)
<b>ORENITRAM MONTH 1 TITRATION KT</b>	T5	PA; QL (336 EA per 365 days)
<b>ORENITRAM MONTH 2 TITRATION KT</b>	T5	PA; QL (672 EA per 365 days)
<b>ORENITRAM MONTH 3 TITRATION KT</b>	T5	PA; QL (504 EA per 365 days)
<b>ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG</b>	T4	PA; QL (93 EA per 31 days)
<b>ORENITRAM ORAL TABLET EXTENDED RELEASE 0.25 MG, 1 MG</b>	T5	PA; QL (186 EA per 31 days)
<b>ORENITRAM ORAL TABLET EXTENDED RELEASE 2.5 MG</b>	T5	PA; QL (521 EA per 31 days)
<b>ORENITRAM ORAL TABLET EXTENDED RELEASE 5 MG</b>	T5	PA; QL (261 EA per 31 days)
<b>PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG</b>	T2	
<i>pentoxifylline</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>perindopril erbumine</i>	T1	
<i>phenoxybenzamine</i>	T5	PA
<i>pindolol</i>	T1	
<b>PLAVIX ORAL TABLET 75 MG</b>	T4	
<b>PRADAXA ORAL CAPSULE 110 MG</b>	T4	QL (124 EA per 31 days)
<b>PRADAXA ORAL CAPSULE 150 MG, 75 MG</b>	T4	QL (62 EA per 31 days)
<b>PRADAXA ORAL PELLETS IN PACKET 110 MG, 30 MG, 40 MG, 50 MG</b>	T5	QL (124 EA per 31 days)
<b>PRADAXA ORAL PELLETS IN PACKET 150 MG, 20 MG</b>	T5	QL (62 EA per 31 days)
<b>PRALUENT PEN</b>	T4	PA; QL (2 ML per 28 days)
<i>prasugrel</i>	T3	
<i>pravastatin</i>	T1	
<i>prazosin</i>	T1	
<b>PREVALITE ORAL POWDER IN PACKET</b>	T2	
<b>PROCARDIA XL</b>	T4	
<b>PROMACTA ORAL POWDER IN PACKET 12.5 MG</b>	T5	PA; QL (372 EA per 31 days)
<b>PROMACTA ORAL POWDER IN PACKET 25 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>PROMACTA ORAL TABLET 12.5 MG, 25 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>PROMACTA ORAL TABLET 50 MG, 75 MG</b>	T5	PA; QL (62 EA per 31 days)
<i>propafenone</i>	T2	
<i>propranolol oral capsule, extended release 24 hr</i>	T2	
<i>propranolol oral solution</i>	T1	
<i>propranolol oral tablet</i>	T1	
<b>QBRELIS</b>	T5	
<b>QUESTRAN LIGHT</b>	T4	
<b>QUESTRAN ORAL POWDER</b>	T4	
<i>quinapril</i>	T1	
<i>quinidine gluconate oral</i>	T2	
<i>quinidine sulfate oral tablet</i>	T2	
<i>ramipril</i>	T1	
<i>ranolazine</i>	T3	QL (62 EA per 31 days)
<b>REPATHA PUSHTRONEX</b>	T3	PA; QL (7 ML per 28 days)
<b>REPATHA SURECLICK</b>	T3	PA; QL (3 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>REPATHA SYRINGE</b>	T3	PA; QL (3 ML per 28 days)
<i>rosuvastatin</i>	T1	
<b>RYTHMOL SR ORAL CAPSULE,EXTENDED RELEASE 12 HR 225 MG, 425 MG</b>	T4	
<b>RYTHMOL SR ORAL CAPSULE,EXTENDED RELEASE 12 HR 325 MG</b>	T5	
<b>SAVAYSA</b>	T4	QL (31 EA per 31 days)
<i>simvastatin</i>	T1	
<b>SOAANZ</b>	T4	ST
<b>SORINE</b>	T1	
<b>SOTALOL AF</b>	T1	
<i>sotalol oral</i>	T1	
<b>SOTYLIZE</b>	T4	
<i>spironolactone oral tablet</i>	T1	
<i>spironolacton-hydrochlorothiaz</i>	T1	
<b>SULAR ORAL TABLET EXTENDED RELEASE 24 HR 17 MG, 34 MG, 8.5 MG</b>	T4	
<b>TAVALISSE</b>	T5	PA; QL (62 EA per 31 days)
<b>TAZTIA XT</b>	T1	
<b>TEKTURNA</b>	T4	
<i>telmisartan</i>	T1	
<i>telmisartan-amlodipine</i>	T1	
<i>telmisartan-hydrochlorothiazid</i>	T1	
<b>TENORETIC 100</b>	T4	
<b>TENORETIC 50</b>	T4	
<b>TENORMIN</b>	T4	
<i>terazosin</i>	T1	
<b>THALITONE</b>	T4	
<b>TIADYLT ER</b>	T1	
<b>TIAZAC</b>	T4	
<b>TIKOSYN</b>	T3	
<i>timolol maleate oral</i>	T1	
<b>TOPROL XL</b>	T4	
<i>torse mide oral</i>	T1	
<i>trandolapril</i>	T1	
<i>trandolapril-verapamil</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>triamterene</i>	T4	
<i>triamterene-hydrochlorothiazid</i>	T1	
<b>TRIBENZOR</b>	T4	
<b>TRICOR</b>	T4	
<b>TRILIPIX</b>	T4	
<b>UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG</b>	T5	PA; QL (62 EA per 31 days)
<b>UPTRAVI ORAL TABLET 200 MCG</b>	T5	PA; QL (224 EA per 28 days)
<b>UPTRAVI ORAL TABLETS,DOSE PACK</b>	T5	PA; QL (400 EA per 365 days)
<i>valsartan oral solution</i>	T5	QL (2480 ML per 31 days)
<i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i>	T1	QL (62 EA per 31 days)
<i>valsartan oral tablet 320 mg</i>	T1	QL (31 EA per 31 days)
<i>valsartan-hydrochlorothiazide</i>	T2	QL (31 EA per 31 days)
<b>VASCEPA ORAL CAPSULE 0.5 GRAM</b>	T4	QL (248 EA per 31 days)
<b>VASCEPA ORAL CAPSULE 1 GRAM</b>	T4	QL (124 EA per 31 days)
<b>VASERETIC</b>	T4	
<b>VASOTEC</b>	T4	
<b>VECAMYL</b>	T4	
<i>verapamil oral</i>	T2	
<b>VERELAN</b>	T4	
<b>VERELAN PM</b>	T4	
<b>VERQUVO</b>	T4	PA; QL (31 EA per 31 days)
<b>VYNDAMAX</b>	T5	PA; QL (31 EA per 31 days)
<b>VYNDAQEL</b>	T5	PA; QL (124 EA per 31 days)
<b>VYTORIN 10-10</b>	T4	
<b>VYTORIN 10-20</b>	T4	
<b>VYTORIN 10-40</b>	T4	
<b>VYTORIN 10-80</b>	T4	
<i>warfarin</i>	T1	
<b>WELCHOL</b>	T4	
<b>XARELTO DVT-PE TREAT 30D START</b>	T3	QL (51 EA per 30 days)
<b>XARELTO ORAL SUSPENSION FOR RECONSTITUTION</b>	T3	QL (930 ML per 31 days)
<b>XARELTO ORAL TABLET 10 MG, 20 MG</b>	T3	QL (31 EA per 31 days)
<b>XARELTO ORAL TABLET 15 MG</b>	T3	QL (52 EA per 31 days)
<b>XARELTO ORAL TABLET 2.5 MG</b>	T3	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ZESTORETIC</b>	T4	
<b>ZESTRIL</b>	T4	
<b>ZETIA</b>	T4	
<b>ZIAC</b>	T4	
<b>ZOCOR ORAL TABLET 10 MG, 20 MG, 40 MG</b>	T4	
<b>ZONTIVITY</b>	T4	
<b>ZYPITAMAG</b>	T4	
<b>Dermatologicals/Topical Therapy</b>		
<b>ABSORICA</b>	T4	
<b>ABSORICA LD</b>	T4	
<b>ACANYA TOPICAL GEL WITH PUMP</b>	T4	
<b>ACCUTANE</b>	T2	
<i>acitretin</i>	T4	PA
<i>acyclovir topical cream</i>	T3	QL (5 GM per 28 days)
<i>acyclovir topical ointment</i>	T1	QL (30 GM per 30 days)
<b>ACZONE</b>	T4	QL (90 GM per 28 days)
<i>adapalene topical cream</i>	T2	PA
<i>adapalene topical gel 0.3 %</i>	T2	PA
<i>adapalene topical swab</i>	T2	PA
<i>adapalene-benzoyl peroxide</i>	T4	PA
<b>ADBRY</b>	T5	PA; QL (4 ML per 28 days)
<b>AKLIEF</b>	T4	PA
<b>ALA-CORT TOPICAL CREAM 1 %</b>	T1	
<b>ALA-CORT TOPICAL CREAM 2.5 %</b>	T1	QL (30 GM per 28 days)
<b>ALA-SCALP</b>	T4	
<i>alclometasone</i>	T1	
<b>ALTABAX</b>	T4	QL (30 GM per 28 days)
<b>ALTRENO</b>	T4	PA; QL (45 GM per 28 days)
<i>amcinonide topical lotion</i>	T2	
<i>amcinonide topical ointment</i>	T2	
<i>ammonium lactate</i>	T2	
<b>AMNESTEEM</b>	T2	
<b>AMZEEQ</b>	T4	
<b>APEXICON E</b>	T4	QL (60 GM per 28 days)
<b>ARAZLO</b>	T4	PA; QL (45 GM per 28 days)
<b>ATRALIN</b>	T4	PA; QL (45 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>azelaic acid</i>	T4	QL (50 GM per 28 days)
<b>AZELEX</b>	T4	QL (50 GM per 28 days)
<b>BENZAMYCIN</b>	T4	
<i>betamethasone dipropionate</i>	T1	
<i>betamethasone valerate topical cream</i>	T1	
<i>betamethasone valerate topical foam</i>	T4	
<i>betamethasone valerate topical lotion</i>	T1	
<i>betamethasone valerate topical ointment</i>	T1	
<i>betamethasone, augmented</i>	T2	
<i>brimonidine topical</i>	T4	
<b>BRYHALI</b>	T4	QL (100 GM per 28 days)
<i>calcipotriene scalp</i>	T2	QL (60 ML per 28 days)
<i>calcipotriene topical cream</i>	T2	QL (60 GM per 28 days)
<i>calcipotriene topical foam</i>	T4	ST; QL (120 GM per 28 days)
<i>calcipotriene topical ointment</i>	T2	QL (60 GM per 28 days)
<i>calcipotriene-betamethasone</i>	T4	ST; QL (400 GM per 28 days)
<i>calcitriol topical</i>	T3	ST
<b>CAPEX</b>	T4	QL (840 ML per 28 days)
<b>CARAC</b>	T5	PA
<b>CIBINQO</b>	T5	PA; QL (31 EA per 31 days)
<i>ciclopirox topical cream</i>	T2	QL (90 GM per 28 days)
<i>ciclopirox topical gel</i>	T2	QL (45 GM per 28 days)
<i>ciclopirox topical shampoo</i>	T2	QL (120 ML per 28 days)
<i>ciclopirox topical solution</i>	T2	
<i>ciclopirox topical suspension</i>	T2	QL (60 ML per 28 days)
<b>CLARAVIS</b>	T2	
<b>CLEOCIN T TOPICAL LOTION</b>	T4	QL (60 ML per 28 days)
<b>CLINDACIN</b>	T2	QL (100 GM per 28 days)
<b>CLINDACIN ETZ TOPICAL SWAB</b>	T4	
<b>CLINDAGEL</b>	T5	QL (75 ML per 28 days)
<i>clindamycin phosphate topical foam</i>	T2	QL (100 GM per 28 days)
<i>clindamycin phosphate topical gel</i>	T2	QL (75 GM per 28 days)
<i>clindamycin phosphate topical lotion</i>	T2	QL (60 ML per 28 days)
<i>clindamycin phosphate topical solution</i>	T2	QL (60 ML per 28 days)
<i>clindamycin phosphate topical swab</i>	T2	
<i>clindamycin-benzoyl peroxide topical gel</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>clindamycin-benzoyl peroxide topical gel with pump 1.2-2.5 %</i>	T2	
<i>clindamycin-tretinoin</i>	T2	PA; QL (60 GM per 28 days)
<i>clobetasol scalp</i>	T2	QL (50 ML per 28 days)
<i>clobetasol topical cream</i>	T3	QL (60 GM per 28 days)
<i>clobetasol topical foam</i>	T2	QL (100 GM per 28 days)
<i>clobetasol topical gel</i>	T2	QL (60 GM per 28 days)
<i>clobetasol topical lotion</i>	T2	QL (118 ML per 28 days)
<i>clobetasol topical ointment</i>	T3	QL (60 GM per 28 days)
<i>clobetasol topical shampoo</i>	T2	QL (118 ML per 28 days)
<i>clobetasol topical spray,non-aerosol</i>	T2	QL (125 ML per 28 days)
<i>clobetasol-emollient topical cream</i>	T3	QL (60 GM per 28 days)
<i>clobetasol-emollient topical foam</i>	T3	QL (100 GM per 28 days)
<b>CLOBEX TOPICAL LOTION</b>	T4	QL (118 ML per 28 days)
<b>CLOBEX TOPICAL SHAMPOO</b>	T4	QL (118 ML per 28 days)
<b>CLOBEX TOPICAL SPRAY,NON-AEROSOL</b>	T4	QL (125 ML per 28 days)
<i>clocortolone pivalate</i>	T4	
<b>CLODAN</b>	T2	QL (118 ML per 28 days)
<b>CLODERM</b>	T4	
<i>clotrimazole topical cream</i>	T2	QL (45 GM per 28 days)
<i>clotrimazole topical solution</i>	T2	QL (30 ML per 28 days)
<i>clotrimazole-betamethasone topical cream</i>	T2	QL (45 GM per 28 days)
<i>clotrimazole-betamethasone topical lotion</i>	T2	QL (60 ML per 28 days)
<b>CONDYLOX TOPICAL GEL</b>	T3	
<b>CORDRAN TAPE LARGE ROLL</b>	T3	
<b>CORDRAN TOPICAL CREAM 0.05 %</b>	T3	QL (120 GM per 28 days)
<b>CORDRAN TOPICAL LOTION</b>	T3	QL (120 ML per 28 days)
<b>COSENTYX (2 SYRINGES)</b>	T5	PA; QL (2 ML per 28 days)
<b>COSENTYX PEN (2 PENS)</b>	T5	PA; QL (2 ML per 28 days)
<b>COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML</b>	T5	PA; QL (0.5 ML per 28 days)
<b>COSENTYX UNOREADY PEN</b>	T5	PA; QL (2 ML per 28 days)
<b>CROTAN</b>	T4	
<i>dapsone topical</i>	T4	QL (90 GM per 28 days)
<b>DENAVIR</b>	T4	QL (5 GM per 28 days)
<b>DERMA-SMOOTH/FS SCALP OIL</b>	T4	QL (118.28 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>desonide topical cream</i>	T3	QL (60 GM per 28 days)
<i>desonide topical gel</i>	T3	QL (60 GM per 28 days)
<i>desonide topical lotion</i>	T3	QL (118 ML per 28 days)
<i>desonide topical ointment</i>	T3	QL (60 GM per 28 days)
<b>DESOWEN TOPICAL CREAM</b>	T4	QL (60 GM per 28 days)
<i>desoximetasone topical cream</i>	T2	QL (100 GM per 28 days)
<i>desoximetasone topical gel</i>	T2	QL (60 GM per 28 days)
<i>desoximetasone topical ointment 0.05 %</i>	T4	QL (100 GM per 28 days)
<i>desoximetasone topical ointment 0.25 %</i>	T2	QL (100 GM per 28 days)
<i>desoximetasone topical spray,non-aerosol</i>	T2	QL (100 ML per 28 days)
<i>diclofenac sodium topical gel 3 %</i>	T4	PA; QL (100 GM per 28 days)
<b>DIFFERIN TOPICAL CREAM</b>	T4	PA
<b>DIFFERIN TOPICAL GEL WITH PUMP</b>	T4	PA
<b>DIFFERIN TOPICAL LOTION</b>	T4	PA
<i>diflorasone</i>	T4	QL (60 GM per 28 days)
<b>DIPROLENE (AUGMENTED) TOPICAL OINTMENT</b>	T4	
<i>doxepin topical</i>	T4	PA; QL (45 GM per 28 days)
<b>DUOBRII</b>	T5	PA; QL (200 GM per 28 days)
<b>DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML</b>	T5	PA; QL (2.28 ML per 28 days)
<b>DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML</b>	T5	PA; QL (8 ML per 28 days)
<b>DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML</b>	T5	PA; QL (1.34 ML per 28 days)
<b>DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML</b>	T5	PA; QL (2.28 ML per 28 days)
<b>DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML</b>	T5	PA; QL (8 ML per 28 days)
<i>econazole</i>	T2	QL (85 GM per 28 days)
<b>EFUDEX TOPICAL CREAM</b>	T4	
<b>ELIDEL</b>	T4	QL (100 GM per 28 days)
<b>ENSTILAR</b>	T5	ST; QL (60 GM per 28 days)
<b>EPIDUO FORTE</b>	T4	PA
<b>EPIDUO TOPICAL GEL WITH PUMP</b>	T4	PA
<b>EPSOLAY</b>	T4	QL (30 GM per 28 days)
<b>ERTACZO</b>	T4	ST; QL (60 GM per 28 days)
<b>ERY PADS</b>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ERYGEL</b>	T3	QL (60 GM per 28 days)
<i>erythromycin with ethanol topical gel</i>	T2	QL (60 GM per 28 days)
<i>erythromycin with ethanol topical solution</i>	T2	QL (60 ML per 28 days)
<i>erythromycin-benzoyl peroxide</i>	T2	
<b>EUCRISA</b>	T4	PA; QL (60 GM per 30 days)
<b>EXELDERM TOPICAL CREAM</b>	T4	ST; QL (60 GM per 28 days)
<b>EXELDERM TOPICAL SOLUTION</b>	T4	ST; QL (30 ML per 28 days)
<b>FABIOR</b>	T4	PA; QL (100 GM per 28 days)
<b>FINACEA</b>	T4	QL (50 GM per 28 days)
<i>fluocinolone and shower cap</i>	T2	QL (118.28 ML per 28 days)
<i>fluocinolone topical cream 0.01 %</i>	T2	QL (60 GM per 28 days)
<i>fluocinolone topical cream 0.025 %</i>	T2	QL (120 GM per 28 days)
<i>fluocinolone topical ointment</i>	T2	QL (120 GM per 28 days)
<i>fluocinolone topical solution</i>	T2	QL (90 ML per 28 days)
<i>fluocinonide topical cream 0.05 %</i>	T2	QL (60 GM per 28 days)
<i>fluocinonide topical cream 0.1 %</i>	T4	QL (120 GM per 28 days)
<i>fluocinonide topical gel</i>	T2	QL (60 GM per 28 days)
<i>fluocinonide topical ointment</i>	T2	QL (60 GM per 28 days)
<i>fluocinonide topical solution</i>	T2	QL (60 ML per 28 days)
<i>fluocinonide-emollient</i>	T2	QL (60 GM per 28 days)
<i>fluorouracil topical cream 0.5 %</i>	T5	
<i>fluorouracil topical cream 5 %</i>	T2	
<i>fluorouracil topical solution</i>	T2	
<i>flurandrenolide topical cream</i>	T3	QL (120 GM per 28 days)
<i>flurandrenolide topical lotion</i>	T3	QL (120 ML per 28 days)
<i>fluticasone propionate topical cream</i>	T2	
<i>fluticasone propionate topical lotion</i>	T4	QL (120 ML per 28 days)
<i>fluticasone propionate topical ointment</i>	T2	
<i>gentamicin topical</i>	T2	QL (60 GM per 28 days)
<i>halcinonide</i>	T4	
<i>halobetasol propionate topical cream</i>	T2	QL (50 GM per 28 days)
<i>halobetasol propionate topical foam</i>	T4	QL (120 GM per 28 days)
<i>halobetasol propionate topical ointment</i>	T2	QL (50 GM per 28 days)
<b>HALOG</b>	T4	
<i>hydrocortisone butyrate topical cream</i>	T2	QL (45 GM per 28 days)
<i>hydrocortisone butyrate topical lotion</i>	T4	QL (118 ML per 28 days)
<i>hydrocortisone butyrate topical ointment</i>	T2	QL (45 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>hydrocortisone butyrate topical solution</i>	T2	QL (60 ML per 28 days)
<i>hydrocortisone topical cream 1 %</i>	T1	
<i>hydrocortisone topical lotion 2.5 %</i>	T1	QL (118 ML per 28 days)
<i>hydrocortisone topical ointment 1 %, 2.5 %</i>	T1	
<i>hydrocortisone valerate</i>	T2	QL (60 GM per 28 days)
<b>HYFTOR</b>	T5	PA; QL (30 GM per 30 days)
<b>ILUMYA</b>	T5	PA; QL (1 ML per 84 days)
<i>imiquimod topical cream in metered-dose pump</i>	T5	
<i>imiquimod topical cream in packet 5 %</i>	T2	
<i>isotretinoin</i>	T2	
<i>ivermectin topical cream</i>	T4	
<b>JUBLIA</b>	T4	
<b>KENALOG TOPICAL</b>	T3	QL (100 GM per 28 days)
<b>KERYDIN</b>	T5	
<i>ketoconazole topical cream</i>	T2	QL (60 GM per 28 days)
<i>ketoconazole topical foam</i>	T4	QL (100 GM per 28 days)
<i>ketoconazole topical shampoo</i>	T2	QL (120 ML per 28 days)
<b>KETODAN</b>	T2	ST; QL (100 GM per 28 days)
<b>KLARON</b>	T4	
<b>LEXETTE</b>	T5	QL (200 GM per 28 days)
<i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i>	T2	PA; QL (50 ML per 28 days)
<i>lidocaine topical adhesive patch, medicated 5 %</i>	T2	PA; QL (93 EA per 31 days)
<i>lidocaine topical ointment</i>	T2	PA; QL (50 GM per 28 days)
<b>LIDOCAINE VISCOUS</b>	T2	
<i>lidocaine-prilocaine topical cream</i>	T2	PA; QL (30 GM per 28 days)
<b>LIDODERM</b>	T4	PA; QL (93 EA per 31 days)
<b>LOCOID LIPOCREAM</b>	T4	QL (60 GM per 28 days)
<b>LOCOID TOPICAL LOTION</b>	T4	QL (118 ML per 28 days)
<b>LOPROX TOPICAL SHAMPOO</b>	T4	QL (120 ML per 28 days)
<i>luliconazole</i>	T4	QL (60 GM per 28 days)
<b>LUZU</b>	T4	QL (60 GM per 28 days)
<i>mafenide acetate</i>	T4	
<i>malathion</i>	T2	
<i>methoxsalen</i>	T5	
<b>METROCREAM</b>	T4	
<b>METROGEL TOPICAL GEL 1 %</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>METROLOTION</b>	T4	
<i>metronidazole topical cream</i>	T2	
<i>metronidazole topical gel 0.75 %</i>	T2	
<i>metronidazole topical gel 1 %</i>	T1	
<i>metronidazole topical lotion</i>	T2	
<b>MIRVASO</b>	T4	
<i>mometasone topical</i>	T2	
<i>mupirocin</i>	T2	
<i>mupirocin calcium</i>	T4	ST
<i>naftifine topical cream 1 %</i>	T4	ST; QL (90 GM per 28 days)
<i>naftifine topical cream 2 %</i>	T4	ST; QL (60 GM per 28 days)
<i>naftifine topical gel 2 %</i>	T4	ST; QL (60 GM per 28 days)
<b>NAFTIN TOPICAL GEL 1 %</b>	T4	ST; QL (90 GM per 28 days)
<b>NAFTIN TOPICAL GEL 2 %</b>	T4	ST; QL (60 GM per 28 days)
<b>NATROBA</b>	T4	
<b>NEO-SYNALAR</b>	T4	
<b>NEUAC</b>	T2	
<b>NORITATE</b>	T5	
<b>NYAMYC</b>	T2	QL (60 GM per 28 days)
<i>nystatin topical cream</i>	T2	QL (30 GM per 28 days)
<i>nystatin topical ointment</i>	T2	QL (30 GM per 28 days)
<i>nystatin topical powder</i>	T2	QL (60 GM per 28 days)
<i>nystatin-triamcinolone</i>	T3	QL (60 GM per 28 days)
<b>NYSTOP</b>	T2	QL (60 GM per 28 days)
<b>ONEXTON TOPICAL GEL WITH PUMP</b>	T4	
<b>OPZELURA</b>	T5	PA; QL (60 GM per 7 days)
<b>OVIDE</b>	T4	
<i>oxiconazole</i>	T4	ST; QL (90 GM per 28 days)
<b>OXISTAT TOPICAL CREAM</b>	T4	ST; QL (90 GM per 28 days)
<b>OXISTAT TOPICAL LOTION</b>	T4	ST; QL (60 ML per 28 days)
<b>PANDEL</b>	T5	QL (80 GM per 28 days)
<b>PANRETIN</b>	T5	PA-NS
<i>penciclovir</i>	T3	QL (5 GM per 28 days)
<i>permethrin</i>	T2	
<i>pimecrolimus</i>	T3	QL (100 GM per 28 days)
<b>PLIAGLIS</b>	T4	PA; QL (100 GM per 28 days)
<i>podofilox</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>PRUDOXIN</b>	T4	PA; QL (45 GM per 28 days)
<b>REGRANEX</b>	T5	PA
<b>RETIN-A</b>	T4	PA; QL (45 GM per 28 days)
<b>RETIN-A MICRO</b>	T4	PA; QL (45 GM per 28 days)
<b>RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %</b>	T5	PA; QL (50 GM per 28 days)
<b>RHOFADE</b>	T4	
<b>SANTYL</b>	T3	QL (180 GM per 30 days)
<i>selenium sulfide topical lotion</i>	T1	
<b>SILIQ</b>	T5	PA; QL (6 ML per 28 days)
<b>SILVADENE</b>	T4	
<i>silver sulfadiazine</i>	T1	
<b>SKYRIZI SUBCUTANEOUS PEN INJECTOR</b>	T5	PA; QL (1 ML per 84 days)
<b>SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML</b>	T5	PA; QL (1 ML per 84 days)
<b>SOOLANTRA</b>	T4	
<b>SORILUX</b>	T4	ST; QL (120 GM per 28 days)
<b>SOTYKTU</b>	T5	PA; QL (31 EA per 31 days)
<i>spinosad</i>	T4	
<b>SSD</b>	T4	
<b>STELARA SUBCUTANEOUS SOLUTION</b>	T5	PA; QL (0.5 ML per 84 days)
<b>STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML</b>	T5	PA; QL (0.5 ML per 84 days)
<b>STELARA SUBCUTANEOUS SYRINGE 90 MG/ML</b>	T5	PA; QL (1 ML per 56 days)
<i>sulfacetamide sodium (acne)</i>	T1	
<b>SULFAMYLON TOPICAL CREAM</b>	T3	
<b>SYNALAR TOPICAL CREAM</b>	T4	QL (120 GM per 28 days)
<b>SYNALAR TOPICAL SOLUTION</b>	T4	QL (90 ML per 28 days)
<b>TACLONEX</b>	T5	ST; QL (400 GM per 28 days)
<i>tacrolimus topical</i>	T2	QL (100 GM per 28 days)
<b>TALTZ AUTOINJECTOR</b>	T5	PA; QL (1 ML per 28 days)
<b>TALTZ SYRINGE</b>	T5	PA; QL (1 ML per 28 days)
<i>tavaborole</i>	T4	
<i>tazarotene topical cream</i>	T4	PA; QL (60 GM per 28 days)
<i>tazarotene topical foam</i>	T4	PA; QL (100 GM per 28 days)
<i>tazarotene topical gel</i>	T4	PA; QL (100 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TAZORAC TOPICAL CREAM</b>	T4	PA; QL (60 GM per 28 days)
<b>TAZORAC TOPICAL GEL</b>	T4	PA; QL (100 GM per 28 days)
<b>TEXACORT</b>	T4	
<b>TOPICORT TOPICAL CREAM</b>	T4	QL (100 GM per 28 days)
<b>TOPICORT TOPICAL GEL</b>	T4	QL (60 GM per 28 days)
<b>TOPICORT TOPICAL OINTMENT 0.05 %</b>	T4	QL (100 GM per 28 days)
<b>TOPICORT TOPICAL SPRAY, NON-AEROSOL</b>	T4	QL (100 ML per 28 days)
<b>TOVET EMOLLIENT</b>	T3	QL (100 GM per 28 days)
<b>TREMFYA</b>	T5	PA; QL (1 ML per 56 days)
<i>tretinoin</i>	T2	PA; QL (45 GM per 28 days)
<i>tretinoin microspheres topical gel</i>	T2	PA; QL (50 GM per 28 days)
<i>tretinoin microspheres topical gel with pump 0.08 %</i>	T4	PA; QL (50 GM per 28 days)
<i>triamcinolone acetonide topical aerosol</i>	T4	QL (100 GM per 28 days)
<i>triamcinolone acetonide topical cream</i>	T1	
<i>triamcinolone acetonide topical lotion</i>	T1	
<i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i>	T1	
<i>triamcinolone acetonide topical ointment 0.05 %</i>	T4	
<b>TRIANEX</b>	T4	
<b>TRIDERM TOPICAL CREAM</b>	T1	
<b>TWYNEO</b>	T4	PA; QL (30 GM per 28 days)
<b>ULTRAVATE TOPICAL LOTION</b>	T5	QL (120 ML per 28 days)
<b>VALCHLOR</b>	T5	PA-NS
<b>VANOS</b>	T4	QL (120 GM per 28 days)
<b>VECTICAL</b>	T4	ST
<b>VELTIN</b>	T4	PA; QL (60 GM per 28 days)
<b>VERDESO</b>	T4	QL (100 GM per 28 days)
<b>VTAMA</b>	T5	PA; QL (60 GM per 28 days)
<b>WINLEVI</b>	T4	PA; QL (60 GM per 28 days)
<b>XERESE</b>	T5	
<b>ZENATANE</b>	T2	
<b>ZIANA</b>	T4	PA; QL (60 GM per 28 days)
<b>ZILXI</b>	T4	
<b>ZONALON</b>	T4	PA; QL (30 GM per 28 days)
<b>ZORYVE</b>	T4	PA; QL (60 GM per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ZOVIRAX TOPICAL CREAM</b>	T4	QL (5 GM per 28 days)
<b>ZOVIRAX TOPICAL OINTMENT</b>	T4	QL (30 GM per 30 days)
<b>ZTLIDO</b>	T4	PA; QL (93 EA per 31 days)
<b>ZYCLARA TOPICAL CREAM IN METERED-DOSE PUMP</b>	T5	
<b>Diagnostics / Miscellaneous Agents</b>		
<i>acamprosate</i>	T2	
<b>AGRYLIN</b>	T4	
<i>anagrelide</i>	T2	
<b>ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG</b>	T5	PA
<b>AURYXIA</b>	T5	PA; QL (372 EA per 31 days)
<b>BUPHENYL</b>	T5	PA
<i>bupropion hcl (smoking deter)</i>	T2	QL (62 EA per 31 days)
<b>CARBAGLU</b>	T5	PA
<i>carglumic acid</i>	T5	PA
<b>CARNITOR ORAL</b>	T4	PA-BvD
<i>cevimeline</i>	T2	
<b>CHEMET</b>	T4	
<b>CLINIMIX 4.25%/D5W SULFIT FREE</b>	T4	PA-BvD
<b>CLINIMIX E 2.75%/D5W SULF FREE</b>	T4	PA-BvD
<b>CUVRIOR</b>	T5	PA; QL (310 EA per 31 days)
<i>d10 %-0.45 % sodium chloride</i>	T2	
<i>d2.5 %-0.45 % sodium chloride</i>	T2	
<i>d5 % and 0.9 % sodium chloride</i>	T2	
<i>d5 %-0.45 % sodium chloride</i>	T2	
<i>deferasirox oral granules in packet</i>	T5	PA
<i>deferasirox oral tablet 180 mg, 360 mg</i>	T5	PA
<i>deferasirox oral tablet 90 mg</i>	T4	PA
<i>deferasirox oral tablet, dispersible</i>	T5	PA
<i>deferiprone</i>	T5	PA
<i>dextrose 10 % and 0.2 % nacl</i>	T2	
<i>dextrose 10 % in water (d10w)</i>	T2	
<i>dextrose 5 % in water (d5w) intravenous piggyback</i>	T2	
<i>dextrose 5%-0.2 % sod chloride</i>	T2	
<i>disulfiram</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>droxidopa oral capsule 100 mg</i>	T5	PA; QL (465 EA per 31 days)
<i>droxidopa oral capsule 200 mg, 300 mg</i>	T5	PA; QL (186 EA per 31 days)
<b>ENDARI</b>	T4	PA; QL (180 EA per 30 days)
<b>EVOXAC</b>	T4	
<b>EXJADE</b>	T5	PA
<b>EXSERVAN</b>	T5	PA; QL (62 EA per 31 days)
<b>FERRIPROX (2 TIMES A DAY)</b>	T5	PA
<b>FERRIPROX ORAL SOLUTION</b>	T5	PA
<b>FERRIPROX ORAL TABLET 500 MG</b>	T5	PA
<b>FOSRENOL ORAL POWDER IN PACKET</b>	T5	
<b>FOSRENOL ORAL TABLET,CHEWABLE 1,000 MG, 750 MG</b>	T5	
<b>FOSRENOL ORAL TABLET,CHEWABLE 500 MG</b>	T4	
<b>GLASSIA</b>	T5	PA
<b>INCRELEX</b>	T5	PA
<b>JADENU ORAL TABLET 180 MG, 90 MG</b>	T4	PA
<b>JADENU ORAL TABLET 360 MG</b>	T5	PA
<b>JADENU SPRINKLE</b>	T4	PA
<i>lanthanum oral tablet,chewable 1,000 mg, 500 mg</i>	T5	
<i>lanthanum oral tablet,chewable 750 mg</i>	T4	
<i>levocarnitine (with sugar)</i>	T2	PA-BvD
<i>levocarnitine oral tablet</i>	T2	PA-BvD
<b>LITFULO</b>	T5	PA; QL (28 EA per 28 days)
<b>LITHOSTAT</b>	T5	
<b>LOKELMA</b>	T3	PA; QL (93 EA per 31 days)
<i>midodrine</i>	T2	
<b>NICOTROL</b>	T4	
<b>NICOTROL NS</b>	T5	
<i>nitisinone</i>	T5	
<b>NITYR</b>	T5	
<b>NORTHERA ORAL CAPSULE 100 MG</b>	T5	PA; QL (465 EA per 31 days)
<b>NORTHERA ORAL CAPSULE 200 MG, 300 MG</b>	T5	PA; QL (186 EA per 31 days)
<b>OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM</b>	T5	PA; QL (186 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>OLPRUVA ORAL PELLETS IN PACKET 4 GRAM</b>	T5	PA; QL (155 EA per 31 days)
<b>OLPRUVA ORAL PELLETS IN PACKET 5 GRAM</b>	T5	PA; QL (124 EA per 31 days)
<b>OLPRUVA ORAL PELLETS IN PACKET 6 GRAM</b>	T5	PA; QL (93 EA per 31 days)
<b>OLPRUVA ORAL PELLETS IN PACKET 6.67 GRAM</b>	T5	PA; QL (62 EA per 31 days)
<b>ORFADIN</b>	T5	
<b>OXBRYTA ORAL TABLET 300 MG</b>	T5	PA; QL (248 EA per 31 days)
<b>OXBRYTA ORAL TABLET 500 MG</b>	T5	PA; QL (155 EA per 31 days)
<b>OXBRYTA ORAL TABLET FOR SUSPENSION</b>	T5	PA; QL (248 EA per 31 days)
<b>PHEBURANE</b>	T5	PA; QL (620 GM per 31 days)
<i>pilocarpine hcl oral</i>	T2	
<b>PROLASTIN-C INTRAVENOUS RECON SOLN</b>	T5	PA
<b>PYRUKYND ORAL TABLET 20 MG, 5 MG (4-WEEK PACK), 50 MG</b>	T5	PA; QL (56 EA per 28 days)
<b>PYRUKYND ORAL TABLET 5 MG</b>	T5	PA; QL (14 EA per 365 days)
<b>PYRUKYND ORAL TABLETS,DOSE PACK</b>	T5	PA; QL (28 EA per 365 days)
<b>RAVICTI</b>	T5	PA
<b>RENAGEL ORAL TABLET 800 MG</b>	T5	
<b>REVELA ORAL POWDER IN PACKET</b>	T4	
<b>REVCOVI</b>	T5	
<b>RILUTEK</b>	T5	
<i>riluzole</i>	T4	
<i>risedronate oral tablet 30 mg</i>	T2	
<b>SALAGEN (PILOCARPINE)</b>	T4	
<i>sevelamer carbonate</i>	T3	
<i>sevelamer hcl</i>	T3	
<i>sodium chloride 0.9 % intravenous piggyback</i>	T2	
<i>sodium chloride irrigation</i>	T2	
<i>sodium phenylbutyrate</i>	T5	PA
<i>sodium polystyrene sulfonate oral powder</i>	T2	
<b>SPS (WITH SORBITOL) ORAL</b>	T2	
<b>SYPRINE</b>	T5	QL (248 EA per 31 days)
<b>TAVNEOS</b>	T5	PA; QL (186 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>THIOLA</b>	T5	PA
<b>THIOLA EC</b>	T5	PA
<b>TIGLUTIK</b>	T5	PA
<i>tiopronin</i>	T5	PA
<i>trientine oral capsule 250 mg</i>	T3	QL (248 EA per 31 days)
<i>varenicline oral tablet</i>	T4	QL (60 EA per 30 days)
<i>varenicline oral tablets,dose pack</i>	T4	QL (106 EA per 365 days)
<b>VELPHORO</b>	T5	
<b>VELTASSA</b>	T3	PA; QL (30 EA per 30 days)
<b>XURIDEN</b>	T5	PA; QL (124 EA per 31 days)
<b>ZEMAIRA</b>	T5	PA
<b>ZOKINVY</b>	T5	PA
<b>Ear, Nose / Throat Medications</b>		
<i>acetic acid otic (ear)</i>	T2	
<i>azelastine nasal aerosol,spray</i>	T2	QL (30 ML per 25 days)
<b>CETRAXAL</b>	T4	
<i>chlorhexidine gluconate mucous membrane</i>	T1	
<b>CIPRO HC</b>	T4	
<i>ciprofloxacin hcl otic (ear)</i>	T1	
<i>ciprofloxacin-dexamethasone</i>	T3	
<i>ciprofloxacin-fluocinolone</i>	T4	
<b>DERMOTIC OIL</b>	T4	
<b>FLAC OTIC OIL</b>	T2	
<i>fluocinolone acetonide oil</i>	T2	
<i>hydrocortisone-acetic acid</i>	T2	
<i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i>	T1	QL (30 ML per 28 days)
<i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i>	T1	QL (15 ML per 28 days)
<i>neomycin-polymyxin-hc otic (ear)</i>	T2	
<i>ofloxacin otic (ear)</i>	T2	
<i>olopatadine nasal</i>	T2	QL (30.5 GM per 30 days)
<b>OTOVEL</b>	T4	
<b>PERIOGARD</b>	T1	
<i>triamcinolone acetonide dental</i>	T2	
<b>Endocrine/Diabetes</b>		
<i>acarbose</i>	T1	QL (93 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ACTHAR</b>	T5	PA
<b>ACTOPLUS MET ORAL TABLET 15-850 MG</b>	T4	QL (93 EA per 31 days)
<b>ACTOS</b>	T4	QL (31 EA per 31 days)
<b>ADMELOG SOLOSTAR U-100 INSULIN</b>	T4	
<b>ADMELOG U-100 INSULIN LISPRO</b>	T4	
<b>AFREZZA INHALATION CARTRIDGE WITH INHALER 12 UNIT, 4 UNIT, 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT</b>	T4	
<b>AFREZZA INHALATION CARTRIDGE WITH INHALER 4 UNIT (90)/ 8 UNIT (90), 8 UNIT (90)/ 12 UNIT (90)</b>	T5	
<b>ALCOHOL PADS</b>	T2	
<b>ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 0.5 MG</b>	T4	PA
<b>ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 1 MG, 2 MG, 5 MG</b>	T5	PA
<i>alogliptin</i>	T4	ST; QL (31 EA per 31 days)
<i>alogliptin-metformin</i>	T4	ST; QL (62 EA per 31 days)
<i>alogliptin-pioglitazone oral tablet 12.5-30 mg, 25-15 mg, 25-30 mg, 25-45 mg</i>	T4	ST; QL (31 EA per 31 days)
<b>ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP</b>	T3	PA
<b>APIDRA SOLOSTAR U-100 INSULIN</b>	T4	
<b>APIDRA U-100 INSULIN</b>	T4	
<b>AVEED</b>	T4	PA
<b>BAQSIMI</b>	T3	
<b>BASAGLAR KWIKPEN U-100 INSULIN</b>	T4	
<b>BASAGLAR TEMPO PEN(U-100)INSLN</b>	T4	
<b>BYDUREON BCISE</b>	T4	PA
<b>BYETTA</b>	T4	PA
<i>cabergoline</i>	T2	
<i>calcitonin (salmon) nasal</i>	T2	PA-BvD
<i>calcitriol oral capsule</i>	T2	PA-BvD
<i>calcitriol oral solution</i>	T3	PA-BvD
<b>CERDELGA</b>	T5	PA; QL (62 EA per 31 days)
<i>cinacalcet oral tablet 30 mg, 60 mg</i>	T3	PA-BvD; QL (62 EA per 31 days)
<i>cinacalcet oral tablet 90 mg</i>	T3	PA-BvD; QL (124 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>CORTEF</b>	T4	
<b>CORTROPHIN GEL</b>	T5	PA
<b>CYCLOSET</b>	T4	
<b>CYTOMEL</b>	T4	
<i>danazol</i>	T2	
<b>DDAVP ORAL</b>	T4	
<b>DEPO-TESTOSTERONE</b>	T4	PA
<i>desmopressin nasal spray,non-aerosol 10 mcg/spray (0.1 ml)</i>	T4	
<i>desmopressin oral</i>	T2	
<b>DEXABLISS</b>	T2	
<i>dexamethasone oral solution</i>	T1	
<i>dexamethasone oral tablet</i>	T1	
<i>dexamethasone oral tablets,dose pack</i>	T2	
<i>diazoxide</i>	T3	
<i>doxercalciferol oral capsule 0.5 mcg, 2.5 mcg</i>	T2	PA-BvD
<i>doxercalciferol oral capsule 1 mcg</i>	T4	PA-BvD
<b>DUETACT</b>	T4	QL (31 EA per 31 days)
<b>EMFLAZA</b>	T5	PA
<b>ERMEZA</b>	T4	
<b>EUTHYROX</b>	T4	
<b>FARXIGA</b>	T4	ST; QL (31 EA per 31 days)
<b>FIASP FLEXTOUCH U-100 INSULIN</b>	T3	
<b>FIASP PENFILL U-100 INSULIN</b>	T3	
<b>FIASP U-100 INSULIN</b>	T3	
<i>fludrocortisone</i>	T2	
<b>FORTESTA</b>	T4	PA
<b>GALAFOLD</b>	T5	PA; QL (14 EA per 28 days)
<i>glimepiride</i>	T1	
<i>glipizide oral tablet 10 mg, 5 mg</i>	T1	
<i>glipizide oral tablet extended release 24hr</i>	T1	
<i>glipizide-metformin</i>	T1	
<b>GLUCAGEN HYPOKIT</b>	T3	
<b>GLUCAGON EMERGENCY KIT (HUMAN)</b>	T3	
<b>GLUCOTROL XL</b>	T4	
<b>GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 1,000 MG</b>	T5	ST; QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 500 MG</b>	T5	ST; QL (31 EA per 31 days)
<i>glyburide</i>	T2	
<i>glyburide micronized</i>	T2	
<i>glyburide-metformin</i>	T2	
<b>GLYNASE</b>	T4	
<b>GLYXAMBI</b>	T3	QL (31 EA per 31 days)
<b>GVOKE</b>	T3	
<b>GVOKE HYPOPEN 2-PACK</b>	T3	
<b>GVOKE PFS 1-PACK SYRINGE</b>	T3	
<b>HEMADY</b>	T4	PA-NS
<b>HUMALOG JUNIOR KWIKPEN U-100</b>	T3	
<b>HUMALOG KWIKPEN INSULIN</b>	T3	
<b>HUMALOG MIX 50-50 INSULN U-100</b>	T3	
<b>HUMALOG MIX 50-50 KWIKPEN</b>	T3	
<b>HUMALOG MIX 75-25 KWIKPEN</b>	T3	
<b>HUMALOG MIX 75-25(U-100)INSULN</b>	T3	
<b>HUMALOG TEMPO PEN(U-100)INSULN</b>	T3	
<b>HUMALOG U-100 INSULIN</b>	T3	
<b>HUMULIN 70/30 U-100 INSULIN</b>	T3	
<b>HUMULIN 70/30 U-100 KWIKPEN</b>	T3	
<b>HUMULIN N NPH INSULIN KWIKPEN</b>	T3	
<b>HUMULIN N NPH U-100 INSULIN</b>	T3	
<b>HUMULIN R REGULAR U-100 INSULN</b>	T3	
<b>HUMULIN R U-500 (CONC) INSULIN</b>	T3	
<b>HUMULIN R U-500 (CONC) KWIKPEN</b>	T3	
<i>hydrocortisone oral</i>	T1	
<b>INPEFA ORAL TABLET 200 MG</b>	T4	ST; QL (62 EA per 31 days)
<i>insulin asp prt-insulin aspart</i>	T3	
<i>insulin aspart u-100</i>	T3	
<i>insulin degludec</i>	T4	
<i>insulin glargine</i>	T4	
<i>insulin glargine-yfgn</i>	T4	
<i>insulin lispro</i>	T3	
<i>insulin lispro protamin-lispro</i>	T3	
<b>INVOKAMET</b>	T3	QL (62 EA per 31 days)
<b>INVOKAMET XR</b>	T3	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>INVOKANA ORAL TABLET 100 MG</b>	T3	QL (62 EA per 31 days)
<b>INVOKANA ORAL TABLET 300 MG</b>	T3	QL (31 EA per 31 days)
<b>ISTURISA ORAL TABLET 1 MG</b>	T5	PA; QL (248 EA per 31 days)
<b>ISTURISA ORAL TABLET 10 MG</b>	T5	PA; QL (186 EA per 31 days)
<b>ISTURISA ORAL TABLET 5 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>JANUMET</b>	T3	QL (62 EA per 31 days)
<b>JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG</b>	T3	QL (31 EA per 31 days)
<b>JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG</b>	T3	QL (62 EA per 31 days)
<b>JANUVIA ORAL TABLET 100 MG, 50 MG</b>	T3	QL (31 EA per 31 days)
<b>JANUVIA ORAL TABLET 25 MG</b>	T3	QL (93 EA per 31 days)
<b>JARDIANCE ORAL TABLET 10 MG</b>	T3	QL (62 EA per 31 days)
<b>JARDIANCE ORAL TABLET 25 MG</b>	T3	QL (31 EA per 31 days)
<b>JATENZO ORAL CAPSULE 158 MG, 198 MG</b>	T4	PA; QL (124 EA per 31 days)
<b>JATENZO ORAL CAPSULE 237 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>JAVYGTOR</b>	T5	PA
<b>JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG</b>	T3	QL (62 EA per 31 days)
<b>JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG</b>	T3	QL (62 EA per 31 days)
<b>JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG</b>	T3	QL (31 EA per 31 days)
<b>JYNARQUE ORAL TABLET</b>	T5	PA; QL (112 EA per 28 days)
<b>JYNARQUE ORAL TABLETS, SEQUENTIAL</b>	T5	PA; QL (56 EA per 28 days)
<b>KAZANO</b>	T4	ST; QL (62 EA per 31 days)
<b>KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 2.5-1,000 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>KOMBIGLYZE XR ORAL TABLET, ER MULTIPHASE 24 HR 5-1,000 MG, 5-500 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>KORLYM</b>	T5	PA; QL (124 EA per 31 days)
<b>KUVAN</b>	T5	PA
<b>LANTUS SOLOSTAR U-100 INSULIN</b>	T3	
<b>LANTUS U-100 INSULIN</b>	T3	
<b>LEVEMIR FLEXPEN</b>	T3	
<b>LEVEMIR U-100 INSULIN</b>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>levothyroxine oral capsule</i>	T4	
<i>levothyroxine oral tablet</i>	T1	
<b>LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG</b>	T3	
<i>liothyronine oral</i>	T2	
<b>LYUMJEV KWIKPEN U-100 INSULIN</b>	T4	
<b>LYUMJEV KWIKPEN U-200 INSULIN</b>	T4	
<b>LYUMJEV TEMPO PEN(U-100)INSULN</b>	T4	
<b>LYUMJEV U-100 INSULIN</b>	T4	
<b>MEDROL (PAK)</b>	T4	
<b>MEDROL ORAL TABLET 16 MG, 2 MG, 4 MG, 8 MG</b>	T4	
<i>metformin oral solution</i>	T4	ST; QL (791 ML per 31 days)
<i>metformin oral tablet 1,000 mg, 500 mg, 850 mg</i>	T1	
<i>metformin oral tablet 625 mg</i>	T4	QL (124 EA per 31 days)
<i>metformin oral tablet extended release 24 hr</i>	T1	
<i>metformin oral tablet extended release 24hr 1,000 mg</i>	T4	ST; QL (62 EA per 31 days)
<i>metformin oral tablet extended release 24hr 500 mg</i>	T4	ST; QL (31 EA per 31 days)
<i>metformin oral tablet,er gast.retention 24 hr 1,000 mg</i>	T5	ST; QL (62 EA per 31 days)
<i>metformin oral tablet,er gast.retention 24 hr 500 mg</i>	T4	ST; QL (31 EA per 31 days)
<i>methimazole oral tablet 10 mg, 5 mg</i>	T2	
<b>METHITEST</b>	T5	PA
<i>methylprednisolone</i>	T2	
<i>methyltestosterone oral capsule</i>	T5	PA
<i>miglitol</i>	T2	
<i>miglustat</i>	T5	PA; QL (93 EA per 31 days)
<b>MILLIPRED ORAL TABLET</b>	T2	
<b>MOUNJARO</b>	T3	PA
<b>MYALEPT</b>	T5	PA
<i>nateglinide</i>	T1	QL (93 EA per 31 days)
<b>NATESTO</b>	T4	PA
<b>NATPARA</b>	T5	PA; QL (31 EA per 31 days)
<b>NESINA</b>	T4	ST; QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>NOCDURNA (MEN)</b>	T4	QL (31 EA per 31 days)
<b>NOCDURNA (WOMEN)</b>	T4	QL (31 EA per 31 days)
<b>NOVOLIN 70/30 U-100 INSULIN</b>	T3	
<b>NOVOLIN 70-30 FLEXPEN U-100</b>	T3	
<b>NOVOLIN N FLEXPEN</b>	T3	
<b>NOVOLIN N NPH U-100 INSULIN</b>	T3	
<b>NOVOLIN R FLEXPEN</b>	T3	
<b>NOVOLIN R REGULAR U100 INSULIN</b>	T3	
<b>NOVOLOG FLEXPEN U-100 INSULIN</b>	T3	
<b>NOVOLOG MIX 70-30 U-100 INSULN</b>	T3	
<b>NOVOLOG MIX 70-30FLEXPEN U-100</b>	T3	
<b>NOVOLOG PENFILL U-100 INSULIN</b>	T3	
<b>NOVOLOG U-100 INSULIN ASPART</b>	T3	
<b>ONGLYZA</b>	T4	ST; QL (31 EA per 31 days)
<b>ORAPRED ODT</b>	T4	
<b>ORLISSA ORAL TABLET 150 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>ORLISSA ORAL TABLET 200 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>OSENI ORAL TABLET 12.5-30 MG, 25-15 MG, 25-30 MG, 25-45 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)</b>	T3	PA
<b>PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML</b>	T5	PA; QL (15 ML per 30 days)
<b>PALYNZIQ SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML</b>	T5	PA; QL (4 ML per 30 days)
<b>PALYNZIQ SUBCUTANEOUS SYRINGE 20 MG/ML</b>	T5	PA; QL (90 ML per 30 days)
<i>paricalcitol oral</i>	T2	PA-BvD
<i>pioglitazone</i>	T1	QL (31 EA per 31 days)
<i>pioglitazone-glimepiride</i>	T1	QL (31 EA per 31 days)
<i>pioglitazone-metformin</i>	T1	QL (93 EA per 31 days)
<i>prednisolone</i>	T2	
<i>prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i>	T2	
<i>prednisolone sodium phosphate oral tablet, disintegrating</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>PREDNISON</b>	T4	
<i>prednisone oral solution</i>	T2	
<i>prednisone oral tablet</i>	T1	
<i>prednisone oral tablets,dose pack</i>	T2	
<b>PROGLYCEM</b>	T4	
<i>propylthiouracil</i>	T2	
<b>QTERN</b>	T4	ST; QL (31 EA per 31 days)
<b>RAYALDEE</b>	T5	QL (62 EA per 31 days)
<b>RAYOS</b>	T5	
<b>RECORLEV</b>	T5	PA; QL (248 EA per 31 days)
<i>repaglinide oral tablet 0.5 mg</i>	T1	QL (124 EA per 31 days)
<i>repaglinide oral tablet 1 mg</i>	T2	QL (124 EA per 31 days)
<i>repaglinide oral tablet 2 mg</i>	T2	QL (248 EA per 31 days)
<b>REZVOGLAR KWIKPEN</b>	T4	
<b>ROCALTROL</b>	T4	PA-BvD
<b>RYBELSUS</b>	T3	PA
<b>SAMSCA</b>	T5	PA
<i>sapropterin</i>	T5	PA
<i>saxagliptin</i>	T4	ST; QL (31 EA per 31 days)
<i>saxagliptin-metformin oral tablet, er multiphase 24 hr 2.5-1,000 mg</i>	T4	ST; QL (62 EA per 31 days)
<i>saxagliptin-metformin oral tablet, er multiphase 24 hr 5-1,000 mg, 5-500 mg</i>	T4	ST; QL (31 EA per 31 days)
<b>SEGLUROMET</b>	T4	ST; QL (62 EA per 31 days)
<b>SEMGLEE(INSULIN GLARGINE-YFGN)</b>	T4	
<b>SEMGLEE(INSULIN GLARG-YFGN)PEN</b>	T4	
<b>SENSIPAR ORAL TABLET 30 MG, 60 MG</b>	T4	PA-BvD; QL (62 EA per 31 days)
<b>SENSIPAR ORAL TABLET 90 MG</b>	T5	PA-BvD; QL (124 EA per 31 days)
<b>SOLIQUA 100/33</b>	T3	QL (18 ML per 30 days)
<b>SOMAVERT</b>	T5	PA
<b>STEGLATRO</b>	T4	ST; QL (31 EA per 31 days)
<b>STEGLUJAN</b>	T4	ST; QL (31 EA per 31 days)
<b>SYMLINPEN 120</b>	T5	QL (10.8 ML per 28 days)
<b>SYMLINPEN 60</b>	T5	QL (6 ML per 28 days)
<b>SYNAREL</b>	T5	PA
<b>SYNJARDY</b>	T3	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>SYNTHROID</b>	T3	
<b>TAPERDEX</b>	T4	
<b>TARPEYO</b>	T5	PA; QL (124 EA per 31 days)
<b>TESTIM</b>	T4	PA
<i>testosterone cypionate</i>	T2	PA
<i>testosterone enanthate</i>	T2	PA
<i>testosterone transdermal gel in metered-dose pump 10 mg/0.5 gram /actuation, 12.5 mg/ 1.25 gram (1 %)</i>	T4	PA
<i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i>	T3	PA
<i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i>	T4	PA
<i>testosterone transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)</i>	T3	PA
<i>testosterone transdermal solution in metered pump w/app</i>	T4	PA
<b>THYQUIDITY</b>	T4	
<b>TIROSINT</b>	T4	
<b>TIROSINT-SOL</b>	T4	
<b>TLANDO</b>	T4	PA; QL (124 EA per 31 days)
<i>tolvaptan</i>	T5	PA
<b>TOUJEO MAX U-300 SOLOSTAR</b>	T3	
<b>TOUJEO SOLOSTAR U-300 INSULIN</b>	T3	
<b>TRADJENTA</b>	T3	QL (31 EA per 31 days)
<b>TRESIBA FLEXTOUCH U-100</b>	T3	
<b>TRESIBA FLEXTOUCH U-200</b>	T3	
<b>TRESIBA U-100 INSULIN</b>	T3	
<b>TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG</b>	T3	QL (31 EA per 31 days)
<b>TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG</b>	T3	QL (62 EA per 31 days)
<b>TRULICITY</b>	T3	PA
<b>UNITHROID</b>	T3	
<b>VICTOZA 3-PAK</b>	T3	PA
<b>VOGELXO TRANSDERMAL GEL</b>	T4	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP</b>	T4	PA
<b>VOXZOGO</b>	T5	PA; QL (31 EA per 31 days)
<b>XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG</b>	T4	ST; QL (31 EA per 31 days)
<b>XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG</b>	T4	ST; QL (62 EA per 31 days)
<b>XULTOPHY 100/3.6</b>	T3	QL (15 ML per 30 days)
<b>XYOSTED</b>	T4	PA
<b>ZAVESCA</b>	T5	PA; QL (93 EA per 31 days)
<b>ZEGALOGUE AUTOINJECTOR</b>	T3	
<b>ZEGALOGUE SYRINGE</b>	T3	
<b>ZEMPLAR ORAL CAPSULE 1 MCG, 2 MCG</b>	T4	PA-BvD
<b>Gastroenterology</b>		
<b>ACIPHEX</b>	T4	QL (62 EA per 31 days)
<i>alosetron oral tablet 0.5 mg</i>	T5	PA; QL (93 EA per 31 days)
<i>alosetron oral tablet 1 mg</i>	T5	PA; QL (62 EA per 31 days)
<b>AMITIZA</b>	T4	QL (62 EA per 31 days)
<i>amoxicil-clarithromy-lansopraz</i>	T2	
<b>ANTIVERT ORAL TABLET 50 MG</b>	T4	
<b>ANTIVERT ORAL TABLET,CHEWABLE</b>	T4	
<b>ANUSOL-HC TOPICAL</b>	T4	
<b>ANZEMET ORAL TABLET 50 MG</b>	T4	PA-BvD
<i>aprepitant</i>	T4	PA-BvD
<b>APRISO</b>	T4	
<b>AZULFIDINE</b>	T4	
<b>AZULFIDINE EN-TABS</b>	T4	
<i>balsalazide</i>	T2	
<i>betaine</i>	T5	
<i>bismuth subcit k-metronidz-tcn</i>	T4	
<b>BONJESTA</b>	T4	PA; QL (62 EA per 31 days)
<i>budesonide oral capsule,delayed,extend.release</i>	T4	
<i>budesonide oral tablet,delayed and ext.release</i>	T5	
<i>budesonide rectal</i>	T4	
<b>BYLVAY ORAL CAPSULE 1,200 MCG</b>	T5	PA; QL (186 EA per 31 days)
<b>BYLVAY ORAL CAPSULE 400 MCG</b>	T5	PA; QL (558 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>BYLVAY ORAL PELLETT 200 MCG</b>	T5	PA; QL (1116 EA per 31 days)
<b>BYLVAY ORAL PELLETT 600 MCG</b>	T5	PA; QL (372 EA per 31 days)
<b>CANASA</b>	T5	
<b>CARAFATE ORAL SUSPENSION</b>	T3	
<b>CARAFATE ORAL TABLET</b>	T4	
<b>CHENODAL</b>	T5	PA
<i>chlordiazepoxide-clidinium</i>	T2	
<b>CHOLBAM</b>	T5	PA
<i>cimetidine</i>	T2	
<b>CIMZIA</b>	T5	PA; QL (2 EA per 28 days)
<b>CIMZIA POWDER FOR RECONST</b>	T5	PA; QL (2 EA per 28 days)
<b>CLENPIQ</b>	T4	
<b>COLAZAL</b>	T4	
<b>COMPRO</b>	T2	
<b>CONSTULOSE</b>	T2	
<b>CREON</b>	T3	
<i>cromolyn oral</i>	T4	
<b>CUVPOSA</b>	T4	
<b>CYSTADANE</b>	T5	
<b>CYTOTEC</b>	T4	
<b>DARTISLA</b>	T4	PA; QL (124 EA per 31 days)
<b>DELZICOL</b>	T4	
<b>DEXILANT</b>	T4	QL (31 EA per 31 days)
<i>dexlansoprazole</i>	T4	QL (31 EA per 31 days)
<b>DICLEGIS</b>	T4	PA; QL (124 EA per 31 days)
<i>dicyclomine oral capsule</i>	T2	
<i>dicyclomine oral solution</i>	T2	
<i>dicyclomine oral tablet</i>	T2	
<b>DIPENTUM</b>	T5	
<i>diphenoxylate-atropine oral liquid</i>	T3	
<i>diphenoxylate-atropine oral tablet</i>	T2	
<i>doxylamine-pyridoxine (vit b6)</i>	T4	PA; QL (124 EA per 31 days)
<i>dronabinol oral capsule 10 mg</i>	T4	PA-BvD
<i>dronabinol oral capsule 2.5 mg, 5 mg</i>	T2	PA-BvD
<b>EMEND ORAL CAPSULE 80 MG</b>	T4	PA-BvD
<b>EMEND ORAL CAPSULE,DOSE PACK</b>	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>EMEND ORAL SUSPENSION FOR RECONSTITUTION</b>	T4	PA-BvD
<b>ENULOSE</b>	T2	
<i>esomeprazole magnesium oral capsule, delayed release(dr/ec)</i>	T2	QL (31 EA per 31 days)
<i>esomeprazole magnesium oral granules dr for susp in packet</i>	T2	QL (31 EA per 31 days)
<i>famotidine oral suspension</i>	T1	
<i>famotidine oral tablet 20 mg, 40 mg</i>	T1	
<b>GASTROCROM</b>	T4	
<b>GATTEX 30-VIAL</b>	T5	PA
<b>GAVILYTE-C</b>	T2	
<b>GAVILYTE-G</b>	T2	
<b>GENERLAC</b>	T2	
<b>GIMOTI</b>	T4	PA; QL (9.8 ML per 28 days)
<b>GLYCATE</b>	T4	PA
<i>glycopyrrolate oral solution</i>	T4	
<i>glycopyrrolate oral tablet 1 mg, 2 mg</i>	T2	
<i>glycopyrrolate oral tablet 1.5 mg</i>	T4	PA
<b>GOLYTELY</b>	T4	
<i>granisetron hcl oral</i>	T2	PA-BvD
<b>HELIDAC</b>	T4	
<i>hydrocortisone rectal</i>	T3	
<i>hydrocortisone topical cream with perineal applicator 2.5 %</i>	T1	
<i>hydrocortisone-pramoxine rectal cream 1-1 %</i>	T4	
<b>IBSRELA</b>	T5	PA; QL (62 EA per 31 days)
<b>KONVOMEF</b>	T4	
<b>KRISTALOSE</b>	T4	ST
<i>lactulose oral packet</i>	T5	ST
<i>lactulose oral solution 10 gram/15 ml</i>	T1	
<i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i>	T3	QL (31 EA per 31 days)
<i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i>	T3	QL (62 EA per 31 days)
<i>lansoprazole oral tablet, disintegrat, delay rel 15 mg</i>	T3	QL (31 EA per 31 days)
<i>lansoprazole oral tablet, disintegrat, delay rel 30 mg</i>	T3	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LIALDA</b>	T4	
<b>LIBRAX (WITH CLIDINIUM)</b>	T5	
<b>LINZESS</b>	T3	QL (31 EA per 31 days)
<b>LIVMARLI</b>	T5	PA; QL (93 ML per 31 days)
<b>LOMOTIL</b>	T4	
<i>loperamide oral capsule</i>	T2	
<b>LOTRONEX ORAL TABLET 0.5 MG</b>	T5	PA; QL (93 EA per 31 days)
<b>LOTRONEX ORAL TABLET 1 MG</b>	T5	PA; QL (62 EA per 31 days)
<i>lubiprostone</i>	T3	QL (62 EA per 31 days)
<b>MARINOL</b>	T4	PA-BvD
<i>meclizine oral tablet 12.5 mg, 25 mg</i>	T2	
<i>mesalamine oral capsule (with del rel tablets)</i>	T3	
<i>mesalamine oral capsule, extended release</i>	T5	
<i>mesalamine oral capsule, extended release 24hr</i>	T4	
<i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i>	T3	
<i>mesalamine oral tablet, delayed release (dr/ec) 800 mg</i>	T4	
<i>mesalamine rectal enema</i>	T2	
<i>mesalamine rectal suppository</i>	T4	
<i>methscopolamine</i>	T2	
<i>metoclopramide hcl oral solution</i>	T2	
<i>metoclopramide hcl oral tablet</i>	T2	
<i>metoclopramide hcl oral tablet, disintegrating 5 mg</i>	T2	
<i>misoprostol</i>	T2	
<b>MOTEGRITY</b>	T4	PA; QL (31 EA per 31 days)
<b>MOVANTIK</b>	T3	QL (31 EA per 31 days)
<b>MOVIPREP</b>	T4	
<b>MYTESI</b>	T5	QL (62 EA per 31 days)
<b>NEXIUM</b>	T4	QL (31 EA per 31 days)
<b>NEXIUM PACKET</b>	T3	QL (31 EA per 31 days)
<i>nizatidine oral capsule</i>	T2	
<b>OICALIVA</b>	T5	PA; QL (31 EA per 31 days)
<i>omeprazole oral capsule, delayed release (dr/ec)</i>	T1	
<i>omeprazole-sodium bicarbonate oral capsule</i>	T2	
<i>omeprazole-sodium bicarbonate oral packet</i>	T5	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>ondansetron</i>	T2	PA-BvD
<i>ondansetron hcl oral solution</i>	T2	PA-BvD
<i>ondansetron hcl oral tablet 4 mg, 8 mg</i>	T2	PA-BvD
<b>OSMOPREP</b>	T4	
<b>PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,500-35,500- 61,500 UNIT, 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 21,000-54,700- 83,900 UNIT, 37,000-97,300- 149,900 UNIT, 4,200-14,200- 24,600 UNIT</b>	T4	
<i>pantoprazole oral granules dr for susp in packet</i>	T4	
<i>pantoprazole oral tablet,delayed release (dr/ec)</i>	T1	
<i>peg 3350-electrolytes</i>	T2	
<i>peg3350-sod sul-nacl-kcl-asb-c</i>	T4	
<i>peg-electrolyte soln</i>	T2	
<b>PENTASA ORAL CAPSULE, EXTENDED RELEASE 250 MG</b>	T3	
<b>PENTASA ORAL CAPSULE, EXTENDED RELEASE 500 MG</b>	T5	
<b>PEPCID ORAL TABLET</b>	T4	
<b>PERTZYE</b>	T4	
<b>PLENVU</b>	T4	
<b>PREVACID ORAL CAPSULE,DELAYED RELEASE(DR/EC) 30 MG</b>	T4	QL (62 EA per 31 days)
<b>PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 15 MG</b>	T4	QL (31 EA per 31 days)
<b>PREVACID SOLUTAB ORAL TABLET,DISINTEGRAT, DELAY REL 30 MG</b>	T4	QL (62 EA per 31 days)
<b>PRILOSEC ORAL SUSP,DELAYED RELEASE FOR RECON</b>	T4	
<i>prochlorperazine</i>	T2	
<i>prochlorperazine maleate</i>	T2	
<b>PROCTO-MED HC</b>	T2	
<b>PROCTOSOL HC TOPICAL</b>	T2	
<b>PROCTOZONE-HC</b>	T2	
<b>PROTONIX ORAL</b>	T4	
<b>PYLERA</b>	T5	
<i>rabeprazole oral tablet,delayed release (dr/ec)</i>	T2	QL (62 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>RECTIV</b>	T4	
<b>REGLAN ORAL</b>	T4	
<b>RELISTOR ORAL</b>	T5	PA; QL (93 EA per 31 days)
<b>RELISTOR SUBCUTANEOUS SOLUTION</b>	T4	PA; QL (18.6 ML per 31 days)
<b>RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML</b>	T5	PA; QL (18.6 ML per 31 days)
<b>RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML</b>	T5	PA; QL (12.4 ML per 31 days)
<b>RELTONE</b>	T4	ST
<b>ROBINUL FORTE</b>	T4	
<b>ROBINUL ORAL</b>	T4	
<b>ROWASA RECTAL ENEMA KIT</b>	T4	
<b>SANCUSO</b>	T5	
<i>scopolamine base</i>	T3	QL (10 EA per 30 days)
<b>SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML)</b>	T5	PA; QL (1.2 ML per 56 days)
<b>SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 360 MG/2.4 ML (150 MG/ML)</b>	T5	PA; QL (2.4 ML per 56 days)
<i>sodium,potassium,mag sulfates</i>	T4	
<b>SUCRAID</b>	T5	
<i>sucralfate</i>	T2	
<b>SUFLAVE</b>	T4	
<i>sulfasalazine</i>	T2	
<b>SUPREP BOWEL PREP KIT</b>	T3	
<b>SUTAB</b>	T4	
<b>SYMPROIC</b>	T4	PA; QL (31 EA per 31 days)
<b>SYNDROS</b>	T5	PA
<b>TALICIA</b>	T4	
<b>TRANSDERM-SCOP</b>	T3	QL (10 EA per 30 days)
<i>trimethobenzamide oral</i>	T2	PA
<b>TRULANCE</b>	T4	QL (31 EA per 31 days)
<b>UCERIS ORAL</b>	T5	
<b>UCERIS RECTAL</b>	T4	
<b>URSO 250</b>	T4	ST
<b>URSO FORTE</b>	T4	ST
<i>ursodiol oral capsule 200 mg, 400 mg</i>	T4	ST
<i>ursodiol oral capsule 300 mg</i>	T3	
<i>ursodiol oral tablet</i>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>VARUBI</b>	T4	PA-BvD
<b>VIBERZI</b>	T5	PA; QL (62 EA per 31 days)
<b>VIOKACE ORAL TABLET 10,440-39,150-39,150 UNIT</b>	T4	
<b>VIOKACE ORAL TABLET 20,880-78,300-78,300 UNIT</b>	T5	
<b>VOWST</b>	T5	PA; QL (12 EA per 14 days)
<b>ZEGERID</b>	T5	
<b>ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT</b>	T3	
<b>Immunology, Vaccines / Biotechnology</b>		
<b>ABRYSVO</b>	T3	QL (2 EA per 365 days)
<b>ACTHIB (PF)</b>	T3	
<b>ACTIMMUNE</b>	T5	PA
<b>ADACEL(TDAP ADOLESN/ADULT)(PF)</b>	T3	
<b>ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML</b>	T4	PA-BvD
<b>ARANESP (IN POLYSORBATE) INJECTION SOLUTION 200 MCG/ML</b>	T5	PA-BvD
<b>ARANESP (IN POLYSORBATE) INJECTION SYRINGE 10 MCG/0.4 ML, 100 MCG/0.5 ML, 25 MCG/0.42 ML, 40 MCG/0.4 ML</b>	T4	PA-BvD
<b>ARANESP (IN POLYSORBATE) INJECTION SYRINGE 150 MCG/0.3 ML, 200 MCG/0.4 ML, 300 MCG/0.6 ML, 500 MCG/ML, 60 MCG/0.3 ML</b>	T5	PA-BvD
<b>ARCALYST</b>	T5	PA
<b>AREXVY (PF)</b>	T3	QL (2 EA per 365 days)
<b>AVONEX INTRAMUSCULAR PEN INJECTOR KIT</b>	T5	QL (4 EA per 28 days)
<b>AVONEX INTRAMUSCULAR SYRINGE KIT</b>	T5	QL (4 EA per 28 days)
<i>bcg vaccine, live (pf)</i>	T4	
<b>BESREMI</b>	T5	PA-NS; QL (2 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>BETASERON SUBCUTANEOUS KIT</b>	T5	QL (14 EA per 28 days)
<b>BEXSERO</b>	T3	
<b>BIVIGAM</b>	T5	PA
<b>BOOSTRIX TDAP</b>	T3	
<b>DAPTACEL (DTAP PEDIATRIC) (PF)</b>	T3	
<b>EGRIFTA SV</b>	T5	PA
<b>ENGERIX-B (PF)</b>	T3	PA-BvD
<b>ENGERIX-B PEDIATRIC (PF)</b>	T3	PA-BvD
<b>EPOGEN INJECTION SOLUTION 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML</b>	T4	PA-BvD
<b>EXTAVIA SUBCUTANEOUS KIT</b>	T5	QL (15 EA per 30 days)
<b>FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %</b>	T5	PA
<b>FULPHILA</b>	T5	
<b>FYLNETRA</b>	T5	
<b>GAMMAGARD LIQUID</b>	T5	PA
<b>GAMMAGARD S-D (IGA &lt; 1 MCG/ML)</b>	T5	PA
<b>GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)</b>	T4	PA
<b>GAMMAPLEX</b>	T5	PA
<b>GAMMAPLEX (WITH SORBITOL)</b>	T5	PA
<b>GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)</b>	T3	PA
<b>GARDASIL 9 (PF)</b>	T3	
<b>GENOTROPIN</b>	T5	PA
<b>GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML</b>	T4	PA
<b>GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML</b>	T5	PA
<b>GRANIX</b>	T5	
<b>GRASTEK</b>	T4	PA
<b>HAVRIX (PF)</b>	T3	
<b>HEPLISAV-B (PF)</b>	T3	PA-BvD
<b>HIBERIX (PF)</b>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>HUMATROPE INJECTION CARTRIDGE 12 MG (36 UNIT), 24 MG (72 UNIT)</b>	T5	PA
<b>HUMATROPE INJECTION CARTRIDGE 6 MG (18 UNIT)</b>	T4	PA
<b>IMOVAX RABIES VACCINE (PF)</b>	T3	PA-BvD
<b>INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE</b>	T3	
<b>IPOL</b>	T3	
<b>IXIARO (PF)</b>	T3	
<b>JYNNEOS (PF)(STOCKPILE)</b>	T3	PA-BvD
<b>KINRIX (PF) INTRAMUSCULAR SYRINGE</b>	T3	
<b>LEUKINE INJECTION RECON SOLN</b>	T5	PA
<b>MENACTRA (PF) INTRAMUSCULAR SOLUTION</b>	T3	
<b>MENQUADFI (PF)</b>	T4	
<b>MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT</b>	T3	
<b>M-M-R II (PF)</b>	T3	
<b>NEULASTA</b>	T5	
<b>NEUPOGEN</b>	T5	
<b>NGENLA</b>	T5	PA
<b>NIVESTYM</b>	T5	
<b>NORDITROPIN FLEXPRO</b>	T5	PA
<b>NUTROPIN AQ NUSPIN</b>	T5	PA
<b>NYVEPRIA</b>	T5	
<b>OCTAGAM</b>	T5	PA
<b>ODACTRA</b>	T4	PA
<b>OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML)</b>	T5	PA
<b>OMNITROPE SUBCUTANEOUS CARTRIDGE 5 MG/1.5 ML (3.3 MG/ML)</b>	T4	PA
<b>OMNITROPE SUBCUTANEOUS RECON SOLN</b>	T5	PA
<b>ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY</b>	T4	PA
<b>PANZYGA</b>	T5	PA
<b>PEDIARIX (PF)</b>	T3	PA-BvD
<b>PEDVAX HIB (PF)</b>	T3	
<b>PEGASYS</b>	T5	PA

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>PENTACEL (PF) INTRAMUSCULAR KIT 15LF-48MCG-62DU -10 MCG/0.5ML</b>	T3	
<b>PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML</b>	T5	QL (1 ML per 28 days)
<b>PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML</b>	T5	QL (1 ML per 28 days)
<b>PREHEVBRIO (PF)</b>	T3	PA-BvD
<b>PRIORIX (PF)</b>	T3	
<b>PRIVIGEN</b>	T5	PA
<b>PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML</b>	T3	PA-BvD
<b>PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML</b>	T5	PA-BvD
<b>PROQUAD (PF)</b>	T3	
<b>QUADRACEL (PF)</b>	T3	
<b>RABAVERT (PF)</b>	T3	PA-BvD
<b>REBIF (WITH ALBUMIN)</b>	T5	QL (6 ML per 28 days)
<b>REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML</b>	T5	QL (6 ML per 28 days)
<b>REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6)</b>	T5	QL (4.2 ML per 365 days)
<b>REBIF TITRATION PACK</b>	T5	QL (8.4 ML per 365 days)
<b>RECOMBIVAX HB (PF)</b>	T3	PA-BvD
<b>RELEUKO SUBCUTANEOUS</b>	T5	
<b>RETACRIT</b>	T3	PA-BvD
<b>ROTARIX</b>	T3	
<b>ROTATEQ VACCINE</b>	T3	
<b>SAIZEN</b>	T5	PA
<b>SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG</b>	T5	PA
<b>SHINGRIX (PF)</b>	T3	QL (2 EA per 999 days)
<b>SKYTROFA</b>	T5	PA
<b>SOGROYA</b>	T5	PA
<b>TDVAX</b>	T3	
<b>TENIVAC (PF)</b>	T3	
<i>tetanus,diphtheria tox ped(pf)</i>	T4	
<b>TICOVAC</b>	T3	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TRUMENBA</b>	T3	
<b>TWINRIX (PF)</b>	T3	
<b>TYPHIM VI</b>	T3	
<b>UDENYCA</b>	T5	
<b>UDENYCA AUTOINJECTOR</b>	T5	
<b>VAQTA (PF)</b>	T3	
<b>VARIVAX (PF)</b>	T3	
<b>YF-VAX (PF)</b>	T3	
<b>ZARXIO</b>	T5	
<b>ZIEXTENZO</b>	T5	
<b>ZOMACTON</b>	T4	PA
<b>ZORBTIVE</b>	T5	PA
<b>Miscellaneous Supplies</b>		
<b>ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2"</b>	T4	
<b>GAUZE PAD TOPICAL BANDAGE 2 X 2 "</b>	T2	
<i>insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge</i>	T3	
<i>pen needle, diabetic needle 29 gauge x 1/2"</i>	T4	
<b>Musculoskeletal / Rheumatology</b>		
<b>ACTEMRA ACTPEN</b>	T5	PA; QL (3.6 ML per 28 days)
<b>ACTEMRA SUBCUTANEOUS</b>	T5	PA; QL (3.6 ML per 28 days)
<b>ACTONEL ORAL TABLET 150 MG, 35 MG</b>	T4	
<i>adalimumab-fkjp</i>	T5	PA; QL (2 EA per 28 days)
<i>alendronate oral solution</i>	T1	
<i>alendronate oral tablet 10 mg, 35 mg, 70 mg</i>	T1	
<i>allopurinol oral tablet 100 mg, 300 mg</i>	T1	
<i>allopurinol oral tablet 200 mg</i>	T4	
<b>AMJEVITA(CF) AUTOINJECTOR</b>	T5	PA; QL (1.6 EA per 28 days)
<b>AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML</b>	T5	PA; QL (0.4 ML per 28 days)
<b>AMJEVITA(CF) SUBCUTANEOUS SYRINGE 20 MG/0.4 ML</b>	T5	PA; QL (0.8 EA per 28 days)
<b>AMJEVITA(CF) SUBCUTANEOUS SYRINGE 40 MG/0.8 ML</b>	T5	PA; QL (1.6 EA per 28 days)
<b>ARAVA</b>	T5	
<b>ATELVIA</b>	T4	
<b>BENLYSTA SUBCUTANEOUS</b>	T5	PA; QL (4 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>BINOSTO</b>	T4	
<i>colchicine</i>	T4	QL (62 EA per 31 days)
<b>COLCRYS</b>	T4	QL (124 EA per 31 days)
<b>CUPRIMINE</b>	T5	
<b>CYLTEZO(CF)</b>	T5	PA; QL (2 EA per 28 days)
<b>CYLTEZO(CF) PEN</b>	T5	PA; QL (2 EA per 28 days)
<b>CYLTEZO(CF) PEN CROHN'S-UC-HS</b>	T5	PA; QL (12 EA per 365 days)
<b>CYLTEZO(CF) PEN PSORIASIS-UV</b>	T5	PA; QL (8 EA per 365 days)
<b>DEPEN TITRATABS</b>	T5	
<b>ENBREL MINI</b>	T5	PA; QL (7.84 ML per 28 days)
<b>ENBREL SUBCUTANEOUS SOLUTION</b>	T5	PA; QL (4 ML per 28 days)
<b>ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5)</b>	T5	PA; QL (4 ML per 28 days)
<b>ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML)</b>	T5	PA; QL (7.84 ML per 28 days)
<b>ENBREL SURECLICK</b>	T5	PA; QL (7.84 ML per 28 days)
<b>EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML ( 105MG/1.17MLX2)</b>	T5	PA; QL (2.34 ML per 28 days)
<b>EVISTA</b>	T3	
<i>febuxostat</i>	T4	PA
<b>FORTEO</b>	T5	PA; QL (2.4 ML per 28 days)
<b>FOSAMAX ORAL TABLET 70 MG</b>	T4	
<b>FOSAMAX PLUS D</b>	T4	
<b>HADLIMA</b>	T5	PA; QL (1.6 ML per 28 days)
<b>HADLIMA PUSHTOUCH</b>	T5	PA; QL (1.6 ML per 28 days)
<b>HADLIMA(CF)</b>	T5	PA; QL (0.8 ML per 28 days)
<b>HADLIMA(CF) PUSHTOUCH</b>	T5	PA; QL (0.8 ML per 28 days)
<b>HULIO(CF)</b>	T5	PA; QL (2 EA per 28 days)
<b>HULIO(CF) PEN</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA PEN</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA PEN CROHNS-UC-HS START</b>	T5	PA; QL (6 EA per 28 days)
<b>HUMIRA PEN PSOR-UEVITS-ADOL HS</b>	T5	PA; QL (4 EA per 28 days)
<b>HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA(CF)</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML</b>	T5	PA; QL (3 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML-40 MG/0.4 ML</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA(CF) PEN</b>	T5	PA; QL (2 EA per 28 days)
<b>HUMIRA(CF) PEN CROHNS-UC-HS</b>	T5	PA; QL (3 EA per 28 days)
<b>HUMIRA(CF) PEN PEDIATRIC UC</b>	T5	PA; QL (4 EA per 28 days)
<b>HUMIRA(CF) PEN PSOR-UV-ADOL HS</b>	T5	PA; QL (3 EA per 28 days)
<b>HYRIMOZ PEN CROHN'S-UC STARTER</b>	T5	PA; QL (4.8 ML per 365 days)
<b>HYRIMOZ PEN PSORIASIS STARTER</b>	T5	PA; QL (3.2 ML per 365 days)
<b>HYRIMOZ(CF) PEDI CROHN STARTER</b>	T5	PA; QL (2.4 ML per 365 days)
<b>HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML</b>	T5	PA; QL (0.8 ML per 28 days)
<b>HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 80 MG/0.8 ML</b>	T5	PA; QL (1.6 ML per 28 days)
<b>HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML</b>	T5	PA; QL (0.2 ML per 28 days)
<b>HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 20 MG/0.2 ML</b>	T5	PA; QL (0.4 ML per 28 days)
<b>HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 40 MG/0.4 ML</b>	T5	PA; QL (0.8 ML per 28 days)
<i>ibandronate oral</i>	T2	
<b>KEVZARA</b>	T5	PA; QL (2.28 ML per 28 days)
<b>KINERET</b>	T5	PA; QL (18.76 ML per 28 days)
<i>leflunomide</i>	T2	
<b>MITIGARE</b>	T3	QL (62 EA per 31 days)
<b>OLUMIANT</b>	T5	PA; QL (31 EA per 31 days)
<b>ORENCIA CLICKJECT</b>	T5	PA; QL (4 ML per 28 days)
<b>ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML</b>	T5	PA; QL (4 ML per 28 days)
<b>ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML</b>	T5	PA; QL (1.6 ML per 28 days)
<b>ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML</b>	T5	PA; QL (2.8 ML per 28 days)
<b>OTEZLA</b>	T5	PA; QL (62 EA per 31 days)
<b>OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)</b>	T5	PA; QL (55 EA per 28 days)
<b>OTREXUP (PF)</b>	T4	PA
<i>penicillamine</i>	T5	
<i>probenecid</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>probenecid-colchicine</i>	T2	
<b>PROLIA</b>	T4	PA; QL (1 ML per 180 days)
<i>raloxifene</i>	T3	
<b>RASUVO (PF)</b>	T4	PA
<b>RIDAURA</b>	T3	
<b>RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG</b>	T5	PA; QL (31 EA per 31 days)
<b>RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG</b>	T5	PA; QL (168 EA per 365 days)
<i>risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg</i>	T2	
<i>risedronate oral tablet, delayed release (dr/ec)</i>	T2	
<b>SAVELLA</b>	T4	PA
<b>SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML</b>	T5	PA; QL (1 ML per 28 days)
<b>SIMPONI SUBCUTANEOUS PEN INJECTOR 50 MG/0.5 ML</b>	T5	PA; QL (0.5 ML per 28 days)
<b>SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML</b>	T5	PA; QL (1 ML per 28 days)
<b>SIMPONI SUBCUTANEOUS SYRINGE 50 MG/0.5 ML</b>	T5	PA; QL (0.5 ML per 28 days)
<i>teriparatide</i>	T5	PA; QL (2.48 ML per 28 days)
<b>TYMLOS</b>	T5	PA; QL (1.56 ML per 30 days)
<b>ULORIC</b>	T4	PA
<b>XELJANZ ORAL SOLUTION</b>	T5	PA; QL (310 ML per 31 days)
<b>XELJANZ ORAL TABLET</b>	T5	PA; QL (62 EA per 31 days)
<b>XELJANZ XR</b>	T5	PA; QL (31 EA per 31 days)
<b>YUFLYMA(CF)</b>	T5	PA; QL (2 EA per 28 days)
<b>YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML</b>	T5	PA; QL (2 EA per 28 days)
<b>YUSIMRY(CF) PEN</b>	T5	PA; QL (1.6 ML per 28 days)
<b>Obstetrics / Gynecology</b>		
<b>ACTIVELLA</b>	T4	
<b>ALTAVERA (28)</b>	T2	
<b>ALYACEN 1/35 (28)</b>	T2	
<b>AMABELZ</b>	T2	
<b>AMETHIA</b>	T2	
<b>ANGELIQ</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ANNOVERA</b>	T4	
<b>APRI</b>	T2	
<b>ARANELLE (28)</b>	T2	
<b>ASHLYNA</b>	T2	
<b>AUBRA EQ</b>	T2	
<b>AVIANE</b>	T2	
<b>AYGESTIN</b>	T4	
<b>BALCOLTRA</b>	T4	
<b>BALZIVA (28)</b>	T2	
<b>BEYAZ</b>	T4	
<b>BIJUVA</b>	T4	
<b>BLISOVI 24 FE</b>	T2	
<b>BLISOVI FE 1.5/30 (28)</b>	T2	
<b>BRIELLYN</b>	T2	
<b>CAMILA</b>	T2	
<b>CAMRESE LO</b>	T2	
<b>CLEOCIN VAGINAL</b>	T4	
<b>CLIMARA</b>	T4	
<b>CLIMARA PRO</b>	T4	
<i>clindamycin phosphate vaginal</i>	T2	
<b>CLINDESSE</b>	T4	
<b>COMBIPATCH</b>	T4	
<b>CRINONE</b>	T4	PA
<b>CRYSELLE (28)</b>	T2	
<b>CYRED EQ</b>	T2	
<b>DEBLITANE</b>	T2	
<b>DELESTROGEN</b>	T4	
<b>DEPO-ESTRADIOL</b>	T4	
<b>DEPO-PROVERA INTRAMUSCULAR SUSPENSION 150 MG/ML</b>	T4	
<b>DEPO-PROVERA INTRAMUSCULAR SYRINGE</b>	T4	
<b>DEPO-SUBQ PROVERA 104</b>	T4	
<i>desog-e.estradiol/e.estradiol</i>	T2	
<i>desogestrel-ethinyl estradiol</i>	T2	
<b>DIVIGEL</b>	T4	
<b>DOLISHALE</b>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>DOTTI</b>	T2	
<i>drospirenone-e.estradiol-lm.fa oral tablet 3-0.02-0.451 mg (24) (4)</i>	T2	
<i>drospirenone-ethinyl estradiol</i>	T2	
<b>DUAVEE</b>	T4	
<b>ELESTRIN</b>	T4	
<b>ELURYNG</b>	T3	
<b>ENPRESSE</b>	T2	
<b>ENSKYCE</b>	T2	
<b>ERRIN</b>	T2	
<b>ESTARYLLA</b>	T2	
<b>ESTRACE</b>	T4	
<i>estradiol oral</i>	T1	
<i>estradiol transdermal gel in packet</i>	T4	
<i>estradiol transdermal patch semiweekly</i>	T2	
<i>estradiol transdermal patch weekly</i>	T2	
<i>estradiol vaginal</i>	T4	
<i>estradiol valerate</i>	T2	
<i>estradiol-norethindrone acet</i>	T2	
<b>ESTRING</b>	T4	
<b>ESTROGEL</b>	T4	
<i>ethynodiol diac-eth estradiol</i>	T2	
<i>etonogestrel-ethinyl estradiol</i>	T3	
<b>EVAMIST</b>	T4	
<b>FALMINA (28)</b>	T2	
<b>FEMRING</b>	T4	
<b>FINZALA</b>	T2	
<b>FYAVOLV</b>	T2	
<b>GEMMILY</b>	T4	
<b>GYNAZOLE-1</b>	T3	
<b>HAILEY 24 FE</b>	T2	
<b>HALOETTE</b>	T3	
<b>ICLEVIA</b>	T2	
<b>IMVEXXY MAINTENANCE PACK</b>	T4	
<b>IMVEXXY STARTER PACK</b>	T4	
<b>INCASSIA</b>	T2	
<b>INTRAROSA</b>	T4	PA; QL (28 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>INTROVALE</b>	T2	
<b>ISIBLOOM</b>	T2	
<b>JASMIEL (28)</b>	T2	
<b>JINTELI</b>	T2	
<b>JULEBER</b>	T2	
<b>JUNEL 1.5/30 (21)</b>	T2	
<b>JUNEL 1/20 (21)</b>	T2	
<b>JUNEL FE 1.5/30 (28)</b>	T2	
<b>JUNEL FE 1/20 (28)</b>	T2	
<b>JUNEL FE 24</b>	T2	
<b>KAITLIB FE</b>	T2	
<b>KARIVA (28)</b>	T2	
<b>KELNOR 1/35 (28)</b>	T2	
<b>KELNOR 1-50 (28)</b>	T2	
<b>KURVELO (28)</b>	T2	
<b>KYLEENA</b>	T4	
<i>l norgest/e.estradiol-e.estradiol</i>	T2	
<b>LARIN 1.5/30 (21)</b>	T2	
<b>LARIN 1/20 (21)</b>	T2	
<b>LARIN FE 1.5/30 (28)</b>	T2	
<b>LARIN FE 1/20 (28)</b>	T2	
<b>LAYOLIS FE</b>	T4	
<b>LEENA 28</b>	T2	
<b>LESSINA</b>	T2	
<b>LEVONEST (28)</b>	T2	
<i>levonorgestrel-ethinyl estradiol</i>	T2	
<i>levonorg-eth estradiol triphasic</i>	T2	
<b>LEVORA-28</b>	T2	
<b>LILETTA</b>	T4	
<b>LO LOESTRIN FE</b>	T4	
<b>LOESTRIN 1.5/30 (21)</b>	T4	
<b>LOESTRIN 1/20 (21)</b>	T4	
<b>LOESTRIN FE 1.5/30 (28-DAY)</b>	T4	
<b>LOESTRIN FE 1/20 (28-DAY)</b>	T4	
<b>LORYNA (28)</b>	T2	
<b>LOSEASONIQUE</b>	T4	
<b>LOW-OGESTREL (28)</b>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>LUTERA (28)</b>	T2	
<b>LYLEQ</b>	T2	
<b>LYLLANA</b>	T2	
<b>LYZA</b>	T2	
<b>MARLISSA (28)</b>	T2	
<i>medroxyprogesterone</i>	T2	
<b>MENEST</b>	T4	
<b>MENOSTAR</b>	T4	
<b>MERZEE</b>	T4	
<i>metronidazole vaginal</i>	T2	
<b>MIBELAS 24 FE</b>	T2	
<b>MICONAZOLE-3 VAGINAL SUPPOSITORY</b>	T2	
<b>MICROGESTIN 1.5/30 (21)</b>	T2	
<b>MICROGESTIN 1/20 (21)</b>	T2	
<b>MICROGESTIN 24 FE</b>	T4	
<b>MICROGESTIN FE 1.5/30 (28)</b>	T2	
<b>MICROGESTIN FE 1/20 (28)</b>	T2	
<b>MILI</b>	T2	
<b>MIMVEY</b>	T2	
<b>MINIVELLE</b>	T4	
<b>MIRENA</b>	T4	
<b>MYFEMBREE</b>	T5	PA; QL (31 EA per 31 days)
<b>NATAZIA</b>	T4	
<b>NECON 0.5/35 (28)</b>	T2	
<b>NEXPLANON</b>	T4	
<b>NEXTSTELLIS</b>	T4	
<b>NIKKI (28)</b>	T2	
<b>NORA-BE</b>	T2	
<i>noreth-ethinyl estradiol-iron</i>	T2	
<i>norethindrone (contraceptive)</i>	T2	
<i>norethindrone acetate</i>	T2	
<i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg</i>	T2	
<i>norethindrone-e.estradiol-iron oral capsule</i>	T4	
<i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9)</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>norethindrone-e.estradiol-iron oral tablet,chewable</i>	T2	
<i>norgestimate-ethinyl estradiol</i>	T2	
<b>NORTREL 0.5/35 (28)</b>	T2	
<b>NORTREL 1/35 (21)</b>	T2	
<b>NORTREL 1/35 (28)</b>	T2	
<b>NORTREL 7/7/7 (28)</b>	T2	
<b>NUVARING</b>	T4	
<b>NYLIA 1/35 (28)</b>	T2	
<b>NYLIA 7/7/7 (28)</b>	T2	
<b>NYMYO</b>	T2	
<b>OCELLA</b>	T2	
<b>ORIAHNN</b>	T5	PA; QL (56 EA per 28 days)
<b>OSPHENA</b>	T4	PA; QL (31 EA per 31 days)
<b>PHEXXI</b>	T4	
<b>PIMTREA (28)</b>	T2	
<b>PORTIA 28</b>	T2	
<b>PREFEST</b>	T4	
<b>PREMARIN ORAL</b>	T4	
<b>PREMARIN VAGINAL</b>	T3	
<b>PREMPHASE</b>	T4	
<b>PREMPRO</b>	T4	
<i>progesterone micronized</i>	T2	
<b>PROMETRIUM</b>	T4	
<b>PROVERA</b>	T4	
<b>QUARTETTE</b>	T4	
<b>RECLIPSEN (28)</b>	T2	
<b>RIVELSA</b>	T4	
<b>SAFYRAL</b>	T4	
<b>SEASONIQUE</b>	T4	
<b>SETLAKIN</b>	T2	
<b>SHAROBEL</b>	T2	
<b>SKYLA</b>	T4	
<b>SLYND</b>	T4	
<b>SPRINTEC (28)</b>	T2	
<b>SRONYX</b>	T2	
<b>SYEDA</b>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TARINA 24 FE</b>	T2	
<b>TARINA FE 1-20 EQ (28)</b>	T2	
<i>terconazole</i>	T2	
<b>TILIA FE</b>	T2	
<i>tranexamic acid oral</i>	T2	
<b>TRI-ESTARYLLA</b>	T2	
<b>TRI-LEGEST FE</b>	T2	
<b>TRI-LO-ESTARYLLA</b>	T2	
<b>TRI-LO-SPRINTEC</b>	T2	
<b>TRI-MILI</b>	T2	
<b>TRI-NYMYO</b>	T2	
<b>TRI-SPRINTEC (28)</b>	T2	
<b>TRIVORA (28)</b>	T2	
<b>TRI-VYLIBRA</b>	T2	
<b>TRI-VYLIBRA LO</b>	T2	
<b>TYBLUME</b>	T4	
<b>TYDEMY</b>	T2	
<b>VAGIFEM</b>	T4	
<b>VANDAZOLE</b>	T3	
<b>VELIVET TRIPHASIC REGIMEN (28)</b>	T2	
<b>VEOZAH</b>	T4	PA; QL (31 EA per 31 days)
<b>VESTURA (28)</b>	T2	
<b>VIENVA</b>	T2	
<b>VIVELLE-DOT</b>	T4	
<b>VYFEMLA (28)</b>	T2	
<b>VYLIBRA</b>	T2	
<b>WYMZYA FE</b>	T2	
<b>XULANE</b>	T2	
<b>YASMIN (28)</b>	T4	
<b>YAZ (28)</b>	T4	
<b>YUVAFEM</b>	T4	
<b>ZAFEMY</b>	T2	
<b>ZOVIA 1-35 (28)</b>	T2	
<b>Ophthalmology</b>		
<i>acetazolamide</i>	T2	
<b>ACULAR</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ACULAR LS</b>	T4	
<b>ACUVAIL (PF)</b>	T4	
<b>ALOMIDE</b>	T3	
<b>ALPHAGAN P</b>	T3	
<b>ALREX</b>	T4	
<i>apraclonidine</i>	T2	
<i>atropine ophthalmic (eye) drops</i>	T2	
<b>AZASITE</b>	T4	
<i>azelastine ophthalmic (eye)</i>	T2	
<b>AZOPT</b>	T4	
<i>bacitracin ophthalmic (eye)</i>	T2	
<i>bacitracin-polymyxin b</i>	T2	
<i>bepotastine besilate</i>	T4	
<b>BEPREVE</b>	T4	
<b>BESIVANCE</b>	T4	
<i>betaxolol ophthalmic (eye)</i>	T2	
<b>BETIMOL</b>	T4	
<b>BETOPTIC S</b>	T4	
<i>bimatoprost ophthalmic (eye)</i>	T2	
<i>brimonidine ophthalmic (eye) drops 0.15 %, 0.2 %</i>	T2	
<i>brimonidine-timolol</i>	T3	
<i>brinzolamide</i>	T4	
<i>bromfenac</i>	T2	
<b>BROMSITE</b>	T4	
<i>carteolol</i>	T2	
<b>CEQUA</b>	T4	ST; QL (60 EA per 30 days)
<b>CILOXAN OPHTHALMIC (EYE) OINTMENT</b>	T3	
<i>ciprofloxacin hcl ophthalmic (eye)</i>	T1	
<b>COMBIGAN</b>	T3	
<b>COSOPT</b>	T4	
<b>COSOPT (PF)</b>	T4	
<i>cromolyn ophthalmic (eye)</i>	T2	
<i>cyclosporine ophthalmic (eye)</i>	T3	QL (60 EA per 30 days)
<b>CYSTADROPS</b>	T5	PA; QL (20 ML per 28 days)
<b>CYSTARAN</b>	T5	PA; QL (60 ML per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>dexamethasone sodium phosphate ophthalmic (eye)</i>	T2	
<i>diclofenac sodium ophthalmic (eye)</i>	T1	
<i>difluprednate</i>	T3	
<i>dorzolamide</i>	T2	
<i>dorzolamide-timolol</i>	T2	
<i>dorzolamide-timolol (pf) ophthalmic (eye) dropperette</i>	T4	
<b>DUREZOL</b>	T4	
<i>epinastine</i>	T2	
<i>erythromycin ophthalmic (eye)</i>	T2	
<b>EYSUVIS</b>	T4	QL (8.3 ML per 30 days)
<b>FLAREX</b>	T4	
<i>fluorometholone</i>	T2	
<i>flurbiprofen sodium</i>	T2	
<b>FML FORTE</b>	T4	
<b>FML LIQUIFILM</b>	T4	
<i>gatifloxacin</i>	T3	
<i>gentamicin ophthalmic (eye) drops</i>	T1	
<b>ILEVRO</b>	T3	
<b>INVELTYS</b>	T4	
<b>IOPIDINE OPHTHALMIC (EYE) DROPPERETTE</b>	T4	
<b>ISTALOL</b>	T4	
<b>IYUZEH</b>	T4	ST; QL (30 EA per 30 days)
<i>ketorolac ophthalmic (eye)</i>	T2	
<b>LACRISERT</b>	T3	
<i>latanoprost</i>	T1	
<i>levobunolol ophthalmic (eye) drops 0.5 %</i>	T1	
<i>levofloxacin ophthalmic (eye) drops 0.5 %</i>	T2	
<b>LOTEMAX</b>	T4	
<b>LOTEMAX SM</b>	T4	
<i>loteprednol etabonate</i>	T4	
<b>LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %</b>	T3	QL (5 ML per 31 days)
<b>MAXIDEX</b>	T4	
<b>MAXITROL</b>	T4	
<i>methazolamide</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>MIEBO</b>	T5	ST; QL (12 ML per 30 days)
<i>moxifloxacin ophthalmic (eye) drops</i>	T3	
<b>NATACYN</b>	T3	
<i>neomycin-bacitracin-poly-hc</i>	T2	
<i>neomycin-bacitracin-polymyxin</i>	T2	
<i>neomycin-polymyxin b-dexameth</i>	T2	
<i>neomycin-polymyxin-gramicidin</i>	T2	
<i>neomycin-polymyxin-hc ophthalmic (eye)</i>	T2	
<b>NEO-POLYCIN</b>	T2	
<b>NEO-POLYCIN HC</b>	T2	
<b>NEVANAC</b>	T4	
<b>OCUFLOX</b>	T4	
<i>ofloxacin ophthalmic (eye)</i>	T2	
<i>olopatadine ophthalmic (eye) drops 0.1 %</i>	T3	
<b>OXERVATE</b>	T5	PA; QL (112 ML per 56 days)
<b>PHOSPHOLINE IODIDE</b>	T5	PA; QL (5 ML per 25 days)
<i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i>	T2	
<b>POLYCIN</b>	T2	
<i>polymyxin b sulf-trimethoprim</i>	T1	
<b>PRED FORTE</b>	T4	
<b>PRED MILD</b>	T4	
<i>prednisolone acetate</i>	T1	
<i>prednisolone sodium phosphate ophthalmic (eye)</i>	T2	
<b>PROLENSA</b>	T4	
<b>RESTASIS</b>	T3	QL (60 EA per 30 days)
<b>RESTASIS MULTIDOSE</b>	T3	QL (5.5 ML per 27 days)
<b>RHOPRESSA</b>	T4	ST
<b>ROCKLATAN</b>	T4	ST
<b>SIMBRINZA</b>	T4	
<i>sulfacetamide sodium ophthalmic (eye) drops</i>	T2	
<i>sulfacetamide sodium ophthalmic (eye) ointment</i>	T1	
<i>sulfacetamide-prednisolone</i>	T2	
<i>tafluprost (pf)</i>	T4	
<i>timolol maleate (pf)</i>	T4	
<i>timolol maleate ophthalmic (eye) drops</i>	T1	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>timolol maleate ophthalmic (eye) drops, once daily</i>	T2	
<i>timolol maleate ophthalmic (eye) gel forming solution</i>	T2	
<b>TIMOPTIC OCUDOSE (PF)</b>	T4	
<b>TOBRADEX OPHTHALMIC (EYE) OINTMENT</b>	T3	
<b>TOBRADEX ST</b>	T3	
<i>tobramycin ophthalmic (eye)</i>	T1	
<i>tobramycin-dexamethasone</i>	T2	
<b>TOBREX OPHTHALMIC (EYE) OINTMENT</b>	T3	
<b>TRAVATAN Z</b>	T4	
<i>travoprost</i>	T3	
<i>trifluridine</i>	T2	
<b>TYRVAYA</b>	T4	ST; QL (8.4 ML per 30 days)
<b>VERKAZIA</b>	T5	PA; QL (120 EA per 30 days)
<b>VIGAMOX</b>	T4	
<b>VUITY</b>	T4	PA; QL (2.5 ML per 25 days)
<b>VYZULTA</b>	T4	ST; QL (5 ML per 31 days)
<b>XALATAN</b>	T4	
<b>XDEMVIY</b>	T5	PA; QL (10 ML per 42 days)
<b>XELPROS</b>	T4	
<b>XIIDRA</b>	T3	QL (60 EA per 30 days)
<b>ZERVIAE</b>	T4	
<b>ZIOPTAN (PF)</b>	T4	
<b>ZIRGAN</b>	T4	ST
<b>ZYLET</b>	T4	
<b>ZYMAXID</b>	T3	
<b>Respiratory And Allergy</b>		
<b>ACCOLATE ORAL TABLET 10 MG</b>	T4	QL (93 EA per 31 days)
<i>acetylcysteine</i>	T2	PA-BvD
<b>ADCIRCA</b>	T5	PA; QL (62 EA per 31 days)
<b>ADEMPAS</b>	T5	PA; QL (93 EA per 31 days)
<b>ADVAIR DISKUS</b>	T4	QL (60 EA per 30 days)
<b>ADVAIR HFA</b>	T4	QL (12 GM per 30 days)
<b>AIRDUO DIGIHALER</b>	T4	PA; QL (2 EA per 365 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>AIRDUO RESPICLICK</b>	T4	QL (1 EA per 30 days)
<i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i>	T3	QL (17 GM per 30 days)
<i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i>	T3	QL (13.4 GM per 30 days)
<i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i>	T4	ST; QL (36 GM per 30 days)
<i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg/3 ml (0.083 %), 2.5 mg/0.5 ml</i>	T2	PA-BvD
<i>albuterol sulfate oral syrup</i>	T1	
<i>albuterol sulfate oral tablet</i>	T1	
<b>ALVESCO</b>	T4	QL (12.2 GM per 30 days)
<b>ALYQ</b>	T5	PA; QL (62 EA per 31 days)
<i>ambrisentan</i>	T5	PA; QL (31 EA per 31 days)
<b>ANORO ELLIPTA</b>	T3	QL (60 EA per 30 days)
<i>arformoterol</i>	T4	PA-BvD
<b>ARMONAIR DIGIHALER</b>	T4	PA; QL (2 EA per 365 days)
<b>ARNUITY ELLIPTA</b>	T4	QL (30 EA per 30 days)
<b>ASMANEX HFA</b>	T3	QL (13 GM per 30 days)
<b>ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60)</b>	T3	QL (1 EA per 30 days)
<b>ATROVENT HFA</b>	T3	QL (25.8 GM per 30 days)
<b>AUVI-Q INJECTION AUTO-INJECTOR 0.1 MG/0.1 ML, 0.15 MG/0.15 ML</b>	T4	ST
<b>AUVI-Q INJECTION AUTO-INJECTOR 0.3 MG/0.3 ML</b>	T5	ST
<i>azelastine-fluticasone</i>	T4	QL (23 GM per 30 days)
<b>BECONASE AQ</b>	T4	QL (25 GM per 21 days)
<b>BERINERT INTRAVENOUS KIT</b>	T5	PA
<b>BEVESPI AEROSPHERE</b>	T4	QL (10.7 GM per 30 days)
<i>bosentan</i>	T5	PA; QL (62 EA per 31 days)
<b>BREO ELLIPTA</b>	T3	QL (60 EA per 30 days)
<b>BREZTRI AEROSPHERE</b>	T3	QL (10.7 GM per 30 days)
<b>BRONCHITOL</b>	T5	PA; QL (560 EA per 28 days)
<b>BROVANA</b>	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>budesonide inhalation</i>	T2	PA-BvD
<i>budesonide-formoterol</i>	T4	QL (10.2 GM per 30 days)
<i>carbinoxamine maleate oral liquid</i>	T4	PA
<i>carbinoxamine maleate oral tablet 4 mg</i>	T4	PA
<i>cetirizine oral solution 1 mg/ml</i>	T1	QL (310 ML per 31 days)
<b>CINRYZE</b>	T5	PA; QL (20 EA per 28 days)
<b>CLARINEX ORAL TABLET</b>	T4	QL (31 EA per 31 days)
<b>CLARINEX-D 12 HOUR</b>	T4	
<i>clemastine oral syrup</i>	T2	PA
<i>clemastine oral tablet 2.68 mg</i>	T2	
<b>COMBIVENT RESPIMAT</b>	T3	QL (4 GM per 30 days)
<i>cromolyn inhalation</i>	T2	PA-BvD
<i>cyproheptadine</i>	T2	PA
<b>DALIRESP</b>	T4	QL (31 EA per 31 days)
<i>desloratadine</i>	T2	QL (31 EA per 31 days)
<b>DUAKLIR PRESSAIR</b>	T5	QL (1 EA per 30 days)
<b>DULERA</b>	T4	QL (13 GM per 30 days)
<b>DYMISTA</b>	T4	ST; QL (23 GM per 30 days)
<i>epinephrine injection auto-injector</i>	T3	
<b>EPIPEN 2-PAK</b>	T4	
<b>EPIPEN JR 2-PAK</b>	T4	
<b>ESBRIET ORAL CAPSULE</b>	T5	PA; QL (279 EA per 31 days)
<b>ESBRIET ORAL TABLET 267 MG</b>	T5	PA; QL (279 EA per 31 days)
<b>ESBRIET ORAL TABLET 801 MG</b>	T5	PA; QL (93 EA per 31 days)
<b>FASENRA</b>	T5	PA; QL (1 ML per 56 days)
<b>FASENRA PEN</b>	T5	PA; QL (1 ML per 56 days)
<b>FIRAZYR</b>	T5	PA; QL (18 ML per 30 days)
<b>FLOVENT DISKUS</b>	T3	QL (60 EA per 30 days)
<b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION</b>	T3	QL (12 GM per 30 days)
<b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 220 MCG/ACTUATION</b>	T3	QL (24 GM per 30 days)
<b>FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION</b>	T3	QL (10.6 GM per 30 days)
<i>flunisolide</i>	T2	QL (50 ML per 25 days)
<i>fluticasone furoate-vilanterol</i>	T4	ST; QL (60 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation</i>	T4	ST; QL (12 GM per 30 days)
<i>fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation</i>	T4	ST; QL (24 GM per 30 days)
<i>fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation</i>	T4	ST; QL (10.6 GM per 30 days)
<i>fluticasone propionate nasal</i>	T1	QL (16 GM per 30 days)
<i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated</i>	T3	QL (1 EA per 30 days)
<i>fluticasone propion-salmeterol inhalation blister with device</i>	T3	QL (60 EA per 30 days)
<i>fluticasone propion-salmeterol inhalation hfa aerosol inhaler</i>	T4	ST; QL (12 GM per 30 days)
<i>formoterol fumarate</i>	T4	PA-BvD
<b>HAEGARDA</b>	T5	PA
<i>hydroxyzine hcl oral solution 10 mg/5 ml</i>	T2	PA
<i>hydroxyzine hcl oral tablet</i>	T2	PA
<i>hydroxyzine pamoate</i>	T2	PA
<i>icatibant</i>	T5	PA; QL (18 ML per 30 days)
<b>INCRUSE ELLIPTA</b>	T3	QL (30 EA per 30 days)
<i>ipratropium bromide inhalation</i>	T1	PA-BvD
<i>ipratropium-albuterol</i>	T2	PA-BvD
<b>KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 50 MG, 75 MG</b>	T5	PA; QL (56 EA per 28 days)
<b>KALYDECO ORAL GRANULES IN PACKET 25 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>KALYDECO ORAL TABLET</b>	T5	PA; QL (62 EA per 31 days)
<b>LETAIRIS</b>	T5	PA; QL (31 EA per 31 days)
<i>levalbuterol hcl</i>	T2	PA-BvD
<i>levalbuterol tartrate</i>	T3	QL (30 GM per 30 days)
<i>levocetirizine oral solution</i>	T2	QL (310 ML per 31 days)
<i>levocetirizine oral tablet</i>	T1	QL (31 EA per 31 days)
<b>LIQREV</b>	T5	PA; QL (744 ML per 31 days)
<i>mometasone nasal</i>	T3	QL (34 GM per 30 days)
<i>montelukast</i>	T2	QL (31 EA per 31 days)
<b>NUCALA SUBCUTANEOUS AUTO-INJECTOR</b>	T5	PA; QL (3 ML per 28 days)
<b>NUCALA SUBCUTANEOUS RECON SOLN</b>	T5	PA; QL (3 EA per 28 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML</b>	T5	PA; QL (3 ML per 28 days)
<b>NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML</b>	T5	PA; QL (0.4 ML per 28 days)
<b>OFEV</b>	T5	PA; QL (62 EA per 31 days)
<b>OMNARIS</b>	T4	QL (12.5 GM per 30 days)
<b>OPSUMIT</b>	T5	PA; QL (31 EA per 31 days)
<b>ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG</b>	T5	PA; QL (62 EA per 31 days)
<b>ORKAMBI ORAL GRANULES IN PACKET 75-94 MG</b>	T5	QL (62 EA per 31 days)
<b>ORKAMBI ORAL TABLET</b>	T5	PA; QL (124 EA per 31 days)
<b>ORLADEYO</b>	T5	PA; QL (31 EA per 31 days)
<b>PERFOROMIST</b>	T4	PA-BvD
<i>pirfenidone oral capsule</i>	T5	PA; QL (279 EA per 31 days)
<i>pirfenidone oral tablet 267 mg</i>	T5	PA; QL (279 EA per 31 days)
<i>pirfenidone oral tablet 534 mg, 801 mg</i>	T5	PA; QL (93 EA per 31 days)
<b>PROAIR DIGIHALER</b>	T4	PA; QL (2 EA per 365 days)
<b>PROAIR RESPICLICK</b>	T4	ST; QL (2 EA per 30 days)
<i>promethazine oral</i>	T2	PA
<i>promethazine rectal suppository 12.5 mg, 25 mg</i>	T2	
<b>PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG</b>	T2	
<b>PROVENTIL HFA</b>	T4	ST; QL (13.4 GM per 30 days)
<b>PULMICORT</b>	T4	PA-BvD
<b>PULMICORT FLEXHALER</b>	T4	QL (1 EA per 30 days)
<b>PULMOZYME</b>	T5	PA
<b>QNASL NASAL HFA AEROSOL INHALER 40 MCG/ACTUATION</b>	T4	QL (6.8 GM per 30 days)
<b>QNASL NASAL HFA AEROSOL INHALER 80 MCG/ACTUATION</b>	T4	QL (10.6 GM per 30 days)
<b>QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION</b>	T3	QL (10.6 GM per 30 days)
<b>QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION</b>	T3	QL (21.2 GM per 30 days)
<b>REVATIO ORAL SUSPENSION FOR RECONSTITUTION</b>	T5	PA; QL (784 ML per 31 days)
<b>REVATIO ORAL TABLET</b>	T5	PA; QL (372 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>roflumilast oral tablet 250 mcg</i>	T4	QL (31 EA per 31 days)
<i>roflumilast oral tablet 500 mcg</i>	T3	QL (31 EA per 31 days)
<b>RUCONEST</b>	T5	PA
<b>RYALTRIS</b>	T4	ST; QL (29 GM per 30 days)
<b>RYCLORA</b>	T4	
<b>RYVENT</b>	T4	PA
<b>SAJAZIR</b>	T5	PA; QL (18 ML per 30 days)
<b>SEREVENT DISKUS</b>	T3	QL (60 EA per 30 days)
<i>sildenafil (pulm.hypertension) oral suspension for reconstitution</i>	T4	PA; QL (784 ML per 31 days)
<i>sildenafil (pulm.hypertension) oral tablet</i>	T3	PA; QL (372 EA per 31 days)
<b>SINGULAIR</b>	T4	QL (31 EA per 31 days)
<b>SPIRIVA RESPIMAT</b>	T3	QL (4 GM per 30 days)
<b>SPIRIVA WITH HANDIHALER</b>	T3	QL (30 EA per 30 days)
<b>STIOLTO RESPIMAT</b>	T3	QL (4 GM per 30 days)
<b>STRIVERDI RESPIMAT</b>	T4	QL (4 GM per 30 days)
<b>SYMBICORT</b>	T3	QL (10.2 GM per 30 days)
<b>SYMDEKO</b>	T5	PA; QL (56 EA per 28 days)
<b>SYMJEPI</b>	T4	
<i>tadalafil (pulm. hypertension)</i>	T5	PA; QL (62 EA per 31 days)
<b>TADLIQ</b>	T5	PA; QL (310 ML per 31 days)
<b>TAKHZYRO SUBCUTANEOUS SOLUTION</b>	T5	PA; QL (4 ML per 28 days)
<b>TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML</b>	T5	PA; QL (2 ML per 28 days)
<b>TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML)</b>	T5	PA; QL (4 ML per 28 days)
<i>terbutaline oral</i>	T2	
<b>THEO-24</b>	T4	
<i>theophylline oral solution</i>	T2	
<i>theophylline oral tablet extended release 12 hr 300 mg, 450 mg</i>	T2	
<i>theophylline oral tablet extended release 24 hr</i>	T2	
<i>tiotropium bromide</i>	T3	QL (30 EA per 30 days)
<b>TRACLEER ORAL TABLET</b>	T5	PA; QL (62 EA per 31 days)
<b>TRACLEER ORAL TABLET FOR SUSPENSION</b>	T5	PA; QL (124 EA per 31 days)
<b>TRELEGY ELLIPTA</b>	T3	QL (60 EA per 30 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL</b>	T5	PA; QL (56 EA per 28 days)
<b>TRIKAFTA ORAL TABLETS, SEQUENTIAL</b>	T5	PA; QL (84 EA per 28 days)
<b>TUDORZA PRESSAIR</b>	T4	QL (1 EA per 30 days)
<b>TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG (112)- 32 MCG (84)</b>	T5	PA; QL (392 EA per 365 days)
<b>TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG</b>	T5	PA
<b>TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16(112)-32(112) -48(28) MCG</b>	T5	PA; QL (504 EA per 365 days)
<b>VENTAVIS</b>	T5	PA
<b>VENTOLIN HFA</b>	T3	QL (36 GM per 30 days)
<b>VISTARIL</b>	T4	PA
<b>WIXELA INHUB</b>	T3	QL (60 EA per 30 days)
<b>XHANCE</b>	T4	QL (32 ML per 30 days)
<b>XOLAIR</b>	T5	PA
<b>XOPENEX HFA</b>	T4	ST; QL (30 GM per 30 days)
<b>YUPELRI</b>	T5	PA-BvD
<i>zafirlukast oral tablet 10 mg</i>	T2	QL (93 EA per 31 days)
<i>zafirlukast oral tablet 20 mg</i>	T2	QL (62 EA per 31 days)
<b>ZETONNA</b>	T4	QL (6.1 GM per 30 days)
<i>zileuton</i>	T5	PA; QL (124 EA per 31 days)
<b>ZYFLO</b>	T4	PA; QL (124 EA per 31 days)
<b>Urologicals</b>		
<i>alfuzosin</i>	T2	QL (31 EA per 31 days)
<i>bethanechol chloride</i>	T2	
<b>CIALIS ORAL TABLET 2.5 MG</b>	T4	PA; QL (62 EA per 31 days)
<b>CIALIS ORAL TABLET 5 MG</b>	T4	PA; QL (31 EA per 31 days)
<b>CYSTAGON</b>	T3	
<i>darifenacin</i>	T3	QL (31 EA per 31 days)
<b>DETROL</b>	T4	QL (62 EA per 31 days)
<b>DETROL LA</b>	T4	QL (31 EA per 31 days)
<i>dutasteride</i>	T2	QL (31 EA per 31 days)
<i>dutasteride-tamsulosin</i>	T3	QL (31 EA per 31 days)

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.



<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>ELMIRON</b>	T5	
<b>ENTADFI</b>	T4	PA; QL (31 EA per 31 days)
<i>fesoterodine</i>	T3	QL (31 EA per 31 days)
<i>finasteride oral tablet 5 mg</i>	T2	
<i>flavoxate</i>	T2	
<b>FLOMAX</b>	T4	
<b>GELNIQUE TRANSDERMAL GEL IN PACKET</b>	T4	QL (30 GM per 30 days)
<b>GEMTESA</b>	T4	QL (31 EA per 31 days)
<b>JALYN</b>	T4	QL (31 EA per 31 days)
<b>MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON</b>	T3	QL (300 ML per 30 days)
<b>MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR</b>	T3	QL (31 EA per 31 days)
<i>oxybutynin chloride oral syrup</i>	T2	
<i>oxybutynin chloride oral tablet 5 mg</i>	T2	
<i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg</i>	T2	QL (31 EA per 31 days)
<i>oxybutynin chloride oral tablet extended release 24hr 15 mg</i>	T3	QL (62 EA per 31 days)
<b>OXYTROL</b>	T4	QL (8 EA per 28 days)
<i>potassium citrate oral tablet extended release</i>	T2	
<b>PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET</b>	T5	PA
<b>PROSCAR</b>	T4	
<b>RAPAFLO</b>	T4	
<i>silodosin</i>	T4	
<i>solifenacin</i>	T3	QL (31 EA per 31 days)
<i>tadalafil oral tablet 2.5 mg</i>	T4	PA; QL (62 EA per 31 days)
<i>tadalafil oral tablet 5 mg</i>	T4	PA; QL (31 EA per 31 days)
<i>tamsulosin</i>	T1	
<i>tolterodine oral capsule,extended release 24hr</i>	T3	QL (31 EA per 31 days)
<i>tolterodine oral tablet</i>	T3	QL (62 EA per 31 days)
<b>TOVIAZ</b>	T4	QL (31 EA per 31 days)
<i>trospium oral capsule,extended release 24hr</i>	T2	QL (31 EA per 31 days)
<i>trospium oral tablet</i>	T2	QL (93 EA per 31 days)
<b>UROCIT-K 10</b>	T4	
<b>UROCIT-K 15</b>	T4	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<b>UROCIT-K 5</b>	T4	
<b>UROXATRAL</b>	T4	QL (31 EA per 31 days)
<b>VESICARE</b>	T4	QL (31 EA per 31 days)
<b>VESICARE LS</b>	T4	QL (310 ML per 31 days)
<b>Vitamins, Hematinics / Electrolytes</b>		
<i>calcium acetate(phosphat bind)</i>	T2	
<b>CLINIMIX 5%/D15W SULFITE FREE</b>	T4	PA-BvD
<b>CLINIMIX 4.25%/D10W SULF FREE</b>	T4	PA-BvD
<b>CLINIMIX 5%-D20W(SULFITE-FREE)</b>	T4	PA-BvD
<b>CLINIMIX E 4.25%/D10W SUL FREE</b>	T4	PA-BvD
<b>CLINIMIX E 4.25%/D5W SULF FREE</b>	T4	PA-BvD
<b>CLINIMIX E 5%/D15W SULFIT FREE</b>	T4	PA-BvD
<b>CLINIMIX E 5%/D20W SULFIT FREE</b>	T4	PA-BvD
<b>CLINISOL SF 15 %</b>	T4	PA-BvD
<b>DOJOLVI</b>	T5	PA
<i>electrolyte-148</i>	T4	PA-BvD
<i>fluoride (sodium) oral tablet</i>	T2	
<b>INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %</b>	T4	PA-BvD
<b>ISOLYTE S PH 7.4</b>	T3	PA-BvD
<b>ISOLYTE-P IN 5 % DEXTROSE</b>	T3	PA-BvD
<b>KLOR-CON</b>	T3	
<b>KLOR-CON 10</b>	T3	
<b>KLOR-CON 8</b>	T3	
<b>KLOR-CON M10</b>	T1	
<b>KLOR-CON M15</b>	T1	
<b>KLOR-CON M20</b>	T1	
<i>magnesium sulfate injection</i>	T2	
<b>NUTRILIPID</b>	T4	PA-BvD
<b>PLASMA-LYTE 148</b>	T4	PA-BvD
<b>PLASMA-LYTE A</b>	T4	PA-BvD
<b>PLENAMINE</b>	T3	PA-BvD
<i>potassium chlorid-d5-0.45%nacl</i>	T2	
<i>potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l</i>	T2	
<i>potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l</i>	T2	

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

<b>Drug Name</b>	<b>Drug Tier</b>	<b>Requirements/Limits</b>
<i>potassium chloride in lr-d5 intravenous parenteral solution 20 meq/l</i>	T2	
<i>potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml</i>	T2	
<i>potassium chloride intravenous</i>	T2	
<i>potassium chloride oral capsule, extended release</i>	T1	
<i>potassium chloride oral liquid</i>	T2	
<i>potassium chloride oral packet</i>	T2	
<i>potassium chloride oral tablet extended release</i>	T1	
<i>potassium chloride oral tablet,er particles/crystals</i>	T1	
<i>potassium chloride-0.45 % nacl</i>	T2	
<i>potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l</i>	T2	
<i>potassium chloride-d5-0.9%nacl</i>	T2	
<b>PREMASOL 10 %</b>	T4	PA-BvD
<b>PRENATAL VITAMIN PLUS LOW IRON</b>	T2	PA
<b>PROSOL 20 %</b>	T4	PA-BvD
<i>sodium chloride 0.45 % intravenous</i>	T2	
<i>sodium chloride 3 % hypertonic</i>	T2	
<i>sodium chloride 5 % hypertonic</i>	T2	
<b>TPN ELECTROLYTES</b>	T4	
<b>TRAVASOL 10 %</b>	T3	PA-BvD
<b>TROPHAMINE 10 %</b>	T4	PA-BvD

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

You can find information on what the symbols and abbreviations on this table mean by going the beginning of this table.

## Index of Drugs

<i>abacavir</i> .....	5	<i>adefovir</i> .....	5	<b>ALUNBRIG</b> .....	18
<i>abacavir-lamivudine</i> .....	5	<b>ADEMPAS</b> .....	114	<b>ALVESCO</b> .....	115
<b>ABELCET</b> .....	5	<b>ADLARITY</b> .....	26	<b>ALYACEN 1/35 (28)</b> .....	104
<b>ABILIFY</b> .....	26	<b>ADMELOG SOLOSTAR U-100 INSULIN</b> .....	83	<b>ALYQ</b> .....	115
<b>ABILIFY ASIMTUFII</b> .....	26	<b>ADMELOG U-100 INSULIN LISPRO</b> .....	83	<b>AMABELZ</b> .....	104
<b>ABILIFY MAINTENA</b> .....	26	<b>ADVAIR DISKUS</b> .....	114	<i>amantadine hcl</i> .....	5
<b>ABILIFY MYCITE MAINTENANCE KIT</b> .....	26	<b>ADVAIR HFA</b> .....	114	<b>AMBIEN</b> .....	27
<b>ABILIFY MYCITE STARTER KIT</b> .....	26	<b>ADZENYS XR-ODT</b> .....	26	<b>AMBIEN CR</b> .....	27
<i>abiraterone</i> .....	17, 18	<b>AEMCOLO</b> .....	5	<b>AMBISOME</b> .....	5
<b>ABRYSVO</b> .....	97	<b>AFINITOR</b> .....	18	<i>ambrisentan</i> .....	115
<b>ABSORICA</b> .....	70	<b>AFINITOR DISPERZ</b> .....	18	<i>amcinonide</i> .....	70
<b>ABSORICA LD</b> .....	70	<b>AFREZZA</b> .....	83	<b>AMETHIA</b> .....	104
<i>acamprosate</i> .....	79	<b>AGRYLIN</b> .....	79	<i>amikacin</i> .....	5
<b>ACANYA</b> .....	70	<b>AIMOVIG AUTOINJECTOR</b> .....	26, 27	<i>amiloride</i> .....	58
<i>acarbose</i> .....	82	<b>AIRDUO DIGIHALER</b> .....	114	<i>amiloride-hydrochlorothiazide</i> ..	58
<b>ACCOLATE</b> .....	114	<b>AIRDUO RESPICLICK</b> .....	115	<i>amiodarone</i> .....	58
<b>ACCUTANE</b> .....	70	<b>AJOVY AUTOINJECTOR</b> .....	27	<b>AMITIZA</b> .....	91
<i>acebutolol</i> .....	58	<b>AJOVY SYRINGE</b> .....	27	<i>amitriptyline</i> .....	27
<i>acetaminophen-caff-dihydrocod</i> ..	26	<b>AKLIEF</b> .....	70	<i>amitriptyline-chlordiazepoxide</i> ..	27
<i>acetaminophen-codeine</i> .....	26	<b>ALA-CORT</b> .....	70	<b>AMJEVITA(CF)</b> .....	101
<i>acetazolamide</i> .....	110	<b>ALA-SCALP</b> .....	70	<b>AMJEVITA(CF) AUTOINJECTOR</b> .....	101
<i>acetic acid</i> .....	82	<i>albendazole</i> .....	5	<i>amlodipine</i> .....	59
<i>acetylcysteine</i> .....	114	<i>albuterol sulfate</i> .....	115	<i>amlodipine-atorvastatin</i> .....	59
<b>ACIPHEX</b> .....	91	<i>alclometasone</i> .....	70	<i>amlodipine-benazepril</i> .....	59
<i>acitretin</i> .....	70	<b>ALCOHOL PADS</b> .....	83	<i>amlodipine-olmesartan</i> .....	59
<b>ACTEMRA</b> .....	101	<b>ALDACTONE</b> .....	58	<i>amlodipine-valsartan</i> .....	59
<b>ACTEMRA ACTPEN</b> .....	101	<b>ALECENSA</b> .....	18	<i>amlodipine-valsartan-hcthiazyd</i> ..	59
<b>ACTHAR</b> .....	83	<i>alendronate</i> .....	101	<i>ammonium lactate</i> .....	70
<b>ACTHIB (PF)</b> .....	97	<i>alfuzosin</i> .....	120	<b>AMNESTEEM</b> .....	70
<b>ACTIMMUNE</b> .....	97	<i>aliskiren</i> .....	58	<i>amoxapine</i> .....	27
<b>ACTIVELLA</b> .....	104	<b>ALKINDI SPRINKLE</b> .....	83	<i>amoxicil-clarithromy-lansopraz</i> ..	91
<b>ACTONEL</b> .....	101	<i>allopurinol</i> .....	101	<i>amoxicillin</i> .....	5
<b>ACTOPLUS MET</b> .....	83	<b>ALLZITAL</b> .....	27	<i>amoxicillin-pot clavulanate</i> .....	5
<b>ACTOS</b> .....	83	<i>almotriptan malate</i> .....	27	<i>amphetamine sulfate</i> .....	27
<b>ACULAR</b> .....	110	<i>alogliptin</i> .....	83	<i>amphotericin b</i> .....	5
<b>ACULAR LS</b> .....	111	<i>alogliptin-metformin</i> .....	83	<i>amphotericin b liposome</i> .....	5
<b>ACUVAIL (PF)</b> .....	111	<i>alogliptin-pioglitazone</i> .....	83	<i>ampicillin</i> .....	5
<i>acyclovir</i> .....	5, 70	<b>ALOMIDE</b> .....	111	<i>ampicillin sodium</i> .....	5
<i>acyclovir sodium</i> .....	5	<i>alosepron</i> .....	91	<i>ampicillin-sulbactam</i> .....	5
<b>ACZONE</b> .....	70	<b>ALPHAGAN P</b> .....	111	<b>AMPYRA</b> .....	27
<b>ADACEL(TDAP</b> .....		<i>alprazolam</i> .....	27	<b>AMRIX</b> .....	27
<b>ADOLESN/ADULT)(PF)</b> .....	97	<b>ALPRAZOLAM INTENSOL</b> ..	27	<b>AMZEEQ</b> .....	70
<i>adalimumab-fkjp</i> .....	101	<b>ALREX</b> .....	111	<b>ANAFRANIL</b> .....	27
<i>adapalene</i> .....	70	<b>ALTABAX</b> .....	70	<i>anagrelide</i> .....	79
<i>adapalene-benzoyl peroxide</i> .....	70	<b>ALTACE</b> .....	58	<i>anastrozole</i> .....	18
<b>ADBRY</b> .....	70	<b>ALTAVERA (28)</b> .....	104	<b>ANCOBON</b> .....	5
<b>ADCIRCA</b> .....	114	<b>ALTOPREV</b> .....	58	<b>ANDROGEL</b> .....	83
<b>ADDERALL</b> .....	26	<b>ALTRENO</b> .....	70	<b>ANGELIQ</b> .....	104
<b>ADDERALL XR</b> .....	26			<b>ANNOVERA</b> .....	105
				<b>ANORO ELLIPTA</b> .....	115

ANTARA.....	59	<i>atazanavir</i> .....	5	<b>BACTRIM DS</b> .....	6
ANTIVERT.....	91	<b>ATELVIA</b> .....	101	<b>BAFIERTAM</b> .....	29
ANUSOL-HC.....	91	<i>atenolol</i> .....	59	<b>BALCOLTRA</b> .....	105
ANZEMET.....	91	<i>atenolol-chlorthalidone</i> .....	59	<i>balsalazide</i> .....	91
APEXICON E.....	70	<b>ATIVAN</b> .....	28	<b>BALVERSA</b> .....	18
<b>APIDRA SOLOSTAR U-100</b>		<i>atomoxetine</i> .....	28	<b>BALZIVA (28)</b> .....	105
<b>INSULIN</b> .....	83	<b>ATORVALIQ</b> .....	59	<b>BANZEL</b> .....	29
<b>APIDRA U-100 INSULIN</b> .....	83	<i>atorvastatin</i> .....	59	<b>BAQSIMI</b> .....	83
<b>APLENZIN</b> .....	27	<i>atovaquone</i> .....	5	<b>BARACLUDGE</b> .....	6
<b>APOKYN</b> .....	27	<i>atovaquone-proguanil</i> .....	5	<b>BASAGLAR KWIKPEN U-</b>	
<i>apomorphine</i> .....	27	<b>ATRALIN</b> .....	70	<b>100 INSULIN</b> .....	83
<i>apraclonidine</i> .....	111	<i>atropine</i> .....	111	<b>BASAGLAR TEMPO</b>	
<i>aprepitant</i> .....	91	<b>ATROVENT HFA</b> .....	115	<b>PEN(U-100)INSLN</b> .....	83
<b>APRI</b> .....	105	<b>AUBAGIO</b> .....	28	<b>BAXDELA</b> .....	6
<b>APRISO</b> .....	91	<b>AUBRA EQ</b> .....	105	<i>bcg vaccine, live (pf)</i> .....	97
<b>APTENSIO XR</b> .....	27	<b>AUGMENTIN</b> .....	5	<b>BECONASE AQ</b> .....	115
<b>APTIOM</b> .....	27	<b>AUGMENTIN ES-600</b> .....	5	<b>BELBUCA</b> .....	29
<b>APTIVUS</b> .....	5	<b>AURYXIA</b> .....	79	<b>BELSOMRA</b> .....	29
<b>ARALAST NP</b> .....	79	<b>AUSTEDO</b> .....	28	<i>benazepril</i> .....	59
<b>ARANELLE (28)</b> .....	105	<b>AUSTEDO XR</b> .....	28	<i>benazepril-hydrochlorothiazide</i> ..	59
<b>ARANESP (IN</b>		<b>AUSTEDO XR TITRATION</b>		<b>BENICAR</b> .....	59
<b>POLYSORBATE)</b> .....	97	<b>KT(WK1-4)</b> .....	28	<b>BENICAR HCT</b> .....	59
<b>ARAVA</b> .....	101	<b>AUVELITY</b> .....	28	<b>BENLYSTA</b> .....	101
<b>ARAZLO</b> .....	70	<b>AUVI-Q</b> .....	115	<b>BENZAMYCIN</b> .....	71
<b>ARCALYST</b> .....	97	<b>AVALIDE</b> .....	59	<i>benznidazole</i> .....	6
<b>AREXVY (PF)</b> .....	97	<b>AVAPRO</b> .....	59	<i>benztropine</i> .....	29
<i>arformoterol</i> .....	115	<b>AVEED</b> .....	83	<i>bepotastine besilate</i> .....	111
<b>ARICEPT</b> .....	28	<b>AVIANE</b> .....	105	<b>BEPREVE</b> .....	111
<b>ARIKAYCE</b> .....	5	<b>AVONEX</b> .....	97	<b>BERINERT</b> .....	115
<b>ARIMIDEX</b> .....	18	<b>AVYCAZ</b> .....	5	<b>BESIVANCE</b> .....	111
<i>aripiprazole</i> .....	28	<b>AYGESTIN</b> .....	105	<b>BESREMI</b> .....	97
<b>ARISTADA</b> .....	28	<b>AYVAKIT</b> .....	18	<i>betaine</i> .....	91
<b>ARISTADA INITIO</b> .....	28	<b>AZACTAM</b> .....	6	<i>betamethasone dipropionate</i> .....	71
<b>ARIXTRA</b> .....	59	<b>AZASAN</b> .....	18	<i>betamethasone valerate</i> .....	71
<i>armodafinil</i> .....	28	<b>AZASITE</b> .....	111	<i>betamethasone, augmented</i> .....	71
<b>ARMONAIR DIGIHALER</b> ..	115	<i>azathioprine</i> .....	18	<b>BETAPACE AF</b> .....	59
<b>ARNUITY ELLIPTA</b> .....	115	<i>azelaic acid</i> .....	71	<b>BETASERON</b> .....	98
<b>AROMASIN</b> .....	18	<i>azelastine</i> .....	82, 111	<i>betaxolol</i> .....	59, 111
<b>ARTHROTEC 50</b> .....	28	<i>azelastine-fluticasone</i> .....	115	<i>bethanechol chloride</i> .....	120
<b>ARTHROTEC 75</b> .....	28	<b>AZELEX</b> .....	71	<b>BETHKIS</b> .....	6
<b>ASCOMP WITH CODEINE</b> ..	28	<b>AZILECT</b> .....	29	<b>BETIMOL</b> .....	111
<i>asenapine maleate</i> .....	28	<i>azithromycin</i> .....	6	<b>BETOPTIC S</b> .....	111
<b>ASHLYNA</b> .....	105	<b>AZOPT</b> .....	111	<b>BEVESPI AEROSPHERE</b> ....	115
<b>ASMANEX HFA</b> .....	115	<b>AZOR</b> .....	59	<i>bexarotene</i> .....	18
<b>ASMANEX TWISTHALER</b> ..	115	<b>AZSTARYS</b> .....	29	<b>BEXSERO</b> .....	98
<i>aspirin-dipyridamole</i> .....	59	<i>aztreonam</i> .....	6	<b>BEYAZ</b> .....	105
<b>ASPRUZYO SPRINKLE</b> .....	59	<b>AZULFIDINE</b> .....	91	<i>bicalutamide</i> .....	18
<b>ASSURE ID INSULIN</b>		<b>AZULFIDINE EN-TABS</b> .....	91	<b>BICILLIN C-R</b> .....	6
<b>SAFETY</b> .....	101	<i>bacitracin</i> .....	111	<b>BICILLIN L-A</b> .....	6
<b>ASTAGRAF XL</b> .....	18	<i>bacitracin-polymyxin b</i> .....	111	<b>BIDIL</b> .....	59
<b>ATACAND</b> .....	59	<i>baclofen</i> .....	29	<b>BIJUVA</b> .....	105
<b>ATACAND HCT</b> .....	59	<b>BACTRIM</b> .....	6	<b>BIKTARVY</b> .....	6

<b>BILTRICIDE</b> .....	6	<b>CABLIVI</b> .....	60	<i>cefadroxil</i> .....	6
<i>bimatoprost</i> .....	111	<b>CABOMETYX</b> .....	18	<i>cefazolin</i> .....	6
<b>BINOSTO</b> .....	102	<b>CADUET</b> .....	60	<i>cefdinir</i> .....	6
<i>bismuth subcit k-metronidz-ten</i> ...	91	<i>calcipotriene</i> .....	71	<i>cefepime</i> .....	6
<i>bisoprolol fumarate</i> .....	59	<i>calcipotriene-betamethasone</i> .....	71	<i>cefixime</i> .....	6
<i>bisoprolol-hydrochlorothiazide</i> ..	59	<i>calcitonin (salmon)</i> .....	83	<i>cefotetan</i> .....	6
<b>BIVIGAM</b> .....	98	<i>calcitriol</i> .....	71, 83	<i>cefoxitin</i> .....	6
<b>BLISOVI 24 FE</b> .....	105	<i>calcium acetate(phosphat bind)</i>	122	<i>cefpodoxime</i> .....	6
<b>BLISOVI FE 1.5/30 (28)</b> .....	105	<b>CALQUENCE</b> .....	18	<i>cefprozil</i> .....	6
<b>BONJESTA</b> .....	91	<b>CALQUENCE</b>		<i>ceftazidime</i> .....	7
<b>BOOSTRIX TDAP</b> .....	98	( <b>ACALABRUTINIB MAL</b> ).....	18	<i>ceftriaxone</i> .....	7
<i>bosentan</i> .....	115	<b>CAMBIA</b> .....	30	<i>cefuroxime axetil</i> .....	7
<b>BOSULIF</b> .....	18	<b>CAMILA</b> .....	105	<i>cefuroxime sodium</i> .....	7
<b>BRAFTOVI</b> .....	18	<b>CAMRESE LO</b> .....	105	<b>CELEBREX</b> .....	30
<b>BREO ELLIPTA</b> .....	115	<b>CAMZYOS</b> .....	60	<i>celecoxib</i> .....	30
<b>BREZTRI AEROSPHERE</b> ...	115	<b>CANASA</b> .....	92	<b>CELEXA</b> .....	30
<b>BRIELLYN</b> .....	105	<b>CANCIDAS</b> .....	6	<b>CELLCEPT</b> .....	18, 19
<b>BRILINTA</b> .....	59	<i>candesartan</i> .....	60	<b>CELONTIN</b> .....	30
<i>brimonidine</i> .....	71, 111	<i>candesartan-hydrochlorothiazid</i> .	60	<i>cephalexin</i> .....	7
<i>brimonidine-timolol</i> .....	111	<b>CAPEX</b> .....	71	<b>CEQUA</b> .....	111
<i>brinzolamide</i> .....	111	<b>CAPLYTA</b> .....	30	<b>CERDELGA</b> .....	83
<b>BRIVIACT</b> .....	29	<b>CAPRELSA</b> .....	18	<i>cetirizine</i> .....	116
<i>bromfenac</i> .....	111	<i>captopril</i> .....	60	<b>CETRAXAL</b> .....	82
<i>bromocriptine</i> .....	29	<b>CARAC</b> .....	71	<i>cevimeline</i> .....	79
<b>BROMSITE</b> .....	111	<b>CARAFATE</b> .....	92	<b>CHEMET</b> .....	79
<b>BRONCHITOL</b> .....	115	<b>CARBAGLU</b> .....	79	<b>CHENODAL</b> .....	92
<b>BROVANA</b> .....	115	<i>carbamazepine</i> .....	30	<i>chlordiazepoxide hcl</i> .....	30
<b>BRUKINSA</b> .....	18	<b>CARBATROL</b> .....	30	<i>chlordiazepoxide-clidinium</i> .....	92
<b>BRYHALI</b> .....	71	<i>carbidopa</i> .....	30	<i>chlorhexidine gluconate</i> .....	82
<i>budesonide</i> .....	91, 116	<i>carbidopa-levodopa</i> .....	30	<i>chloroquine phosphate</i> .....	7
<i>budesonide-formoterol</i> .....	116	<i>carbidopa-levodopa-entacapone</i>	30	<i>chlorpromazine</i> .....	30
<i>bumetanide</i> .....	59	<i>carbinoxamine maleate</i> .....	116	<i>chlorthalidone</i> .....	60
<b>BUPAP</b> .....	29	<b>CARDIZEM</b> .....	60	<i>chlorzoxazone</i> .....	30
<b>BUPHENYL</b> .....	79	<b>CARDIZEM CD</b> .....	60	<b>CHOLBAM</b> .....	92
<i>buprenorphine</i> .....	29	<b>CARDIZEM LA</b> .....	60	<i>cholestyramine (with sugar)</i> .....	60
<i>buprenorphine hcl</i> .....	29	<b>CARDURA</b> .....	60	<b>CHOLESTYRAMINE</b>	
<i>buprenorphine-naloxone</i> .....	29	<b>CARDURA XL</b> .....	60	<b>LIGHT</b> .....	60
<i>bupropion hcl</i> .....	29	<i>carglumic acid</i> .....	79	<b>CIALIS</b> .....	120
<i>bupropion hcl (smoking deter)</i> ...	79	<i>carisoprodol</i> .....	30	<b>CIBINQO</b> .....	71
<i>buspiron</i> .....	29	<b>CARNITOR</b> .....	79	<i>ciclopirox</i> .....	71
<i>butalbital-acetaminop-caf-cod</i>		<b>CAROSPIR</b> .....	60	<i>cilostazol</i> .....	60
.....	29, 30	<i>carteolol</i> .....	111	<b>CILOXAN</b> .....	111
<i>butalbital-acetaminophen</i> .....	30	<b>CARTIA XT</b> .....	60	<b>CIMDUO</b> .....	7
<i>butalbital-acetaminophen-caff</i> ...	30	<i>carvedilol</i> .....	60	<i>cimetidine</i> .....	92
<i>butalbital-aspirin-caffeine</i> .....	30	<i>carvedilol phosphate</i> .....	60	<b>CIMZIA</b> .....	92
<i>butorphanol</i> .....	30	<b>CASODEX</b> .....	18	<b>CIMZIA POWDER FOR</b>	
<b>BUTRANS</b> .....	30	<i>caspofungin</i> .....	6	<b>RECONST</b> .....	92
<b>BYDUREON BCISE</b> .....	83	<b>CATAPRES-TTS-1</b> .....	60	<i>cinacalcet</i> .....	83
<b>BYETTA</b> .....	83	<b>CATAPRES-TTS-2</b> .....	60	<b>CINRYZE</b> .....	116
<b>BYLVAY</b> .....	91, 92	<b>CATAPRES-TTS-3</b> .....	60	<b>CIPRO</b> .....	7
<b>BYSTOLIC</b> .....	59	<b>CAYSTON</b> .....	6	<b>CIPRO HC</b> .....	82
<i>cabergoline</i> .....	83	<i>cefaclor</i> .....	6	<i>ciprofloxacin hcl</i> .....	7, 82, 111

<i>ciprofloxacin in 5 % dextrose</i> .....	7	<b>CLODAN</b> .....	72	<b>COSOFT (PF)</b> .....	111
<i>ciprofloxacin-dexamethasone</i> .....	82	<b>CLODERM</b> .....	72	<b>COTELLIC</b> .....	19
<i>ciprofloxacin-fluocinolone</i> .....	82	<i>clomipramine</i> .....	31	<b>COTEMPLA XR-ODT</b> .....	31
<i>citalopram</i> .....	31	<i>clonazepam</i> .....	31	<b>COZAAR</b> .....	61
<b>CLARAVIS</b> .....	71	<i>clonidine</i> .....	60	<b>CREON</b> .....	92
<b>CLARINEX</b> .....	116	<i>clonidine hcl</i> .....	31, 60	<b>CRESEMBA</b> .....	7
<b>CLARINEX-D 12 HOUR</b> .....	116	<i>clopidogrel</i> .....	60	<b>CRESTOR</b> .....	61
<i>clarithromycin</i> .....	7	<i>clorazepate dipotassium</i> .....	31	<b>CRINONE</b> .....	105
<i>clemastine</i> .....	116	<i>clotrimazole</i> .....	7, 72	<i>cromolyn</i> .....	92, 111, 116
<b>CLENPIQ</b> .....	92	<i>clotrimazole-betamethasone</i> .....	72	<b>CROTAN</b> .....	72
<b>CLEOCIN</b> .....	7, 105	<i>clozapine</i> .....	31	<b>CRYSELLE (28)</b> .....	105
<b>CLEOCIN HCL</b> .....	7	<b>CLOZARIL</b> .....	31	<b>CUBICIN RF</b> .....	7
<b>CLEOCIN PEDIATRIC</b> .....	7	<b>COARTEM</b> .....	7	<b>CUPRIMINE</b> .....	102
<b>CLEOCIN T</b> .....	71	<i>codeine sulfate</i> .....	31	<b>CUVPOSA</b> .....	92
<b>CLIMARA</b> .....	105	<i>codeine-butalbital-asa-caff</i> .....	31	<b>CUVRIOR</b> .....	79
<b>CLIMARA PRO</b> .....	105	<b>COLAZAL</b> .....	92	<i>cyclobenzaprine</i> .....	32
<b>CLINDACIN</b> .....	71	<i>colchicine</i> .....	102	<i>cyclophosphamide</i> .....	19
<b>CLINDACIN ETZ</b> .....	71	<b>COLCRYS</b> .....	102	<b>CYCLOSET</b> .....	84
<b>CLINDAGEL</b> .....	71	<i>colesevelam</i> .....	60	<i>cyclosporine</i> .....	19, 111
<i>clindamycin hcl</i> .....	7	<b>COLESTID</b> .....	60	<i>cyclosporine modified</i> .....	19
<i>clindamycin in 5 % dextrose</i> .....	7	<i>colestipol</i> .....	60	<b>CYLTEZO(CF)</b> .....	102
<b>CLINDAMYCIN</b>		<i>colistin (colistimethate na)</i> .....	7	<b>CYLTEZO(CF) PEN</b> .....	102
<b>PEDIATRIC</b> .....	7	<b>COMBIGAN</b> .....	111	<b>CYLTEZO(CF) PEN</b>	
<i>clindamycin phosphate</i> ... 7, 71, 105		<b>COMBIPATCH</b> .....	105	<b>CROHN'S-UC-HS</b> .....	102
<i>clindamycin-benzoyl peroxide</i>		<b>COMBIVENT RESPIMAT</b> ..	116	<b>CYLTEZO(CF) PEN</b>	
.....	71, 72	<b>COMBIVIR</b> .....	7	<b>PSORIASIS-UV</b> .....	102
<i>clindamycin-tretinoin</i> .....	72	<b>COMETRIQ</b> .....	19	<b>CYMBALTA</b> .....	32
<b>CLINDESSE</b> .....	105	<b>COMPLERA</b> .....	7	<i>cyproheptadine</i> .....	116
<b>CLINIMIX 5%/D15W</b>		<b>COMPRO</b> .....	92	<b>CYRED EQ</b> .....	105
<b>SULFITE FREE</b> .....	122	<b>COMTAN</b> .....	31	<b>CYSTADANE</b> .....	92
<b>CLINIMIX 4.25%/D10W</b>		<b>CONCERTA</b> .....	31	<b>CYSTADROPS</b> .....	111
<b>SULF FREE</b> .....	122	<b>CONDYLOX</b> .....	72	<b>CYSTAGON</b> .....	120
<b>CLINIMIX 4.25%/D5W</b>		<b>CONJUPRI</b> .....	61	<b>CYSTARAN</b> .....	111
<b>SULFIT FREE</b> .....	79	<b>CONSTULOSE</b> .....	92	<b>CYTOMEL</b> .....	84
<b>CLINIMIX 5%-</b>		<b>CONZIP</b> .....	31	<b>CYTOTEC</b> .....	92
<b>D20W(SULFITE-FREE)</b> .....	122	<b>COPAXONE</b> .....	31	<i>d10 %-0.45 % sodium chloride</i> ...79	
<b>CLINIMIX E 2.75%/D5W</b>		<b>COPIKTRA</b> .....	19	<i>d2.5 %-0.45 % sodium chloride</i> ..79	
<b>SULF FREE</b> .....	79	<b>CORDRAN</b> .....	72	<i>d5 % and 0.9 % sodium</i>	
<b>CLINIMIX E 4.25%/D10W</b>		<b>CORDRAN TAPE LARGE</b>		<i>chloride</i> .....	79
<b>SUL FREE</b> .....	122	<b>ROLL</b> .....	72	<i>d5 %-0.45 % sodium chloride</i> ....79	
<b>CLINIMIX E 4.25%/D5W</b>		<b>COREG</b> .....	61	<i>dabigatran etexilate</i> .....	61
<b>SULF FREE</b> .....	122	<b>COREG CR</b> .....	61	<i>dalfampridine</i> .....	32
<b>CLINIMIX E 5%/D15W</b>		<b>CORGARD</b> .....	61	<b>DALIRESP</b> .....	116
<b>SULFIT FREE</b> .....	122	<b>CORLANOR</b> .....	61	<b>DALVANCE</b> .....	7
<b>CLINIMIX E 5%/D20W</b>		<b>CORTEF</b> .....	84	<i>danazol</i> .....	84
<b>SULFIT FREE</b> .....	122	<b>CORTROPHIN GEL</b> .....	84	<b>DANTRIUM</b> .....	32
<b>CLINISOL SF 15 %</b> .....	122	<b>COSENTYX</b> .....	72	<i>dantrolene</i> .....	32
<i>clobazam</i> .....	31	<b>COSENTYX (2 SYRINGES)</b> ...72		<i>dapsone</i> .....	7, 72
<i>clobetasol</i> .....	72	<b>COSENTYX PEN (2 PENS)</b> ....72		<b>DAPTACEL (DTAP</b>	
<i>clobetasol-emollient</i> .....	72	<b>COSENTYX UNOREADY</b>		<b>PEDIATRIC) (PF)</b> .....	98
<b>CLOBEX</b> .....	72	<b>PEN</b> .....	72	<i>daptomycin</i> .....	7
<i>clocortolone pivalate</i> .....	72	<b>COSOFT</b> .....	111	<i>darifenacin</i> .....	120



<b>DARTISLA</b> .....	92	<i>dextroamphetamine-</i>	<i>donepezil</i> .....	34
<i>darunavir ethanolate</i> .....	7	<i>amphetamine</i> .....	<b>DOPTELET (10 TAB PACK)</b> .....	61
<b>DAURISMO</b> .....	19	<i>dextrose 10 % and 0.2 % nacl</i> ....	<b>DOPTELET (15 TAB PACK)</b> .....	62
<b>DAYBUE</b> .....	32	<i>dextrose 10 % in water (d10w)</i> ..	<b>DOPTELET (30 TAB PACK)</b> .....	62
<b>DAYPRO</b> .....	32	<i>dextrose 5 % in water (d5w)</i> .....	<b>DORYX</b> .....	8
<b>DAYTRANA</b> .....	32	<i>dextrose 5%-0.2 % sod chloride</i> ..	<b>DORYX MPC</b> .....	8
<b>DAYVIGO</b> .....	32	<b>DHIVY</b> .....	<i>dorzolamide</i> .....	112
<b>DDAVP</b> .....	84	<b>DIACOMIT</b> .....	<i>dorzolamide-timolol</i> .....	112
<b>DEBLITANE</b> .....	105	<b>DIASTAT</b> .....	<i>dorzolamide-timolol (pf)</i> .....	112
<i>deferasirox</i> .....	79	<b>DIASTAT ACUDIAL</b> .....	<b>DOTTI</b> .....	106
<i>deferiprone</i> .....	79	<i>diazepam</i> .....	<b>DOVATO</b> .....	8
<b>DELESTROGEN</b> .....	105	<b>DIAZEPAM INTENSOL</b> .....	<i>doxazosin</i> .....	62
<b>DELSTRIGO</b> .....	8	<i>diazoxide</i> .....	<i>doxepin</i> .....	34, 73
<b>DELZICOL</b> .....	92	<b>DIBENZYLINE</b> .....	<i>doxercalciferol</i> .....	84
<i>demeclocycline</i> .....	8	<b>DICLEGIS</b> .....	<b>DOXY-100</b> .....	8
<b>DEMEROL</b> .....	32	<i>diclofenac epolamine</i> .....	<i>doxycycline hyclate</i> .....	8
<b>DEMEROL (PF)</b> .....	32	<i>diclofenac potassium</i> .....	<i>doxycycline monohydrate</i> .....	8
<b>DEMSEER</b> .....	61	<i>diclofenac sodium</i> .....	<i>doxylamine-pyridoxine (vit b6)</i> ..	92
<b>DENAVIR</b> .....	72	<i>diclofenac-misoprostol</i> .....	<i>dronabinol</i> .....	92
<b>DEPAKOTE</b> .....	32	<i>dicloxacillin</i> .....	<i>drospirenone-e.estradiol-lm.fa</i> ..	106
<b>DEPAKOTE ER</b> .....	32	<i>dicyclomine</i> .....	<i>drospirenone-ethinyl estradiol</i> ..	106
<b>DEPAKOTE SPRINKLES</b> .....	32	<b>DIFFERIN</b> .....	<b>DROXIA</b> .....	19
<b>DEPEN TITRATABS</b> .....	102	<b>DIFICID</b> .....	<i>droxidopa</i> .....	80
<b>DEPO-ESTRADIOL</b> .....	105	<i>diflorasone</i> .....	<b>DUAKLIR PRESSAIR</b> .....	116
<b>DEPO-PROVERA</b> .....	105	<b>DIFLUCAN</b> .....	<b>DUAVEE</b> .....	106
<b>DEPO-SUBQ PROVERA</b> 104	105	<i>diflunisal</i> .....	<b>DUETACT</b> .....	84
<b>DEPO-TESTOSTERONE</b> .....	84	<i>difluprednate</i> .....	<b>DUEXIS</b> .....	34
<b>DERMA-SMOOTH/FS</b>		<i>digoxin</i> .....	<b>DULERA</b> .....	116
<b>SCALP OIL</b> .....	72	<i>dihydroergotamine</i> .....	<i>duloxetine</i> .....	34
<b>DERMOTIC OIL</b> .....	82	<b>DILANTIN</b> .....	<b>DUOBRII</b> .....	73
<b>DESCOVY</b> .....	8	<b>DILANTIN EXTENDED</b> .....	<b>DUOPA</b> .....	34
<i>desipramine</i> .....	32	<b>DILANTIN INFATABS</b> .....	<b>DUPIXENT PEN</b> .....	73
<i>desloratadine</i> .....	116	<b>DILANTIN-125</b> .....	<b>DUPIXENT SYRINGE</b> .....	73
<i>desmopressin</i> .....	84	<b>DILAUDID</b> .....	<b>DUREZOL</b> .....	112
<i>desog-e.estradiol/e.estradiol</i> ....	105	<i>diltiazem hcl</i> .....	<i>dutasteride</i> .....	120
<i>desogestrel-ethinyl estradiol</i> ....	105	<b>DILT-XR</b> .....	<i>dutasteride-tamsulosin</i> .....	120
<i>desonide</i> .....	73	<i>dimethyl fumarate</i> .....	<b>DYANA VEL XR</b> .....	34
<b>DESOWEN</b> .....	73	<b>DIOVAN</b> .....	<b>DYMISTA</b> .....	116
<i>desoximetasone</i> .....	73	<b>DIOVAN HCT</b> .....	<b>DYRENIUM</b> .....	62
<i>desvenlafaxine</i> .....	32	<b>DIPENTUM</b> .....	<b>E.E.S. 400</b> .....	9
<i>desvenlafaxine succinate</i> .....	32	<i>diphenoxylate-atropine</i> .....	<b>E.E.S. GRANULES</b> .....	9
<b>DETROL</b> .....	120	<b>DIPROLENE</b>	<i>econazole</i> .....	73
<b>DETROL LA</b> .....	120	<b>(AUGMENTED)</b> .....	<b>EDARBI</b> .....	62
<b>DEXABLISS</b> .....	84	<i>dipyridamole</i> .....	<b>EDARBYCLOR</b> .....	62
<i>dexamethasone</i> .....	84	<i>disopyramide phosphate</i> .....	<b>EDECIN</b> .....	62
<i>dexamethasone sodium</i>		<i>disulfiram</i> .....	<b>EDLUAR</b> .....	34
<i>phosphate</i> .....	112	<b>DIURIL</b> .....	<b>EDURANT</b> .....	9
<b>DEXEDRINE SPANSULE</b> .....	32	<i>divalproex</i> .....	<i>efavirenz</i> .....	9
<b>DEXILANT</b> .....	92	<b>DIVIGEL</b> .....	<i>efavirenz-emtricitabin-tenofov</i> ....	9
<i>dexlansoprazole</i> .....	92	<i>dofetilide</i> .....	<i>efavirenz-lamivu-tenofov disop</i> ....	9
<i>dexmethylphenidate</i> .....	32	<b>DOJOLVI</b> .....	<b>EFFEXOR XR</b> .....	35
<i>dextroamphetamine sulfate</i> ... 32,	33	<b>DOLISHALE</b> .....	<b>EFFIENT</b> .....	62

<b>EFUDEX</b> .....	73	<b>EPIPEN 2-PAK</b> .....	116	<b>EUCRISA</b> .....	74
<b>EGRIFTA SV</b> .....	98	<b>EPIPEN JR 2-PAK</b> .....	116	<b>EUTHYROX</b> .....	84
<i>electrolyte-148</i> .....	122	<b>EPITOL</b> .....	35	<b>EVAMIST</b> .....	106
<b>ELESTRIN</b> .....	106	<b>EPIVIR</b> .....	9	<b>EVEKEO</b> .....	35
<i>eletriptan</i> .....	35	<i>eplerenone</i> .....	62	<b>EVEKEO ODT</b> .....	35
<b>ELIDEL</b> .....	73	<b>EPOGEN</b> .....	98	<b>EVENITY</b> .....	102
<b>ELIGARD</b> .....	19	<b>EPRONTIA</b> .....	35	<i>everolimus (antineoplastic)</i> .....	19
<b>ELIGARD (3 MONTH)</b> .....	19	<b>EPSOLAY</b> .....	73	<i>everolimus</i>	
<b>ELIGARD (4 MONTH)</b> .....	19	<b>EPZICOM</b> .....	9	<i>(immunosuppressive)</i> .....	19
<b>ELIGARD (6 MONTH)</b> .....	19	<b>EQUETRO</b> .....	35	<b>EVISTA</b> .....	102
<b>ELIQUIS</b> .....	62	<b>ERAXIS(WATER DILUENT)</b> ..	9	<b>EVOTAZ</b> .....	10
<b>ELIQUIS DVT-PE TREAT</b>		<i>ergoloid</i> .....	35	<b>EVOXAC</b> .....	80
<b>30D START</b> .....	62	<i>ergotamine-caffeine</i> .....	35	<b>EVRYSDI</b> .....	35
<b>ELMIRON</b> .....	121	<b>ERIVEDGE</b> .....	19	<b>EXELDERM</b> .....	74
<b>ELURYNG</b> .....	106	<b>ERLEADA</b> .....	19	<b>EXELON PATCH</b> .....	35
<b>EMCYT</b> .....	19	<i>erlotinib</i> .....	19	<i>exemestane</i> .....	19
<b>EMEND</b> .....	92, 93	<b>ERMEZA</b> .....	84	<b>EXFORGE</b> .....	62
<b>EMFLAZA</b> .....	84	<b>ERRIN</b> .....	106	<b>EXFORGE HCT</b> .....	62
<b>EMGALITY PEN</b> .....	35	<b>ERTACZO</b> .....	73	<b>EXJADE</b> .....	80
<b>EMGALITY SYRINGE</b> .....	35	<i>ertapenem</i> .....	9	<b>EXKIVITY</b> .....	19
<b>EMSAM</b> .....	35	<b>ERY PADS</b> .....	73	<b>EXSERVAN</b> .....	80
<i>emtricitabine</i> .....	9	<b>ERYGEL</b> .....	74	<b>EXTAVIA</b> .....	98
<i>emtricitabine-tenofovir (tdf)</i> .....	9	<b>ERYPED 200</b> .....	9	<b>EYSUVIS</b> .....	112
<b>EMTRIVA</b> .....	9	<b>ERYPED 400</b> .....	9	<b>EZALLOR SPRINKLE</b> .....	62
<b>EMVERM</b> .....	9	<b>ERY-TAB</b> .....	9	<i>ezetimibe</i> .....	62
<i>enalapril maleate</i> .....	62	<b>ERYTHROCIN</b> .....	9	<i>ezetimibe-simvastatin</i> .....	62
<i>enalapril-hydrochlorothiazide</i> ....	62	<b>ERYTHROCIN (AS</b>		<b>FABIOR</b> .....	74
<b>ENBREL</b> .....	102	<b>STEARATE)</b> .....	9	<b>FALMINA (28)</b> .....	106
<b>ENBREL MINI</b> .....	102	<i>erythromycin</i> .....	10, 112	<i>famciclovir</i> .....	10
<b>ENBREL SURECLICK</b> .....	102	<i>erythromycin ethylsuccinate</i> .....	9	<i>famotidine</i> .....	93
<b>ENDARI</b> .....	80	<i>erythromycin with ethanol</i> .....	74	<b>FANAPT</b> .....	35, 36
<b>ENDOCET</b> .....	35	<i>erythromycin-benzoyl peroxide</i> ..	74	<b>FARESTON</b> .....	20
<b>ENGERIX-B (PF)</b> .....	98	<b>ESBRIET</b> .....	116	<b>FARXIGA</b> .....	84
<b>ENGERIX-B PEDIATRIC</b>		<i>escitalopram oxalate</i> .....	35	<b>FASENRA</b> .....	116
<b>(PF)</b> .....	98	<b>ESGIC</b> .....	35	<b>FASENRA PEN</b> .....	116
<i>enoxaparin</i> .....	62	<i>esomeprazole magnesium</i> .....	93	<i>febuxostat</i> .....	102
<b>ENPRESSE</b> .....	106	<b>ESTARYLLA</b> .....	106	<i>felbamate</i> .....	36
<b>ENSKYCE</b> .....	106	<i>estazolam</i> .....	35	<b>FELBATOL</b> .....	36
<b>ENSPRYNG</b> .....	19	<b>ESTRACE</b> .....	106	<b>FELDENE</b> .....	36
<b>ENSTILAR</b> .....	73	<i>estradiol</i> .....	106	<i>felodipine</i> .....	62
<i>entacapone</i> .....	35	<i>estradiol valerate</i> .....	106	<b>FEMARA</b> .....	20
<b>ENTADFI</b> .....	121	<i>estradiol-norethindrone acet</i> ...	106	<b>FEMRING</b> .....	106
<i>entecavir</i> .....	9	<b>ESTRING</b> .....	106	<i>fenofibrate</i> .....	62
<b>ENTRESTO</b> .....	62	<b>ESTROGEL</b> .....	106	<i>fenofibrate micronized</i> .....	62
<b>ENULOSE</b> .....	93	<i>eszopiclone</i> .....	35	<i>fenofibrate nanocrystallized</i> .....	62
<b>ENVARUS XR</b> .....	19	<i>ethacrynic acid</i> .....	62	<i>fenofibric acid (choline)</i> .....	62
<b>EPCLUSA</b> .....	9	<i>ethambutol</i> .....	10	<b>FENOGLIDE</b> .....	63
<b>EPIDIOLEX</b> .....	35	<i>ethosuximide</i> .....	35	<i>fenopropfen</i> .....	36
<b>EPIDUO</b> .....	73	<i>ethynodiol diac-eth estradiol</i> ...	106	<i>fentanyl</i> .....	36
<b>EPIDUO FORTE</b> .....	73	<i>etodolac</i> .....	35	<i>fentanyl citrate</i> .....	36
<i>epinastine</i> .....	112	<i>etonogestrel-ethinyl estradiol</i> ..	106	<b>FENTORA</b> .....	36, 37
<i>epinephrine</i> .....	116	<i>etravirine</i> .....	10	<b>FERRIPROX</b> .....	80

<b>FERRIPROX (2 TIMES A DAY)</b> .....	80	<i>flurandrenolide</i> .....	74	<b>GAVILYTE-G</b> .....	93
<i>fesoterodine</i> .....	121	<i>flurbiprofen</i> .....	37	<b>GAVRETO</b> .....	20
<b>FETZIMA</b> .....	37	<i>flurbiprofen sodium</i> .....	112	<i>gefitinib</i> .....	20
<b>FEXMID</b> .....	37	<i>fluticasone furoate-vilanterol</i> ...	116	<b>GELNIQUE</b> .....	121
<b>FIASP FLEXTOUCH U-100</b>		<i>fluticasone propionate</i> .....	74, 117	<i>gemfibrozil</i> .....	63
<b>INSULIN</b> .....	84	<i>fluticasone propion-salmeterol</i> ..	117	<b>GEMMILY</b> .....	106
<b>FIASP PENFILL U-100</b>		<i>fluvastatin</i> .....	63	<b>GEMTESA</b> .....	121
<b>INSULIN</b> .....	84	<i>fluvoxamine</i> .....	37	<b>GENERLAC</b> .....	93
<b>FIASP U-100 INSULIN</b> .....	84	<b>FML FORTE</b> .....	112	<b>GENGRAF</b> .....	20
<b>FILSPARI</b> .....	63	<b>FML LIQUIFILM</b> .....	112	<b>GENOTROPIN</b> .....	98
<b>FINACEA</b> .....	74	<b>FOCALIN</b> .....	37	<b>GENOTROPIN MINIQUICK</b> ..	98
<i>finasteride</i> .....	121	<b>FOCALIN XR</b> .....	37	<i>gentamicin</i> .....	10, 74, 112
<i>finngolimod</i> .....	37	<i>fondaparinux</i> .....	63	<i>gentamicin in nacl (iso-osm)</i> .....	10
<b>FINTEPLA</b> .....	37	<b>FORFIVO XL</b> .....	37	<b>GENVOYA</b> .....	10
<b>FINZALA</b> .....	106	<i>formoterol fumarate</i> .....	117	<b>GEODON</b> .....	38
<b>FIORICET</b> .....	37	<b>FORTEO</b> .....	102	<b>GILENYA</b> .....	38
<b>FIORICET WITH CODEINE</b> ..	37	<b>FORTESTA</b> .....	84	<b>GILOTRIF</b> .....	20
<b>FIRAZYR</b> .....	116	<b>FOSAMAX</b> .....	102	<b>GIMOTI</b> .....	93
<b>FIRDAPSE</b> .....	37	<b>FOSAMAX PLUS D</b> .....	102	<b>GLASSIA</b> .....	80
<b>FIRMAGON KIT W</b>		<i>fosamprenavir</i> .....	10	<i>glatiramer</i> .....	38
<b>DILUENT SYRINGE</b> .....	20	<i>fosfomycin tromethamine</i> .....	10	<b>GLATOPA</b> .....	38
<b>FIRVANQ</b> .....	10	<i>fosinopril</i> .....	63	<b>GLEEVEC</b> .....	20
<b>FLAC OTIC OIL</b> .....	82	<i>fosinopril-hydrochlorothiazide</i> ...	63	<b>GLEOSTINE</b> .....	20
<b>FLAGYL</b> .....	10	<b>FOSRENOL</b> .....	80	<i>glimepiride</i> .....	84
<b>FLAREX</b> .....	112	<b>FOTIVDA</b> .....	20	<i>glipizide</i> .....	84
<i>flavoxate</i> .....	121	<b>FRAGMIN</b> .....	63	<i>glipizide-metformin</i> .....	84
<b>FLEBOGAMMA DIF</b> .....	98	<b>FROVA</b> .....	37	<b>GLUCAGEN HYPOKIT</b> .....	84
<i>flecainide</i> .....	63	<i>frovatriptan</i> .....	38	<b>GLUCAGON EMERGENCY</b>	
<b>FLECTOR</b> .....	37	<b>FULPHILA</b> .....	98	<b>KIT (HUMAN)</b> .....	84
<b>FLEQSUVY</b> .....	37	<b>FUROSCIX</b> .....	63	<b>GLUCOTROL XL</b> .....	84
<b>FLOLIPID</b> .....	63	<i>furosemide</i> .....	63	<b>GLUMETZA</b> .....	84, 85
<b>FLOMAX</b> .....	121	<b>FUZEON</b> .....	10	<i>glyburide</i> .....	85
<b>FLOVENT DISKUS</b> .....	116	<b>FYAVOLV</b> .....	106	<i>glyburide micronized</i> .....	85
<b>FLOVENT HFA</b> .....	116	<b>FYCOMPA</b> .....	38	<i>glyburide-metformin</i> .....	85
<i>fluconazole</i> .....	10	<b>FYLNETRA</b> .....	98	<b>GLYCATE</b> .....	93
<i>fluconazole in nacl (iso-osm)</i> .....	10	<i>gabapentin</i> .....	38	<i>glycopyrrolate</i> .....	93
<i>flucytosine</i> .....	10	<b>GALAFOLD</b> .....	84	<b>GLYNASE</b> .....	85
<i>fludrocortisone</i> .....	84	<i>galantamine</i> .....	38	<b>GLYXAMBI</b> .....	85
<i>flunisolide</i> .....	116	<b>GAMMAGARD LIQUID</b> .....	98	<b>GOCOVRI</b> .....	38
<i>fluocinolone</i> .....	74	<b>GAMMAGARD S-D (IGA &lt; 1</b>		<b>GOLYTELY</b> .....	93
<i>fluocinolone acetonide oil</i> .....	82	<b>MCG/ML)</b> .....	98	<b>GRALISE</b> .....	38
<i>fluocinolone and shower cap</i> .....	74	<b>GAMMAKED</b> .....	98	<i>granisetron hcl</i> .....	93
<i>fluocinonide</i> .....	74	<b>GAMMAPLEX</b> .....	98	<b>GRANIX</b> .....	98
<i>fluocinonide-emollient</i> .....	74	<b>GAMMAPLEX (WITH</b>		<b>GRASTEK</b> .....	98
<i>fluoride (sodium)</i> .....	122	<b>SORBITOL)</b> .....	98	<i>griseofulvin microsize</i> .....	10
<i>fluorometholone</i> .....	112	<b>GAMUNEX-C</b> .....	98	<i>griseofulvin ultramicrosize</i> .....	10
<i>fluorouracil</i> .....	74	<b>GARDASIL 9 (PF)</b> .....	98	<i>guanfacine</i> .....	38, 63
<i>fluoxetine</i> .....	37	<b>GASTROCROM</b> .....	93	<b>GVOKE</b> .....	85
<i>fluoxetine (pmdd)</i> .....	37	<i>gatifloxacin</i> .....	112	<b>GVOKE HYPOPEN 2-PACK</b> ..	85
<i>fluphenazine decanoate</i> .....	37	<b>GATTEX 30-VIAL</b> .....	93	<b>GVOKE PFS 1-PACK</b>	
<i>fluphenazine hcl</i> .....	37	<b>GAUZE PAD</b> .....	101	<b>SYRINGE</b> .....	85
		<b>GAVILYTE-C</b> .....	93	<b>GYNAZOLE-1</b> .....	106

<b>HADLIMA</b> .....	102	<b>HUMIRA(CF)</b> .....	102	<i>ibandronate</i> .....	103
<b>HADLIMA PUSHTOUCH</b> ....	102	<b>HUMIRA(CF) PEDI</b>		<b>IBRANCE</b> .....	20
<b>HADLIMA(CF)</b> .....	102	<b>CROHNS STARTER</b> ....	102, 103	<b>IBSRELA</b> .....	93
<b>HADLIMA(CF)</b>		<b>HUMIRA(CF) PEN</b> .....	103	<b>IBU</b> .....	39
<b>PUSHTOUCH</b> .....	102	<b>HUMIRA(CF) PEN</b>		<i>ibuprofen</i> .....	39
<b>HAEGARDA</b> .....	117	<b>CROHNS-UC-HS</b> .....	103	<i>ibuprofen-famotidine</i> .....	39
<b>HAILEY 24 FE</b> .....	106	<b>HUMIRA(CF) PEN</b>		<i>icatibant</i> .....	117
<i>halcinonide</i> .....	74	<b>PEDIATRIC UC</b> .....	103	<b>ICLEVIA</b> .....	106
<b>HALCION</b> .....	38	<b>HUMIRA(CF) PEN PSOR-</b>		<b>ICLUSIG</b> .....	20
<b>HALDOL DECANOATE</b> .....	38	<b>UV-ADOL HS</b> .....	103	<i>icosapent ethyl</i> .....	63
<i>halobetasol propionate</i> .....	74	<b>HUMULIN 70/30 U-100</b>		<b>IDHIFA</b> .....	20
<b>HALOETTE</b> .....	106	<b>INSULIN</b> .....	85	<b>ILEVRO</b> .....	112
<b>HALOG</b> .....	74	<b>HUMULIN 70/30 U-100</b>		<b>ILUMYA</b> .....	75
<i>haloperidol</i> .....	38	<b>KWIKPEN</b> .....	85	<i>imatinib</i> .....	20
<i>haloperidol decanoate</i> .....	38	<b>HUMULIN N NPH INSULIN</b>		<b>IMBRUVICA</b> .....	20
<i>haloperidol lactate</i> .....	38	<b>KWIKPEN</b> .....	85	<i>imipenem-cilastatin</i> .....	10
<b>HARVONI</b> .....	10	<b>HUMULIN N NPH U-100</b>		<i>imipramine hcl</i> .....	39
<b>HAVRIX (PF)</b> .....	98	<b>INSULIN</b> .....	85	<i>imipramine pamoate</i> .....	39
<b>HELIDAC</b> .....	93	<b>HUMULIN R REGULAR U-</b>		<i>imiquimod</i> .....	75
<b>HEMADY</b> .....	85	<b>100 INSULN</b> .....	85	<b>IMITREX</b> .....	39, 40
<i>heparin (porcine)</i> .....	63	<b>HUMULIN R U-500 (CONC)</b>		<b>IMITREX STATDOSE PEN</b> ..	40
<b>HEPLISAV-B (PF)</b> .....	98	<b>INSULIN</b> .....	85	<b>IMITREX STATDOSE</b>	
<b>HETLIOZ</b> .....	38	<b>HUMULIN R U-500 (CONC)</b>		<b>REFILL</b> .....	40
<b>HETLIOZ LQ</b> .....	39	<b>KWIKPEN</b> .....	85	<b>IMOVAX RABIES</b>	
<b>HIBERIX (PF)</b> .....	98	<i>hydralazine</i> .....	63	<b>VACCINE (PF)</b> .....	99
<b>HIPREX</b> .....	10	<b>HYDREA</b> .....	20	<b>IMPAVIDO</b> .....	10
<b>HORIZANT</b> .....	39	<i>hydrochlorothiazide</i> .....	63	<b>IMURAN</b> .....	20
<b>HULIO(CF)</b> .....	102	<i>hydrocodone bitartrate</i> .....	39	<b>IMVEXXY MAINTENANCE</b>	
<b>HULIO(CF) PEN</b> .....	102	<i>hydrocodone-acetaminophen</i> .....	39	<b>PACK</b> .....	106
<b>HUMALOG JUNIOR</b>		<i>hydrocodone-ibuprofen</i> .....	39	<b>IMVEXXY STARTER PACK</b>	
<b>KWIKPEN U-100</b> .....	85	<i>hydrocortisone</i> .....	75, 85, 93	.....	106
<b>HUMALOG KWIKPEN</b>		<i>hydrocortisone butyrate</i> .....	74, 75	<b>INBRIJA</b> .....	40
<b>INSULIN</b> .....	85	<i>hydrocortisone valerate</i> .....	75	<b>INCASSIA</b> .....	106
<b>HUMALOG MIX 50-50</b>		<i>hydrocortisone-acetic acid</i> .....	82	<b>INCRELEX</b> .....	80
<b>INSULN U-100</b> .....	85	<i>hydrocortisone-pramoxine</i> .....	93	<b>INCRUSE ELLIPTA</b> .....	117
<b>HUMALOG MIX 50-50</b>		<i>hydromorphone</i> .....	39	<i>indapamide</i> .....	63
<b>KWIKPEN</b> .....	85	<i>hydromorphone (pf)</i> .....	39	<b>INDERAL LA</b> .....	63
<b>HUMALOG MIX 75-25</b>		<i>hydroxychloroquine</i> .....	10	<b>INDOCIN</b> .....	40
<b>KWIKPEN</b> .....	85	<i>hydroxyurea</i> .....	20	<i>indomethacin</i> .....	40
<b>HUMALOG MIX 75-25(U-</b>		<i>hydroxyzine hcl</i> .....	117	<b>INFANRIX (DTAP) (PF)</b> .....	99
<b>100)INSULN</b> .....	85	<i>hydroxyzine pamoate</i> .....	117	<b>INGREZZA</b> .....	40
<b>HUMALOG TEMPO PEN(U-</b>		<b>HYFTOR</b> .....	75	<b>INGREZZA INITIATION</b>	
<b>100)INSULN</b> .....	85	<b>HYRIMOZ PEN CROHN'S-</b>		<b>PACK</b> .....	40
<b>HUMALOG U-100 INSULIN</b> ..	85	<b>UC STARTER</b> .....	103	<b>INLYTA</b> .....	20
<b>HUMATIN</b> .....	10	<b>HYRIMOZ PEN PSORIASIS</b>		<b>INNOPRAN XL</b> .....	64
<b>HUMATROPE</b> .....	99	<b>STARTER</b> .....	103	<b>INPEFA</b> .....	85
<b>HUMIRA</b> .....	102	<b>HYRIMOZ(CF)</b> .....	103	<b>INQOVI</b> .....	20
<b>HUMIRA PEN</b> .....	102	<b>HYRIMOZ(CF) PEDI</b>		<b>INREBIC</b> .....	20
<b>HUMIRA PEN CROHNS-</b>		<b>CROHN STARTER</b> .....	103	<b>INSPIRA</b> .....	64
<b>UC-HS START</b> .....	102	<b>HYRIMOZ(CF) PEN</b> .....	103	<i>insulin asp prt-insulin aspart</i> .....	85
<b>HUMIRA PEN PSOR-</b>		<b>HYSINGLA ER</b> .....	39	<i>insulin aspart u-100</i> .....	85
<b>UVEITS-ADOL HS</b> .....	102	<b>HYZAAR</b> .....	63	<i>insulin degludec</i> .....	85

<i>insulin glargine</i> .....	85	<b>JANUMET XR</b> .....	86	<b>KLONOPIN</b> .....	41
<i>insulin glargine-yfgn</i> .....	85	<b>JANUVIA</b> .....	86	<b>KLOR-CON</b> .....	122
<i>insulin lispro</i> .....	85	<b>JARDIANCE</b> .....	86	<b>KLOR-CON 10</b> .....	122
<i>insulin lispro protamin-lispro</i> .....	85	<b>JASMIEL (28)</b> .....	107	<b>KLOR-CON 8</b> .....	122
<i>insulin syringe-needle u-100</i> .....	101	<b>JATENZO</b> .....	86	<b>KLOR-CON M10</b> .....	122
<b>INTELENCE</b> .....	10	<b>JAVYGTOR</b> .....	86	<b>KLOR-CON M15</b> .....	122
<b>INTRALIPID</b> .....	122	<b>JAYPIRCA</b> .....	20	<b>KLOR-CON M20</b> .....	122
<b>INTRAROSA</b> .....	106	<b>JENTADUETO</b> .....	86	<b>KLOXXADO</b> .....	41
<b>INTROVALE</b> .....	107	<b>JENTADUETO XR</b> .....	86	<b>KOMBIGLYZE XR</b> .....	86
<b>INTUNIVER</b> .....	40	<b>JINTELI</b> .....	107	<b>KONVOMEF</b> .....	93
<b>INVANZ</b> .....	10	<b>JORNAY PM</b> .....	41	<b>KORLYM</b> .....	86
<b>INVEGA</b> .....	40	<b>JUBLIA</b> .....	75	<b>KOSELUGO</b> .....	21
<b>INVEGA HAFYERA</b> .....	40	<b>JULEBER</b> .....	107	<b>KRAZATI</b> .....	21
<b>INVEGA SUSTENNA</b> .....	40	<b>JULUCA</b> .....	11	<b>KRINTAFEL</b> .....	11
<b>INVEGA TRINZA</b> .....	41	<b>JUNEL 1.5/30 (21)</b> .....	107	<b>KRISTALOSE</b> .....	93
<b>INVELTYS</b> .....	112	<b>JUNEL 1/20 (21)</b> .....	107	<b>KURVELO (28)</b> .....	107
<b>INVOKAMET</b> .....	85	<b>JUNEL FE 1.5/30 (28)</b> .....	107	<b>KUVAN</b> .....	86
<b>INVOKAMET XR</b> .....	85	<b>JUNEL FE 1/20 (28)</b> .....	107	<b>KYLEENA</b> .....	107
<b>INVOKANA</b> .....	86	<b>JUNEL FE 24</b> .....	107	<i>l norgest/e.estradiol-e.estrad</i> ....	107
<b>IOPIDINE</b> .....	112	<b>JUXTAPID</b> .....	64	<i>labetalol</i> .....	64
<b>IPOL</b> .....	99	<b>JYNARQUE</b> .....	86	<i>lacosamide</i> .....	41
<i>ipratropium bromide</i> .....	82, 117	<b>JYNNEOS</b>		<b>LACRISERT</b> .....	112
<i>ipratropium-albuterol</i> .....	117	(PF)(STOCKPILE).....	99	<i>lactulose</i> .....	93
<i>irbesartan</i> .....	64	<b>KAITLIB FE</b> .....	107	<b>LAMICTAL</b> .....	41
<i>irbesartan-hydrochlorothiazide</i> ..	64	<b>KALETRA</b> .....	11	<b>LAMICTAL ODT</b> .....	41
<b>IRESSA</b> .....	20	<b>KALYDECO</b> .....	117	<b>LAMICTAL STARTER</b>	
<b>ISENTRESS</b> .....	11	<b>KAPVAY</b> .....	41	(BLUE) KIT.....	41
<b>ISENTRESS HD</b> .....	11	<b>KARIVA (28)</b> .....	107	<b>LAMICTAL STARTER</b>	
<b>ISIBLOOM</b> .....	107	<b>KATERZIA</b> .....	64	(GREEN) KIT.....	41
<b>ISOLYTE S PH 7.4</b> .....	122	<b>KAZANO</b> .....	86	<b>LAMICTAL STARTER</b>	
<b>ISOLYTE-P IN 5 %</b>		<b>KELNOR 1/35 (28)</b> .....	107	(ORANGE) KIT.....	41
<b>DEXTROSE</b> .....	122	<b>KELNOR 1-50 (28)</b> .....	107	<b>LAMICTAL XR</b> .....	41
<i>isoniazid</i> .....	11	<b>KENALOG</b> .....	75	<b>LAMICTAL XR STARTER</b>	
<b>ISORDIL</b> .....	64	<b>KEPPRA</b> .....	41	(BLUE).....	41
<b>ISORDIL TITRADOSE</b> .....	64	<b>KEPPRA XR</b> .....	41	<b>LAMICTAL XR STARTER</b>	
<i>isosorbide dinitrate</i> .....	64	<b>KERENDIA</b> .....	64	(GREEN).....	41
<i>isosorbide mononitrate</i> .....	64	<b>KERYDIN</b> .....	75	<b>LAMICTAL XR STARTER</b>	
<i>isosorbide-hydralazine</i> .....	64	<b>KESIMPTA PEN</b> .....	41	(ORANGE).....	42
<i>isotretinoin</i> .....	75	<i>ketoconazole</i> .....	11, 75	<i>lamivudine</i> .....	11
<i>isradipine</i> .....	64	<b>KETODAN</b> .....	75	<i>lamivudine-zidovudine</i> .....	11
<b>ISTALOL</b> .....	112	<i>ketoprofen</i> .....	41	<i>lamotrigine</i> .....	42
<b>ISTURISA</b> .....	86	<i>ketorolac</i> .....	41, 112	<b>LAMPIT</b> .....	11
<i>itraconazole</i> .....	11	<b>KEVEYIS</b> .....	41	<b>LANOXIN</b> .....	64
<i>ivermectin</i> .....	11, 75	<b>KEVZARA</b> .....	103	<i>lansoprazole</i> .....	93
<b>IXIARO (PF)</b> .....	99	<b>KINERET</b> .....	103	<i>lanthanum</i> .....	80
<b>IYUZEH</b> .....	112	<b>KINRIX (PF)</b> .....	99	<b>LANTUS SOLOSTAR U-100</b>	
<b>JADENU</b> .....	80	<b>KISQALI</b> .....	21	<b>INSULIN</b> .....	86
<b>JADENU SPRINKLE</b> .....	80	<b>KISQALI FEMARA CO-</b>		<b>LANTUS U-100 INSULIN</b> .....	86
<b>JAKAFI</b> .....	20	<b>PACK</b> .....	21	<i>lapatinib</i> .....	21
<b>JALYN</b> .....	121	<b>KITABIS PAK</b> .....	11	<b>LARIN 1.5/30 (21)</b> .....	107
<b>JANTOVEN</b> .....	64	<b>KLARON</b> .....	75	<b>LARIN 1/20 (21)</b> .....	107
<b>JANUMET</b> .....	86	<b>KLISYRI</b> .....	21	<b>LARIN FE 1.5/30 (28)</b> .....	107

<b>LARIN FE 1/20 (28)</b> .....	107	<i>linezolid in dextrose 5%</i> .....	11	<b>LOTRONEX</b> .....	94
<b>LASIX</b> .....	64	<b>LINZESS</b> .....	94	<i>lovastatin</i> .....	65
<i>latanoprost</i> .....	112	<i>liothyronine</i> .....	87	<b>LOVAZA</b> .....	65
<b>LATUDA</b> .....	42	<b>LIPITOR</b> .....	64	<b>LOVENOX</b> .....	65
<b>LAYOLIS FE</b> .....	107	<b>LIPOFEN</b> .....	64	<b>LOW-OGESTREL (28)</b> .....	107
<i>ledipasvir-sofosbuvir</i> .....	11	<b>LIQREV</b> .....	117	<i>loxapine succinate</i> .....	43
<b>LEENA 28</b> .....	107	<i>lisdexamfetamine</i> .....	42	<i>lubiprostone</i> .....	94
<i>leflunomide</i> .....	103	<i>lisinopril</i> .....	64	<b>LUCEMYRA</b> .....	43
<i>lenalidomide</i> .....	21	<i>lisinopril-hydrochlorothiazide</i> ....	64	<i>luliconazole</i> .....	75
<b>LENVIMA</b> .....	21	<b>LITFULO</b> .....	80	<b>LUMAKRAS</b> .....	21
<b>LESCOL XL</b> .....	64	<i>lithium carbonate</i> .....	42	<b>LUMIGAN</b> .....	112
<b>LESSINA</b> .....	107	<i>lithium citrate</i> .....	42	<b>LUMRYZ</b> .....	43
<b>LETAIRIS</b> .....	117	<b>LITHOBID</b> .....	42	<b>LUNESTA</b> .....	43
<i>letrozole</i> .....	21	<b>LITHOSTAT</b> .....	80	<b>LUPKYNIS</b> .....	21
<i>leucovorin calcium</i> .....	21	<b>LIVALO</b> .....	64	<b>LUPRON DEPOT</b> .....	21
<b>LEUKERAN</b> .....	21	<b>LIVMARLI</b> .....	94	<b>LUPRON DEPOT (3</b>	
<b>LEUKINE</b> .....	99	<b>LIVTENCITY</b> .....	11	<b>MONTH)</b> .....	21
<i>leuprolide</i> .....	21	<b>LO LOESTRIN FE</b> .....	107	<b>LUPRON DEPOT (4</b>	
<i>leuprolide (3 month)</i> .....	21	<b>LOCOID</b> .....	75	<b>MONTH)</b> .....	21
<i>levabuterol hcl</i> .....	117	<b>LOCOID LIPOCREAM</b> .....	75	<b>LUPRON DEPOT (6</b>	
<i>levabuterol tartrate</i> .....	117	<b>LODINE</b> .....	42	<b>MONTH)</b> .....	21
<i>levamlodipine</i> .....	64	<b>LODOCO</b> .....	64	<b>LUPRON DEPOT-PED</b> ....	21, 22
<b>LEVEMIR FLEXPEN</b> .....	86	<b>LODOSYN</b> .....	42	<b>LUPRON DEPOT-PED (3</b>	
<b>LEVEMIR U-100 INSULIN</b> ....	86	<b>LOESTRIN 1.5/30 (21)</b> .....	107	<b>MONTH)</b> .....	21
<i>levetiracetam</i> .....	42	<b>LOESTRIN 1/20 (21)</b> .....	107	<i>lurasidone</i> .....	43
<i>levobunolol</i> .....	112	<b>LOESTRIN FE 1.5/30 (28-</b>		<b>LUTERA (28)</b> .....	108
<i>levocarnitine</i> .....	80	<b>DAY)</b> .....	107	<b>LUZU</b> .....	75
<i>levocarnitine (with sugar)</i> .....	80	<b>LOESTRIN FE 1/20 (28-</b>		<b>LYBALVI</b> .....	43
<i>levocetirizine</i> .....	117	<b>DAY)</b> .....	107	<b>LYLEQ</b> .....	108
<i>levofloxacin</i> .....	11, 112	<b>LOFENA</b> .....	42	<b>LYLLANA</b> .....	108
<i>levofloxacin in d5w</i> .....	11	<b>LOKELMA</b> .....	80	<b>LYNPARZA</b> .....	22
<b>LEVONEST (28)</b> .....	107	<b>LOMOTIL</b> .....	94	<b>LYRICA</b> .....	43
<i>levonorgestrel-ethinyl estrad</i> ....	107	<b>LONSURF</b> .....	21	<b>LYRICA CR</b> .....	43
<i>levonorg-eth estrad triphasic</i> ....	107	<i>loperamide</i> .....	94	<b>LYSODREN</b> .....	22
<b>LEVORA-28</b> .....	107	<b>LOPID</b> .....	64	<b>LYTGOBI</b> .....	22
<i>levorphanol tartrate</i> .....	42	<i>lopinavir-ritonavir</i> .....	11	<b>LYUMJEV KWIKPEN U-100</b>	
<i>levothyroxine</i> .....	87	<b>LOPRESSOR</b> .....	64	<b>INSULIN</b> .....	87
<b>LEVOXYL</b> .....	87	<b>LOPROX</b> .....	75	<b>LYUMJEV KWIKPEN U-200</b>	
<b>LEXAPRO</b> .....	42	<i>lorazepam</i> .....	42	<b>INSULIN</b> .....	87
<b>LEXETTE</b> .....	75	<b>LORAZEPAM INTENSOL</b> ....	42	<b>LYUMJEV TEMPO PEN(U-</b>	
<b>LEXIVA</b> .....	11	<b>LORBRENA</b> .....	21	<b>100)INSULN</b> .....	87
<b>LIALDA</b> .....	94	<b>LOREEV XR</b> .....	42	<b>LYUMJEV U-100 INSULIN</b> ....	87
<b>LIBRAX (WITH</b>		<b>LORYNA (28)</b> .....	107	<b>LYVISPAH</b> .....	43
<b>CLIDINIUM)</b> .....	94	<b>LORZONE</b> .....	43	<b>LYZA</b> .....	108
<b>LICART</b> .....	42	<i>losartan</i> .....	64	<b>MACROBID</b> .....	11
<i>lidocaine</i> .....	75	<i>losartan-hydrochlorothiazide</i> ....	64	<b>MACRODANTIN</b> .....	11, 12
<i>lidocaine hcl</i> .....	75	<b>LOSEASONIQUE</b> .....	107	<i>mafenide acetate</i> .....	75
<b>LIDOCAINE VISCOUS</b> .....	75	<b>LOTEMAX</b> .....	112	<i>magnesium sulfate</i> .....	122
<i>lidocaine-prilocaine</i> .....	75	<b>LOTEMAX SM</b> .....	112	<b>MALARONE</b> .....	12
<b>LIDODERM</b> .....	75	<b>LOTENSIN</b> .....	65	<b>MALARONE PEDIATRIC</b> ....	12
<b>LILETTA</b> .....	107	<i>loteprednol etabonate</i> .....	112	<i>malathion</i> .....	75
<i>linezolid</i> .....	11	<b>LOTREL</b> .....	65	<i>maraviroc</i> .....	12

<b>MARINOL</b> .....	94	<i>meprobamate</i> .....	44	<b>MIEBO</b> .....	113
<b>MARLISSA (28)</b> .....	108	<b>MEPRON</b> .....	12	<b>MIGERGOT</b> .....	45
<b>MARPLAN</b> .....	43	<i>mercaptapurine</i> .....	22	<i>miglitol</i> .....	87
<b>MATULANE</b> .....	22	<i>meropenem</i> .....	12	<i>miglustat</i> .....	87
<b>MATZIM LA</b> .....	65	<b>MERZEE</b> .....	108	<b>MIGRANAL</b> .....	45
<b>MAVENCLAD (10 TABLET PACK)</b> .....	43	<i>mesalamine</i> .....	94	<b>MILI</b> .....	108
<b>MAVENCLAD (4 TABLET PACK)</b> .....	43	<b>MESNEX</b> .....	22	<b>MILLIPRED</b> .....	87
<b>MAVENCLAD (5 TABLET PACK)</b> .....	43	<b>MESTINON</b> .....	44	<b>MIMVEY</b> .....	108
<b>MAVENCLAD (6 TABLET PACK)</b> .....	43	<b>MESTINON TIMESPAN</b> .....	44	<b>MINIPRESS</b> .....	65
<b>MAVENCLAD (7 TABLET PACK)</b> .....	43	<i>metaxalone</i> .....	44	<b>MINIVELLE</b> .....	108
<b>MAVENCLAD (8 TABLET PACK)</b> .....	43	<i>metformin</i> .....	87	<i>minocycline</i> .....	12
<b>MAVENCLAD (9 TABLET PACK)</b> .....	43	<i>methadone</i> .....	44	<b>MINOLIRA ER</b> .....	12
<b>MAVYRET</b> .....	12	<i>methamphetamine</i> .....	44	<i>minoxidil</i> .....	65
<b>MAXALT</b> .....	43	<i>methazolamide</i> .....	112	<b>MIRAPEX ER</b> .....	45
<b>MAXALT-MLT</b> .....	43	<i>methenamine hippurate</i> .....	12	<b>MIRENA</b> .....	108
<b>MAXIDEX</b> .....	112	<i>methimazole</i> .....	87	<i>mirtazapine</i> .....	45
<b>MAXITROL</b> .....	112	<b>METHITEST</b> .....	87	<b>MIRVASO</b> .....	76
<b>MAXZIDE</b> .....	65	<i>methocarbamol</i> .....	44	<i>misoprostol</i> .....	94
<b>MAXZIDE-25MG</b> .....	65	<i>methotrexate sodium</i> .....	22	<b>MITIGARE</b> .....	103
<b>MAYZENT</b> .....	43	<i>methotrexate sodium (pf)</i> .....	22	<b>M-M-R II (PF)</b> .....	99
<b>MAYZENT STARTER(FOR 1MG MAINT)</b> .....	43	<i>methoxsalen</i> .....	75	<i>modafinil</i> .....	45
<b>MAYZENT STARTER(FOR 2MG MAINT)</b> .....	43	<i>methscopolamine</i> .....	94	<i>moexipril</i> .....	65
<i>meclizine</i> .....	94	<i>methsuximide</i> .....	44	<i>molindone</i> .....	45
<i>meclofenamate</i> .....	43	<b>METHYLIN</b> .....	44	<i>mometasone</i> .....	76, 117
<b>MEDROL</b> .....	87	<i>methylphenidate hcl</i> .....	44, 45	<i>montelukast</i> .....	117
<b>MEDROL (PAK)</b> .....	87	<i>methylprednisolone</i> .....	87	<i>morphine</i> .....	45
<i>medroxyprogesterone</i> .....	108	<i>methyltestosterone</i> .....	87	<i>morphine concentrate</i> .....	45
<i>mefenamic acid</i> .....	43	<i>metoclopramide hcl</i> .....	94	<b>MOTEGRITY</b> .....	94
<i>mefloquine</i> .....	12	<i>metolazone</i> .....	65	<b>MOUNJARO</b> .....	87
<i>megestrol</i> .....	22	<i>metoprolol succinate</i> .....	65	<b>MOVANTIK</b> .....	94
<b>MEKINIST</b> .....	22	<i>metoprolol ta-hydrochlorothiaz.</i> .....	65	<b>MOVIPREP</b> .....	94
<b>MEKTOVI</b> .....	22	<i>metoprolol tartrate</i> .....	65	<i>moxifloxacin</i> .....	12, 113
<i>meloxicam</i> .....	43	<b>METROCREAM</b> .....	75	<i>moxifloxacin-sod.chloride(iso)</i> ...	12
<i>meloxicam submicronized</i> .....	43	<b>METROGEL</b> .....	75	<b>MS CONTIN</b> .....	45
<i>memantine</i> .....	43, 44	<b>METROLOTION</b> .....	76	<b>MULPLETA</b> .....	65
<b>MENACTRA (PF)</b> .....	99	<i>metronidazole</i> .....	12, 76, 108	<b>MULTAQ</b> .....	65
<b>MENEST</b> .....	108	<i>metronidazole in nacl (iso-os)</i> ....	12	<i>mupirocin</i> .....	76
<b>MENOSTAR</b> .....	108	<i>metyrosine</i> .....	65	<i>mupirocin calcium</i> .....	76
<b>MENQUADFI (PF)</b> .....	99	<i>mexiletine</i> .....	65	<b>MYALEPT</b> .....	87
<b>MENVEO A-C-Y-W-135-DIP (PF)</b> .....	99	<b>MIBELAS 24 FE</b> .....	108	<b>MYAMBUTOL</b> .....	12
<i>meperidine</i> .....	44	<i>micafungin</i> .....	12	<b>MYCAMINE</b> .....	12
<i>meperidine (pf)</i> .....	44	<b>MICARDIS</b> .....	65	<b>MYCAPSSA</b> .....	22
		<b>MICARDIS HCT</b> .....	65	<b>MYCOBUTIN</b> .....	12
		<b>MICONAZOLE-3</b> .....	108	<i>mycophenolate mofetil</i> .....	22
		<b>MICROGESTIN 1.5/30 (21)</b> ..	108	<i>mycophenolate sodium</i> .....	22
		<b>MICROGESTIN 1/20 (21)</b> ....	108	<b>MYDAYIS</b> .....	45
		<b>MICROGESTIN 24 FE</b> .....	108	<b>MYFEMBREE</b> .....	108
		<b>MICROGESTIN FE 1.5/30 (28)</b> .....	108	<b>MYFORTIC</b> .....	22
		<b>MICROGESTIN FE 1/20 (28)</b> .....	108	<b>MYRBETRIQ</b> .....	121
		<i>midodrine</i> .....	80	<b>MYSOLINE</b> .....	45
				<b>MYTESI</b> .....	94
				<i>nabumetone</i> .....	45

<i>nadolol</i> .....	65	<b>NEXAVAR</b> .....	22	<b>NORTREL 0.5/35 (28)</b> .....	109
<i>nafticillin</i> .....	12	<b>NEXIUM</b> .....	94	<b>NORTREL 1/35 (21)</b> .....	109
<i>naftifine</i> .....	76	<b>NEXIUM PACKET</b> .....	94	<b>NORTREL 1/35 (28)</b> .....	109
<b>NAFTIN</b> .....	76	<b>NEXLETOL</b> .....	65	<b>NORTREL 7/7/7 (28)</b> .....	109
<b>NALFON</b> .....	46	<b>NEXLIZET</b> .....	65	<i>nortriptyline</i> .....	47
<b>NALOCET</b> .....	46	<b>NEXPLANON</b> .....	108	<b>NORVASC</b> .....	66
<i>naloxone</i> .....	46	<b>NEXTSTELLIS</b> .....	108	<b>NORVIR</b> .....	13
<i>naltrexone</i> .....	46	<b>NGENLA</b> .....	99	<b>NOURIANZ</b> .....	47
<b>NAMENDA</b> .....	46	<i>niacin</i> .....	65	<b>NOVOLIN 70/30 U-100</b>	
<b>NAMENDA TITRATION</b>		<b>NIACOR</b> .....	65	<b>INSULIN</b> .....	88
<b>PAK</b> .....	46	<i>nicardipine</i> .....	66	<b>NOVOLIN 70-30 FLEXPEN</b>	
<b>NAMENDA XR</b> .....	46	<b>NICOTROL</b> .....	80	<b>U-100</b> .....	88
<b>NAMZARIC</b> .....	46	<b>NICOTROL NS</b> .....	80	<b>NOVOLIN N FLEXPEN</b> .....	88
<b>NAPRELAN CR</b> .....	46	<i>nifedipine</i> .....	66	<b>NOVOLIN N NPH U-100</b>	
<i>naproxen</i> .....	46	<b>NIKKI (28)</b> .....	108	<b>INSULIN</b> .....	88
<i>naproxen sodium</i> .....	46	<b>NILANDRON</b> .....	22	<b>NOVOLIN R FLEXPEN</b> .....	88
<i>naproxen-esomeprazole</i> .....	46	<i>nilutamide</i> .....	22	<b>NOVOLIN R REGULAR</b>	
<i>naratriptan</i> .....	46	<i>nimodipine</i> .....	66	<b>U100 INSULIN</b> .....	88
<b>NARCAN</b> .....	46	<b>NINLARO</b> .....	22	<b>NOVOLOG FLEXPEN U-100</b>	
<b>NARDIL</b> .....	46	<i>nisoldipine</i> .....	66	<b>INSULIN</b> .....	88
<b>NATACYN</b> .....	113	<i>nitazoxanide</i> .....	13	<b>NOVOLOG MIX 70-30 U-100</b>	
<b>NATAZIA</b> .....	108	<i>nitisinone</i> .....	80	<b>INSULIN</b> .....	88
<i>nateglinide</i> .....	87	<b>NITRO-BID</b> .....	66	<b>NOVOLOG MIX 70-</b>	
<b>NATESTO</b> .....	87	<b>NITRO-DUR</b> .....	66	<b>30FLEXPEN U-100</b> .....	88
<b>NATPARA</b> .....	87	<i>nitrofurantoin</i> .....	13	<b>NOVOLOG PENFILL U-100</b>	
<b>NATROBA</b> .....	76	<i>nitrofurantoin macrocrystal</i> .....	13	<b>INSULIN</b> .....	88
<b>NAYZILAM</b> .....	46	<i>nitrofurantoin monohyd/m-cryst</i> .....	13	<b>NOVOLOG U-100 INSULIN</b>	
<i>nebivolol</i> .....	65	<i>nitroglycerin</i> .....	66	<b>ASPART</b> .....	88
<b>NEBUPENT</b> .....	12	<b>NITROLINGUAL</b> .....	66	<b>NOXAFIL</b> .....	13
<b>NECON 0.5/35 (28)</b> .....	108	<b>NITROSTAT</b> .....	66	<b>NUBEQA</b> .....	23
<i>nefazodone</i> .....	46	<b>NITYR</b> .....	80	<b>NUCALA</b> .....	117, 118
<i>neomycin</i> .....	12	<b>NIVESTYM</b> .....	99	<b>NUCYNTA</b> .....	47
<i>neomycin-bacitracin-poly-hc</i> ....	113	<i>nizatidine</i> .....	94	<b>NUCYNTA ER</b> .....	47
<i>neomycin-bacitracin-polymyxin</i>	113	<b>NOCDURNA (MEN)</b> .....	88	<b>NUDEXTA</b> .....	47
<i>neomycin-polymyxin b-</i>		<b>NOCDURNA (WOMEN)</b> .....	88	<b>NUPLAZID</b> .....	47
<i>dexameth</i> .....	113	<b>NORA-BE</b> .....	108	<b>NURTEC ODT</b> .....	47
<i>neomycin-polymyxin-gramicidin</i>		<b>NORDITROPIN FLEXPRO</b> ... 99		<b>NUTRILIPID</b> .....	122
.....	113	<i>noreth-ethinyl estradiol-iron</i> ....	108	<b>NUTROPIN AQ NUSPIN</b> .....	99
<i>neomycin-polymyxin-hc</i> .....	82, 113	<i>norethindrone (contraceptive)</i> ..	108	<b>NUVARING</b> .....	109
<b>NEO-POLYCIN</b> .....	113	<i>norethindrone acetate</i> .....	108	<b>NUVIGIL</b> .....	47
<b>NEO-POLYCIN HC</b> .....	113	<i>norethindrone ac-eth estradiol</i> ..	108	<b>NUZYRA</b> .....	13
<b>NEORAL</b> .....	22	<i>norethindrone-e.estradiol-iron</i>		<b>NYAMYC</b> .....	76
<b>NEO-SYNALAR</b> .....	76	.....	108, 109	<b>NYLIA 1/35 (28)</b> .....	109
<b>NERLYNX</b> .....	22	<b>NORGESIC</b> .....	46	<b>NYLIA 7/7/7 (28)</b> .....	109
<b>NESINA</b> .....	87	<b>NORGESIC FORTE</b> .....	47	<b>NYMALIZE</b> .....	66
<b>NEUAC</b> .....	76	<i>norgestimate-ethinyl estradiol</i> ..	109	<b>NYMYO</b> .....	109
<b>NEULASTA</b> .....	99	<b>NORITATE</b> .....	76	<i>nystatin</i> .....	13, 76
<b>NEUPOGEN</b> .....	99	<b>NORLIQVA</b> .....	66	<i>nystatin-triamcinolone</i> .....	76
<b>NEUPRO</b> .....	46	<b>NORPACE</b> .....	66	<b>NYSTOP</b> .....	76
<b>NEURONTIN</b> .....	46	<b>NORPACE CR</b> .....	66	<b>NYVEPRIA</b> .....	99
<b>NEVANAC</b> .....	113	<b>NORPRAMIN</b> .....	47	<b>OICALIVA</b> .....	94
<i>nevirapine</i> .....	12	<b>NORTHERA</b> .....	80	<b>OCELLA</b> .....	109



<b>OCTAGAM</b> .....	99	<i>oseltamivir</i> .....	13	<i>pen needle, diabetic</i> .....	101
<i>octreotide acetate</i> .....	23	<b>OSENI</b> .....	88	<i> penciclovir</i> .....	76
<b>OCUFLOX</b> .....	113	<b>OSMOLEX ER</b> .....	47	<i> penicillamine</i> .....	103
<b>ODACTRA</b> .....	99	<b>OSMOPREP</b> .....	95	<i> penicillin g pot in dextrose</i> .....	13
<b>ODEFSEY</b> .....	13	<b>OSPHENA</b> .....	109	<i> penicillin g potassium</i> .....	13
<b>ODOMZO</b> .....	23	<b>OTEZLA</b> .....	103	<i> penicillin g sodium</i> .....	13
<b>OFEV</b> .....	118	<b>OTEZLA STARTER</b> .....	103	<i> penicillin v potassium</i> .....	13
<i> ofloxacin</i> .....	13, 82, 113	<b>OTOVEL</b> .....	82	<b>PENNSAID</b> .....	49
<i> olanzapine</i> .....	47	<b>OTREXUP (PF)</b> .....	103	<b>PENTACEL (PF)</b> .....	100
<i> olanzapine-fluoxetine</i> .....	47	<b>OVIDE</b> .....	76	<b>PENTAM</b> .....	13
<i> olmesartan</i> .....	66	<i> oxacillin</i> .....	13	<i> pentamidine</i> .....	13
<i> olmesartan-amlodipin-hcthiazyd</i> .....	66	<i> oxacillin in dextrose(iso-osm)</i> .....	13	<b>PENTASA</b> .....	95
<i> olmesartan-hydrochlorothiazide</i> .....	66	<i> oxaprozin</i> .....	47	<i> pentazocine-naloxone</i> .....	49
<i> olopatadine</i> .....	82, 113	<i> oxazepam</i> .....	47	<i> pentoxifylline</i> .....	66
<b>OLPRUVA</b> .....	80, 81	<b>OXBRYTA</b> .....	81	<b>PEPCID</b> .....	95
<b>OLUMIANT</b> .....	103	<i> oxcarbazepine</i> .....	47	<b>PERCOCET</b> .....	49
<i> omega-3 acid ethyl esters</i> .....	66	<b>OXERVATE</b> .....	113	<b>PERFOROMIST</b> .....	118
<i> omeprazole</i> .....	94	<i> oxiconazole</i> .....	76	<i> perindopril erbumine</i> .....	67
<i> omeprazole-sodium bicarbonate</i> .....	94	<b>OXISTAT</b> .....	76	<b>PERIOGARD</b> .....	82
<b>OMNARIS</b> .....	118	<b>OXTELLAR XR</b> .....	47	<i> permethrin</i> .....	76
<b>OMNITROPE</b> .....	99	<i> oxybutynin chloride</i> .....	121	<i> perphenazine</i> .....	49
<i> ondansetron</i> .....	95	<i> oxycodone</i> .....	47, 48	<i> perphenazine-amitriptyline</i> .....	49
<i> ondansetron hcl</i> .....	95	<i> oxycodone-acetaminophen</i> .....	48	<b>PERSERIS</b> .....	49
<b>ONEXTON</b> .....	76	<b>OXYCONTIN</b> .....	48	<b>PERTZYE</b> .....	95
<b>ONFI</b> .....	47	<i> oxymorphone</i> .....	48	<b>PHEBURANE</b> .....	81
<b>ONGENTYS</b> .....	47	<b>OXYTROL</b> .....	121	<i> phenelzine</i> .....	49
<b>ONGLYZA</b> .....	88	<b>OZEMPIC</b> .....	88	<i> phenobarbital</i> .....	49
<b>ONUREG</b> .....	23	<b>PACERONE</b> .....	66	<i> phenoxybenzamine</i> .....	67
<b>ONZETRA XSAIL</b> .....	47	<i> paliperidone</i> .....	48	<b>PHENYTEK</b> .....	49
<b>OPSUMIT</b> .....	118	<b>PALYNZIQ</b> .....	88	<i> phenytoin</i> .....	49
<b>OPZELURA</b> .....	76	<b>PAMELOR</b> .....	48	<i> phenytoin sodium extended</i> .....	49
<b>ORACEA</b> .....	13	<b>PANCREAZE</b> .....	95	<b>PHEXXI</b> .....	109
<b>ORALAIR</b> .....	99	<b>PANDEL</b> .....	76	<b>PHOSPHOLINE IODIDE</b> .....	113
<b>ORAPRED ODT</b> .....	88	<b>PANRETIN</b> .....	76	<b>PIFELTRO</b> .....	13
<b>ORENCIA</b> .....	103	<i> pantoprazole</i> .....	95	<i> pilocarpine hcl</i> .....	81, 113
<b>ORENCIA CLICKJECT</b> .....	103	<b>PANZYGA</b> .....	99	<i> pimecrolimus</i> .....	76
<b>ORENITRAM</b> .....	66	<i> paricalcitol</i> .....	88	<i> pimozide</i> .....	49
<b>ORENITRAM MONTH 1</b>		<b>PARLODEL</b> .....	48	<b>PIMTREA (28)</b> .....	109
<b>TITRATION KT</b> .....	66	<b>PARNATE</b> .....	48	<i> pindolol</i> .....	67
<b>ORENITRAM MONTH 2</b>		<i> paromomycin</i> .....	13	<i> pioglitazone</i> .....	88
<b>TITRATION KT</b> .....	66	<i> paroxetine hcl</i> .....	48	<i> pioglitazone-glimepiride</i> .....	88
<b>ORENITRAM MONTH 3</b>		<i> paroxetine</i>		<i> pioglitazone-metformin</i> .....	88
<b>TITRATION KT</b> .....	66	<i> mesylate(menop.sym)</i> .....	48	<i> piperacillin-tazobactam</i> .....	13
<b>ORFADIN</b> .....	81	<b>PAXIL</b> .....	48	<b>PIQRAY</b> .....	23
<b>ORGOVYX</b> .....	23	<b>PAXIL CR</b> .....	49	<i> pirfenidone</i> .....	118
<b>ORIAHNN</b> .....	109	<b>PEDIARIX (PF)</b> .....	99	<i> piroxicam</i> .....	49
<b>ORILISSA</b> .....	88	<b>PEDVAX HIB (PF)</b> .....	99	<b>PLAQUENIL</b> .....	13
<b>ORKAMBI</b> .....	118	<i> peg 3350-electrolytes</i> .....	95	<b>PLASMA-LYTE 148</b> .....	122
<b>ORLADEYO</b> .....	118	<i> peg3350-sod sul-nacl-kcl-asb-c</i> .....	95	<b>PLASMA-LYTE A</b> .....	122
<i> orphenadrine citrate</i> .....	47	<b>PEGASYS</b> .....	99	<b>PLAVIX</b> .....	67
<i> orphenadrine-asa-caffeine</i> .....	47	<i> peg-electrolyte soln</i> .....	95	<b>PLEGRIDY</b> .....	100
<b>ORSERDU</b> .....	23	<b>PEMAZYRE</b> .....	23	<b>PLENAMINE</b> .....	122

<b>PLENVU</b> .....	95	<b>PREVALITE</b> .....	67	<b>PURIXAN</b> .....	23
<b>PLIAGLIS</b> .....	76	<b>PREVYMIS</b> .....	14	<b>PYLERA</b> .....	95
<i>podofilox</i> .....	76	<b>PREZCOBIX</b> .....	14	<i>pyrazinamide</i> .....	14
<b>POLYCIN</b> .....	113	<b>PREZISTA</b> .....	14	<i>pyridostigmine bromide</i> .....	49, 50
<i>polymyxin b sulfate</i> .....	14	<b>PRIFTIN</b> .....	14	<i>pyrimethamine</i> .....	14
<i>polymyxin b sulf-trimethoprim</i> ..	113	<b>PRILOSEC</b> .....	95	<b>PYRUKYND</b> .....	81
<b>POMALYST</b> .....	23	<i>primaquine</i> .....	14	<b>QBRELIS</b> .....	67
<b>PONVORY</b> .....	49	<b>PRIMAXIN IV</b> .....	14	<b>QELBREE</b> .....	50
<b>PONVORY 14-DAY</b>		<i>primidone</i> .....	49	<b>QINLOCK</b> .....	23
<b>STARTER PACK</b> .....	49	<b>PRIORIX (PF)</b> .....	100	<b>QNASL</b> .....	118
<b>PORTIA 28</b> .....	109	<b>PRISTIQ</b> .....	49	<b>QTERN</b> .....	89
<i>posaconazole</i> .....	14	<b>PRIVIGEN</b> .....	100	<b>QUADRACEL (PF)</b> .....	100
<i>potassium chlorid-d5-</i>		<b>PROAIR DIGIHALER</b> .....	118	<b>QUALAQUIN</b> .....	14
<i>0.45%nacl</i> .....	122	<b>PROAIR RESPICLICK</b> .....	118	<b>QUARTETTE</b> .....	109
<i>potassium chloride</i> .....	123	<i>probenecid</i> .....	103	<b>QUDEXY XR</b> .....	50
<i>potassium chloride in 0.9%nacl</i>	122	<i>probenecid-colchicine</i> .....	104	<b>QUESTRAN</b> .....	67
<i>potassium chloride in 5 % dex</i> ..	122	<b>PROCARDIA XL</b> .....	67	<b>QUESTRAN LIGHT</b> .....	67
<i>potassium chloride in lr-d5</i> .....	123	<b>PROCENTRA</b> .....	49	<i>quetiapine</i> .....	50
<i>potassium chloride in water</i> .....	123	<i>prochlorperazine</i> .....	95	<b>QUILLICHEW ER</b> .....	50
<i>potassium chloride-0.45 % nacl</i>	123	<i>prochlorperazine maleate</i> .....	95	<b>QUILLIVANT XR</b> .....	50
<i>potassium chloride-d5-</i>		<b>PROCRT</b> .....	100	<i>quinapril</i> .....	67
<i>0.2%nacl</i> .....	123	<b>PROCTO-MED HC</b> .....	95	<i>quinidine gluconate</i> .....	67
<i>potassium chloride-d5-</i>		<b>PROCTOSOL HC</b> .....	95	<i>quinidine sulfate</i> .....	67
<i>0.9%nacl</i> .....	123	<b>PROCTOZONE-HC</b> .....	95	<i>quinine sulfate</i> .....	14
<i>potassium citrate</i> .....	121	<b>PROCYSBI</b> .....	121	<b>QULIPTA</b> .....	50
<b>PRADAXA</b> .....	67	<i>progesterone micronized</i> .....	109	<b>QUVIVIQ</b> .....	50
<b>PRALUENT PEN</b> .....	67	<b>PROGLYCEM</b> .....	89	<b>QVAR REDIHALER</b> .....	118
<i>pramipexole</i> .....	49	<b>PROGRAF</b> .....	23	<b>RABAVERT (PF)</b> .....	100
<i>prasugrel</i> .....	67	<b>PROLASTIN-C</b> .....	81	<i>rabeprazole</i> .....	95
<i>pravastatin</i> .....	67	<b>PROLATE</b> .....	49	<b>RADICAVA ORS STARTER</b>	
<i>praziquantel</i> .....	14	<b>PROLENSA</b> .....	113	<b>KIT SUSP</b> .....	50
<i>prazosin</i> .....	67	<b>PROLIA</b> .....	104	<i>raloxifene</i> .....	104
<b>PRED FORTE</b> .....	113	<b>PROMACTA</b> .....	67	<i>ramelteon</i> .....	50
<b>PRED MILD</b> .....	113	<i>promethazine</i> .....	118	<i>ramipril</i> .....	67
<i>prednisolone</i> .....	88	<b>PROMETHEGAN</b> .....	118	<i>ranolazine</i> .....	67
<i>prednisolone acetate</i> .....	113	<b>PROMETRIUM</b> .....	109	<b>RAPAFLO</b> .....	121
<i>prednisolone sodium phosphate</i>		<i>propafenone</i> .....	67	<b>RAPAMUNE</b> .....	23
.....	88, 113	<i>propranolol</i> .....	67	<i>rasagiline</i> .....	50
<i>prednisone</i> .....	89	<i>propylthiouracil</i> .....	89	<b>RASUVO (PF)</b> .....	104
<b>PREDNISONA INTENSOL</b> ....	89	<b>PROQUAD (PF)</b> .....	100	<b>RAVICTI</b> .....	81
<b>PREFEST</b> .....	109	<b>PROSCAR</b> .....	121	<b>RAYALDEE</b> .....	89
<i>pregabalin</i> .....	49	<b>PROSOL 20 %</b> .....	123	<b>RAYOS</b> .....	89
<b>PREHEVBRIO (PF)</b> .....	100	<b>PROTONIX</b> .....	95	<b>REBIF (WITH ALBUMIN)</b> ...	100
<b>PREMARIN</b> .....	109	<i>protriptyline</i> .....	49	<b>REBIF REBIDOSE</b> .....	100
<b>PREMASOL 10 %</b> .....	123	<b>PROVENTIL HFA</b> .....	118	<b>REBIF TITRATION PACK</b> ..	100
<b>PREMPHASE</b> .....	109	<b>PROVERA</b> .....	109	<b>RECLIPSEN (28)</b> .....	109
<b>PREMPRO</b> .....	109	<b>PROVIGIL</b> .....	49	<b>RECOMBIVAX HB (PF)</b> .....	100
<b>PRENATAL VITAMIN</b>		<b>PROZAC</b> .....	49	<b>RECORLEV</b> .....	89
<b>PLUS LOW IRON</b> .....	123	<b>PRUDOXIN</b> .....	77	<b>RECTIV</b> .....	96
<i>pretomanid</i> .....	14	<b>PULMICORT</b> .....	118	<b>REGLAN</b> .....	96
<b>PREVACID</b> .....	95	<b>PULMICORT FLEXHALER</b>	118	<b>REGRANEX</b> .....	77
<b>PREVACID SOLUTAB</b> .....	95	<b>PULMOZYME</b> .....	118	<b>RELAFEN DS</b> .....	50

<b>RELENZA DISKHALER</b> .....	14	<b>RIVELSA</b> .....	109	<b>SELZENTRY</b> .....	14
<b>RELEUKO</b> .....	100	<i>rizatriptan</i> .....	51	<b>SEMGLEE(INSULIN</b>	
<b>RELEXXII</b> .....	50	<b>ROBINUL</b> .....	96	<b>GLARGINE-YFGN)</b> .....	89
<b>RELISTOR</b> .....	96	<b>ROBINUL FORTE</b> .....	96	<b>SEMGLEE(INSULIN</b>	
<b>REL PAX</b> .....	50	<b>ROCALTROL</b> .....	89	<b>GLARG-YFGN)PEN</b> .....	89
<b>RELTONE</b> .....	96	<b>ROCKLATAN</b> .....	113	<b>SENSIPAR</b> .....	89
<b>RELYVRIO</b> .....	50	<i>roflumilast</i> .....	119	<b>SEREVENT DISKUS</b> .....	119
<b>REMERON</b> .....	50	<i>ropinirole</i> .....	51	<b>SEROQUEL</b> .....	52
<b>REMERON SOLTAB</b> .....	50	<i>rosuvastatin</i> .....	68	<b>SEROQUEL XR</b> .....	52
<b>RENAGEL</b> .....	81	<b>ROTARIX</b> .....	100	<b>SEROSTIM</b> .....	100
<b>REVELA</b> .....	81	<b>ROTATEQ VACCINE</b> .....	100	<i>sertraline</i> .....	52
<i>repaglinide</i> .....	89	<b>ROWASA</b> .....	96	<b>SETLAKIN</b> .....	109
<b>REPATHA PUSHTRONEX</b> ....	67	<b>ROWEEPR</b> .....	51	<i>sevelamer carbonate</i> .....	81
<b>REPATHA SURECLICK</b> .....	67	<b>ROXICODONE</b> .....	52	<i>sevelamer hcl</i> .....	81
<b>REPATHA SYRINGE</b> .....	68	<b>ROXYBOND</b> .....	52	<b>SEYSARA</b> .....	14
<b>RESTASIS</b> .....	113	<b>ROZEREM</b> .....	52	<b>SHAROBEL</b> .....	109
<b>RESTASIS MULTIDOSE</b> ....	113	<b>ROZLYTREK</b> .....	23	<b>SHINGRIX (PF)</b> .....	100
<b>RESTORIL</b> .....	50	<b>RUBRACA</b> .....	23	<b>SIGNIFOR</b> .....	24
<b>RETACRIT</b> .....	100	<b>RUCONEST</b> .....	119	<b>SIKLOS</b> .....	24
<b>RETEVMO</b> .....	23	<i>rufinamide</i> .....	52	<i>sildenafil (pulm.hypertension)</i> ..	119
<b>RETIN-A</b> .....	77	<b>RUKOBIA</b> .....	14	<b>SILENOR</b> .....	52
<b>RETIN-A MICRO</b> .....	77	<b>RYALTRIS</b> .....	119	<b>SILIQ</b> .....	77
<b>RETIN-A MICRO PUMP</b> .....	77	<b>RYBELSUS</b> .....	89	<i>silodosin</i> .....	121
<b>RETROVIR</b> .....	14	<b>RYCLORA</b> .....	119	<b>SILVADENE</b> .....	77
<b>REVATIO</b> .....	118	<b>RYDAPT</b> .....	23	<i>silver sulfadiazine</i> .....	77
<b>REVCovi</b> .....	81	<b>RYTARY</b> .....	52	<b>SIMBRINZA</b> .....	113
<b>REVLIMID</b> .....	23	<b>RYTHMOL SR</b> .....	68	<b>SIMPONI</b> .....	104
<b>REXULTI</b> .....	51	<b>RYVENT</b> .....	119	<i>simvastatin</i> .....	68
<b>REYATAZ</b> .....	14	<b>SABRIL</b> .....	52	<b>SINEMET</b> .....	52
<b>REYVOW</b> .....	51	<b>SAFYRAL</b> .....	109	<b>SINGULAIR</b> .....	119
<b>REZLIDHIA</b> .....	23	<b>SAIZEN</b> .....	100	<i>sirolimus</i> .....	24
<b>REZUROCK</b> .....	23	<b>SAJAZIR</b> .....	119	<b>SIRTURO</b> .....	14
<b>REZVOGLAR KWIKPEN</b> .....	89	<b>SALAGEN (PILOCARPINE)</b> . 81		<b>SITAVIG</b> .....	14
<b>RHOFADE</b> .....	77	<b>SAMSCA</b> .....	89	<b>SIVEXTRO</b> .....	15
<b>RHOPRESSA</b> .....	113	<b>SANCUSO</b> .....	96	<b>SKYCLARYS</b> .....	52
<i>ribavirin</i> .....	14	<b>SANDIMMUNE</b> .....	23	<b>SKYLA</b> .....	109
<b>RIDAURA</b> .....	104	<b>SANDOSTATIN</b> .....	24	<b>SKYRIZI</b> .....	77, 96
<i>rifabutin</i> .....	14	<b>SANTYL</b> .....	77	<b>SKYTROFA</b> .....	100
<i>rifampin</i> .....	14	<b>SAPHRIS</b> .....	52	<b>SLYND</b> .....	109
<b>RILUTEK</b> .....	81	<i>sapropterin</i> .....	89	<b>SOAAZ</b> .....	68
<i>riluzole</i> .....	81	<b>SAVAYSA</b> .....	68	<i>sodium chloride</i> .....	81
<i>rimantadine</i> .....	14	<b>SAVELLA</b> .....	104	<i>sodium chloride 0.45 %</i> .....	123
<b>RINVOQ</b> .....	104	<i>saxagliptin</i> .....	89	<i>sodium chloride 0.9 %</i> .....	81
<i>risedronate</i> .....	81, 104	<i>saxagliptin-metformin</i> .....	89	<i>sodium chloride 3 % hypertonic</i>	
<b>RISPERDAL</b> .....	51	<b>SCSEMBLIX</b> .....	24	.....	123
<b>RISPERDAL CONSTA</b> .....	51	<i>scopolamine base</i> .....	96	<i>sodium chloride 5 % hypertonic</i>	
<i>risperidone</i> .....	51	<b>SEASONIQUE</b> .....	109	.....	123
<b>RITALIN</b> .....	51	<b>SECUADO</b> .....	52	<i>sodium oxybate</i> .....	52
<b>RITALIN LA</b> .....	51	<b>SEGLENTIS</b> .....	52	<i>sodium phenylbutyrate</i> .....	81
<i>ritonavir</i> .....	14	<b>SEGLUROMET</b> .....	89	<i>sodium polystyrene sulfonate</i> .....	81
<i>rivastigmine</i> .....	51	<i>selegiline hcl</i> .....	52	<i>sodium,potassium,mag sulfates</i> ..	96
<i>rivastigmine tartrate</i> .....	51	<i>selenium sulfide</i> .....	77	<i>sofosbuvir-velpatasvir</i> .....	15

<b>SOGROYA</b> .....	100	<b>SUBVENITE STARTER</b>		<b>TAFINLAR</b> .....	24
<i>solifenacin</i> .....	121	<b>(GREEN) KIT</b> .....	53	<i>tafluprost (pf)</i> .....	113
<b>SOLQUA 100/33</b> .....	89	<b>SUBVENITE STARTER</b>		<b>TAGRISSE</b> .....	24
<b>SOLODYN</b> .....	15	<b>(ORANGE) KIT</b> .....	53	<b>TAKHZYRO</b> .....	119
<b>SOLOSEC</b> .....	15	<b>SUCRAID</b> .....	96	<b>TALICIA</b> .....	96
<b>SOLTAMOX</b> .....	24	<i>sucralfate</i> .....	96	<b>TALTZ AUTOINJECTOR</b> .....	77
<b>SOMA</b> .....	52	<b>SUFLAVE</b> .....	96	<b>TALTZ SYRINGE</b> .....	77
<b>SOMAVERT</b> .....	89	<b>SULAR</b> .....	68	<b>TALZENNA</b> .....	24
<b>SOOLANTRA</b> .....	77	<i>sulfacetamide sodium</i> .....	113	<b>TAMIFLU</b> .....	15
<i>sorafenib</i> .....	24	<i>sulfacetamide sodium (acne)</i> .....	77	<i>tamoxifen</i> .....	24
<b>SORILUX</b> .....	77	<i>sulfacetamide-prednisolone</i> .....	113	<i>tamsulosin</i> .....	121
<b>SORINE</b> .....	68	<i>sulfadiazine</i> .....	15	<b>TAPERDEX</b> .....	90
<i>sotalol</i> .....	68	<i>sulfamethoxazole-trimethoprim</i> ..	15	<b>TARGADOX</b> .....	15
<b>SOTALOL AF</b> .....	68	<b>SULFAMYLON</b> .....	77	<b>TARGRETIN</b> .....	24
<b>SOTYKTU</b> .....	77	<i>sulfasalazine</i> .....	96	<b>TARINA 24 FE</b> .....	110
<b>SOTYLIZE</b> .....	68	<i>sulindac</i> .....	53	<b>TARINA FE 1-20 EQ (28)</b> .....	110
<b>SOVALDI</b> .....	15	<i>sumatriptan</i> .....	53	<b>TARPEYO</b> .....	90
<i>spinosad</i> .....	77	<i>sumatriptan succinate</i> .....	53	<b>TASCENSO ODT</b> .....	53
<b>SPIRIVA RESPIMAT</b> .....	119	<i>sumatriptan-naproxen</i> .....	53	<b>TASIGNA</b> .....	24
<b>SPIRIVA WITH</b>		<i>sunitinib malate</i> .....	24	<i>tasimelteon</i> .....	53
<b>HANDIHALER</b> .....	119	<b>SUNLENCA</b> .....	15	<b>TASMAR</b> .....	53
<i>spironolactone</i> .....	68	<b>SUNOSI</b> .....	53	<i>tavaborole</i> .....	77
<i>spironolacton-hydrochlorothiaz.</i>	68	<b>SUPRAX</b> .....	15	<b>TAVALISSE</b> .....	68
<b>SPORANOX</b> .....	15	<b>SUPREP BOWEL PREP KIT</b>	96	<b>TAVNEOS</b> .....	81
<b>SPRINTEC (28)</b> .....	109	<b>SUTAB</b> .....	96	<i>tazarotene</i> .....	77
<b>SPRITAM</b> .....	52	<b>SUTENT</b> .....	24	<b>TAZICEF</b> .....	15
<b>SPRIX</b> .....	52	<b>SYEDA</b> .....	109	<b>TAZORAC</b> .....	78
<b>SPRYCEL</b> .....	24	<b>SYMBICORT</b> .....	119	<b>TAZTIA XT</b> .....	68
<b>SPS (WITH SORBITOL)</b> .....	81	<b>SYMBYAX</b> .....	53	<b>TAZVERIK</b> .....	24
<b>SRONYX</b> .....	109	<b>SYMDEKO</b> .....	119	<b>TDVAX</b> .....	100
<b>SSD</b> .....	77	<b>SYMFI</b> .....	15	<b>TECFIDERA</b> .....	53
<b>STALEVO 100</b> .....	52	<b>SYMFI LO</b> .....	15	<b>TEFLARO</b> .....	15
<b>STALEVO 125</b> .....	52	<b>SYMJEPI</b> .....	119	<b>TEGRETOL</b> .....	53, 54
<b>STALEVO 150</b> .....	52	<b>SYMLINPEN 120</b> .....	89	<b>TEGRETOL XR</b> .....	54
<b>STALEVO 200</b> .....	52	<b>SYMLINPEN 60</b> .....	89	<b>TEGSEDI</b> .....	54
<b>STALEVO 50</b> .....	52	<b>SYMPAZAN</b> .....	53	<b>TEKTRUNA</b> .....	68
<b>STALEVO 75</b> .....	52	<b>SYMPROIC</b> .....	96	<i>telmisartan</i> .....	68
<b>STEGLATRO</b> .....	89	<b>SYMTUZA</b> .....	15	<i>telmisartan-amlodipine</i> .....	68
<b>STEGLUJAN</b> .....	89	<b>SYNALAR</b> .....	77	<i>telmisartan-hydrochlorothiazid</i> ..	68
<b>STELARA</b> .....	77	<b>SYNAREL</b> .....	89	<i>temazepam</i> .....	54
<b>STIOLTO RESPIMAT</b> .....	119	<b>SYNDROS</b> .....	96	<b>TENCON</b> .....	54
<b>STIVARGA</b> .....	24	<b>SYNJARDY</b> .....	89	<b>TENIVAC (PF)</b> .....	100
<b>STRATTERA</b> .....	52, 53	<b>SYNRIBO</b> .....	24	<i>tenofovir disoproxil fumarate</i> .....	15
<i>streptomycin</i> .....	15	<b>SYNTHROID</b> .....	90	<b>TENORETIC 100</b> .....	68
<b>STRIBILD</b> .....	15	<b>SYPRINE</b> .....	81	<b>TENORETIC 50</b> .....	68
<b>STRIVERDI RESPIMAT</b> .....	119	<b>TABLOID</b> .....	24	<b>TENORMIN</b> .....	68
<b>STROMEKTOL</b> .....	15	<b>TABRECTA</b> .....	24	<b>TEPMETKO</b> .....	24
<b>SUBOXONE</b> .....	53	<b>TACLONEX</b> .....	77	<i>terazosin</i> .....	68
<b>SUBVENITE</b> .....	53	<i>tacrolimus</i> .....	24, 77	<i>terbinafine hcl</i> .....	15
<b>SUBVENITE STARTER</b>		<i>tadalafil</i> .....	121	<i>terbutaline</i> .....	119
<b>(BLUE) KIT</b> .....	53	<i>tadalafil (pulm. hypertension)</i> ..	119	<i>terconazole</i> .....	110
		<b>TADLIQ</b> .....	119	<i>teriflunomide</i> .....	54

<i>teriparatide</i> .....	104	<b>TOPAMAX</b> .....	54	<i>trifluoperazine</i> .....	54
<b>TESTIM</b> .....	90	<b>TOPICORT</b> .....	78	<i>trifluridine</i> .....	114
<i>testosterone</i> .....	90	<i>topiramate</i> .....	54	<i>trihexyphenidyl</i> .....	54
<i>testosterone cypionate</i> .....	90	<b>TOPROL XL</b> .....	68	<b>TRIJARDY XR</b> .....	90
<i>testosterone enanthate</i> .....	90	<i>toremifene</i> .....	24	<b>TRIKAFTA</b> .....	120
<i>tetanus, diphtheria tox ped(pf)</i> ... 100		<i>torseamide</i> .....	68	<b>TRI-LEGEST FE</b> .....	110
<i>tetrabenazine</i> .....	54	<b>TOSYMRA</b> .....	54	<b>TRILEPTAL</b> .....	54
<i>tetracycline</i> .....	15	<b>TOUJEO MAX U-300</b>		<b>TRILIPIX</b> .....	69
<b>TEXACORT</b> .....	78	<b>SOLOSTAR</b> .....	90	<b>TRI-LO-ESTARYLLA</b> .....	110
<b>THALITONE</b> .....	68	<b>TOUJEO SOLOSTAR U-300</b>		<b>TRI-LO-SPRINTEC</b> .....	110
<b>THALOMID</b> .....	24	<b>INSULIN</b> .....	90	<i>trimethobenzamide</i> .....	96
<b>THEO-24</b> .....	119	<b>TOVET EMOLLIENT</b> .....	78	<i>trimethoprim</i> .....	16
<i>theophylline</i> .....	119	<b>TOVIAZ</b> .....	121	<b>TRI-MILI</b> .....	110
<b>THIOLA</b> .....	82	<b>TPN ELECTROLYTES</b> .....	123	<i>trimipramine</i> .....	55
<b>THIOLA EC</b> .....	82	<b>TRACLEER</b> .....	119	<b>TRINTELLIX</b> .....	55
<i>thioridazine</i> .....	54	<b>TRADJENTA</b> .....	90	<b>TRI-NYMYO</b> .....	110
<i>thiothixene</i> .....	54	<i>tramadol</i> .....	54	<b>TRI-SPRINTEC (28)</b> .....	110
<b>THYQUIDITY</b> .....	90	<i>tramadol-acetaminophen</i> .....	54	<b>TRIUMEQ</b> .....	16
<b>TIADYLT ER</b> .....	68	<i>trandolapril</i> .....	68	<b>TRIUMEQ PD</b> .....	16
<i>tiagabine</i> .....	54	<i>trandolapril-verapamil</i> .....	68	<b>TRIVORA (28)</b> .....	110
<b>TIAZAC</b> .....	68	<i>tranexamic acid</i> .....	110	<b>TRI-VYLIBRA</b> .....	110
<b>TIBSOVO</b> .....	24	<b>TRANSDERM-SCOP</b> .....	96	<b>TRI-VYLIBRA LO</b> .....	110
<b>TICOVAC</b> .....	100	<i>tranylcypromine</i> .....	54	<b>TRIZIVIR</b> .....	16
<i>tigecycline</i> .....	15	<b>TRAVASOL 10 %</b> .....	123	<b>TROKENDI XR</b> .....	55
<b>TIGLUTIK</b> .....	82	<b>TRAVATAN Z</b> .....	114	<b>TROPHAMINE 10 %</b> .....	123
<b>TIKOSYN</b> .....	68	<i>travoprost</i> .....	114	<i>trospium</i> .....	121
<b>TILIA FE</b> .....	110	<i>trazodone</i> .....	54	<b>TRUDHESA</b> .....	55
<i>timolol maleate</i> ..... 68, 113, 114		<b>TRECATOR</b> .....	16	<b>TRULANCE</b> .....	96
<i>timolol maleate (pf)</i> .....	113	<b>TRELEGY ELLIPTA</b> .....	119	<b>TRULICITY</b> .....	90
<b>TIMOPTIC OCUDOSE (PF)</b> .....	114	<b>TRELSTAR</b> .....	24	<b>TRUMENBA</b> .....	101
<i>tinidazole</i> .....	15	<b>TREMFYA</b> .....	78	<b>TRUVADA</b> .....	16
<i>tiopronin</i> .....	82	<b>TRESIBA FLEXTOUCH U-</b>		<b>TUDORZA PRESSAIR</b> .....	120
<i>tiotropium bromide</i> .....	119	<b>100</b> .....	90	<b>TUKYSA</b> .....	25
<b>TIROSINT</b> .....	90	<b>TRESIBA FLEXTOUCH U-</b>		<b>TURALIO</b> .....	25
<b>TIROSINT-SOL</b> .....	90	<b>200</b> .....	90	<b>TWINRIX (PF)</b> .....	101
<b>TIVICAY</b> .....	15, 16	<b>TRESIBA U-100 INSULIN</b> .....	90	<b>TWYNEO</b> .....	78
<b>TIVICAY PD</b> .....	16	<i>tretinoin</i> .....	78	<b>TYBLUME</b> .....	110
<i>tizanidine</i> .....	54	<i>tretinoin (antineoplastic)</i> .....	24	<b>TYBOST</b> .....	16
<b>TLANDO</b> .....	90	<i>tretinoin microspheres</i> .....	78	<b>TYDEMY</b> .....	110
<b>TOBI</b> .....	16	<b>TREXALL</b> .....	25	<b>TYGACIL</b> .....	16
<b>TOBI PODHALER</b> .....	16	<b>TREXIMET</b> .....	54	<b>TYKERB</b> .....	25
<b>TOBRADEX</b> .....	114	<b>TREZIX</b> .....	54	<b>TYMLOS</b> .....	104
<b>TOBRADEX ST</b> .....	114	<i>triamcinolone acetonide</i> ..... 78, 82		<b>TYPHIM VI</b> .....	101
<i>tobramycin</i> .....	16, 114	<i>triamterene</i> .....	69	<b>TYRVAYA</b> .....	114
<i>tobramycin in 0.225 % nacl</i> .....	16	<i>triamterene-hydrochlorothiazid</i> ..	69	<b>TYVASO DPI</b> .....	120
<i>tobramycin sulfate</i> .....	16	<b>TRIANEX</b> .....	78	<b>UBRELVY</b> .....	55
<i>tobramycin-dexamethasone</i> .....	114	<i>triazolam</i> .....	54	<b>UCERIS</b> .....	96
<b>TOBREX</b> .....	114	<b>TRIBENZOR</b> .....	69	<b>UDENYCA</b> .....	101
<i>tolcapone</i> .....	54	<b>TRICOR</b> .....	69	<b>UDENYCA</b>	
<b>TOLSURA</b> .....	16	<b>TRIDERM</b> .....	78	<b>AUTOINJECTOR</b> .....	101
<i>tolterodine</i> .....	121	<i>trientine</i> .....	82	<b>ULORIC</b> .....	104
<i>tolvaptan</i> .....	90	<b>TRI-ESTARYLLA</b> .....	110	<b>ULTRAVATE</b> .....	78

UNASYN.....	16	<i>verapamil</i> .....	69	VYTORIN 10-20.....	69
UNITHROID.....	90	VERDESO.....	78	VYTORIN 10-40.....	69
UPTRAVI.....	69	VERELAN.....	69	VYTORIN 10-80.....	69
UROCIT-K 10.....	121	VERELAN PM.....	69	VYVANSE.....	56
UROCIT-K 15.....	121	VERKAZIA.....	114	VYZULTA.....	114
UROCIT-K 5.....	122	VERQUVO.....	69	WAKIX.....	56
UROXATRAL.....	122	VERSACLOZ.....	56	<i>warfarin</i> .....	69
URSO 250.....	96	VERZENIO.....	25	WELCHOL.....	69
URSO FORTE.....	96	VESICARE.....	122	WELIREG.....	25
<i>ursodiol</i> .....	96	VESICARE LS.....	122	WELLBUTRIN SR.....	56
UZEDY.....	55	VESTURA (28).....	110	WELLBUTRIN XL.....	56
VABOMERE.....	16	VFEND.....	16	WINLEVI.....	78
VAGIFEM.....	110	VFEND IV.....	16	WIXELA INHUB.....	120
<i>valacyclovir</i> .....	16	VIBERZI.....	97	WYMZYA FE.....	110
VALCHLOR.....	78	VIBRAMYCIN.....	17	XALATAN.....	114
VALCYTE.....	16	VIBRAMYCIN (CALCIUM)..	17	XALKORI.....	25
<i>valganciclovir</i> .....	16	VIBRAMYCIN (MONO).....	17	XANAX.....	56
VALIUM.....	55	VICTOZA 3-PAK.....	90	XANAX XR.....	56
<i>valproic acid</i> .....	55	VIENVA.....	110	XARELTO.....	69
<i>valproic acid (as sodium salt)</i> .....	55	<i>vigabatrin</i> .....	56	XARELTO DVT-PE TREAT	
<i>valsartan</i> .....	69	VIGADRONE.....	56	30D START.....	69
<i>valsartan-hydrochlorothiazide</i> ...	69	VIGAMOX.....	114	XATMEP.....	25
VALTOCO.....	55	VIIBRYD.....	56	XCOPRI.....	56
VALTRESX.....	16	VIJOICE.....	25	XCOPRI MAINTENANCE	
VANCOCIN.....	16	<i>vilazodone</i> .....	56	PACK.....	56
<i>vancomycin</i> .....	16	VIMOVO.....	56	XCOPRI TITRATION PACK	
VANDAZOLE.....	110	VIMPAT.....	56	.....	56, 57
VANFLYTA.....	25	VIOKACE.....	97	XDEMVI.....	114
VANOS.....	78	VIRACEPT.....	17	XELJANZ.....	104
VAQTA (PF).....	101	VIREAD.....	17	XELJANZ XR.....	104
<i>varenicline</i> .....	82	VISTARIL.....	120	XELPROS.....	114
VARIVAX (PF).....	101	VITRAKVI.....	25	XELSTRYM.....	57
VARUBI.....	97	VIVELLE-DOT.....	110	XENAZINE.....	57
VASCEPA.....	69	VIVITROL.....	56	XENLETA.....	17
VASERETIC.....	69	VIVJOA.....	17	XERESE.....	78
VASOTEC.....	69	VIZIMPRO.....	25	XERMELO.....	25
VECAMYL.....	69	VOGELXO.....	90, 91	XGEVA.....	25
VECTICAL.....	78	VONJO.....	25	XHANCE.....	120
VELIVET TRIPHASIC		<i>voriconazole</i> .....	17	XIFAXAN.....	17
REGIMEN (28).....	110	VOSEVI.....	17	XIGDUO XR.....	91
VELPHORO.....	82	VOTRIENT.....	25	XIIDRA.....	114
VELTASSA.....	82	VOWST.....	97	XIMINO.....	17
VELTIN.....	78	VOXZOGO.....	91	XOFLUZA.....	17
VEMLIDY.....	16	VRAYLAR.....	56	XOLAIR.....	120
VENCLEXTA.....	25	VTAMA.....	78	XOPENEX HFA.....	120
VENCLEXTA STARTING		VUITY.....	114	XOSPATA.....	25
PACK.....	25	VUMERITY.....	56	XPOVIO.....	25
<i>venlafaxine</i> .....	55, 56	VYFEMLA (28).....	110	XTAMPZA ER.....	57
<i>venlafaxine besylate</i> .....	55	VYLIBRA.....	110	XTANDI.....	25
VENTAVIS.....	120	VYNDAMAX.....	69	XULANE.....	110
VENTOLIN HFA.....	120	VYNDAQEL.....	69	XULTOPHY 100/3.6.....	91
VEOZAH.....	110	VYTORIN 10-10.....	69	XURIDEN.....	82

<b>XYOSTED</b> .....	91	<i>zileuton</i> .....	120
<b>XYREM</b> .....	57	<b>ZILXI</b> .....	78
<b>XYWAV</b> .....	57	<b>ZIMHI</b> .....	57
<b>YASMIN (28)</b> .....	110	<b>ZIOPTAN (PF)</b> .....	114
<b>YAZ (28)</b> .....	110	<i>ziprasidone hcl</i> .....	57
<b>YF-VAX (PF)</b> .....	101	<i>ziprasidone mesylate</i> .....	57
<b>YONSA</b> .....	26	<b>ZIPSOR</b> .....	57
<b>YUFLYMA(CF)</b> .....	104	<b>ZIRGAN</b> .....	114
<b>YUFLYMA(CF)</b>		<b>ZITHROMAX</b> .....	17
<b>AUTOINJECTOR</b> .....	104	<b>ZITHROMAX TRI-PAK</b> .....	17
<b>YUPELRI</b> .....	120	<b>ZITHROMAX Z-PAK</b> .....	17
<b>YUSIMRY(CF) PEN</b> .....	104	<b>ZOCOR</b> .....	70
<b>YUVAFEM</b> .....	110	<b>ZOKINVY</b> .....	82
<b>ZAFEMY</b> .....	110	<b>ZOLINZA</b> .....	26
<i>zafirlukast</i> .....	120	<i>zolmitriptan</i> .....	57
<i>zaleplon</i> .....	57	<b>ZOLOFT</b> .....	57
<b>ZANAFLEX</b> .....	57	<i>zolpidem</i> .....	57, 58
<b>ZARONTIN</b> .....	57	<b>ZOMACTON</b> .....	101
<b>ZARXIO</b> .....	101	<b>ZOMIG</b> .....	58
<b>ZAVESCA</b> .....	91	<b>ZONALON</b> .....	78
<b>ZAVZPRET</b> .....	57	<b>ZONEGRAN</b> .....	58
<b>ZEGALOGUE</b>		<b>ZONISADE</b> .....	58
<b>AUTOINJECTOR</b> .....	91	<i>zonisamide</i> .....	58
<b>ZEGALOGUE SYRINGE</b> .....	91	<b>ZONTIVITY</b> .....	70
<b>ZEGERID</b> .....	97	<b>ZORBTIVE</b> .....	101
<b>ZEJULA</b> .....	26	<b>ZORTRESS</b> .....	26
<b>ZELAPAR</b> .....	57	<b>ZORYVE</b> .....	78
<b>ZELBORAF</b> .....	26	<b>ZOSYN IN DEXTROSE</b>	
<b>ZEMAIRA</b> .....	82	<b>(ISO-OSM)</b> .....	17
<b>ZEMBRACE SYMTOUCH</b> .....	57	<b>ZOVIA 1-35 (28)</b> .....	110
<b>ZEMDRI</b> .....	17	<b>ZOVIRAX</b> .....	79
<b>ZEMPLAR</b> .....	91	<b>ZTALMY</b> .....	58
<b>ZENATANE</b> .....	78	<b>ZTLIDO</b> .....	79
<b>ZENPEP</b> .....	97	<b>ZUBSOLV</b> .....	58
<b>ZENZEDI</b> .....	57	<b>ZYCLARA</b> .....	79
<b>ZEPATIER</b> .....	17	<b>ZYDELIG</b> .....	26
<b>ZEPOSIA</b> .....	57	<b>ZYFLO</b> .....	120
<b>ZEPOSIA STARTER KIT</b>		<b>ZYKADIA</b> .....	26
<b>(28-DAY)</b> .....	57	<b>ZYLET</b> .....	114
<b>ZEPOSIA STARTER PACK</b>		<b>ZYMAXID</b> .....	114
<b>(7-DAY)</b> .....	57	<b>ZYPITAMAG</b> .....	70
<b>ZERBAXA</b> .....	17	<b>ZYPREXA</b> .....	58
<b>ZERVIA TE</b> .....	114	<b>ZYPREXA RELPREVV</b> .....	58
<b>ZESTORETIC</b> .....	70	<b>ZYPREXA ZYDIS</b> .....	58
<b>ZESTRIL</b> .....	70	<b>ZYTIGA</b> .....	26
<b>ZETIA</b> .....	70	<b>ZYVOX</b> .....	17
<b>ZETONNA</b> .....	120		
<b>ZIAC</b> .....	70		
<b>ZIAGEN</b> .....	17		
<b>ZIANA</b> .....	78		
<i>zidovudine</i> .....	17		
<b>ZIEXTENZO</b> .....	101		

# Acitretin

---

## Products Affected

- *acitretin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Actemra

## Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Part A covered for Covid-19 in hospitalized patients
<b>Required Medical Information</b>	Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For giant cell arteritis, patients must have therapeutic failure or intolerance to one systemic corticosteroid (e.g., prednisone). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have therapeutic failure or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis.
<b>Age Restrictions</b>	Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Acthar H.P.

## Products Affected

- ACTHAR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>Covered for the following indications: 1. Infantile spasms (West syndrome) in children less than 2 years of age. 2. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 3. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 4. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 5. Dermatologic diseases 6. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction 7. Ophthalmic diseases 8. Respiratory diseases 9. Gout and unable to take first-line therapies. 10. Pediatric acquired epileptic aphasia. 11. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 2 through 10, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	1 month

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	Gout, Epileptic Aphasia
<b>Part B Prerequisite</b>	No

# Actimmune

---

## Products Affected

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Adalimumab

## Products Affected

- *adalimumab-fkjp*
- **HADLIMA**
- **HADLIMA PUSH TOUCH**
- **HADLIMA(CF)**
- **HADLIMA(CF) PUSH TOUCH**
- **HULIO(CF)**
- **HULIO(CF) PEN**
- **YUFLYMA(CF)**
- **YUFLYMA(CF) AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML**
- **YUSIMRY(CF) PEN**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 2 immunosuppressants.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	Therapeutic failure or intolerance to 2 of the following preferred products is required: Humira, Cyltezo, and Hyrimoz. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Adbry

---

## Products Affected

- ADBRY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADHD Drugs

---

## Products Affected

- *clonidine hcl oral tablet extended release 12 hr* • **KAPVAY**
- *guanfacine oral tablet extended release 24 hr*
- **INTUNIV ER**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Adlarity

---

## Products Affected

- ADLARITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- one of the following (1 or 2): 1) therapeutic failure or intolerance to donepezil tablets, 2) Unable to take daily oral donepezil due to impaired memory.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Afinitor

## Products Affected

- **AFINITOR** *mg, 2.5 mg, 5 mg, 7.5 mg*
- **AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG** • *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- *everolimus (antineoplastic) oral tablet 10*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy 4) Candidacy for surgical resection
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Afinitor, documentation of failure on generic everolimus tablets is required. For brand Afinitor Disperz, documentation of failure on generic everolimus tablets for suspension is required
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Aimovig

## Products Affected

- **AIMOVIG AUTOINJECTOR  
SUBCUTANEOUS AUTO-INJECTOR  
140 MG/ML, 70 MG/ML**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in migraine frequency
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Airduo Digihaler

---

## Products Affected

- AIRDUO DIGIHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of asthma -AND- Inadequate response to non-digitized LABA/ICS inhaler-AND- Attestation that a digital inhaler is required.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ajovy

## Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in migraine frequency
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Alecensa

---

## Products Affected

- ALECENSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Alkindi

---

## Products Affected

- **ALKINDI SPRINKLE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of adrenocortical insufficiency -AND- Therapeutic failure or intolerance to oral generic hydrocortisone tablets.
<b>Age Restrictions</b>	Deny if greater than 17 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Alpha1-Proteinase Inhibitors

## Products Affected

- ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS
- RECON SOLN
- ZEMAIRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite medical therapy (bronchodilators, corticosteroids) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	Covered under Part B when furnished incident to a physician service and is not self-administered.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No



# Alunbrig

---

## Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Amlodipine Liquid

---

## Products Affected

- **KATERZIA**
- **NORLIQVA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Inability to swallow amlodipine tablets
<b>Age Restrictions</b>	Deny if less than 6 years of age for Hypertension
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ampyra

---

## Products Affected

- AMPYRA
- *dalfampridine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	History of seizure disorder, Cr Cl less than 50ml/min
<b>Required Medical Information</b>	Documentation of diagnosis -AND- documentation that the patient is ambulatory and has walking impairment as evidenced by one of the following. 1. Functional status score (EDSS score). 2. Timed 25-foot Walk Test (T25W).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For brand Ampyra, documentation of failure on generic dalfampridine. For reauthorization, documentation supporting improvement in walking impairment from baseline is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Anabolic Steroids

---

## Products Affected

- **METHITEST**
- *methyltestosterone oral capsule*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Apokyn

---

## Products Affected

- APOKYN
- *apomorphine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to one of the following generic products: pramipexole, ropinirole, entacapone, selegiline or rasagiline
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Arikayce

---

## Products Affected

- ARIKAYCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Mycobacterium avium complex lung disease -AND- Attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing 2 of the following: 1) macrolide 2) rifamycin or 3) ethambutal -AND- Arikayce will be used in conjunction with a background multidrug regimen.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Armonair Digihaler

---

## Products Affected

- ARMONAIR DIGIHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of asthma -AND- Inadequate response to non-digitized ICS inhaler-AND- Attestation that a digital inhaler is required.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Aspruzyo Sprinkle

---

## Products Affected

- ASPRUZYO SPRINKLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic angina -AND- Therapeutic failure, contraindication, or intolerance to one beta-blocker (e.g., propranolol oral solution, metoprolol tartrate, propranolol immediate-release) -AND- Inability to swallow generic ranolazine tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ATTR-CM drugs

## Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) -AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) - AND- Primary (light chain) amyloidosis has been ruled out by immunohistochemistry, mass spectrometry or scintigraphy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Atypical Antipsychotics

---

## Products Affected

- **ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG**
  - **ABILIFY MYCITE STARTER KIT**
- ORAL TABLET WITH SENSOR, STRIP, POD 10 MG**
  - **ABILIFY ORAL TABLET**
  - *aripiprazole*
  - **REXULTI ORAL TABLET**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and therapeutic failure on 1 alternative antidepressant is required (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For Rexulti, trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Aubagio

---

## Products Affected

- **AUBAGIO**
- *teriflunomide*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other disease modifying agents such as fingolimod, interferons, Copaxone, Tysabri
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Auryxia

---

## Products Affected

- AURYXIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment of iron deficiency anemia
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Austedo

---

## Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 6 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 6 MG
- AUSTEDO XR TITRATION KT(WK1-4)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Auvelity

---

## Products Affected

- AUVELITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of major depressive disorder (MDD) -AND- Therapeutic failure or intolerance to generic bupropion hydrochloride tablets -AND- Therapeutic failure, intolerance or contraindication to one other generic antidepressant (e.g. SNRI, SSRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ayvakit

---

## Products Affected

- AYVAKIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For unresectable or metastatic Gastrointestinal Stromal Tumor (GIST), PDGFRA exon 18 mutation status. For Advanced Systemic Mastocytosis (AdvSM), platelet count greater than or equal to $50 \times 10^9/L$ AND aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or Mast cell leukemia (MCL). For Indolent System Mastocytosis, platelet count greater than or equal to $50 \times 10^9/L$ .
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bafiertam

---

## Products Affected

- **BAFIERTAM**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Balversa

---

## Products Affected

- **BALVERSA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR3 or FGFR2 mutation status as detected by an FDA approved test 2) alternatives tried/failed within labelled time frame
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Banzel

---

## Products Affected

- **BANZEL**
- *rufinamide*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Patients with familial short QT syndrome
<b>Required Medical Information</b>	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Belbuca

## Products Affected

- BELBUCA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Benlysta

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Documentation of active systemic lupus erythematosus (SLE) -AND- documentation of positive anti-nuclear antibody (ANA) titer (greater than or equal to 1:80) or anti-double-stranded DNA antibody (anti-dsDNA) greater than or equal to 30IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment with use of at least one of the following (alone or in combination): 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -OR- Documentation of active lupus nephritis -AND- documentation of positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment which includes corticosteroids (e.g. prednisone) with at least one of the following: 1.) mycophenolate for induction followed by mycophenolate for maintenance 2.) cyclophosphamide for induction followed by azathioprine for maintenance</p>
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For SLE reauthorization, attestation of disease stability or improvement - AND- attestation the member will continue to receive standard of care therapy with corticosteroids, antimalarials, or immunosuppressives. For active LN reauthorization, attestation of disease stability or improvement - AND- attestation the member will continue to receive standard of care therapy with mycophenolate or azathioprine. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Benznidazole

---

## Products Affected

- *benznidazole*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	Deny if less than 2 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Berinert

## Products Affected

- **BERINERT INTRAVENOUS KIT**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
<b>Required Medical Information</b>	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
<b>Age Restrictions</b>	Deny if less than 5 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Besremi

---

## Products Affected

- **BESREMI**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of polycythemia vera
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bonjesta

---

## Products Affected

- **BONJESTA**
- **DICLEGIS**
- *doxylamine-pyridoxine (vit b6)*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	9 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bosulif

---

## Products Affected

- **BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis AND all of the following, if applicable to diagnosis: 1) phase of CML 2) Philadelphia chromosome status 3) alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Braftovi

---

## Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use in wild-type BRAF melanoma or wild-type BRAF CRC
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) alternatives tried/failed 3) concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bronchitol

---

## Products Affected

- BRONCHITOL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis -AND- Passed a Bronchitol Tolerance Test -AND- Used in conjunction with standard therapies for the management of cystic fibrosis to improve pulmonary function (e.g. bronchodilators, antibiotics, anti-inflammatory therapy).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of increase in FEV1
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Brukinsa

---

## Products Affected

- BRUKINSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Buphenyl

---

## Products Affected

- **BUPHENYL**
- *sodium phenylbutyrate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment of acute hyperammonemia in urea cycle disorders
<b>Required Medical Information</b>	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Buphenyl, trial and failure of generic sodium phenylbutyrate is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Butrans

## Products Affected

- *buprenorphine*
- **BUTRANS**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Bylvay

---

## Products Affected

- **BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG**
- **BYLVAY ORAL PELLETT 200 MCG, 600 MCG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following diagnoses (1-2): 1) progressive familial intrahepatic cholestasis confirmed by genetic testing -AND- pruritis -OR- 2) Alagille syndrome -AND- cholestatic pruritis -AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cablivi

---

## Products Affected

- CABLIVI INJECTION KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of acquired thrombocytopenic purpura (aTTP) -AND- Used in conjunction with plasma exchange and immunosuppressive therapy (i.e. systemic corticosteroids or rituximab)
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	75 days initial authorization, 28 days reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of remaining signs and symptoms of persistent disease (e.g. suppressed ADAMTS 13 activity level remain present)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cabometyx

---

## Products Affected

- CABOMETYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) alternatives tried/failed 2) attestation of first line use 3) concomitant therapy 4) radioactive iodine refractory status
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Calquence

---

## Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Camzyos

## Products Affected

- CAMZYOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy -AND- Left ventricular ejection fraction of greater than or equal to 55% -AND- Valsalva left ventricular outflow tract peak gradient of greater than or equal to 50 mmHg at rest or after provocation -AND- Therapeutic failure or intolerance to one of the following (1 or 2) or contraindication to all: 1) Non-vasodilating beta blocker (e.g. metoprolol) 2) non-dihydropyridine calcium channel blocker (e.g. diltiazem) -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement in pV02 by greater than or equal to 1.5 mL/kg/min plus at least 1 NYHA class reduction or improvement in pV02 by greater than or equal to 3.0 mL/kg/min without NYHA class worsening -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Caplyta

---

## Products Affected

- CAPLYTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Caprelsa

---

## Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Carac

---

## Products Affected

- CARAC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Trial and failure of 1 generic fluorouracil topical product (with shared indication) is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Carbaglu

---

## Products Affected

- **CARBAGLU**
- *carglumic acid*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Carbinoxamine

---

## Products Affected

- *carbinoxamine maleate oral liquid*
- *carbinoxamine maleate oral tablet 4 mg*
- **RYVENT**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Failure, contraindication or intolerance to 2 antihistamines indicated for diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cayston

---

## Products Affected

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cerdelga

## Products Affected

- CERDELGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm <sup>3</sup> . 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## CF drugs

---

### Products Affected

- **BETHKIS**
  - **KITABIS PAK**
  - **TOBI**
  - **TOBI PODHALER**
- *tobramycin in 0.225 % nacl*
  - *tobramycin inhalation*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis. For Bethkis: failure on, intolerance to, or contraindication to generic tobramycin inhalation solution
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Chenodal

---

## Products Affected

- CHENODAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of radiolucent gallstones AND an inadequate response or intolerance to ursodiol therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months for initial approval with an additional 12 months upon renewal
<b>Other Criteria</b>	Safety of use beyond 24 months is not established. For reauthorization, attestation of partial dissolution of gallstones
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Cholbam

---

## Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of bile acid synthesis disorders due to single enzyme defects (e.g. AKR1D1, CTX, CYP7A1) -OR- documentation of use as adjunctive therapy for peroxisomal disorders (PDs), including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Cialis

---

## Products Affected

- **CIALIS ORAL TABLET 2.5 MG, 5 MG**
- *tadalafil oral tablet 2.5 mg, 5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of benign prostatic hyperplasia (BPH) and trial/failure of at least two alternative medications in the following classes (alpha-1 adrenergic blockers and/or 5-alpha reductase inhibitors)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Cialis, trial and failure of generic tadalafil is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cibinqo

## Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of one of the following (1 or 2): 1) trial & failure or intolerance to at least one topical corticosteroid or one topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- 2) severe atopic dermatitis and the member is incapable of applying topical therapies due to the extent of body surface area involvement or severe atopic dermatitis and topical therapies are contraindicated due to severely damaged skin.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For Atopic Dermatitis, patients must have a trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cimzia

## Products Affected

- CIMZIA
- CIMZIA POWDER FOR RECONST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs). For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	<p>For Crohn's disease, patients must have therapeutic failure or intolerance to 2 of the following preferred biologic products: Humira, Stelara, Rinvoq, and Skyrizi. For Rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For plaque psoriasis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Skyrizi, and Enbrel. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Rinvoq, and Xeljanz/Xeljanz XR. For Psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Cosentyx, Enbrel, Humira, Xeljanz/Xeljanz XR, Otezla, Stelara, Rinvoq, and Skyrizi. For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cinryze

## Products Affected

- CINRYZE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two prophylactic therapies simultaneously.
<b>Required Medical Information</b>	For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
<b>Age Restrictions</b>	Deny if less than 6 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Citalopram Capsule

---

## Products Affected

- *citalopram oral capsule*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of major depressive disorder -AND- citalpram 20 mg has been received for greater than or equal to 7 days -AND- Therapeutic failure or intolerance to generic citalopram tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Clemastine Syrup

---

## Products Affected

- *clemastine oral syrup*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of allergic rhinitis or mild, uncomplicated allergic skin manifestations of urticaria and angioedema -AND- Therapeutic failure, contraindication or intolerance to one generic antihistamine product - AND- Therapeutic failure or intolerance to generic clemastine fumarate tablets or an inability to swallow tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cometriq

---

## Products Affected

- **COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of progressive, metastatic medullary thyroid cancer
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Copiktra

---

## Products Affected

- **COPIKTRA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Corlanor

---

## Products Affected

- **CORLANOR ORAL SOLUTION**
- **CORLANOR ORAL TABLET 5 MG, 7.5 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis AND all of the following: 1) Normal sinus rhythm. 2) Resting heart rate greater than or equal to 70 beats per minute. 3) Left ventricular ejection fraction less than or equal to 35 percent, when applicable. 4) In adult patients (greater than or equal to 18 years), trial/failure of maximum tolerated dose of one beta-blocker used for treatment of heart failure (e.g., bisoprolol, carvedilol, metoprolol succinate) OR contraindication to beta-blocker use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For oral solution, attestation of inability to swallow tablets is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cosentyx

## Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. For enthesitis-related arthritis, inadequate response or intolerance to at least 1 non-biologic disease modifying anti-rheumatic drugs (DMARD), or all are contraindicated.
<b>Age Restrictions</b>	Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 18 years of age for all other indications
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cotellic

---

## Products Affected

- COTELLIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) Concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Crinone

---

## Products Affected

- CRINONE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use to promote fertility
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Cuvrior

---

## Products Affected

- CUVRIOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of stable Wilson's disease -AND- Previously tolerated one penicillamine product used for de-coppering (e.g., generic penicillamine tablet or capsule, Depen) -AND- Therapeutic failure or intolerance to generic trientine hydrochloride
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Cysteamine Ophthalmic Drops

---

## Products Affected

- CYSTADROPS
- CYSTARAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Daraprim

---

## Products Affected

- *pyrimethamine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Under CMS Review
<b>Required Medical Information</b>	Under CMS Review
<b>Age Restrictions</b>	Under CMS Review
<b>Prescriber Restrictions</b>	Under CMS Review
<b>Coverage Duration</b>	Under CMS Review
<b>Other Criteria</b>	Under CMS Review
<b>Indications</b>	Under CMS Review
<b>Off Label Uses</b>	Under CMS Review
<b>Part B Prerequisite</b>	No

# Dartisla ODT

---

## Products Affected

- DARTISLA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Documentation of adjunctive therapy -AND- Therapeutic failure or intolerance to generic glycopyrrolate 2 mg tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Daurismo

---

## Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Daybue

---

## Products Affected

- DAYBUE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis confirmed by all of the following (1 thru 4): 1) Partial or complete loss of acquired purposeful hand skills, 2) Partial or complete loss of acquired spoken language, 3) Gait abnormalities: impaired or absence of ability, 4) Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing, and washing/rubbing automatisms
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Daytrana

---

## Products Affected

- DAYTRANA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	Deny if less than 6 years of age or greater than 17 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Deferasirox

## Products Affected

- *deferasirox*
- **EXJADE**
- **JADENU**
- **JADENU SPRINKLE**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Jadenu and brand Exjade, trial and failure of deferasirox (generic Exjade) is required. For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Diacomit

---

## Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Dravets syndrome - AND- Used in combination with clobazam
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation supporting reduction in seizure frequency
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Dihydroergotamine

---

## Products Affected

- *dihydroergotamine nasal*
- **MIGRANAL**
- **TRUDHESA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Dojolvi

---

## Products Affected

- DOJOLVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of molecularly confirmed long-chain fatty acid oxidation disorders
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Doptelet

## Products Affected

- **DOPTELET (10 TAB PACK)**
- **DOPTELET (15 TAB PACK)**
- **DOPTELET (30 TAB PACK)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -OR- Documentation of chronic immune thrombocytopenia -AND- Trial, intolerance, or inadequate response to corticosteroid therapy, immunoglobulin therapy or splenectomy -AND- One of the following (1 or 2): 1) Platelet count less than or equal to $50 \times 10^9/L$ and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). 2) Platelets count of less than or equal to $30 \times 10^9/L$
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	For thrombocytopenia with chronic liver disease- 1 mo. For chronic immune thrombocytopenia- 12 mo.
<b>Other Criteria</b>	Platelet count is provided for applicable dosing.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Doxepin Cream

---

## Products Affected

- *doxepin topical*
- **PRUDOXIN**
- **ZONALON**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- course of therapy will not exceed 8 days -AND- experienced therapeutic failure, intolerance, or contraindication to one of the following (1 or 2): 1) at least 2 generic formulary topical corticosteroids. 2) generic topical tacrolimus or pimecrolimus for topic dermatitis with the facial or anogenital involvement.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Duexis

---

## Products Affected

- DUEXIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Duexis2

---

## Products Affected

- *ibuprofen-famotidine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen used in combination with famotidine. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than ibuprofen) used in combination with another generic formulary H2-receptor blocker (other than famotidine).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Duobrii

---

## Products Affected

- DUOBRII

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of plaque psoriasis -AND- therapeutic failure or intolerance to generic tazarotene cream -AND- therapeutic failure or intolerance to 1 high-potency topical corticosteroid (e.g. betamethasone dipropionate 0.05%, halobetasol propionate 0.05%)
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Dupixent

## Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following (1-2): 1) moderate to severe atopic dermatitis 2) trial & failure, or intolerance to at least one topical corticosteroid -OR- If 2 years of age or older, topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) -OR- The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin -OR- Documentation of the following (3-6): 3) moderate-to-severe asthma 4) documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration 5) Blood eosinophils greater than or equal to 150 cells/uL -OR- patient is currently taking daily or alternate-day oral corticosteroids 6) using a medium- or high-dose inhaled corticosteroid and a long acting beta agonist -OR- Documentation of the following (7-8): 7) chronic rhinosinusitis with nasal polyposis (CRSwNP) 8) trial & failure, intolerance or contraindication to intra-nasal corticosteroid and 14 day course of oral corticosteroids -OR- Documentation of the following (9-12): 9) eosinophilic esophagitis 10) weight at least 40 kg 11) esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy 12) clinical symptoms of esophageal dysfunction -OR- Documentation of the following (13): 13) prurigo nodularis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of positive clinical response to therapy, for atopic dermatitis -OR- attestation of decreased rescue medication or oral corticosteroid use, decreased frequency of severe asthma exacerbation, increased pulmonary function from baseline (e.g. FEV1) or reduction in reported asthma related symptoms, for asthma -OR- attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score, for CRSwNP -OR- attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction, for EoE -OR- attestation of reduction in itch from baseline, for prurigo nodularis
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EGFR Tyrosine Kinase Inhibitors

## Products Affected

- *erlotinib*
- **EXKIVITY**
- **GILOTRIF**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Afatinib products: tumors with resistant EGFR mutations. Erlotinib products: use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy.
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) Epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions, exon 21 (L858R) substitution mutations or exon 20 insertion mutations 2) Alternatives tried/failed 3) Concomitant therapy 4) Line of therapy in which medication will be used
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Egrifra

---

## Products Affected

- EGRIFRA SV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of HIV and lipodystrophy, member must actively be receiving antiretroviral therapy including protease inhibitors, nucleoside reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Emflaza

## Products Affected

- EMFLAZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Duchenne muscular dystrophy (DMD) with mutation of dystrophin gene -AND- onset of weakness or history of DMD starting before age 5 -AND- One of the following (1, 2, or 3). 1) Documented trial/failure, intolerance or contraindication to prednisone. 2) Documented trial of prednisone has resulted in intolerable adverse events (e.g. diabetes, hypertension that is difficult to manage, Cushingoid features, truncal obesity, greater than or equal to 10 percent increase in body weight over a 6 month period). 3) Documented severe behavioral adverse event while on prednisone that warrants prednisone dose reduction impacting efficacy for management of DMD (i.e. abnormal behavior, aggression, irritability, disturbance in mood)
<b>Age Restrictions</b>	Deny if less than 2 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Emgality

## Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE  
SUBCUTANEOUS SYRINGE 120  
MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For episodic cluster headaches, characterized by severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when left untreated -AND- Attack frequency of at least one attack every other day during the cluster period.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency is required. For reauthorization of cluster headache, attestation of reduction in the number of mean weekly cluster headaches from baseline is required.
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Enbrel

## Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE  
25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)
- ENBREL SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis or less than 2 years of age for Juvenile Idiopathic Arthritis or Less than 4 years of age for Plaque Psoriasis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Endari

---

## Products Affected

- ENDARI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Sickle Cell Disease with 2 or more sickle cell acute complications (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.) -AND-documentation of previous trial of hydroxyurea or plans of continued therapy while taking Endari
<b>Age Restrictions</b>	Deny if less than 5 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of stability in sickle cell acute complications or decrease in number of sickle cell acute complications is required (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Enspryng

---

## Products Affected

- ENSPRYNG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of neuromyelitis optica spectrum disorder (NMOSD) - AND- Attestation of anti-aquaporin-4 (AQP4) antibody positive -AND- Not used in combination with another monoclonal antibody used for the treatment of NMOSD.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of decrease in number of NMOSD relapses. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Entadfi

---

## Products Affected

- ENTADFI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of use for the initial treatment of benign prostatic hyperplasia (BPH) -AND- Trial/failure of finasteride used in combination with tadalafil.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For reauthorization, attestation that the member is reinitiating treatment for BPH.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Epclusa

---

## Products Affected

- **EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG**
- **EPCLUSA ORAL TABLET**
- *sofosbuvir-velpatasvir*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance
<b>Age Restrictions</b>	Deny if less than 3 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Epidiolex

---

## Products Affected

- EPIDIOLEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents.
<b>Age Restrictions</b>	Deny if less than 1 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation supporting reduction in seizure frequency
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Eprontia

---

## Products Affected

- **EPRONTIA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Erivedge

---

## Products Affected

- ERIVEDGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if disease is locally advanced all of the following: 1) disease has recurred following surgery, or is not a candidate for surgery, 2) is not a candidate for radiation.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Erleada

---

## Products Affected

- **ERLEADA ORAL TABLET 240 MG, 60 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Eucrisa

---

## Products Affected

- EUCRISA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following (1 and 2): 1) mild to moderate atopic dermatitis 2) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement
<b>Age Restrictions</b>	Deny if less than 3 months of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	If 2 years of age or older, therapeutic failure of one of the following is required: topical tacrolimus -OR- topical pimecrolimus. Reauthorization or continuation of therapy will be approved when documentation of improvement or response to therapy is provided.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Evekeo

## Products Affected

- *amphetamine sulfate*
- EVEKEO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Obesity
<b>Required Medical Information</b>	Documentation of diagnosis. For narcolepsy the following are required: Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B)Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP.
<b>Age Restrictions</b>	Deny if less than 6 years of age for narcolepsy or 3 years of age for ADHD
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For narcolepsy, trial and failure, intolerance to 2 of the following generic alternatives is required: immediate release amphetamine/dextroamphetamine, dextroamphetamine, and methylphenidate. For ADHD, trial/failure or intolerance to 2 unique generic stimulants (e.g. methylphenidate) is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Evenity

## Products Affected

- **EVENITY SUBCUTANEOUS SYRINGE  
210MG/2.34ML ( 105MG/1.17MLX2)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Postmenopausal woman at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. A cumulative lifetime approval of romosozumab will be limited to a coverage duration of 12 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Evrysdi

## Products Affected

- EVRYSDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of spinal muscular atrophy -AND- Baseline motor function test results (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT) -AND- Not using concomitantly with Spinraza -AND- Molecular genetic testing of 5q SMA showing Homozygous gene deletion, Homozygous conversion mutation or Compound heterozygote
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	For reauthorization, attestation of stable or clinically significant improvement in Spinal Muscular Atrophy associated symptoms (e.g. stabilization or decreased decline in motor function compared to the predicted natural history trajectory of disease) -OR- Stable or improved motor function results compared to baseline (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Exservan

---

## Products Affected

- EXSERVAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of stability or improvement in symptoms of ALS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Fasenra

## Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of severe asthma -AND- history of at least one asthma exacerbations requiring oral or systemic corticosteroid treatment in the past 12 months -AND- documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration despite regular treatment with (a. or b.): a) high dose inhaled corticosteroid and additional asthma controller medication or b.) a medium or high dose inhaled corticosteroid plus a long-acting beta agonist with or without oral corticosteroids and additional asthma controller medication
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter within 6 weeks of initiation of therapy or greater than or equal to 300 cells/uL within 12 months of screening. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Fecal Microbiota Products

---

## Products Affected

- VOWST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a recent diagnosis of recurrent <i>Clostridioides difficile</i> infection (CDI) -AND- Will be used for prophylaxis and not treatment of recurrent CDI -AND- Attestation that antibiotic treatment for the most recent recurrent CDI is complete or will be completed.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	For reauthorization, attestation of recurrent CDI episodes after administration of the initial fecal microbiota product -AND- Will be used for prophylaxis and not treatment of recurrent CDI.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ferriprox

## Products Affected

- *deferiprone*
- **FERRIPROX (2 TIMES A DAY)**
- **FERRIPROX ORAL SOLUTION**
- **FERRIPROX ORAL TABLET 500 MG**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of transfusional iron overload due to thalassemia syndromes, sickle cell disease and other anemias -AND- transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -AND- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Trial and failure of deferasirox (generic Exjade) is required. For reauthorization, continued requirement for regular blood transfusions - AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Fetzima

---

## Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL HR 120 MG, 20 MG, 40 MG, 80 MG 24HR DOSE PACK**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of major depressive disorder and trial and failure of two other antidepressants.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Filspari

## Products Affected

- FILSPARI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with renin-angiotensin system inhibitors (i.e., ACE inhibitors, ARBs, aliskiren) or endothelin receptor antagonists (e.g., Letairis, Opsumit, Tracleer)
<b>Required Medical Information</b>	Documentation of primary immunoglobulin A nephropathy confirmed by biopsy -AND- Risk for rapid disease progression, evidenced by urine protein-to-creatinine ratio greater than or equal to 1.5 g/g or proteinuria greater than or equal to 1 g/day -AND- Therapeutic failure, contraindication, or intolerance to an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, reduction in urine protein-to-creatinine ratio or proteinuria from baseline is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Fintepla

---

## Products Affected

- FINTEPLA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam).
<b>Age Restrictions</b>	Deny if less than 2 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Firazyr

## Products Affected

- **FIRAZYR**
- *icatibant*
- **SAJAZIR**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
<b>Required Medical Information</b>	For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Firazyr, therapeutic failure, intolerance or contraindication to icatibant.
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Firdapse

---

## Products Affected

- **FIRDAPSE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Flector

---

## Products Affected

- *diclofenac epolamine*
- **FLECTOR**
- **LICART**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis AND one of the following (1,2 or 3): 1) trial/failure, intolerance, or contraindication to 2 oral generic NSAIDs one of which must be diclofenac 2) hypersensitivity to oral NSAIDs 3) history or high risk for adverse gastrointestinal effects associated with oral NSAID use.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Fleqsuvy

---

## Products Affected

- *baclofen oral suspension*
- **FLEQSUVY**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Forteo

## Products Affected

- **FORTEO**
- *teriparatide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. For brand Forteo, trial and failure of teriparatide is required. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Forteo/teriparatide will be limited to a coverage duration of 24 months in the absence of provider attestation that the member remains at or has returned to having a high risk for fracture
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Fotivda

---

## Products Affected

- FOTIVDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if applicable to diagnosis, previous therapies tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Furoscix

---

## Products Affected

- **FUROSCIX**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of heart failure classified as NYHA Class II/III - AND- chronic heart failure medication regimen includes an oral loop diuretic (e.g. furosemide, bumetanide, torsemide) -AND- treatment with oral diuretics will replace the use of Furoscix as soon as practical.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gabapentin

## Products Affected

- *gabapentin oral capsule 100 mg, 300 mg, 400 mg*
- *gabapentin oral solution 250 mg/5 ml*
- *gabapentin oral tablet 600 mg, 800 mg*
- **NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG**
- **NEURONTIN ORAL SOLUTION**
- **NEURONTIN ORAL TABLET 600 MG, 800 MG**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Galafold

---

## Products Affected

- GALAFOLD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Fabry disease confirmed by biochemical or genetic test -AND- Presence of an amenable GLA variant causing Fabry disease in the clinical context of the patient -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy - AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gattex

## Products Affected

- GATTEX 30-VIAL

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel AND if age 18 and older, dependence on parenteral nutrition or intravenous nutritional support for at least 12 months AND requiring parenteral nutrition at least 3 times per week -OR- Documentation of SBS having less than 200 cm of functional small bowel AND age 1 to 17 years of age AND Dependence on parenteral nutrition AND weight of at least 10 kg.
<b>Age Restrictions</b>	Deny if less than 1 year of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gavreto

---

## Products Affected

- GAVRETO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET mutant or fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate)
<b>Age Restrictions</b>	Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gilenya

---

## Products Affected

- *fingolimod*
- GILENYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of Gilenya and other disease modifying agents such as interferons, Copaxone, Tysabri
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	Brand Gilenya requires therapeutic failure or intolerance to generic fingolimod. For Brand Gilenya 0.25mg, failure of generic is not required if age is between 10-17 years old and weight is less than or equal to 40kg.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gimoti

## Products Affected

- GIMOTI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acute or recurrent diabetic gastroparesis -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Therapeutic failure or intolerance to generic metoclopramide tablets or generic metoclopramide solution -AND- If over 65 years of age, member was titrated to a stable does of metoclopramide tablets or solution at 10mg four times a day before switching to Gimoti therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 weeks
<b>Other Criteria</b>	For reauthorization, treatment is for a new episode of diabetic gastroparesis -AND- There has been a 2 week drug holiday without Gimoti since its last administration -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Attestation that extended therapy with Gimoti outweighs risk of developing tardive dyskinesia.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Gleevec

---

## Products Affected

- **GLEEVEC ORAL TABLET 100 MG, 400 MG**
- *imatinib oral tablet 100 mg, 400 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) Alternatives tried 2) Concomitant therapy 3) mutation status, if applicable to diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gleostine

---

## Products Affected

- GLEOSTINE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following (1. or 2.): 1) Diagnosis of primary or metastatic brain tumor(s) -AND- member has previously received surgical and/or radiotherapeutic procedure(s), or 2) Diagnosis of Hodgkin's Lymphoma -AND- member is using Gleostine in combination with other chemotherapies -AND- member has experienced disease progression with initial chemotherapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GLP1

## Products Affected

- **BYDUREON BCISE** **ML), 1 MG/DOSE (4 MG/3 ML), 2**
- **BYETTA** **MG/DOSE (8 MG/3 ML)**
- **MOUNJARO** • **RYBELSUS**
- **OZEMPIC SUBCUTANEOUS PEN** • **TRULICITY**
- INJECTOR 0.25 MG OR 0.5 MG (2 MG/3** • **VICTOZA 3-PAK**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Obesity or use for weight loss
<b>Required Medical Information</b>	Documentation of diabetes mellitus type 2
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For Bydureon Bcise or Byetta, therapeutic failure or intolerance to two, or contraindication to all of the following: Mounjaro, Ozempic, Rybelsus, Trulicity, or Victoza.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Glycate

---

## Products Affected

- **GLYCATE**
- *glycopyrrolate oral tablet 1.5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of using as an adjunctive treatment for peptic ulcer disease -AND- Therapeutic failure or intolerance to generic glycopyrrolate 1mg tablet
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy - AND- Additional courses of therapy are required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gocovri

## Products Affected

- **GOCOVRI ORAL  
CAPSULE,EXTENDED RELEASE 24HR  
137 MG, 68.5 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For dyskinesia associated with Parkinson's disease, documentation of concurrent levodopa-based therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine. For off-episodes of Parkinson's disease, documentation of concurrent carbidopa/levodopa therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine -AND- trial and failure, contraindication, or intolerance to one (1) of the following agents: entacapone, pramipexole, rasagiline, ropinirole, or selegiline.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Gralise

---

## Products Affected

- **GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of postherpetic neuralgia (PHN) -AND- Trial and failure or intolerance to generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Grastek

## Products Affected

- **GRASTEK**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy
<b>Required Medical Information</b>	Documentation of allergic rhinitis and use for Timothy grass pollen or cross reactive grass pollens (Sweet Vernal, Orchard, Perennial Rye, Timothy, Kentucky Blue Grass pollen, Redtop, or meadow fescue) -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
<b>Age Restrictions</b>	Deny if less than 5 years of age or greater than 65 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Growth Hormone

## Products Affected

- **GENOTROPIN**
- **GENOTROPIN MINIQUICK**
- **HUMATROPE INJECTION CARTRIDGE**
- **NGENLA**
- **NORDITROPIN FLEXPRO**
- **NUTROPIN AQ NUSPIN**
- **OMNITROPE**
- **SAIZEN**
- **SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG**
- **ZOMACTON**
- **ZORBTIVE**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally for growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss of at least 10 percent from baseline. For short bowel syndrome, receiving management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines. For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Haegarda

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two prophylactic therapies simultaneously.
<b>Required Medical Information</b>	<p>For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I &amp; II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p>
<b>Age Restrictions</b>	Deny if less than 6 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Harvoni

---

## Products Affected

- **HARVONI ORAL PELLETS IN PACKET**
- **HARVONI ORAL TABLET 90-400 MG**
- *ledipasvir-sofosbuvir*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance
<b>Age Restrictions</b>	Deny if less than 3 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Hemady

---

## Products Affected

- **HEMADY**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of multiple myeloma -AND- used in combination with other anti-myeloma agents -AND- therapeutic failure or intolerance to generic dexamethasone.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Hetlioz

## Products Affected

- HETLIOZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use -OR- Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning)
<b>Age Restrictions</b>	Deny if less than 16 years of age for nighttime sleep disturbances in Smith-Magenis Syndrome or deny if less than 18 years of age for Non-24 Hour Sleep-Wake Disorder
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For brand Hetlioz, documentation of trial and failure of generic tasimelteon is required. For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder -OR- attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Hetlioz LQ

---

## Products Affected

- HETLIOZ LQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning)
<b>Age Restrictions</b>	Deny if less than 3 or greater than 15 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome -AND- member is between 3 and 15 years of age
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# High-risk meds

## Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide*
- **ANAFRANIL**
- *benztropine oral*
- *carisoprodol*
- *chlorzoxazone*
- *clomipramine*
- *cyproheptadine*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *ergoloid*
- *ergotamine-caffeine*
- *hydroxyzine hcl oral solution 10 mg/5 ml*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate*
- *imipramine hcl*
- *imipramine pamoate*
- **LORZONE**
- *metaxalone*
- **NORGESIC**
- **NORGESIC FORTE**
- *orphenadrine citrate oral*
- *orphenadrine-asa-caffeine oral tablet 25-385-30 mg*
- *perphenazine-amitriptyline*
- *promethazine oral*
- **SILENOR**
- **SOMA**
- *trimipramine*
- **VISTARIL**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For all medications subject to this PA group, the following information (1 through 3) is required: 1. Documentation of diagnosis 2. Explanation of risk-benefit profile favoring use of the high-risk medication 3. Attestation of an intent to monitor and address treatment-related adverse events. For target tricyclic antidepressants (TCAs), in addition to criteria 1 through 3 above, trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs for the same indication, if available, is required (e.g. SSRIs and SNRIs). If using a TCA for a medically-accepted indication not shared by the safer alternatives listed, then no trial of alternatives is required.
<b>Age Restrictions</b>	Automatic approval if less than 65 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Doxepin doses less than or equal to 6 mg per day will receive automatic approval.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# High-risk meds phenobarbital

## Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Coverage is not provided for use in sedation/insomnia
<b>Required Medical Information</b>	For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required.
<b>Age Restrictions</b>	Automatic approval if less than 65 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	Seizure disorders
<b>Part B Prerequisite</b>	No

# Homozygous FH

## Products Affected

- JUXTAPID

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of homozygous familial hypercholesterolemia (HoFH) supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene -OR- untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents -AND- The member has a current LDL-C greater than 100mg/dL despite use of maximally tolerated statin OR statin intolerance -AND- The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	Patients must have a trial/failure or contraindication to the preferred product Repatha. For reauthorization, documentation showing an LDL-C reduction on Juxtapid therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Horizant

---

## Products Affected

- **HORIZANT ORAL TABLET  
EXTENDED RELEASE 300 MG, 600 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of moderate to severe active primary restless leg syndrome -AND- trial and failure of pramipexole or ropinirole -AND- trial and failure of an additional dopaminergic agent, clonidine or pregabalin -OR- Documentation of post herpetic neuralgia and trial and failure of generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Humira

## Products Affected

- AMJEVITA(CF) AUTOINJECTOR KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML
- AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML
- CYLTEZO(CF)
- CYLTEZO(CF) PEN
- CYLTEZO(CF) PEN CROHN'S-UC-HS
- CYLTEZO(CF) PEN PSORIASIS-UV
- HUMIRA PEN
- HUMIRA PEN CROHN'S-UC-HS START
- HUMIRA PEN PSOR-UEVITS-ADOL HS
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEDI CROHN'S STARTER SUBCUTANEOUS SYRINGE
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHN'S-UC-HS
- HUMIRA(CF) PEN PEDIATRIC UC
- HUMIRA(CF) PEN PSOR-UV-ADOL HS
- HYRIMOZ PEN CROHN'S-UC STARTER
- HYRIMOZ PEN PSORIASIS STARTER
- HYRIMOZ(CF) PEDI CROHN'S STARTER
- HYRIMOZ(CF) PEN SUBCUTANEOUS PEN INJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML
- HYRIMOZ(CF) SUBCUTANEOUS SYRINGE 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For uveitis, inadequate response or intolerance to 2 immunosuppressants.
Age Restrictions	Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit. For Amjevita, therapeutic failure or intolerance to one of the following preferred products is required: Humira, Cyltezo, and Hyrimoz.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Hyftor

---

## Products Affected

- **HYFTOR**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of tuberous sclerosis complex with facial angiofibromas.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy (e.g. decrease in size of facial angiofibromas, decrease in redness of facial angiofibromas)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Ibrance

---

## Products Affected

- **IBRANCE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer -AND- meets one of the following (1 or 2): 1) documentation of use with an aromatase inhibitor as initial endocrine-based therapy -OR- 2) documentation of use with fulvestrant in patients with disease progression following endocrine therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ibsrela

---

## Products Affected

- **IBSRELA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of irritable bowel syndrome with constipation -AND- failure or intolerance to Linzess -AND- if member is female, failure or intolerance to lubiprostone.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Iclusig

---

## Products Affected

- ICLUSIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment of newly-diagnosed chronic phase CML
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Philadelphia chromosome status 2) T315I status 3) Alternatives tried/failed 4) Candidacy for other tyrosine kinase inhibitor therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Idhifa

---

## Products Affected

- **IDHIFA ORAL TABLET 100 MG, 50 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# IG

## Products Affected

- **BIVIGAM**
- **FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %**
- **GAMMAGARD LIQUID**
- **GAMMAGARD S-D (IGA)**
- **GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **GAMMAPLEX**
- **GAMMAPLEX (WITH SORBITOL)**
- **GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **OCTAGAM**
- **PANZYGA**
- **PRIVIGEN**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>Documentation of diagnosis. For select diagnoses the following apply 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to other standard therapies (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to other standard therapies (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant/contraindication to those standard therapies. 3) For Inflammatory Myopathies, the patient is refractory to corticosteroids given in therapeutic doses over at least 4 months OR is intolerant/contraindication to corticosteroids or immunosuppressants. 4) For B-cell CLL, associated with recurrent bacterial infections OR with Associated Hypogammaglobulinemia defined as IgG level less than 600mg/dL or evidence of a specific antibody deficiency. 5) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 6) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to standard fist line therapy (i.e. corticosteroids or immunosuppressants). 7) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mcl and IgG less than 400mg/dL OR recurrent bacterial infections. 8) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 9) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	Myasthenia Gravis syndrome, Multiple Sclerosis, Inflammatory Myopathies, Polymyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases
<b>Part B Prerequisite</b>	No

# Ilumya

## Products Affected

- ILUMYA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy - OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For psoriasis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Imbruvica

---

## Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 280 MG, 420 MG, 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET 140 MG,**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) 17p deletion status 2) Alternatives tried/failed 3) concomitant therapy. For suspension, members must also have an inability to swallow oral tablets or oral capsules.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Inbrija

---

## Products Affected

- **INBRIJA INHALATION CAPSULE,  
W/INHALATION DEVICE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of use for the treatment of intermittent off episodes of Parkinson's disease while on carbidopa/levodopa
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Increlex

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of severe primary IGF-1 deficiency and all of the following: 1) Normal or elevated response (greater than 10 ng/ml) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 2) Serum IGF-1 concentration that is less than or equal to three (3) standard deviations below the normal value based on laboratory reference range. 3) Height less than or equal to three (3) standard deviations below normal (at or below the third percentile for gender and age). 4) If female, bone age less than or equal to 14 years. If male, bone age less than or equal to 16. - OR- Documentation of diagnosis of growth hormone deficiency caused by gene deletion and all of the following: 1) Growth velocity at least 2 standard deviations below the age-appropriate mean or height at least 2.25 standard deviations below the age-appropriate mean. 2) Subnormal response (less than 10 ng/mL) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 3) Development of neutralizing antibodies to growth hormone product(s). 4) If female, bone age of less than or equal to 14 years. If male, bone age less than or equal to 16.
<b>Age Restrictions</b>	Deny if greater than 17 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Ingrezza

---

## Products Affected

- **INGREZZA INITIATION PACK**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of tardive dyskinesia OR documentation of chorea associated with Huntington's disease.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Inlyta

---

## Products Affected

- INLYTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Line of therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Inqovi

## Products Affected

- INQOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation chronic myelomonocytic leukemia. Documentation of de novo or secondary myelodysplastic syndrome -AND- One of the following (1 or 2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts. 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Inrebic

---

## Products Affected

- **INREBIC**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of intermediate-2 or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than $50 \times 10^9/L$
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Baseline platelet count to be provided.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Interferon Alfa

---

## Products Affected

- PEGASYS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Interleukin-1b Blockers

## Products Affected

- ARCALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), documentation of need for maintenance of remission. For Recurrent Pericarditis (RP), documentation of trial/failure or intolerance to one, or contraindication to all of the following: oral nonsteroidal anti-inflammatory drug (NSAID), systemic corticosteroid, or colchicine.
<b>Age Restrictions</b>	Deny if less than 12 years of age for Recurrent Pericarditis and Cryopyrin-Associated Periodic Syndromes
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For DIRA: patient must weigh 10kg or more
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Intrarosa

---

## Products Affected

- INTRAROSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# IPF Agents

## Products Affected

- **ESBRIET ORAL CAPSULE**
- **ESBRIET ORAL TABLET 267 MG, 801 MG**
- **OFEV**
- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For Ofev only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a high-resolution chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For Ofev only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- high resolution chest computing tomography (HRCT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on HRCT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on HRCT
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Iressa

---

## Products Affected

- *gefitinib*
- **IRESSA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
<b>Required Medical Information</b>	Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Iressa, documentation of trial and failure of generic gefitinib is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Isturisa

---

## Products Affected

- **ISTURISA ORAL TABLET 1 MG, 10 MG, 5 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Itraconazole

---

## Products Affected

- *itraconazole*
- **SPORANOX**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth
<b>Other Criteria</b>	Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ivermectin Oral

---

## Products Affected

- *ivermectin oral*
- **STROMEKTOL**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of strongyloidiasis of the intestinal tract (non-disseminated disease) or onchocerciasis -AND- Member weighs greater than or equal to 15kg.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Jakafi

## Products Affected

- JAKAFI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than $50 \times 10^9/L$ -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Baseline platelet count to be provided.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Jaypirca

---

## Products Affected

- **JAYPIRCA ORAL TABLET 100 MG, 50 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Jynarque

## Products Affected

- JYNARQUE ORAL TABLET
- JYNARQUE ORAL TABLETS, SEQUENTIAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of rapidly progressing autosomal dominant polycystic kidney disease defined by one of the following: 1.) Historical decline in eGFR greater than or equal to 5mL/min/1.73 m*2 within a 12 month period. 2.) Decline in eGFR of greater than or equal to 2.5mL/min/1.73m*2 over a period of 5 years. 3.) 5% increase in total kidney volume per year by 3 repeat CT or MRI. 4.) Average kidney length greater than 16.5cm. 5.) Family history of end-stage renal disease before age 58. 6.) Mayo imaging classification of 1C, 1D, or 1E. 7.) Kidney bleeds.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, prescriber attestation of slowed decline of kidney function
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kalydeco

---

## Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kerendia

---

## Products Affected

- **KERENDIA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	eGFR less than or equal to 25 mL/min/1.73 m <sup>2</sup> , serum potassium greater than 5.5 mEq/L
<b>Required Medical Information</b>	Documentation of type 2 diabetes mellitus with chronic kidney disease - AND- one of the following (1. 2. or 3.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor 2) therapeutic failure to at least one SGLT2 inhibitor or 3) contraindication or intolerance to at least one SGLT2 inhibitor.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation that signs or symptoms of hyperkalemia are not present.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kesimpta

---

## Products Affected

- **KESIMPTA PEN**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Keveyis

---

## Products Affected

- **KEVEYIS**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following: 1. Primary hyperkalemic periodic paralysis 2. Primary hypokalemic periodic paralysis 3. Related variants of primary periodic paralysis
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation the number of muscle weakness attacks per week has decreased from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kevzara

## Products Affected

- KEVZARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For polymyalgia rheumatica (PMR), one of the following (1-3): 1) inadequate response to corticosteroids, 2) intolerance to corticosteroid taper, or 3) used in combination with corticosteroid tapering course.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to two of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Kineret

## Products Affected

- KINERET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Rheumatoid Arthritis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kisqali

## Products Affected

- **KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG**
- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following. 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Klisyri

---

## Products Affected

- **KLISYRI**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of actinic keratosis of the face or scalp -AND- Therapeutic failure or intolerance to 1 of the following 1) generic topical imiquimod 5% cream 2) generic fluorouracil 5% topical cream 3) generic fluorouracil topical solution
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For reauthorization, attestation that the member has previously experienced complete or partial clearance of actinic keratosis lesions with Klisyri -AND- additional course of therapy is required for recurrence of actinic keratosis -AND- member is restarting therapy at least 60 days after cessation of an initial Klisyri 5-day course.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Korlym

---

## Products Affected

- KORLYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes with trial and failure, intolerance, or contraindication to one previous therapy for Type 2 Diabetes (e.g. metformin, sulfonylureas, insulin) or using in addition to a therapy for Type 2 diabetes. 2) Glucose intolerance
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Koselugo

---

## Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG,  
25 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN)
<b>Age Restrictions</b>	Deny if less than 2 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Krazati

---

## Products Affected

- **KRAZATI**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) KRAS G12C mutation status, as detected by an FDA-approved test 2) Alternatives tried
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Kuvan

## Products Affected

- **JAVYGTOR**
- **KUVAN**
- *sapropterin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of PKU -AND- documented baseline Phe level greater than 6 mg/dL -AND- clinical documentation of current weight -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, initial therapy has resulted in decrease in phenylalanine levels from baseline or current phenylalanine levels within the range of 120-360 micromol/L -AND- clinical documentation of current weight is required -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day. For brand Kuvan, a trial and failure of generic sapropterin dihydrochloride is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lampit

---

## Products Affected

- LAMPIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Weight of at least 2.5 kg
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Latuda

---

## Products Affected

- **LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG**
- *lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Latuda, documentation of trial and failure of generic lurasidone is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lenvima

---

## Products Affected

- LENVIMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1) Radioactive iodine refractory status 2) Microsatellite instability-high status or mismatch repair deficient status 3) Alternatives tried/failed or attestation of first line use 4) Concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Leukine

## Products Affected

- LEUKINE INJECTION RECON SOLN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Leukotriene Modifiers

---

## Products Affected

- *zileuton*
- **ZYFLO**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of asthma -AND- trial/failure of generic montelukast and generic zafirlukast
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lidoderm

## Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*
- **LIDODERM**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of postherpetic neuralgia (PHN) -AND- trial and failure of 1 other agent used to treat PHN (e.g. gabapentin), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation) -OR- documentation of diabetic peripheral neuropathy (DPN) -AND- trial and failure of one other agent used to treat DPN (e.g. duloxetine), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	diabetic peripheral neuropathy
<b>Part B Prerequisite</b>	No

# Litfulo

---

## Products Affected

- LITFULO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For severe alopecia areata, therapeutic failure/intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Livmarli

---

## Products Affected

- LIVMARLI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following diagnoses (1-2): 1) Alagille syndrome, 2) cholestatic pruritis -AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Livtency

## Products Affected

- LIVTENCITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Diagnosis of CMV prophylaxis.
<b>Required Medical Information</b>	Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet.
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-2): 1) new onset symptomatic CMV infection -OR- 2) virologic relapse with treatment-emergent maribavir resistance.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Lodoco

---

## Products Affected

- **LODOCO**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Under CMS Review
<b>Required Medical Information</b>	Under CMS Review
<b>Age Restrictions</b>	Under CMS Review
<b>Prescriber Restrictions</b>	Under CMS Review
<b>Coverage Duration</b>	Under CMS Review
<b>Other Criteria</b>	Under CMS Review
<b>Indications</b>	Under CMS Review
<b>Off Label Uses</b>	Under CMS Review
<b>Part B Prerequisite</b>	No

# Lokelma

---

## Products Affected

- **LOKELMA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lonsurf

## Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of metastatic colorectal cancer as a single agent or in combination with bevacizumab in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Lorbrena

---

## Products Affected

- **LORBRENA ORAL TABLET 100 MG, 25 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC)
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lotronex

---

## Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*
- **LOTROXEN ORAL TABLET 0.5 MG, 1 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	For irritable bowel syndrome (IBS): Exclude if male gender
<b>Required Medical Information</b>	Documentation of chronic severe diarrhea-predominant IBS -AND- trial and failure or intolerance to one anti-diarrheal (e.g. loperamide), anti-spasmodic, or tricyclic antidepressant, or contraindication to all
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 weeks initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lovaza

---

## Products Affected

- LOVAZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For hypertriglyceridemia, triglycerides greater than or equal to 500mg/dL indicating sever hypertriglyceridemia -AND- Therapeutic failure or intolerance to a prescription, generic omega 3 acid ethyl ester capsules
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, reduction in triglyceride levels from baseline for hypertriglyceridemia
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lumakras

---

## Products Affected

- **LUMAKRAS ORAL TABLET 120 MG,  
320 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and all of the following, if applicable to diagnosis 1) KRAS G12C mutation status, as detected by an FDA-approved test 2) Alternatives tried
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lumryz

## Products Affected

- LUMRYZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Lupkynis

## Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of active lupus nephritis -AND- Documented positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- Trial, contraindication, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- Member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolate mofetil.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 weeks initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of disease stability or disease improvement -AND- member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolate mofetil.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lupron Depot Ped

## Products Affected

- **LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG**
- **LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)**
- **LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of central precocious puberty -AND- advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3 mIU/L or leuprolide-stimulating LH level greater than 3.3-5 mIU/L
<b>Age Restrictions</b>	Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy defined as pre-pubertal slowing/decline, normalization of FSH, normalization LH, normalization of bone age, normalization of estradiol level or normalization of testosterone level
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lybalvi

---

## Products Affected

- LYBALVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lynparza

---

## Products Affected

- LYNPARZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) BRCA mutations 2) Genomic instability status 3) Homologous recombinant repair gene mutations 4) HER2 status 5) Alternatives tried/failed 6) Concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lyrica

## Products Affected

- LYRICA CR
- LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG
- LYRICA ORAL SOLUTION
- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
- *pregabalin oral solution*
- *pregabalin oral tablet extended release 24 hr*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For immediate release and controlled release tablets, documentation of DPN and trial/failure or intolerance to duloxetine -OR- PHN and trial/failure or intolerance to gabapentin. For immediate release capsules, documentation of partial-onset seizures and trial/failure or intolerance to two AEDS -OR- neuropathic pain associated with spinal cord injury -OR- documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lytgobi

---

## Products Affected

- **LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement 2) Previous therapies tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Lyvispah

---

## Products Affected

- LYVISPAH

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Mavenclad

## Products Affected

- MAVENCLAD (10 TABLET PACK)
- MAVENCLAD (4 TABLET PACK)
- MAVENCLAD (5 TABLET PACK)
- MAVENCLAD (6 TABLET PACK)
- MAVENCLAD (7 TABLET PACK)
- MAVENCLAD (8 TABLET PACK)
- MAVENCLAD (9 TABLET PACK)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of Mavenclad and other disease modifying agents such as interferons, Copaxone, Tysabri. Treatment duration greater than 24 months.
<b>Required Medical Information</b>	Documentation of diagnosis of relapse-remitting multiples sclerosis or active secondary progressive disease -AND- therapeutic failure or intolerance to one other disease modifying therapy (e.g. Avonex, Gilenya, Copaxone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	Coverage beyond 24 months will not be approved.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Mavyret

---

## Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance
<b>Age Restrictions</b>	Deny if less than 3 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Mayzent

## Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER(FOR 1MG MAINT)
- MAYZENT STARTER(FOR 2MG MAINT)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use of Mayzent and other disease modifying agents such as interferons, Copaxone, Tysabri.
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Testing for CYP2C9 variants has confirmed member does not have CYP2C9*3/*3 genotype
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Megace

---

## Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Mekinist

## Products Affected

- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis -AND- all of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	For Mekinist powder for oral solution, attestation of inability to swallow Mekinist tablets is required.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Mektovi

---

## Products Affected

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF mutation status 2) Concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Methamphetamine

---

## Products Affected

- *methamphetamine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Obesity
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Motegrity

---

## Products Affected

- **MOTTEGRITY**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic idiopathic constipation -AND- Therapeutic failure, contraindication or intolerance to Linzess and lubiprostone.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Mulpleta

---

## Products Affected

- MULPLETA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Myalept

## Products Affected

- MYALEPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of congenital or acquired generalized lipodystrophy - AND- Leptin levels less than 8 ng/mL for males or less than 12 ng/mL for females -AND- the member has a diagnosis of diabetes or fasting insulin levels greater than 30uU/mL or fasting hypertriglyceridemia greater than 200mg/dL -AND- Therapeutic failure to one previous diabetes therapy (e.g. metformin, insulin) or hypertriglyceridemia therapy (e.g. statin, fibrate)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, decrease in HbA1c from baseline, decrease in fasting plasma glucose from baseline or decrease in fasting triglycerides from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Mycapssa

---

## Products Affected

- MYCAPSSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acromegaly -AND- High pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- Previous response to and tolerated treatment with octreotide or lanreotide.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of decreased or normalized IGF-1 from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Myfembree

## Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Diagnosis of severe hepatic impairment or osteoporosis.
<b>Required Medical Information</b>	Documentation of Diagnosis. For premenopausal woman with uterine leiomyomas, experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For moderate to severe pain associated with endometriosis in premenopausal woman, if the patient is a female of childbearing age, the patient is not pregnant - AND - Inadequate response, failure or contraindication to 2 standard of care treatments (i.e. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist) -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 18 months reauthorization
<b>Other Criteria</b>	For reauthorization of uterine leiomyomas, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For reauthorization of endometriosis, continued pain associated with endometriosis -AND- Attestation of reduction in pain -AND- For women of childbearing age, attestation of not pregnant -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Namenda

---

## Products Affected

- **NAMENDA ORAL TABLET** **21 MG, 28 MG**
- **NAMENDA TITRATION PAK**
- **NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG,**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and trial/failure of generic memantine
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Namzarin

---

## Products Affected

- NAMZARIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and trial/failure of generic memantine and generic donepezil
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Natpara

---

## Products Affected

- NATPARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of use as an adjunct to control hypocalcemia in patients with hypoparathyroidism -AND- Serum calcium concentration is greater than 7.5mg/dL -AND- Attestation of sufficient 25-hydroxyvitamin D stores
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement in total serum calcium from baseline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nayzilam

---

## Products Affected

- NAYZILAM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of seizure clusters or acute repetitive seizures
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Nerlynx

---

## Products Affected

- **NERLYNX**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following. 1) HER2 mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nexavar

---

## Products Affected

- **NEXAVAR**
- *sorafenib*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Nexavar, documentation of trial and failure of generic sorafenib is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nexletol

## Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>1.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite Simon Broome register criteria, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p> <p>2.Hypercholesterolemia ASCVD AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p>
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For reauthorization, documentation showing an LDL-C reduction from baseline AND attestation of continued use of Nexletol or Nexlizet with a maximally tolerated statin, unless statin intolerant. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ninlaro

---

## Products Affected

- NINLARO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Northera

## Products Affected

- *droxidopa oral capsule 100 mg, 200 mg, 300 mg*
- **NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For brand Northera, documentation of trial and failure of generic droxidopa is required. For reauthorization, attestation of increase from baseline of systolic or diastolic blood pressure upon standing -OR- attestation of decrease from baseline of neurogenic orthostatic hypotension symptoms upon standing (e.g., dizziness, feeling faint, etc.).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nourianz

---

## Products Affected

- NOURIANZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to one of the following generic products: ropinirole, pramipexole, entacapone, selegiline, or rasagiline
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nubeqa

---

## Products Affected

- NUBEQA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1. Concomitant therapy 2. History of a bilateral orchiectomy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Nucala

## Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Documentation of diagnosis of severe asthma evidenced by pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration -AND- 1.) A history of 2 or more exacerbations in the previous year or inadequate symptom control with inhaled corticosteroid in combination with 3 months of controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), unless intolerant of or contraindication to all agents -AND- 2 or 3. 2) Greater than or equal to 150 cells/uL screening within 6 weeks of dosing. 3) Greater than or equal to 300 cells/uL within 12 months of screening. -OR- Documentation of eosinophilic granulomatosis with polyangiitis (EGPA) in patients who have a history of relapsing or refractory disease and will be receiving concomitant glucocorticoid treatment with or without immunosuppressive therapy -OR- Documentation of hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause for greater than or equal to 6 months -AND- At least 2 HES flares (HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy) within the past 12 months -AND- Stable on HES therapy for at least 4 weeks (chronic or episodic oral corticosteroids, immunosuppressive or cytotoxic therapy) -OR- Documentation of chronic rhinosinusitis with nasal polyps (CRSwNP) and trial/failure, contraindication, or intolerance to an intranasal corticosteroid.</p>
<b>Age Restrictions</b>	Deny if less than 6 years old for asthma -OR- less than 12 years old for hypereosiniphilic syndrome -OR- less than 18 years old for CRSwNP
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nuedexta

---

## Products Affected

- NUEDEXTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation supporting improvement in symptoms is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nuplazid

---

## Products Affected

- NUPLAZID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hallucinations and delusions associated with Parkinson's disease psychosis
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nurtec

## Products Affected

- NURTEC ODT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For Episodic Migraine Prevention, defined as 4-14 migraine days per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For acute treatment of migraine with or without aura, trial and failure of one generic triptan.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization of episodic migraine prevention, attestation of reduction in migraine frequency. For reauthorization of acute treatment of migraine, attestation of reduction in migraine symptoms.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Nuvigil

## Products Affected

- *armodafinil*
- NUVIGIL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Nuvigil, documentation of failure on modafinil (generic Provigil).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ocaliva

---

## Products Affected

- OCALIVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Compensated cirrhosis with evidence of portal hypertension
<b>Required Medical Information</b>	Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Octreotide

## Products Affected

- *octreotide acetate injection solution*
- **SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate at maximally tolerated doses.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Odactra

## Products Affected

- ODACTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy
<b>Required Medical Information</b>	Documentation of allergic rhinitis due to house dust mites -AND- allergic rhinitis with or without conjunctivitis has been confirmed by skin testing for licensed house dust mite allergen extracts or in vitro testing for IgE antibodies to D. pteronyssinus or D. Farina -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
<b>Age Restrictions</b>	Deny if less than 12 years of age or greater than 65 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Odomzo

---

## Products Affected

- ODOMZO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Olpruva

---

## Products Affected

- **OLPRUVA ORAL PELLETS IN PACKET 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment of acute hyperammonemia in urea cycle disorders
<b>Required Medical Information</b>	Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase -AND- use as an adjunctive therapy to dietary management.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Trial and failure of generic sodium phenylbutyrate is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Olumiant

---

## Products Affected

- OLUMIANT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Part A covered for Covid-19 in hospitalized patients
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severely active rheumatoid arthritis an inadequate response or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide). For severe alopecia areata, inadequate response or intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Rheumatoid Arthritis and Alopecia Areata
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR, with at least 1 being a tumor necrosis factor blocker.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Onfi

## Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- **ONFI ORAL SUSPENSION**
- **ONFI ORAL TABLET**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy
<b>Age Restrictions</b>	Deny if less than 2 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ongentys

---

## Products Affected

- **ONGENTYS**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to the following (1. and 2.): 1) entacapone 2) one of the following generic products: rasagiline, pramipexole, ropinirole, selegiline
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Onureg

---

## Products Affected

- ONUREG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Opzelura

## Products Affected

- OPZELURA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following (1-4): 1) mild to moderate atopic dermatitis (AD), 2) attestation of up to 20 percent of body surface area (excluding scalp) with AD involvement, 3) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement, 4) trial & failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus -OR- Documentation of all of the following (5-7): 5) Nonsegmental vitiligo, 6) body surface area with vitiligo involvement does not exceed 10%, 7) trial & failure or intolerance to at least 1 generic, formulary high or ultrahigh potency topical corticosteroid -OR- vitiligo with facial or anogenital involvement
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Initial authorization: 8 weeks for AD, 24 weeks for vitiligo. Reauthorization: 12 months
<b>Other Criteria</b>	For reauthorization, attestation of positive clinical response to therapy for atopic dermatitis -OR- meaningful repigmentation of affected areas for vitiligo
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Oralair

## Products Affected

- **ORALAIR SUBLINGUAL TABLET 300  
INDX REACTIVITY**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy, therapy initiation during active allergy season
<b>Required Medical Information</b>	Documentation of allergic rhinitis and use for Sweet Vernal, Orchard, Perennial Rye, Timothy or Kentucky Blue Grass pollens -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent
<b>Age Restrictions</b>	Deny if less than 5 years of age or greater than 65 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Orencia

## Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE**  
125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Rheumatoid Arthritis, and Psoriatic Arthritis or less than 2 years of age for Juvenile Idiopathic Arthritis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla and Stelara. For juvenile idiopathic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Xeljanz/Xeljanz solution and Actemra.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Orgovyx

---

## Products Affected

- ORGOVYX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of advanced prostate cancer
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Oriahnn

---

## Products Affected

- ORIAHNN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Diagnosis of severe hepatic impairment or osteoporosis.
<b>Required Medical Information</b>	Documentation of premenopausal woman with uterine leiomyomas - AND- Experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 18 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Orilissa

## Products Affected

- **ORILISSA ORAL TABLET 150 MG, 200 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Diagnosis of severe hepatic impairment or osteoporosis.
<b>Required Medical Information</b>	Documentation of female with diagnosis of endometriosis with moderate to severe pain -AND- For women of childbearing age, attestation of not pregnant -AND- Inadequate response, failure or contraindication to 2 standard of care treatments (e.g. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist, Danazol) -AND- Treatment with Orilissa does not exceed 24 months
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 18 months reauthorization
<b>Other Criteria</b>	For reauthorization, Orilissa is continued to be used for pain associated with endometriosis -AND- attestation of reduction in pain -AND- Total cumulative duration of therapy does not exceed 24 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Orkambi

---

## Products Affected

- **ORKAMBI ORAL TABLET**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis and homozygous F508del mutation
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Orkambi Granules

---

## Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis and homozygous F508del mutation
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Orladeyo

## Products Affected

- ORLADEYO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two prophylactic therapies simultaneously.
<b>Required Medical Information</b>	For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Orserdu

---

## Products Affected

- **ORSERDU ORAL TABLET 345 MG, 86 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) ER mutation status, HER2 mutation status, and ESR1 mutation status 2) Alternatives tried/failed
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Osmolex

---

## Products Affected

- **OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 193 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Parkinson's disease or drug-induced extrapyramidal symptoms -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine
<b>Age Restrictions</b>	Deny if less than 18 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Osphena

---

## Products Affected

- OSPHENA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OTEZLA

## Products Affected

- OTEZLA
- OTEZLA STARTER ORAL TABLETS, DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of diagnosis. For plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to topical triamcinolone for acute flare-up of oral ulcers -AND- inadequate response or intolerance to colchicine for prevention of recurrent oral ulcers
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	12 months
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Otrexup

---

## Products Affected

- OTREXUP (PF)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Oxbryta

---

## Products Affected

- **OXBRYTA ORAL TABLET 300 MG, 500 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea
<b>Age Restrictions</b>	Deny if less than 4 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Oxbryta for Suspension

---

## Products Affected

- **OXBRYTA ORAL TABLET FOR SUSPENSION**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea -AND- one of the following (1 or 2): 1) is eleven years of age or younger -OR- 2) has an inability to swallow tablets
<b>Age Restrictions</b>	Deny if less than 4 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Oxervate

---

## Products Affected

- **OXERVATE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment duration greater than 8 weeks per eye
<b>Required Medical Information</b>	Documentation of diagnosis -AND- affected eye (e.g. right eye, both eyes).
<b>Age Restrictions</b>	Deny if less than 2 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	Coverage beyond 8 weeks per eye will not be approved
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Palynziq

## Products Affected

- **PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of phenylketonuria. Member meets the following criteria 1.) Baseline Phe level greater than 600 micromoles/L -AND- 2.) Failure or intolerance to existing management (i.e. Kuvan therapy) -AND- 3.) Has a prescription for epinephrine agent unless contraindicated.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of reduction in baseline pretreatment Phe levels -OR- blood Phe levels are less than or equal to 600 micromoles/L -OR- attestation that additional therapy with Palynziq is needed to allow adequate trial of maximum dose of 60mg per day for 16 weeks or member is not currently on 60mg per day dose.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Panretin

---

## Products Affected

- PANRETIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Pemazyre

---

## Products Affected

- PEMAZYRE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) Previous therapies tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Pheburane

---

## Products Affected

- PHEBURANE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- therapeutic failure or intolerance to generic sodium phenylbutyrate
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Phenoxybenzamine

---

## Products Affected

- **DIBENZYLINE**
- *phenoxybenzamine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of excessive sweating and hypertension associated with pheochromocytoma supported by one of the following (1. or 2.): 1. Elevated metanephrines in plasma or urine. 2. Tumor evidence from CT scan or MRI
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Phospholine Iodide

---

## Products Affected

- PHOSPHOLINE IODIDE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For diagnosis of elevated intraocular pressure (IOP), the following criteria apply (1 and 2): therapeutic failure or intolerance to generic latanoprost, 2) therapeutic failure, contraindication, or intolerance to one generic ophthalmic alternative that lowers IOP (a. through f.): a) prostaglandin analog, b) ophthalmic beta-blocker, c) alpha-adrenergic agonist, d) carbonic anhydrase inhibitor, e) ophthalmic cholinergic agonist, f) combination products of these classes
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Piqray

---

## Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer in men and postmenopausal women with disease progression on or after endocrine-based therapy -AND- Used in combination with fulvestrant - AND- PI3K mutation positive as detected by an FDA approved test.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Pomalyst

---

## Products Affected

- POMALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ponvory

---

## Products Affected

- **PONVORY**
- **PONVORY 14-DAY STARTER PACK**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Praluent

## Products Affected

- PRALUENT PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance</p>
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	6 months initial authorization, 12 months reauthorization

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	Patients must have a trial/failure or contraindication to the preferred product Repatha. Do not used with another PCSK9 inhibitor or siRNA directed to PCSK9. For reauthorization, documentation showing an LDL-C reduction on Praluent therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Prenatal Vitamins

---

## Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Prescription Drug Combo

---

## Products Affected

- acetaminophen-caff-dihydrocod oral capsule
- acetaminophen-codeine oral solution 120-12 mg/5 ml
- acetaminophen-codeine oral tablet
- **ALPRAZOLAM INTENSOL**
- alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg
- alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg
- alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg
- **AMBIEN**
- **AMBIEN CR**
- **ASCOMP WITH CODEINE**
- butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg
- codeine sulfate
- codeine-bitalbital-asa-caff
- **CONZIP**
- **DEMEROL (PF) INJECTION SYRINGE 25 MG/ML**
- **DEMEROL INJECTION SOLUTION 50 MG/ML**
- **DILAUDID ORAL LIQUID**
- **DILAUDID ORAL TABLET**
- **EDLUAR**
- **ENDOCET**
- eszopiclone
- fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour
- **FIORICET WITH CODEINE**
- **HALCION ORAL TABLET 0.25 MG**
- hydrocodone bitartrate oral capsule, oral only, er 12hr
- hydrocodone bitartrate oral tablet, oral only, ext. rel. 24 hr
- hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml
- hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg
- hydrocodone-ibuprofen
- hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml
- hydromorphone oral liquid
- hydromorphone oral tablet
- hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg
- **HYSINGLA ER**
- levorphanol tartrate
- **LUNESTA**
- meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml
- meperidine oral solution
- meperidine oral tablet 50 mg
- methadone oral solution 10 mg/5 ml, 5 mg/5 ml
- methadone oral tablet 10 mg, 5 mg
- morphine concentrate oral solution
- morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg
- morphine oral capsule, extend. release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg
- morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)
- morphine oral tablet
- morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg
- **MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG**
- **NALOCET**
- **NUCYNTA**
- **NUCYNTA ER**
- oxycodone oral capsule
- oxycodone oral concentrate
- oxycodone oral solution
- oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg
- oxycodone oral tablet, oral only, ext. rel. 12 hr 10 mg, 20 mg
- oxycodone-acetaminophen oral solution 5-325 mg/5 ml

- *oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- **OXYCONTIN ORAL TABLET, ORAL ONLY, EXT. REL. 12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG**
- *oxymorphone oral tablet*
- *oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg*
- **PERCOCET**
- **PROLATE ORAL SOLUTION**
- **PROLATE ORAL TABLET**
- **ROXICODONE ORAL TABLET 15 MG, 30 MG**
- **ROXYBOND**
- **SEGLENTIS**
- *tramadol oral capsule, er biphasic 24 hr 17-*
- 83
- *tramadol oral capsule, er biphasic 24 hr 25-75 100 mg, 200 mg*
- *tramadol oral solution*
- *tramadol oral tablet 100 mg, 50 mg*
- *tramadol oral tablet extended release 24 hr*
- *tramadol oral tablet, er multiphasic 24 hr*
- **TRAMADOL-ACETAMINOPHEN**
- **TREZIX**
- *triazolam*
- **XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG**
- **XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG**
- **XTAMPZA ER**
- *zaleplon oral capsule 10 mg, 5 mg*
- *zolpidem*

PA Criteria	Criteria Details
Exclusion Criteria	



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Required Medical Information</b>	<p>For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine, and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxants (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines, sedative-hypnotics) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	<p>Opiate tx for pain+subs. abuse, app. opiate x 1mo. All other combos and dx approve x 12mo.</p>
<b>Other Criteria</b>	<p>Opiate agonists will receive automatic approval if no recent claims for a substance abuse therapy (e.g. buprenorphine-naloxone) OR a benzodiazepine (e.g. triazolam, alprazolam) OR a benzodiazepine with a centrally acting skeletal muscle relaxant (e.g., carisoprodol) OR a gabapentinoid OR a sedative-hypnotic. Benzodiazepines (e.g. triazolam, alprazolam) will receive automatic approval if no recent claims for an opiate agonist (e.g. oxycodone, hydrocodone, oxymorphone) or an opiate agonist with a centrally acting skeletal muscle relaxant (e.g. carisoprodol). Sedative-hypnotics (e.g. zolpidem) will receive automatic approval if no recent claims for an opiate agonist. Infusible opiate agonists will be covered under Part B when administered via infusion pump.</p>
<b>Indications</b>	<p>All FDA-approved Indications.</p>

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Pretomanid

---

## Products Affected

- *pretomanid*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of extensively drug resistant, treatment intolerant or nonresponsive multidrug resistant tuberculosis -AND- Used as part of a combination regimen with bedaquiline and linezolid -AND- Therapeutic failure, contraindication or intolerance to both of the following (1 and 2): 1. A fluoroquinolone antibiotic 2. Isoniazid or Rifampin.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	26 weeks
<b>Other Criteria</b>	For reauthorization, additional therapy required due to doses of the regimen being missed for safety reasons
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Proair Digihaler

---

## Products Affected

- PROAIR DIGIHALER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of reversible obstructive airway disease (e.g. asthma) or exercise induced bronchospasm -AND- Inadequate response to non-digitized albuterol inhaler -AND- Attestation that a digital inhaler is required.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Procysbi

---

## Products Affected

- **PROCYSBI ORAL GRANULES DEL  
RELEASE IN PACKET**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- previous trial and failure, intolerance, or contraindication to Cystagon (cysteamine bitartrate immediate-release)
<b>Age Restrictions</b>	Deny if less than 1 year of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Prolia

## Products Affected

- PROLIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Provigil

## Products Affected

- *modafinil*
- **PROVIGIL**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of shift work sleep disorder (SWSD) substantiated by excessive sleepiness or insomnia that is temporarily associated with a recurring work schedule that overlaps the usual time for sleep -AND- Symptoms are accompanied by a reduction of total sleep time -AND- Symptoms experienced for at least 3 months -AND- Sleep log or actigraphy monitoring for at least 14 days including both work and free days -AND- Sleep disturbance is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Provigil, documentation of failure on generic modafinil.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	Fatigue associated with Multiple Sclerosis (MS)
<b>Part B Prerequisite</b>	No



# Pulmonary Arterial Hypertension

## Products Affected

- **ADCIRCA**
- **ADEMPAS**
- **ALYQ**
- *ambrisentan*
- *bosentan*
- **LETAIRIS**
- **LIQREV**
- **OPSUMIT**
- **ORENITRAM MONTH 1 TITRATION KT**
- **ORENITRAM MONTH 2 TITRATION KT**
- **ORENITRAM MONTH 3 TITRATION KT**
- **ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG**
- **REVATIO ORAL SUSPENSION FOR RECONSTITUTION**
- **REVATIO ORAL TABLET**
- *sildenafil (pulm.hypertension) oral suspension for reconstitution*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- **TRACLEER ORAL TABLET**
- **TRACLEER ORAL TABLET FOR SUSPENSION**
- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**
- **UPTRAVI ORAL TABLETS,DOSE PACK**
- **VENTAVIS**

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group. For bosentan and Revatio (sildenafil) in pediatric individuals, an exception to RHC will be allowed when the risk of RHC outweighs the benefit -AND- prescriber attests alternative studies have been completed (i.e. CT, MRI or specified test ruling out other causes of pulmonary hypertension). For Adempas, additional diagnosis of CTEPH as documented by right heart catheterization and V/Q scan substantiating mPAP greater than 20 mmHg at rest and PWP less than or equal to 15 mmHg and documented presence of occlusive thrombi within the pulmonary arteries will be approved.</p>
Age Restrictions	
Prescriber Restrictions	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Ventavis covered under Part B when using via nebulizer in the home setting. For brand Adcirca, trial and failure of generic tadalafil or Alyq is required. For brand Letairis, trial and failure of generic ambrisentan is required. For brand Revatio, trial and failure of generic sildenafil is required. For brand Tracleer 62.5mg and 125mg, trial and failure of generic bosentan is required. For Liqrev, trial and failure of generic sildenafil for oral suspension is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Pulmozyme

---

## Products Affected

- PULMOZYME

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of cystic fibrosis -AND- Used in conjunction with standard therapies for management of cystic fibrosis to improve pulmonary function.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Purified Cortrophin Gel

## Products Affected

- CORTROPHIN GEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Covered for the following indications: 1. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy 2. Rheumatic disorders for patients receiving maintenance therapy 3. Collagen diseases for members receiving maintenance therapy 4. Dermatologic diseases, if using for severe psoriasis, then the member is concurrently receiving maintenance therapy 5. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction), if using for atopic dermatitis, then the member is concurrently receiving maintenance therapy 6. Ophthalmic diseases 7. Respiratory diseases 8. Gout and unable to take first-line therapies. 9. Pediatric acquired epileptic aphasia. 10. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 1 through 9, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that Cortrophin is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy.
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	Epileptic Aphasia
<b>Part B Prerequisite</b>	No

# Pyrukynd

## Products Affected

- **PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG**
- **PYRUKYND ORAL TABLETS,DOSE PACK**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hemolytic anemia with pyruvate kinase deficiency, as supported by one of the following (1-2): 1) mutations in the PKLR gene, 2) reduced activity of the pyruvate kinase enzyme.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 weeks initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of increase in hemoglobin level from baseline -OR- decrease in transfusion burden from baseline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Qelbree

---

## Products Affected

- **QELBREE ORAL  
CAPSULE,EXTENDED RELEASE 24HR  
100 MG, 150 MG, 200 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant and generic atomoxetine
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Qinlock

---

## Products Affected

- QINLOCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Quinine

---

## Products Affected

- **QUALAQUIN**
- *quinine sulfate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment or prevention of leg cramps
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	10 days
<b>Other Criteria</b>	Doses for duration greater than 10 days will not be approved
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Qulipta

## Products Affected

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, of which 8 or more are migraine days. The following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in migraine frequency
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Radicava ORS

---

## Products Affected

- **RADICAVA ORS STARTER KIT SUSP**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of amyotrophic lateral sclerosis (ALS)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rasuvo

---

## Products Affected

- RASUVO (PF)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ravicti

---

## Products Affected

- RAVICTI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders
<b>Required Medical Information</b>	Documentation of chronic management of a urea cycle disorders (UCDs)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Recorlev

---

## Products Affected

- **RECORLEV**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of endogenous Cushing's syndrome AND patient is not a candidate for pituitary surgery or surgery has not been curative
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Regranex

---

## Products Affected

- **REGRANEX**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of lower-extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond and have an adequate blood supply -AND- being used as an adjunct to standard ulcer care practices (e.g. sharp debridement, non-weight bearing regimen, infection control) -AND- attestation of a wound care plan.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	20 weeks
<b>Other Criteria</b>	For reauthorization, one of the following (1-2): 1) documentation of decrease in ulcer(s) size without complete ulcer(s) closure -OR- 2) documentation of new lower extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond with an adequate blood supply, attestation of being used as an adjunct to standard ulcer care practices, and attestation of a wound care plan.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Relistor

---

## Products Affected

- **RELISTOR ORAL**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Relistor SC

## Products Affected

- **RELISTOR SUBCUTANEOUS SOLUTION**
- **RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of opioid induced constipation (OIC) due to any of the following (1-3): 1) chronic non-cancer pain, 2) advanced illness or active cancer in palliative care or 3) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (4 to 6): 4) Laxatives 5) lubiprostone 6) Movantik.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Relyvrio

---

## Products Affected

- **RELYVRIO**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Repatha

## Products Affected

- **REPATHA PUSHTRONEX**
- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool, AND LDL-C greater than 100 mg/dL if 18 and older or LDL-C greater than 130 if 17 and younger despite use of maximally tolerated statin or statin intolerance. If 17 and younger will continue to receive concurrent lipid-lowering therapies. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance</p>
<b>Age Restrictions</b>	Deny if less than 18 years of age for ASCVD and Primary Hyperlipidemia, or less than 10 years of age for HoFH and HeFH.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	Do not used with another PCSK9 inhibitor or siRNA directed to PCSK9. For reauthorization, documentation showing an LDL-C reduction on Repatha therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Retevmo

---

## Products Affected

- **RETEVMO ORAL CAPSULE 40 MG, 80 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate)
<b>Age Restrictions</b>	Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Revlimid

## Products Affected

- *lenalidomide*
- **REVLIMID**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial
<b>Required Medical Information</b>	Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rezlidhia

---

## Products Affected

- **REZLIDHIA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rezurock

---

## Products Affected

- **REZUROCK**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic graft-versus-host disease (cGVHD) -AND- therapeutic failure or intolerance to 2 lines of systemic therapy
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Rinvoq

## Products Affected

- **RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe active rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of one of the following (1 or 2): 1) trial & failure, or intolerance to at least one topical corticosteroid -OR- topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus) 2) The member has severe atopic dermatitis and is incapable of applying topical therapies due to the extent of body surface area involvement or topical therapies are contraindicated due to severely damaged skin. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For Non-radiographic Axial Spondyloarthritis, trial & failure or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs) or contraindication to all.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For diagnoses in which tumor necrosis factor (TNF) blockers are also indicated (e.g., Rheumatoid Arthritis, Psoriatic Arthritis), the member has experienced therapeutic failure or intolerance to at least 1 TNF blocker.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Rozlytrek

---

## Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rubraca

---

## Products Affected

- RUBRACA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following. 1) BRCA mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ruconest

## Products Affected

- RUCONEST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy
<b>Required Medical Information</b>	For the treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.
<b>Age Restrictions</b>	Deny if less than 13 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant.
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Rydapt

---

## Products Affected

- RYDAPT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use as single agent induction therapy for AML
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) FLT3 mutations 2) Concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sabril

## Products Affected

- **SABRIL**
- *vigabatrin*
- **VIGADRONE**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms
<b>Age Restrictions</b>	Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Samsca

## Products Affected

- **SAMSCA**
- *tolvaptan*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of symptomatic hypervolemic or euvolemic hyponatremia evidenced by (1. or 2.): 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 month
<b>Other Criteria</b>	Doses must be initiated in the hospital setting to closely monitor serum sodium. Treatment should be limited to 30 days to minimize risk of liver injury. For brand Samsca, a trial and failure of generic tolvaptan is required. For reauthorization, treatment is for a new episode of a clinically significant euvolemic or hypervolemic hyponatremia -AND- on of the following (1. or 2.) 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Savella

---

## Products Affected

- SAVELLA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Scemblix

---

## Products Affected

- **SCSEMBLIX ORAL TABLET 20 MG, 40 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) T3151 mutation status 2) Philadelphia chromosome status 3) Alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sertraline Capsule

---

## Products Affected

- *sertraline oral capsule*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of major depressive disorder or obsessive-compulsive disorder -AND- Sertraline 100mg or sertraline 125mg has been received for greater than or equal to 7 days -AND- Therapeutic failure or intolerance to generic sertraline immediate release tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Signifor

---

## Products Affected

- SIGNIFOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of decrease in urinary free cortisol levels from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Siliq

---

## Products Affected

- SILIQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For psoriasis, patients must have therapeutic failure or intolerance to 2 preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel, and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Simponi

## Products Affected

- **SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML**
- **SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. Simponi 50mg: For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) and Simponi will be used in combination with methotrexate. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). Diagnosis of psoriatic arthritis Simponi 100mg: Diagnosis of moderate to severe ulcerative colitis.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For Rheumatoid arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For ulcerative colitis, patients must have therapeutic failure or intolerance to the preferred products Humira, Stelara and Xeljanz/Xeljanz XR. For ulcerative colitis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No



# Skyclarys

---

## Products Affected

- SKYCLARYS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Friedreichs ataxia confirmed by genetic testing (i.e., FXN gene mutation).
<b>Age Restrictions</b>	Deny if less than 16 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Skyrizi

## Products Affected

- **SKYRIZI SUBCUTANEOUS PEN INJECTOR**
- **SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML**
- **SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohns disease, attestation of clinical response or remission following IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Skytrofa

---

## Products Affected

- SKYTROFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sogroya

---

## Products Affected

- SOGROYA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Solaraze

## Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to one of the following (1 or 2): 1) topical fluorouracil solution or fluorouracil 5% cream 2) topical imiquimod 5% cream
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Somavert

---

## Products Affected

- SOMAVERT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sotyktu

---

## Products Affected

- SOTYKTU

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel and Skyrizi.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sovaldi

---

## Products Affected

- SOVALDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
<b>Age Restrictions</b>	Deny if less than 3 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Sprycel

---

## Products Affected

- **SPRYCEL**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed 3) Concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Statin Liquid

---

## Products Affected

- ATORVALIQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Inability to swallow tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Stelara

## Products Affected

- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For Crohn's Disease, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC. For Ulcerative colitis, attestation of clinical response or remission following single induction dose of IV Stelara within 2 months of initiating therapy with Stelara SC
<b>Age Restrictions</b>	Deny if less than 18 years of age for Crohn's Disease and Ulcerative Colitis or less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Must follow recommended dosing guidelines based upon weight. Psoriasis: For patients weighing less than 100 kilograms (220 pounds), 45 mg dosing will be approved. For patients weighing more than 100 kilograms (220 pounds), 90 mg dosing will be approved. Psoriatic Arthritis: 45 mg dosing will be approved. For patients with co-existent moderate to severe plaque psoriasis weighing greater than 100 kilograms (220 pounds), 90 mg dosing will be approved. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Stivarga

---

## Products Affected

- STIVARGA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sunosi

## Products Affected

- SUNOSI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>For narcolepsy and OSAHS, documentation of trial and failure, contraindication or intolerance to modafinil and armodafinil. For reauthorization, provider attestation of improvement in daytime sleepiness is required.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Sutent

---

## Products Affected

- *sunitinib malate*
- SUTENT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) disease progression on or intolerance to imatinib mesylate 2) high risk of recurrent RCC following nephrectomy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Symdeko

---

## Products Affected

- SYMDEKO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis (CF) in patients who have either the homozygous F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay (e.g. E56K, R117C, A455E)
<b>Age Restrictions</b>	Deny if less than 6 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Sympazan

---

## Products Affected

- SYMPAZAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- therapeutic failure or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam
<b>Age Restrictions</b>	Deny if less than 2 years old
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Symproic

## Products Affected

- SYMPROIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to at least 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Synarel

## Products Affected

- SYNAREL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For central precocious puberty (CPP), advancement of bone age is beyond chronological age -AND- Basal luteinizing hormone (LH) level greater than 0.2-0.3IU/L or leuprolide-stimulating LH level greater than 3.3-5 IU/L. For female with endometriosis, attestation of not pregnant if of childbearing age -AND- Therapeutic failure, contraindication or intolerance to 2 of the following standard of care treatments: NSAIDs, combination hormonal contraceptive, progestin (i.e. medroxyprogesterone injection), GnRH agonist (i.e. Leuprolide) or danazol
<b>Age Restrictions</b>	Deny if greater than 8 years of age for females or greater than 9 years of age for males unless there is medical necessity for treatment of central precocious puberty. Deny if less than 18 years of age for endometriosis.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Endometriosis: 6 months, CPP: 6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization for CPP, attestation of pubertal development slowing from baseline.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Syndros

## Products Affected

- SYNDROS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following (1 or 2): 1) anorexia associated with weight loss in patients with AIDS -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules -OR- 2) nausea and vomiting associated with cancer chemotherapy in adults who have trial and failure, contraindication, or intolerance to a conventional antiemetic treatment (e.g., metoclopramide, promethazine, ondansetron, perphenazine, etc.) -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Covered under Part B when the following are met: 1) used for chemotherapy-induced nausea and vomiting. 2) used as full replacement for IV anti-emetic therapy. 3) using within 48 hours of receiving chemotherapy.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tabrecta

---

## Products Affected

- TABRECTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tadliq

---

## Products Affected

- TADLIQ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Trial and failure of generic tadalafil or Alyq -OR- Inability to swallow tablets is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tagrisso

---

## Products Affected

- TAGRISSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following. 1) EGFR mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Takhzyro

## Products Affected

- **TAKHZYRO SUBCUTANEOUS SOLUTION (150 MG/ML)**
- **TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Member should not be on two prophylactic therapies simultaneously.
<b>Required Medical Information</b>	For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Taltz

## Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs.
<b>Age Restrictions</b>	Deny if less than 18 years of age for Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis or less than 6 years of age for Plaque Psoriasis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For plaque psoriasis patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel and Skyrizi. For ankylosing spondylitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Talzenna

---

## Products Affected

- **TALZENNA**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer as a single agent - OR- Documentation of HRR gene-mutated metastatic castration-resistant prostate cancer in combination with enzalutamide
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Targretin

---

## Products Affected

- *bexarotene oral*
- *bexarotene topical*
- **TARGRETIN ORAL**
- **TARGRETIN TOPICAL**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Targretin, documentation of trial and failure of generic bexarotene is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tarpeyo

---

## Products Affected

- TARPEYO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- one (1) of the following (A or B): A) Used in combination with one (1) of the following (1 or 2): 1) angiotensin-converting enzyme inhibitor (ACE-I), or 2) angiotensin II receptor blocker (ARB), -OR- B) Intolerance or contraindication to both of the following (3 and 4): 3) ACE-I, and 4) ARB.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tascenso ODT

---

## Products Affected

- TASCENSO ODT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use of Gilenya and other disease modifying agents such as interferons, Copaxone, Tysabri
<b>Required Medical Information</b>	Documentation of a relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Tasigna

---

## Products Affected

- TASIGNA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tasimelteon

## Products Affected

- *tasimelteon*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tavalisse

## Products Affected

- TAVALISSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For diagnosis of ITP, the following criteria apply (1 and 2): 1) trial, intolerance, or inadequate response to a corticosteroid, immunoglobulin, or splenectomy. 2) One of the following (A or B): A) Platelet count less than or equal to $50 \times 10^9/L$ and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). B) Platelet count of less than or equal to $30 \times 10^9/L$ .
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tavneos

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis -AND- Prescriber attests to positive test for anti-PR3 or positive test for anti-MPO -AND- Member will continue to receive concomitant standard of care treatment with systemic glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of therapeutic response defined by disease stability or disease improvement -AND- Member will continue to receive concomitant standard of care treatment with glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tazarotene

---

## Products Affected

- **ARAZLO**
- **FABIOR**
- *tazarotene topical foam*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tazorac

## Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- **TAZORAC TOPICAL CREAM**
- **TAZORAC TOPICAL GEL**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tazverik

---

## Products Affected

- TAZVERIK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of locally advanced or metastatic epithelioid sarcoma - AND- Disease is not eligible for complete resection. Documentation of relapsed or refractory follicular lymphoma -AND-Tumors are EZH2 mutation positive, as detected by FDA approved test, in a member that has received at least 2 prior systemic therapies -OR- Prescriber attests there are no satisfactory alternative treatment options.
<b>Age Restrictions</b>	Deny if less than 16 years of age for epithelioid sarcoma or deny if less than 18 years of age for follicular lymphoma
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tecfidera

## Products Affected

- dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*
  - TECFIDERA ORAL**
- CAPSULE, DELAYED  
 RELEASE(DR/EC) 120 MG, 120 MG  
 (14)- 240 MG (46), 240 MG**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	For brand Tecfidera, documentation of failure on generic dimethyl fumarate
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Tegsedi

## Products Affected

- TEGSEDI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of polyneuropathy associated with hereditary TTR (hATTR) amyloidosis with mutation in TTR gene confirmed by genetic testing -AND- Neurologic examination shows clinical signs and symptoms of the disease (e.g. peripheral/autonomic neuropathy, motor disability, carpal tunnel, etc.) -AND- Attestation of peripheral neuropathy impairment score (NIS) of 10 or greater -AND- Not simultaneously utilizing other gene targeted therapy for polyneuropathy of hATTR
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of improvement of polyneuropathy from baseline
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tepmetko

---

## Products Affected

- **TEPMETKO**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Testosterone (androgens)

## Products Affected

- **ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **AVEED**
- **DEPO-TESTOSTERONE**
- **FORTESTA**
- **JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG**
- **NATESTO**
- **TESTIM**
- *testosterone cypionate*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*
- **TLANDO**
- **VOGELXO TRANSDERMAL GEL**
- **VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **XYOSTED**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Documentation of primary or secondary hypogonadism in males with testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, radiation or toxic damage -OR- documentation of primary or secondary hypogonadism in males with multiple symptoms of hypogonadism including at least one of the following specific symptoms: height loss due to vertebral fractures, low trauma fractures, low bone density, incomplete or delayed sexual development, breast discomfort, loss of axillar and/or pubic body hair, hot flushes -OR- documentation of HIV infection in men with weight loss -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only).</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications, Some Medically-accepted Indications.
<b>Off Label Uses</b>	HIV Wasting
<b>Part B Prerequisite</b>	No

# Thalomid

---

## Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis
<b>Required Medical Information</b>	Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Thiola

## Products Affected

- **THIOLA**
- **THIOLA EC**
- *tiopronin*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Confirmation of cystinuria by at least one 24-hour urine collection with measurement of urinary cysteine levels greater than 400 mg/day -AND- Attestation of failure of urine alkalization with potassium citrate (to achieve pH of 7.0).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of urine cystine concentration decreased from baseline -OR- decrease in production of cystine stones is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Thrombopoiesis Stimulating Agents

## Products Affected

- **PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG**
- **PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy (eltrombopag only)-OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Platelet count to be provided
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tibsovo

---

## Products Affected

- TIBSOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) IDH1 mutation status, 2) alternatives tried/failed, 3) comorbidity that precludes use of intensive induction chemotherapy (i.e. age greater than or equal to 75 years, severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Tigan

---

## Products Affected

- *trimethobenzamide oral*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tiglutik

---

## Products Affected

- TIGLUTIK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of stability or improvement in symptoms of ALS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tolsura

---

## Products Affected

- TOLSURA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- Unable to tolerate generic itraconazole capsules
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation the member is still unable to tolerate generic itraconazole capsules
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Topical Lidocaine

---

## Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Transmucosal Fentanyl Citrate

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*  
1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg
- *fentanyl citrate buccal tablet, effervescent*  
100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg
- *FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of therapeutic use and the member is currently receiving and tolerant to long acting opioid therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tremfya

## Products Affected

- TREMFYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For psoriasis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriatic arthritis, patients must have therapeutic failure or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Xeljanz/Xeljanz XR. For psoriasis and psoriatic arthritis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tretinoin

## Products Affected

- *adapalene topical cream*
- *adapalene topical gel 0.3 %*
- *adapalene topical swab*
- *adapalene-benzoyl peroxide*
- **AKLIEF**
- **ALTRENO**
- **ATRALIN**
- *clindamycin-tretinoin*
- **DIFFERIN TOPICAL CREAM**
- **DIFFERIN TOPICAL GEL WITH PUMP**
- **DIFFERIN TOPICAL LOTION**
- **EPIDUO FORTE**
- **EPIDUO TOPICAL GEL WITH PUMP**
- **RETIN-A**
- **RETIN-A MICRO**
- **RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %**
- *tretinoin*
- *tretinoin microspheres topical gel*
- *tretinoin microspheres topical gel with pump 0.08 %*
- **TWYNEO**
- **VELTIN**
- **WINLEVI**
- **ZIANA**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Cosmetic use
<b>Required Medical Information</b>	Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two generic topical non-retinoid acne medications (e.g. clindamycin, sulfacetamide, erythromycin)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Trikafta

---

## Products Affected

- **TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL**
- **TRIKAFTA ORAL TABLETS, SEQUENTIAL**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Tukysa

---

## Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) RAS genetic status 3) Alternatives tried/failed 4) Concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Turalio

---

## Products Affected

- TURALIO ORAL CAPSULE 125 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tykerb

---

## Products Affected

- *lapatinib*
- **TYKERB**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) Alternatives tried/failed 3) Concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Tykerb, trial and failure of generic lapatinib is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tymlos

## Products Affected

- TYMLOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Treatment duration greater than 24 months.
<b>Required Medical Information</b>	Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 months
<b>Other Criteria</b>	Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog teriparatide. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Tyvaso DPI

---

## Products Affected

- **TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16 MCG (112)- 32 MCG (84), 16(112)-32(112) -48(28) MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- results of a right heart catheterization (RHC) meeting all of the following (1., 2., and 3.): 1) mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, 2) pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, 3) PVR greater than or equal to 3 Wood units
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ubrelvy

---

## Products Affected

- **UBRELVY ORAL TABLET 100 MG, 50 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis of acute treatment of migraine with or without aura -AND- trial and failure of one generic triptan.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	Patients must have therapeutic failure, intolerance, or contraindication to Nurtec ODT. For reauthorization, attestation of reduction in migraine symptoms.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Uloric

---

## Products Affected

- *febuxostat*
- **ULORIC**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of chronic management of hyperuricemia due to gout -And- trial/failure, intolerance or contraindication to allopurinol.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Valchlor

---

## Products Affected

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received at least one prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids).
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Valtoco

---

## Products Affected

- VALTOCO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of seizure clusters or acute repetitive seizures
<b>Age Restrictions</b>	Deny if less than 6 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vancomycin

---

## Products Affected

- **VANCOGIN ORAL CAPSULE 125 MG, 250 MG**
- *vancomycin oral capsule 125 mg, 250 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For brand Vancocin, trial and failure of generic vancomycin capsules is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vanflyta

---

## Products Affected

- VANFLYTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Induction, consolidation, or maintenance therapy 2) FLT3 ITD mutation status, as detected by an FDA-approved test 3) Concomitant therapy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Veltassa

---

## Products Affected

- VELTASSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 6.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in serum potassium levels following Veltassa administration and continued treatment for hyperkalemia is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Venbysi XR

---

## Products Affected

- *venlafaxine besylate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- venlafaxine extended-release product at a total daily dose greater than or equal to 75 mg has been received for greater than or equal to 4 days.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Venclexta

---

## Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis and concomitant therapy, if applicable to diagnosis. For newly-diagnosed AML, age greater than or equal to 75 years or presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Veozah

---

## Products Affected

- VEOZAH

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of moderate to severe vasomotor symptoms due to menopause -AND- one of the following (1 or 2): 1) therapeutic failure, contraindication, or intolerance to a generic hormone therapy product, or 2) attestation that hormone therapy is not clinically appropriate
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Verkazia

---

## Products Affected

- VERKAZIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- therapeutic failure or intolerance to 2 of the following medication classes or all are contraindicated: 1) generic ophthalmic antihistamines (e.g., olopatadine), 2) generic ophthalmic mast cell stabilizers (e.g., cromolyn sodium), 3) Generic ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Verquvo

---

## Products Affected

- VERQUVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Verzenio

---

## Products Affected

- VERZENIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Viberzi

## Products Affected

- **VIBERZI**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Severe (Child-Pugh C) hepatic impairment
<b>Required Medical Information</b>	Documentation of diarrhea predominant, irritable bowel syndrome (IBS-D) -AND- trial/failure or intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vioice

---

## Products Affected

- **VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vimovo

---

## Products Affected

- VIMOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vimovo2

---

## Products Affected

- *naproxen-esomeprazole*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) Trial/failure of naproxen used in combination with omeprazole. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than naproxen) used in combination with another generic formulary PPI (other than omeprazole).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vittrakvi

---

## Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or tumors have progressed following treatment.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vivjoa

---

## Products Affected

- VIVJOA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Vivlodex

---

## Products Affected

- *meloxicam submicronized*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- trial and failure or intolerance to generic meloxicam tablets and one additional generic NSAID
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vizimpro

---

## Products Affected

- VIZIMPRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of metastatic non-small cell lung cancer -AND- one of the following (1 or 2): 1. Epidermal growth factor (EGFR) exon 19 deletions - OR- 2. Epidermal growth factor receptor (EGFR) exon 21 L858R substitution mutations.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vonjo

---

## Products Affected

- VONJO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of intermediate or high-risk myelofibrosis -AND- attestation of a platelet count of less than $50 \times 10^9/L$ .
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Voriconazole

---

## Products Affected

- **VFEND IV**
- *voriconazole intravenous*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months
<b>Other Criteria</b>	For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vosevi

## Products Affected

- VOSEVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Votrient

---

## Products Affected

- VOTRIENT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Voxzogo

---

## Products Affected

- VOXZOGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of achondroplasia as evidenced by an FGFR3 gene mutation detected by genetic testing -AND- all of the following (1-2): 1) baseline annualized growth velocity (AGV), 2) attestation that the member's epiphyses have not closed.
<b>Age Restrictions</b>	Deny if less than 5 years of age or greater than 17 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of increase in annualized growth velocity (AGV) from baseline and attestation that the member's epiphyses have not closed are required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vraylar

---

## Products Affected

- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	For a diagnosis of schizophrenia and bipolar I disorder: Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine). For major depressive disorder (MDD): Documentation of diagnosis -AND- being used as an adjunct to an antidepressant for the treatment of MDD -AND- trial, intolerance or contraindication to one other antidepressant in addition to the antidepressant currently being used for the treatment of MDD.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Vtama

---

## Products Affected

- VTAMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vuity

---

## Products Affected

- VUITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis.
<b>Age Restrictions</b>	Deny if less than 18 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Vumerity

---

## Products Affected

- VUMERITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya
<b>Required Medical Information</b>	Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	5 years
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Wakix

## Products Affected

- **WAKIX**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>If no diagnosis of cataplexy, trial and failure, intolerance, or contraindication to generic modafinil and a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, provider attestation of improvement in symptoms of narcolepsy or improvement in symptoms of cataplexy (if applicable).</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

# Welireg

---

## Products Affected

- **WELIREG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of von Hippel Lindau (VHL) syndrome -AND- one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma. 2) CNS hemangioblastoma. 3) Pancreatic neuroendocrine tumor.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xalkori

---

## Products Affected

- XALKORI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) documentation of ALK or ROS1 mutation status
<b>Age Restrictions</b>	Deny if less than 18 years of age for NSCLC. Deny if less than 1 year of age or greater than 21 years of age for ALCL.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xcopri

---

## Products Affected

- **XCOPRI 150MG X1)**
- **XCOPRI MAINTENANCE PACK ORAL • XCOPRI TITRATION PACK  
TABLET 250MG/DAY(150 MG X1-  
100MG X1), 350 MG/DAY (200 MG X1-**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Xdemvy

---

## Products Affected

- XDEMVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis confirmed by identification of Demodex infection via microscopic examination of pulled eyelashes -OR- identification of collarettes via slit-lamp evaluation.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xeljanz

## Products Affected

- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. Xeljanz immediate release for juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID).
<b>Age Restrictions</b>	Deny if less than 18 years of age for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis. For Xeljanz regular release tablet, deny if less than 2 years of age for juvenile idiopathic arthritis
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day for Xeljanz and 11 mg per day for Xeljanz XR will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day for Xeljanz and 22 mg per day for Xeljanz XR will not be approved for ulcerative colitis.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xeljanz Solution

---

## Products Affected

- XELJANZ ORAL SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage.
<b>Age Restrictions</b>	Deny if less than 2 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xenazine

---

## Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*
- **XENAZINE ORAL TABLET 12.5 MG, 25 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- if requesting brand Xenazine, trial and failure or intolerance to generic tetrabenazine has been documented - AND- attestation that the beneficiary is not actively suicidal
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	In patients with comorbid depression, attestation of adequate treatment for depression is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xermelo

---

## Products Affected

- XERMELO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	3 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in average number of daily bowel movements -AND- the member will continue to use in combination with a somatostatin analog.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xgeva

---

## Products Affected

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xifaxan

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline).
Age Restrictions	Deny if less than 18 years of age
Prescriber Restrictions	
Coverage Duration	Hepatic encephalopathy: 1 year. IBS-D: 14 days.
Other Criteria	No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

# Xolair

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of chronic idiopathic urticaria with trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g., cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine) -OR- Documentation of moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen -AND- Baseline IgE titer greater than or equal to 30 IU/mL -AND- symptoms that are inadequately controlled despite a 3 month trial of both 1. and 2. 1) medium-dose inhaled corticosteroid or systemic steroid 2) a long-acting beta-agonist or leukotriene antagonist - AND- patient is currently on a long-acting beta2-agonist, leukotriene modifier, or theophylline -OR- Documentation of add-on maintenance treatment for nasal polyps -AND- trial & failure, intolerance or contraindication to intra-nasal corticosteroids
<b>Age Restrictions</b>	Deny if less than 12 years of age in treatment for chronic idiopathic urticaria -OR- deny if less than 6 years of age for severe persistent asthma -OR- deny if less than 18 years of age for nasal polyps
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For reauthorization, attestation of decreased rescue medication or oral corticosteroid use, decreased frequency of asthma exacerbations, increased pulmonary function from baseline (e.g. FEV1), or reduction in reported asthma related symptoms in treatment of asthma -OR- improved symptoms in treatment of CIU -OR- reduction in nasal polyp score or nasal congestion/obstruction severity score in treatment of nasal polyps.
<b>Indications</b>	All FDA-approved Indications.



<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xospata

---

## Products Affected

- XOSPATA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- FLT3 mutations, if applicable to diagnosis
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xpovio

## Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for relapse or refractory multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xtandi

---

## Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- one of the following (1. or 2.): 1. Concomitant GnRH analog 2. The member has had a bilateral orchiectomy
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xuriden

---

## Products Affected

- XURIDEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of hereditary orotic aciduria
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xyrem

## Products Affected

- *sodium oxybate*
- **XYREM**

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.</p>
<b>Age Restrictions</b>	Deny if less than 7 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	<p>If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Xywav

## Products Affected

- XYWAV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP -AND- Sensitivity to sodium intake due to heart failure, hypertension or impaired renal function. If the member has a diagnosis of cataplexy, provision of baseline number of cataplexy episodes is required. -OR- (II) Diagnosis of idiopathic hypersomnia - AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- documentation the member does not have cataplexy -AND- documentation of less than 2 SOREMPs -AND- documentation of the following (1, 2, or 3): 1) MSLT documenting MSL less than or equal to 8 minutes -OR- 2) polysomnography demonstrating total sleep time greater than or equal to 660 minutes per 24 hours -OR- 3) wrist actigraphy demonstrating total sleep time greater than or equal to 660 minutes per 24 hours.</p>
<b>Age Restrictions</b>	For narcolepsy, deny if less than 7 years of age. For idiopathic hypersomnia, deny if less than 18 years of age.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	If diagnosis of narcolepsy without cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy, idiopathic hypersomnia and cataplexy (if applicable) is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Yonsa

---

## Products Affected

- YONSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following: 1) Alternatives tried/failed 2) Concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zavesca

## Products Affected

- *miglustat*
- ZAVESCA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of mild to moderate type 1 Gaucher disease confirmed by the following (A. or B.) A. (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm <sup>3</sup> -OR- 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B. Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Attestation enzyme replacement therapy (e.g. Cerezyme, Elelyso, or VPRIV) is not a therapeutic option. For brand Zavesca, documentation of failure on generic miglustat.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zavzpret

---

## Products Affected

- ZAVZPRET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of acute migraine headaches with or without aura -AND- Therapeutic failure, contraindication or intolerance to one generic triptan -AND- Inability to swallow capsules/tablets
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 months initial authorization, 12 months reauthorization
<b>Other Criteria</b>	For reauthorization, attestation of reduction in migraine symptoms.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zejula

---

## Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRCA status 2) Alternatives tried/failed
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zelboraf

---

## Products Affected

- **TAFINLAR ORAL CAPSULE**
- **TAFINLAR ORAL TABLET FOR SUSPENSION**
- **ZELBORAF**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Wild-type BRAF melanoma
<b>Required Medical Information</b>	Documentation of diagnosis -AND- both of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed and concomitant therapy, if applicable to diagnosis (e.g. diagnosis of V600K metastatic melanoma and drug regimen of Zelboraf and Cotellic)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For Tafinlar tablets for oral suspension, attestation of inability to swallow Tafinlar capsules is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zepatier

---

## Products Affected

- ZEPATIER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir.
<b>Age Restrictions</b>	Deny if less than 12 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Criteria/duration applied consistent with current AASLD-IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zeposia

---

## Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri.
<b>Required Medical Information</b>	Documentation of diagnosis. For moderate to severe active ulcerative colitis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Ulcerative Colitis: 12 months, Multiple Sclerosis: 24 months
<b>Other Criteria</b>	For moderate to severe active ulcerative colitis, patients must have therapeutic failure or intolerance to 2 of the following preferred products Humira, Xeljanz/Xeljanz XR and Stelara SC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zokinvy

---

## Products Affected

- ZOKINVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of Hutchinson-Gilford Progeria Syndrome with mutation of the LMNA gene and BSA of 0.39 square meters or above -OR- Documentation of processing-deficient Progeroid Laminopathies with BSA of 0.39 square meters or above -AND- one of the following (1 or 2): 1) Heterozygous LMNA mutation and progerin-like protein accumulation 2.) Homozygous ZMPSTE24 mutations or compound heterozygous ZMPSTE23 mutations
<b>Age Restrictions</b>	Deny if less than 12 months of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Zolinza

---

## Products Affected

- ZOLINZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin)
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zolpidem Capsule

## Products Affected

- *zolpidem*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Diagnosis of insomnia characterized by difficulties with sleep onset - AND- therapeutic failure or intolerance to 2 of the following (1-3): 1) eszopiclone, 2) zaleplon, 3) generic zolpidem tablets/zolpidem ER tablets. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators.
<b>Age Restrictions</b>	Deny if greater than 64 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zonisade

---

## Products Affected

- ZONISADE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of partial-onset seizures -AND- Documentation of adjunctive therapy -AND- Inability to swallow capsules -AND- Therapeutic failure/intolerance to 2 or contraindication to all of the following (1-3): 1) generic carbamazepine suspension/chewable tablet/extended-release capsule, 2) generic lacosamide solution, 3) generic oxcarbazepine suspension.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zoryve

---

## Products Affected

- ZORYVE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Ztalmy

---

## Products Affected

- ZTALMY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of seizures associated with CDKL5 deficiency confirmed by genetic testing -AND- therapeutic failure or intolerance to 2 previous antiepileptic therapies
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZTLido

---

## Products Affected

- ZTLIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of postherpetic neuralgia (PHN) -AND- One of the following (1,2 or 3): 1) trial and failure of 1 other agent used to treat PHN (e.g. gabapentin) 2) Inability to swallow oral medication 3) Unable to take an oral medication due to potential adverse events (e.g. sedation)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Patients must have therapeutic failure or contraindication to Lidoderm or lidocaine patch 5%.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zydelig

---

## Products Affected

- ZYDELIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	First line treatment. Combination use with benadmustine and/or rituximab for the treatment of FL.
<b>Required Medical Information</b>	Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Candidacy for use of rituximab alone
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# Zykadia

---

## Products Affected

- ZYKADIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test.
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# Zytiga

---

## Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ZYTIGA ORAL TABLET 250 MG, 500 MG**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of diagnosis -AND- concomitant therapy
<b>Age Restrictions</b>	Deny if less than 18 years of age
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	For brand Zytiga, trial and failure of generic abiraterone is required.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

## Index of Drugs

<b>ABILIFY MYCITE MAINTENANCE KIT ORAL TABLET WITH SENSOR AND STRIP 15 MG, 2 MG, 20 MG, 30 MG, 5 MG</b> .....	27	<i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg</i> .....	296
<b>ABILIFY MYCITE STARTER KIT ORAL TABLET WITH SENSOR, STRIP, POD 10 MG</b> .....	27	<i>alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> .....	296
<b>ABILIFY ORAL TABLET</b> .....	27	<b>ALTRENO</b> .....	400
<i>abiraterone oral tablet 250 mg, 500 mg</i> .....	474	<b>ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG</b> .....	18
<i>acetaminophen-caff-dihydrocod oral capsule</i> .....	296	<b>ALUNBRIG ORAL TABLETS, DOSE PACK</b> .....	18
<i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> .....	296	<b>ALYQ</b> .....	306
<i>acetaminophen-codeine oral tablet</i> .....	296	<b>AMBIEN</b> .....	296
<i>acitretin</i> .....	1	<b>AMBIEN CR</b> .....	296
<b>ACTEMRA ACTPEN</b> .....	2	<i>ambrisentan</i> .....	306
<b>ACTEMRA SUBCUTANEOUS</b> .....	2	<i>amitriptyline</i> .....	154
<b>ACTHAR</b> .....	3	<i>amitriptyline-chlordiazepoxide</i> .....	154
<b>ACTIMMUNE</b> .....	5	<b>AMJEVITA(CF) AUTOINJECTOR</b> .....	159
<i>adalimumab-fkjp</i> .....	6	<b>AMJEVITA(CF) SUBCUTANEOUS SYRINGE 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML</b> .....	159
<i>adapalene topical cream</i> .....	400	<i>amphetamine sulfate</i> .....	114
<i>adapalene topical gel 0.3 %</i> .....	400	<b>AMPYRA</b> .....	20
<i>adapalene topical swab</i> .....	400	<b>ANAFRANIL</b> .....	154
<i>adapalene-benzoyl peroxide</i> .....	400	<b>ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP</b> .....	388
<b>ADBRY</b> .....	8	<b>APOKYN</b> .....	22
<b>ADCIRCA</b> .....	306	<i>apomorphine</i> .....	22
<b>ADEMPAS</b> .....	306	<b>ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG</b> .....	17
<b>ADLARITY</b> .....	10	<b>ARAZLO</b> .....	382
<b>AFINITOR</b> .....	11	<b>ARCALYST</b> .....	178
<b>AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG</b> .....	11	<b>ARIKAYCE</b> .....	23
<b>AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML</b> .....	12	<i>aripiprazole</i> .....	27
<b>AIRDUO DIGIHALER</b> .....	13	<i>armodafinil</i> .....	255
<b>AJOVY AUTOINJECTOR</b> .....	14	<b>ARMONAIR DIGIHALER</b> .....	24
<b>AJOVY SYRINGE</b> .....	14	<b>ASCOMP WITH CODEINE</b> .....	296
<b>AKLIEF</b> .....	400	<b>ASPRUZYO SPRINKLE</b> .....	25
<b>ALECENSA</b> .....	15	<b>ATORVALIQ</b> .....	355
<b>ALKINDI SPRINKLE</b> .....	16	<b>ATRALIN</b> .....	400
<i>alosetron oral tablet 0.5 mg, 1 mg</i> .....	214	<b>AUBAGIO</b> .....	28
<b>ALPRAZOLAM INTENSOL</b> .....	296	<b>AURYXIA</b> .....	29
<i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> .....	296	<b>AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG</b> .....	30
		<b>AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG, 24 MG, 6 MG</b> .....	30

<b>AUSTEDO XR TITRATION KT(WK1-4)</b> .....	30	<b>CARAC</b> .....	59
<b>AUVELITY</b> .....	31	<b>CARBAGLU</b> .....	60
<b>AVEED</b> .....	388	<i>carbinoxamine maleate oral liquid</i> .....	61
<b>AYVAKIT</b> .....	32	<i>carbinoxamine maleate oral tablet 4 mg</i> .....	61
<i>baclofen oral suspension</i> .....	128	<i>carglumic acid</i> .....	60
<b>BAFIERTAM</b> .....	33	<i>carisoprodol</i> .....	154
<b>BALVERSA</b> .....	34	<b>CAYSTON</b> .....	62
<b>BANZEL</b> .....	35	<b>CERDELGA</b> .....	63
<b>BELBUCA</b> .....	36	<b>CHENODAL</b> .....	65
<b>BENLYSTA SUBCUTANEOUS</b> .....	38	<i>chlorzoxazone</i> .....	154
<i>benznidazole</i> .....	40	<b>CHOLBAM</b> .....	66
<i>benztropine oral</i> .....	154	<b>CIALIS ORAL TABLET 2.5 MG, 5 MG</b> .....	67
<b>BERINERT INTRAVENOUS KIT</b> .....	41	<b>CIBINQO</b> .....	68
<b>BESREMI</b> .....	43	<b>CIMZIA</b> .....	69
<b>BETHKIS</b> .....	64	<b>CIMZIA POWDER FOR RECONST</b> .....	69
<i>bexarotene oral</i> .....	375	<b>CINRYZE</b> .....	71
<i>bexarotene topical</i> .....	375	<i>citalopram oral capsule</i> .....	73
<b>BIVIGAM</b> .....	166	<i>clemastine oral syrup</i> .....	74
<b>BONJESTA</b> .....	44	<i>clindamycin-tretinoin</i> .....	400
<i>bosentan</i> .....	306	<i>clobazam oral suspension</i> .....	263
<b>BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG</b> .....	45	<i>clobazam oral tablet</i> .....	263
<b>BRAFTOVI ORAL CAPSULE 75 MG</b> .....	46	<i>clomipramine</i> .....	154
<b>BRONCHITOL</b> .....	47	<i>clonidine hcl oral tablet extended release 12 hr</i> .....	9
<b>BRUKINSA</b> .....	48	<i>codeine sulfate</i> .....	296
<b>BUPHENYL</b> .....	49	<i>codeine-butalbital-asa-caff</i> .....	296
<i>buprenorphine</i> .....	50	<b>COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY)</b> .....	75
<i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg</i> .....	296	<b>CONZIP</b> .....	296
<b>BUTRANS</b> .....	50	<b>COPIKTRA</b> .....	76
<b>BYDUREON BCISE</b> .....	140	<b>CORLANOR ORAL SOLUTION</b> .....	77
<b>BYETTA</b> .....	140	<b>CORLANOR ORAL TABLET 5 MG, 7.5 MG</b> .....	77
<b>BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG</b> .....	52	<b>CORTROPHIN GEL</b> .....	309
<b>BYLVAY ORAL PELLETT 200 MCG, 600 MCG</b> .....	52	<b>COSENTYX (2 SYRINGES)</b> .....	78
<b>CABLIVI INJECTION KIT</b> .....	53	<b>COSENTYX PEN (2 PENS)</b> .....	78
<b>CABOMETYX</b> .....	54	<b>COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML</b> .....	78
<b>CALQUENCE</b> .....	55	<b>COSENTYX UNOREADY PEN</b> .....	78
<b>CALQUENCE (ACALABRUTINIB MAL)</b> .....	55	<b>COTELLIC</b> .....	79
<b>CAMZYOS</b> .....	56	<b>CRINONE</b> .....	80
<b>CAPLYTA</b> .....	57	<b>CUVRIOR</b> .....	81
<b>CAPRELSA ORAL TABLET 100 MG, 300 MG</b> .....	58	<b>CYLTEZO(CF)</b> .....	159
		<b>CYLTEZO(CF) PEN</b> .....	159

<b>CYLTEZO(CF) PEN CROHN'S-UC-HS</b>	<i>droxidopa oral capsule 100 mg, 200 mg,</i>
..... 159	<i>300 mg</i> ..... 247
<b>CYLTEZO(CF) PEN PSORIASIS-UV</b> .. 159	<b>DUEXIS</b> ..... 94
<i>ciproheptadine</i> ..... 154	<b>DUOBRII</b> .....96
<b>CYSTADROPS</b> ..... 82	<b>DUPIXENT PEN SUBCUTANEOUS</b>
<b>CYSTARAN</b> ..... 82	<b>PEN INJECTOR 200 MG/1.14 ML, 300</b>
<i>dalfampridine</i> ..... 20	<b>MG/2 ML</b> .....97
<b>DARTISLA</b> ..... 84	<b>DUPIXENT SYRINGE</b>
<b>DAURISMO ORAL TABLET 100 MG,</b>	<b>SUBCUTANEOUS SYRINGE 100</b>
<b>25 MG</b> ..... 85	<b>MG/0.67 ML, 200 MG/1.14 ML, 300</b>
<b>DAYBUE</b> ..... 86	<b>MG/2 ML</b> .....97
<b>DAYTRANA</b> ..... 87	<b>EDLUAR</b> ..... 296
<i>deferasirox</i> ..... 88	<b>EGRIFTA SV</b> ..... 100
<i>deferiprone</i> ..... 120	<b>EMFLAZA</b> ..... 101
<b>DEMEROL (PF) INJECTION</b>	<b>EMGALITY PEN</b> ..... 102
<b>SYRINGE 25 MG/ML</b> ..... 296	<b>EMGALITY SYRINGE</b>
<b>DEMEROL INJECTION SOLUTION</b>	<b>SUBCUTANEOUS SYRINGE 120</b>
<b>50 MG/ML</b> .....296	<b>MG/ML, 300 MG/3 ML (100 MG/ML X</b>
<b>DEPO-TESTOSTERONE</b> ..... 388	<b>3)</b> ..... 102
<b>DIACOMIT ORAL CAPSULE 250 MG,</b>	<b>ENBREL MINI</b> ..... 104
<b>500 MG</b> ..... 89	<b>ENBREL SUBCUTANEOUS</b>
<b>DIACOMIT ORAL POWDER IN</b>	<b>SOLUTION</b> ..... 104
<b>PACKET 250 MG, 500 MG</b> ..... 89	<b>ENBREL SUBCUTANEOUS SYRINGE</b>
<b>DIBENZYLINE</b> ..... 288	<b>25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)</b> 104
<b>DICLEGIS</b> .....44	<b>ENBREL SURECLICK</b> ..... 104
<i>diclofenac epolamine</i> ..... 127	<b>ENDARI</b> ..... 105
<i>diclofenac sodium topical gel 3 %</i> ..... 350	<b>ENDOCET</b> ..... 296
<b>DIFFERIN TOPICAL CREAM</b> .....400	<b>ENSPRYNG</b> ..... 106
<b>DIFFERIN TOPICAL GEL WITH</b>	<b>ENTADFI</b> ..... 107
<b>PUMP</b> .....400	<b>EPCLUSA ORAL PELLETS IN</b>
<b>DIFFERIN TOPICAL LOTION</b> .....400	<b>PACKET 150-37.5 MG, 200-50 MG</b> ..... 108
<i>dihydroergotamine nasal</i> ..... 90	<b>EPCLUSA ORAL TABLET</b> ..... 108
<b>DILAUDID ORAL LIQUID</b> ..... 296	<b>EPIDIOLEX</b> ..... 109
<b>DILAUDID ORAL TABLET</b> ..... 296	<b>EPIDUO FORTE</b> .....400
<i>dimethyl fumarate oral capsule, delayed</i>	<b>EPIDUO TOPICAL GEL WITH PUMP</b>
<i>release(dr/ec) 120 mg, 120 mg (14)- 240</i>	..... 400
<i>mg (46), 240 mg</i> ..... 385	<b>EPRONTIA</b> ..... 110
<b>DOJOLVI</b> ..... 91	<i>ergoloid</i> ..... 154
<b>DOPTELET (10 TAB PACK)</b> ..... 92	<i>ergotamine-caffeine</i> ..... 154
<b>DOPTELET (15 TAB PACK)</b> ..... 92	<b>ERIVEDGE</b> ..... 111
<b>DOPTELET (30 TAB PACK)</b> ..... 92	<b>ERLEADA ORAL TABLET 240 MG,</b>
<i>doxepin oral capsule</i> ..... 154	<b>60 MG</b> ..... 112
<i>doxepin oral concentrate</i> ..... 154	<i>erlotinib</i> ..... 99
<i>doxepin oral tablet</i> ..... 154	<b>ESBRIET ORAL CAPSULE</b> ..... 180
<i>doxepin topical</i> ..... 93	<b>ESBRIET ORAL TABLET 267 MG,</b>
<i>doxylamine-pyridoxine (vit b6)</i> ..... 44	<b>801 MG</b> ..... 180

<i>eszopiclone</i> .....	296	<b>FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %</b> .....	166
<b>EUCRISA</b> .....	113	<b>FLECTOR</b> .....	127
<b>EVEKEO</b> .....	114	<b>FLEQSUVY</b> .....	128
<b>EVENTY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2)</b> .....	115	<b>FORTEO</b> .....	129
<i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> .....	11	<b>FORTESTA</b> .....	388
<i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> .....	11	<b>FOTIVDA</b> .....	130
<b>EVRYSDI</b> .....	116	<b>FUROSCIX</b> .....	131
<b>EXJADE</b> .....	88	<i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> .....	132
<b>EXKIVITY</b> .....	99	<i>gabapentin oral solution 250 mg/5 ml</i> .....	132
<b>EXSERVAN</b> .....	117	<i>gabapentin oral tablet 600 mg, 800 mg</i> .....	132
<b>FABIOR</b> .....	382	<b>GALAFOLD</b> .....	133
<b>FASENRA</b> .....	118	<b>GAMMAGARD LIQUID</b> .....	166
<b>FASENRA PEN</b> .....	118	<b>GAMMAGARD S-D (IGA &lt; 1 MCG/ML)</b> .....	166
<i>febuxostat</i> .....	408	<b>GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)</b> .....	166
<i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> .....	398	<b>GAMMAPLEX</b> .....	166
<i>fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> .....	398	<b>GAMMAPLEX (WITH SORBITOL)</b> .....	166
<i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour</i> .....	296	<b>GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)</b> .....	166
<b>FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG</b> .....	398	<b>GATTEX 30-VIAL</b> .....	134
<b>FERRIPROX (2 TIMES A DAY)</b> .....	120	<b>GAVRETO</b> .....	135
<b>FERRIPROX ORAL SOLUTION</b> .....	120	<i>gefitinib</i> .....	182
<b>FERRIPROX ORAL TABLET 500 MG</b> .....	120	<b>GENOTROPIN</b> .....	145
<b>FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK</b> .....	121	<b>GENOTROPIN MINIQUICK</b> .....	145
<b>FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG</b> .....	121	<b>GILENYA</b> .....	136
<b>FILSPARI</b> .....	122	<b>GILOTRIF</b> .....	99
<i>fingolimod</i> .....	136	<b>GIMOTI</b> .....	137
<b>FINTEPLA</b> .....	123	<b>GLASSIA</b> .....	17
<b>FIORICET WITH CODEINE</b> .....	296	<b>GLEEVEC ORAL TABLET 100 MG, 400 MG</b> .....	138
<b>FIRAZYR</b> .....	124	<b>GLEOSTINE</b> .....	139
<b>FIRDAPSE</b> .....	126	<b>GLYCATE</b> .....	141
		<i>glycopyrrolate oral tablet 1.5 mg</i> .....	141
		<b>GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG, 68.5 MG</b> .....	142
		<b>GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 450 MG, 600 MG, 750 MG, 900 MG</b> .....	143
		<b>GRASTEK</b> .....	144
		<i>guanfacine oral tablet extended release 24 hr</i> .....	9
		<b>HADLIMA</b> .....	6

<b>HADLIMA PUSHTOUCH</b> .....	6	<i>hydromorphone (pf) injection solution 10</i>	
<b>HADLIMA(CF)</b> .....	6	<i>(mg/ml) (5 ml), 10 mg/ml</i> .....	296
<b>HADLIMA(CF) PUSHTOUCH</b> .....	6	<i>hydromorphone oral liquid</i> .....	296
<b>HAEGARDA</b> .....	147	<i>hydromorphone oral tablet</i> .....	296
<b>HALCION ORAL TABLET 0.25 MG</b> ...	296	<i>hydromorphone oral tablet extended</i>	
<b>HARVONI ORAL PELLETS IN</b>		<i>release 24 hr 12 mg, 16 mg, 32 mg, 8 mg</i> ...	296
<b>PACKET</b> .....	149	<i>hydroxyzine hcl oral solution 10 mg/5 ml</i> ..	154
<b>HARVONI ORAL TABLET 90-400 MG</b>		<i>hydroxyzine hcl oral tablet</i> .....	154
.....	149	<i>hydroxyzine pamoate</i> .....	154
<b>HEMADY</b> .....	150	<b>HYFTOR</b> .....	161
<b>HETLIOZ</b> .....	151	<b>HYRIMOZ PEN CROHN'S-UC</b>	
<b>HETLIOZ LQ</b> .....	153	<b>STARTER</b> .....	159
<b>HORIZANT ORAL TABLET</b>		<b>HYRIMOZ PEN PSORIASIS</b>	
<b>EXTENDED RELEASE 300 MG, 600</b>		<b>STARTER</b> .....	159
<b>MG</b> .....	158	<b>HYRIMOZ(CF) PEDI CROHN</b>	
<b>HULIO(CF)</b> .....	6	<b>STARTER</b> .....	159
<b>HULIO(CF) PEN</b> .....	6	<b>HYRIMOZ(CF) PEN</b>	
<b>HUMATROPE INJECTION</b>		<b>SUBCUTANEOUS PEN INJECTOR 40</b>	
<b>CARTRIDGE</b> .....	145	<b>MG/0.4 ML, 80 MG/0.8 ML</b> .....	159
<b>HUMIRA PEN</b> .....	159	<b>HYRIMOZ(CF) SUBCUTANEOUS</b>	
<b>HUMIRA PEN CROHNS-UC-HS</b>		<b>SYRINGE 10 MG/0.1 ML, 20 MG/0.2</b>	
<b>START</b> .....	159	<b>ML, 40 MG/0.4 ML</b> .....	159
<b>HUMIRA PEN PSOR-UVEITS-ADOL</b>		<b>HYSINGLA ER</b> .....	296
<b>HS</b> .....	159	<b>IBRANCE</b> .....	162
<b>HUMIRA SUBCUTANEOUS</b>		<b>IBSRELA</b> .....	163
<b>SYRINGE KIT 40 MG/0.8 ML</b> .....	159	<i>ibuprofen-famotidine</i> .....	95
<b>HUMIRA(CF)</b> .....	159	<i>icatibant</i> .....	124
<b>HUMIRA(CF) PEDI CROHNS</b>		<b>ICLUSIG</b> .....	164
<b>STARTER SUBCUTANEOUS</b>		<b>IDHIFA ORAL TABLET 100 MG, 50</b>	
<b>SYRINGE KIT 80 MG/0.8 ML, 80</b>		<b>MG</b> .....	165
<b>MG/0.8 ML-40 MG/0.4 ML</b> .....	159	<b>ILUMYA</b> .....	168
<b>HUMIRA(CF) PEN</b> .....	159	<i>imatinib oral tablet 100 mg, 400 mg</i> .....	138
<b>HUMIRA(CF) PEN CROHNS-UC-HS</b> ..	159	<b>IMBRUVICA ORAL CAPSULE 140</b>	
<b>HUMIRA(CF) PEN PEDIATRIC UC</b> ....	159	<b>MG, 70 MG</b> .....	169
<b>HUMIRA(CF) PEN PSOR-UV-ADOL</b>		<b>IMBRUVICA ORAL SUSPENSION</b> ....	169
<b>HS</b> .....	159	<b>IMBRUVICA ORAL TABLET 140 MG,</b>	
<i>hydrocodone bitartrate oral capsule, oral</i>		<b>280 MG, 420 MG</b> .....	169
<i>only, er 12hr</i> .....	296	<i>imipramine hcl</i> .....	154
<i>hydrocodone bitartrate oral tablet,oral</i>		<i>imipramine pamoate</i> .....	154
<i>only,ext.rel.24 hr</i> .....	296	<b>INBRIJA INHALATION CAPSULE,</b>	
<i>hydrocodone-acetaminophen oral solution</i>		<b>W/INHALATION DEVICE</b> .....	170
<i>7.5-325 mg/15 ml</i> .....	296	<b>INCRELEX</b> .....	171
<i>hydrocodone-acetaminophen oral tablet</i>		<b>INGREZZA INITIATION PACK</b> .....	173
<i>10-300 mg, 10-325 mg, 5-300 mg, 5-325</i>		<b>INGREZZA ORAL CAPSULE 40 MG,</b>	
<i>mg, 7.5-300 mg, 7.5-325 mg</i> .....	296	<b>60 MG, 80 MG</b> .....	173
<i>hydrocodone-ibuprofen</i> .....	296	<b>INLYTA</b> .....	174

<b>INQOVI</b> .....	175	<b>KRAZATI</b> .....	199
<b>INREBIC</b> .....	176	<b>KUVAN</b> .....	200
<b>INTRAROSA</b> .....	179	<b>LAMPIT</b> .....	201
<b>INTUNIV ER</b> .....	9	<i>lapatinib</i> .....	404
<b>IRESSA</b> .....	182	<b>LATUDA ORAL TABLET 120 MG, 20</b>	
<b>ISTURISA ORAL TABLET 1 MG, 10</b>		<b>MG, 40 MG, 60 MG, 80 MG</b> .....	202
<b>MG, 5 MG</b> .....	183	<i>ledipasvir-sofosbuvir</i> .....	149
<i>itraconazole</i> .....	184	<i>lenalidomide</i> .....	327
<i>ivermectin oral</i> .....	185	<b>LENVIMA</b> .....	203
<b>JADENU</b> .....	88	<b>LETAIRIS</b> .....	306
<b>JADENU SPRINKLE</b> .....	88	<b>LEUKINE INJECTION RECON SOLN</b>	
<b>JAKAFI</b> .....	186	.....	204
<b>JATENZO ORAL CAPSULE 158 MG,</b>		<i>levorphanol tartrate</i> .....	296
<b>198 MG, 237 MG</b> .....	388	<b>LICART</b> .....	127
<b>JAVYGTOR</b> .....	200	<i>lidocaine hcl mucous membrane solution 4</i>	
<b>JAYPIRCA ORAL TABLET 100 MG,</b>		<i>% (40 mg/ml)</i> .....	397
<b>50 MG</b> .....	187	<i>lidocaine topical adhesive patch,medicated</i>	
<b>JUXTAPID</b> .....	157	<i>5 %</i> .....	206
<b>JYNARQUE ORAL TABLET</b> .....	188	<i>lidocaine topical ointment</i> .....	397
<b>JYNARQUE ORAL TABLETS,</b>		<i>lidocaine-prilocaine topical cream</i> .....	397
<b>SEQUENTIAL</b> .....	188	<b>LIDODERM</b> .....	206
<b>KALYDECO ORAL GRANULES IN</b>		<b>LIQREV</b> .....	306
<b>PACKET 13.4 MG, 25 MG, 50 MG, 75</b>		<b>LITFULO</b> .....	207
<b>MG</b> .....	189	<b>LIVMARLI</b> .....	208
<b>KALYDECO ORAL TABLET</b> .....	189	<b>LIVTENCITY</b> .....	209
<b>KAPVAY</b> .....	9	<b>LODOCO</b> .....	210
<b>KATERZIA</b> .....	19	<b>LOKELMA</b> .....	211
<b>KERENDIA</b> .....	190	<b>LONSURF</b> .....	212
<b>KESIMPTA PEN</b> .....	191	<b>LORBRENA ORAL TABLET 100 MG,</b>	
<b>KEVEYIS</b> .....	192	<b>25 MG</b> .....	213
<b>KEVZARA</b> .....	193	<b>LORZONE</b> .....	154
<b>KINERET</b> .....	194	<b>LOTRONEX ORAL TABLET 0.5 MG,</b>	
<b>KISQALI FEMARA CO-PACK ORAL</b>		<b>1 MG</b> .....	214
<b>TABLET 200 MG/DAY(200 MG X 1)-</b>		<b>LOVAZA</b> .....	215
<b>2.5 MG, 400 MG/DAY(200 MG X 2)-2.5</b>		<b>LUMAKRAS ORAL TABLET 120 MG,</b>	
<b>MG, 600 MG/DAY(200 MG X 3)-2.5</b>		<b>320 MG</b> .....	216
<b>MG</b> .....	195	<b>LUMRYZ</b> .....	217
<b>KISQALI ORAL TABLET 200</b>		<b>LUNESTA</b> .....	296
<b>MG/DAY (200 MG X 1), 400 MG/DAY</b>		<b>LUPKYNIS</b> .....	218
<b>(200 MG X 2), 600 MG/DAY (200 MG X</b>		<b>LUPRON DEPOT-PED (3 MONTH)</b>	
<b>3)</b> .....	195	<b>INTRAMUSCULAR SYRINGE KIT</b>	
<b>KITABIS PAK</b> .....	64	<b>11.25 MG</b> .....	219
<b>KLISYRI</b> .....	196		
<b>KORLYM</b> .....	197		
<b>KOSELUGO ORAL CAPSULE 10 MG,</b>			
<b>25 MG</b> .....	198		

<b>LUPRON DEPOT-PED INTRAMUSCULAR KIT 7.5 MG (PED)</b> .....	219	<i>metaxalone</i> .....	154
<b>LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT</b> .....	219	<i>methadone oral solution 10 mg/5 ml, 5 mg/5 ml</i> .....	296
<i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> .....	202	<i>methadone oral tablet 10 mg, 5 mg</i> .....	296
<b>LYBALVI</b> .....	220	<i>methamphetamine</i> .....	231
<b>LYNPARZA</b> .....	221	<b>METHITEST</b> .....	21
<b>LYRICA CR</b> .....	222	<i>methyltestosterone oral capsule</i> .....	21
<b>LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG</b> .....	222	<i>miglustat</i> .....	459
<b>LYRICA ORAL SOLUTION</b> .....	222	<b>MIGRANAL</b> .....	90
<b>LYTGOBI ORAL TABLET 4 MG, 4 MG (4X 4 MG TB), 4 MG (5X 4 MG TB)</b> .....	223	<i>modafinil</i> .....	304
<b>LYVISPAH</b> .....	224	<i>morphine concentrate oral solution</i> .....	296
<b>MAVENCLAD (10 TABLET PACK)</b> .....	225	<i>morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg</i> .....	296
<b>MAVENCLAD (4 TABLET PACK)</b> .....	225	<i>morphine oral capsule, extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg</i> .....	296
<b>MAVENCLAD (5 TABLET PACK)</b> .....	225	<i>morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> .....	296
<b>MAVENCLAD (6 TABLET PACK)</b> .....	225	<i>morphine oral tablet</i> .....	296
<b>MAVENCLAD (7 TABLET PACK)</b> .....	225	<i>morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> .....	296
<b>MAVENCLAD (8 TABLET PACK)</b> .....	225	<b>MOTEGRITY</b> .....	232
<b>MAVENCLAD (9 TABLET PACK)</b> .....	225	<b>MOUNJARO</b> .....	140
<b>MAVYRET ORAL PELLETS IN PACKET</b> .....	226	<b>MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG</b> .....	296
<b>MAVYRET ORAL TABLET</b> .....	226	<b>MULPLETA</b> .....	233
<b>MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG</b> .....	227	<b>MYALEPT</b> .....	234
<b>MAYZENT STARTER(FOR 1MG MAINT)</b> .....	227	<b>MYCAPSSA</b> .....	235
<b>MAYZENT STARTER(FOR 2MG MAINT)</b> .....	227	<b>MYFEMBREE</b> .....	236
<i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> .....	228	<b>NALOCET</b> .....	296
<i>megestrol oral tablet</i> .....	228	<b>NAMENDA ORAL TABLET</b> .....	238
<b>MEKINIST ORAL RECON SOLN</b> .....	229	<b>NAMENDA TITRATION PAK</b> .....	238
<b>MEKINIST ORAL TABLET 0.5 MG, 2 MG</b> .....	229	<b>NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR 14 MG, 21 MG, 28 MG</b> .....	238
<b>MEKTOVI</b> .....	230	<b>NAMZARIC</b> .....	239
<i>meloxicam submicronized</i> .....	426	<i>naproxen-esomeprazole</i> .....	423
<i>meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml</i> .....	296	<b>NATESTO</b> .....	388
<i>meperidine oral solution</i> .....	296	<b>NATPARA</b> .....	240
<i>meperidine oral tablet 50 mg</i> .....	296	<b>NAYZILAM</b> .....	241
		<b>NERLYNX</b> .....	242
		<b>NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG</b> .....	132
		<b>NEURONTIN ORAL SOLUTION</b> .....	132



<b>NEURONTIN ORAL TABLET 600</b>		<b>ORALAIR SUBLINGUAL TABLET</b>	
<b>MG, 800 MG</b> .....	132	<b>300 INDX REACTIVITY</b> .....	267
<b>NEXAVAR</b> .....	243	<b>ORENCIA CLICKJECT</b> .....	268
<b>NEXLETOL</b> .....	244	<b>ORENCIA SUBCUTANEOUS</b>	
<b>NEXLIZET</b> .....	244	<b>SYRINGE 125 MG/ML, 50 MG/0.4 ML,</b>	
<b>NGENLA</b> .....	145	<b>87.5 MG/0.7 ML</b> .....	268
<b>NINLARO</b> .....	246	<b>ORENITRAM MONTH 1 TITRATION</b>	
<b>NORDITROPIN FLEXPPO</b> .....	145	<b>KT</b> .....	306
<b>NORGESIC</b> .....	154	<b>ORENITRAM MONTH 2 TITRATION</b>	
<b>NORGESIC FORTE</b> .....	154	<b>KT</b> .....	306
<b>NORLIQVA</b> .....	19	<b>ORENITRAM MONTH 3 TITRATION</b>	
<b>NORTHERA ORAL CAPSULE 100</b>		<b>KT</b> .....	306
<b>MG, 200 MG, 300 MG</b> .....	247	<b>ORENITRAM ORAL TABLET</b>	
<b>NOURIANZ</b> .....	248	<b>EXTENDED RELEASE 0.125 MG, 0.25</b>	
<b>NUBEQA</b> .....	249	<b>MG, 1 MG, 2.5 MG, 5 MG</b> .....	306
<b>NUCALA SUBCUTANEOUS AUTO-</b>		<b>ORGOVYX</b> .....	269
<b>INJECTOR</b> .....	250	<b>ORIAHNN</b> .....	270
<b>NUCALA SUBCUTANEOUS RECON</b>		<b>ORILISSA ORAL TABLET 150 MG,</b>	
<b>SOLN</b> .....	250	<b>200 MG</b> .....	271
<b>NUCALA SUBCUTANEOUS</b>		<b>ORKAMBI ORAL GRANULES IN</b>	
<b>SYRINGE 100 MG/ML, 40 MG/0.4 ML</b>	250	<b>PACKET 100-125 MG, 150-188 MG</b> .....	273
<b>NUCYNTA</b> .....	296	<b>ORKAMBI ORAL TABLET</b> .....	272
<b>NUCYNTA ER</b> .....	296	<b>ORLADEYO</b> .....	274
<b>NUEDEXTA</b> .....	252	<i>orphenadrine citrate oral</i> .....	154
<b>NUPLAZID</b> .....	253	<i>orphenadrine-asa-caffeine oral tablet 25-</i>	
<b>NURTEC ODT</b> .....	254	<i>385-30 mg</i> .....	154
<b>NUTROPIN AQ NUSPIN</b> .....	145	<b>ORSERDU ORAL TABLET 345 MG,</b>	
<b>NUVIGIL</b> .....	255	<b>86 MG</b> .....	276
<b>OCALIVA</b> .....	257	<b>OSMOLEX ER ORAL TABLET, IR -</b>	
<b>OCTAGAM</b> .....	166	<b>ER, BIPHASIC 24HR 193 MG</b> .....	277
<i>octreotide acetate injection solution</i> .....	258	<b>OSPHERA</b> .....	278
<b>ODACTRA</b> .....	259	<b>OTEZLA</b> .....	279
<b>ODOMZO</b> .....	260	<b>OTEZLA STARTER ORAL</b>	
<b>OFEV</b> .....	180	<b>TABLETS,DOSE PACK 10 MG (4)-20</b>	
<b>OLPRUVA ORAL PELLETS IN</b>		<b>MG (4)-30 MG (47)</b> .....	279
<b>PACKET 2 GRAM, 3 GRAM, 4 GRAM,</b>		<b>OTREXUP (PF)</b> .....	280
<b>5 GRAM, 6 GRAM, 6.67 GRAM</b> .....	261	<b>OXBRYTA ORAL TABLET 300 MG,</b>	
<b>OLUMIANT</b> .....	262	<b>500 MG</b> .....	281
<b>OMNITROPE</b> .....	145	<b>OXBRYTA ORAL TABLET FOR</b>	
<b>ONFI ORAL SUSPENSION</b> .....	263	<b>SUSPENSION</b> .....	282
<b>ONFI ORAL TABLET</b> .....	263	<b>OXERVATE</b> .....	283
<b>ONGENTYS</b> .....	264	<i>oxycodone oral capsule</i> .....	296
<b>ONUREG</b> .....	265	<i>oxycodone oral concentrate</i> .....	296
<b>OPSUMIT</b> .....	306	<i>oxycodone oral solution</i> .....	296
<b>OPZELURA</b> .....	266	<i>oxycodone oral tablet 10 mg, 15 mg, 20</i>	
		<i>mg, 30 mg, 5 mg</i> .....	296

<i>oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg</i> .....	296	<i>pregabalin oral solution</i> .....	222
<i>oxycodone-acetaminophen oral solution 5-325 mg/5 ml</i> .....	296	<i>pregabalin oral tablet extended release 24 hr</i> .....	222
<i>oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg</i> .....	296	<b>PRENATAL VITAMIN PLUS LOW IRON</b> .....	295
<b>OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG</b> .....	296	<i>pretomanid</i> .....	300
<i>oxymorphone oral tablet</i> .....	296	<b>PRIVIGEN</b> .....	166
<i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> .....	296	<b>PROAIR DIGIHALER</b> .....	301
<b>OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML)</b> .....	140	<b>PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET</b> .....	302
<b>PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML</b> .....	284	<b>PROLASTIN-C INTRAVENOUS RECON SOLN</b> .....	17
<b>PANRETIN</b> .....	285	<b>PROLATE ORAL SOLUTION</b> .....	296
<b>PANZYGA</b> .....	166	<b>PROLATE ORAL TABLET</b> .....	296
<b>PEGASYS</b> .....	177	<b>PROLIA</b> .....	303
<b>PEMAZYRE</b> .....	286	<b>PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG</b> .....	392
<b>PERCOCET</b> .....	296	<b>PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG</b> .....	392
<i>perphenazine-amitriptyline</i> .....	154	<i>promethazine oral</i> .....	154
<b>PHEBURANE</b> .....	287	<b>PROVIGIL</b> .....	304
<i>phenobarbital</i> .....	156	<b>PRUDOXIN</b> .....	93
<i>phenoxybenzamine</i> .....	288	<b>PULMOZYME</b> .....	308
<b>PHOSPHOLINE IODIDE</b> .....	289	<i>pyrimethamine</i> .....	83
<b>PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)</b> .....	290	<b>PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG</b> ....	311
<i>pirfenidone oral capsule</i> .....	180	<b>PYRUKYND ORAL TABLETS,DOSE PACK</b> .....	311
<i>pirfenidone oral tablet 267 mg, 534 mg, 801 mg</i> .....	180	<b>QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 150 MG, 200 MG</b> .....	312
<b>PLIAGLIS</b> .....	397	<b>QINLOCK</b> .....	313
<b>POMALYST</b> .....	291	<b>QUALAQUIN</b> .....	314
<b>PONVORY</b> .....	292	<i>quinine sulfate</i> .....	314
<b>PONVORY 14-DAY STARTER PACK</b> .....	292	<b>QULIPTA</b> .....	315
<b>PRALUENT PEN</b> .....	293	<b>RADICAVA ORS STARTER KIT SUSP</b> .....	316
<i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg</i> .....	222	<b>RASUVO (PF)</b> .....	317
		<b>RAVICTI</b> .....	318
		<b>RECORLEV</b> .....	319
		<b>REGRANEX</b> .....	320
		<b>RELISTOR ORAL</b> .....	321
		<b>RELISTOR SUBCUTANEOUS SOLUTION</b> .....	322

<b>RELISTOR SUBCUTANEOUS</b>		<b>SEROSTIM SUBCUTANEOUS</b>	
<b>SYRINGE 12 MG/0.6 ML, 8 MG/0.4</b>		<b>RECON SOLN 4 MG, 5 MG, 6 MG .....</b>	145
<b>ML.....</b>	322	<i>sertraline oral capsule .....</i>	341
<b>RELYVRIO.....</b>	323	<b>SIGNIFOR.....</b>	342
<b>REPATHA PUSHTRONEX.....</b>	324	<i>sildenafil (pulm.hypertension) oral</i>	
<b>REPATHA SURECLICK.....</b>	324	<i>suspension for reconstitution .....</i>	306
<b>REPATHA SYRINGE.....</b>	324	<i>sildenafil (pulm.hypertension) oral tablet..</i>	306
<b>RETEVMO ORAL CAPSULE 40 MG,</b>		<b>SILENOR.....</b>	154
<b>80 MG.....</b>	326	<b>SILIQ.....</b>	343
<b>RETIN-A.....</b>	400	<b>SIMPONI SUBCUTANEOUS PEN</b>	
<b>RETIN-A MICRO.....</b>	400	<b>INJECTOR 100 MG/ML, 50 MG/0.5</b>	
<b>RETIN-A MICRO PUMP TOPICAL</b>		<b>ML.....</b>	344
<b>GEL WITH PUMP 0.06 %, 0.08 %.....</b>	400	<b>SIMPONI SUBCUTANEOUS</b>	
<b>REVATIO ORAL SUSPENSION FOR</b>		<b>SYRINGE 100 MG/ML, 50 MG/0.5 ML</b>	344
<b>RECONSTITUTION.....</b>	306	<b>SKYCLARYS.....</b>	346
<b>REVATIO ORAL TABLET.....</b>	306	<b>SKYRIZI SUBCUTANEOUS PEN</b>	
<b>REVLIMID.....</b>	327	<b>INJECTOR.....</b>	347
<b>REXULTI ORAL TABLET.....</b>	27	<b>SKYRIZI SUBCUTANEOUS</b>	
<b>REZLIDHIA.....</b>	328	<b>SYRINGE 150 MG/ML.....</b>	347
<b>REZUROCK.....</b>	329	<b>SKYRIZI SUBCUTANEOUS</b>	
<b>RINVOQ ORAL TABLET EXTENDED</b>		<b>WEARABLE INJECTOR 180 MG/1.2</b>	
<b>RELEASE 24 HR 15 MG, 30 MG, 45</b>		<b>ML (150 MG/ML), 360 MG/2.4 ML (150</b>	
<b>MG.....</b>	330	<b>MG/ML).....</b>	347
<b>ROXICODONE ORAL TABLET 15</b>		<b>SKYTROFA.....</b>	348
<b>MG, 30 MG.....</b>	296	<i>sodium oxybate.....</i>	455
<b>ROXYBOND.....</b>	296	<i>sodium phenylbutyrate.....</i>	49
<b>ROZLYTREK ORAL CAPSULE 100</b>		<i>sofosbuvir-velpatasvir.....</i>	108
<b>MG, 200 MG.....</b>	332	<b>SOGROYA.....</b>	349
<b>RUBRACA.....</b>	333	<b>SOMA.....</b>	154
<b>RUCONEST.....</b>	334	<b>SOMAVERT.....</b>	351
<i>rufinamide.....</i>	35	<i>sorafenib.....</i>	243
<b>RYBELSUS.....</b>	140	<b>SOTYKTU.....</b>	352
<b>RYDAPT.....</b>	336	<b>SOVALDI.....</b>	353
<b>RYVENT.....</b>	61	<b>SPORANOX.....</b>	184
<b>SABRIL.....</b>	337	<b>SPRYCEL.....</b>	354
<b>SAIZEN.....</b>	145	<b>STELARA SUBCUTANEOUS</b>	
<b>SAJAZIR.....</b>	124	<b>SOLUTION.....</b>	356
<b>SAMSCA.....</b>	338	<b>STELARA SUBCUTANEOUS</b>	
<b>SANDOSTATIN INJECTION</b>		<b>SYRINGE 45 MG/0.5 ML, 90 MG/ML..</b>	356
<b>SOLUTION 100 MCG/ML, 50</b>		<b>STIVARGA.....</b>	358
<b>MCG/ML, 500 MCG/ML.....</b>	258	<b>STROMEKTOL.....</b>	185
<i>sapropterin.....</i>	200	<i>sunitinib malate.....</i>	361
<b>SAVELLA.....</b>	339	<b>SUNOSI.....</b>	359
<b>SCEMBLIX ORAL TABLET 20 MG,</b>		<b>SUTENT.....</b>	361
<b>40 MG.....</b>	340	<b>SYMDEKO.....</b>	362
<b>SEGLENTIS.....</b>	296	<b>SYMPAZAN.....</b>	363

<b>SYMPROIC</b> .....	364	<i>testosterone transdermal gel in packet</i> .....	388
<b>SYNAREL</b> .....	365	<i>testosterone transdermal solution in</i>	
<b>SYNDROS</b> .....	366	<i>metered pump w/app</i> .....	388
<b>TABRECTA</b> .....	367	<i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> ...	445
<i>tadalafil (pulm. hypertension)</i> .....	306	<b>THALOMID ORAL CAPSULE 100</b>	
<i>tadalafil oral tablet 2.5 mg, 5 mg</i> .....	67	<b>MG, 150 MG, 200 MG, 50 MG</b> .....	390
<b>TADLIQ</b> .....	368	<b>THIOLA</b> .....	391
<b>TAFINLAR ORAL CAPSULE</b> .....	462	<b>THIOLA EC</b> .....	391
<b>TAFINLAR ORAL TABLET FOR</b>		<b>TIBSOVO</b> .....	393
<b>SUSPENSION</b> .....	462	<b>TIGLUTIK</b> .....	395
<b>TAGRISSE</b> .....	369	<i>tiopronin</i> .....	391
<b>TAKHZYRO SUBCUTANEOUS</b>		<b>TLANDO</b> .....	388
<b>SOLUTION</b> .....	370	<b>TOBI</b> .....	64
<b>TAKHZYRO SUBCUTANEOUS</b>		<b>TOBI PODHALER</b> .....	64
<b>SYRINGE 150 MG/ML, 300 MG/2 ML</b>		<i>tobramycin in 0.225 % nacl</i> .....	64
<b>(150 MG/ML)</b> .....	370	<i>tobramycin inhalation</i> .....	64
<b>TALTZ AUTOINJECTOR</b> .....	372	<b>TOLSURA</b> .....	396
<b>TALTZ SYRINGE</b> .....	372	<i>tolvaptan</i> .....	338
<b>TALZENNA</b> .....	374	<b>TRACLEER ORAL TABLET</b> .....	306
<b>TARGRETIN ORAL</b> .....	375	<b>TRACLEER ORAL TABLET FOR</b>	
<b>TARGRETIN TOPICAL</b> .....	375	<b>SUSPENSION</b> .....	306
<b>TARPEYO</b> .....	376	<i>tramadol oral capsule, er biphasic 24 hr 17-</i>	
<b>TASCENSO ODT</b> .....	377	<i>83</i> .....	296
<b>TASIGNA</b> .....	378	<i>tramadol oral capsule, er biphasic 24 hr 25-</i>	
<i>tasimelteon</i> .....	379	<i>75 100 mg, 200 mg</i> .....	296
<b>TAVALISSE</b> .....	380	<i>tramadol oral solution</i> .....	296
<b>TAVNEOS</b> .....	381	<i>tramadol oral tablet 100 mg, 50 mg</i> .....	296
<i>tazarotene topical cream</i> .....	383	<i>tramadol oral tablet extended release 24 hr</i>	
<i>tazarotene topical foam</i> .....	382	.....	296
<i>tazarotene topical gel</i> .....	383	<i>tramadol oral tablet, er multiphasic 24 hr</i> ..	296
<b>TAZORAC TOPICAL CREAM</b> .....	383	<i>tramadol-acetaminophen</i> .....	296
<b>TAZORAC TOPICAL GEL</b> .....	383	<b>TREMFYA</b> .....	399
<b>TAZVERIK</b> .....	384	<i>tretinoin</i> .....	400
<b>TECFIDERA ORAL</b>		<i>tretinoin microspheres topical gel</i> .....	400
<b>CAPSULE, DELAYED</b>		<i>tretinoin microspheres topical gel with</i>	
<b>RELEASE(DR/EC) 120 MG, 120 MG</b>		<i>pump 0.08 %</i> .....	400
<b>(14)- 240 MG (46), 240 MG</b> .....	385	<b>TREZIX</b> .....	296
<b>TEGSEDI</b> .....	386	<i>triazolam</i> .....	296
<b>TEPMETKO</b> .....	387	<b>TRIKAFTA ORAL GRANULES IN</b>	
<i>teriflunomide</i> .....	28	<b>PACKET, SEQUENTIAL</b> .....	401
<i>teriparatide</i> .....	129	<b>TRIKAFTA ORAL TABLETS,</b>	
<b>TESTIM</b> .....	388	<b>SEQUENTIAL</b> .....	401
<i>testosterone cypionate</i> .....	388	<i>trimethobenzamide oral</i> .....	394
<i>testosterone enanthate</i> .....	388	<i>trimipramine</i> .....	154
<i>testosterone transdermal gel in metered-</i>		<b>TRUDHESA</b> .....	90
<i>dose pump</i> .....	388	<b>TRULICITY</b> .....	140

<b>TUKYSA ORAL TABLET 150 MG, 50 MG</b> .....	402	<b>VISTARIL</b> .....	154
<b>TURALIO ORAL CAPSULE 125 MG</b> ..	403	<b>VITRAKVI ORAL CAPSULE 100 MG, 25 MG</b> .....	424
<b>TWYNEO</b> .....	400	<b>VITRAKVI ORAL SOLUTION</b> .....	424
<b>TYKERB</b> .....	404	<b>VIVJOA</b> .....	425
<b>TYMLOS</b> .....	405	<b>VIZIMPRO</b> .....	427
<b>TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16 MCG (112)- 32 MCG (84), 16(112)-32(112) -48(28) MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG</b> .....	406	<b>VOGELXO TRANSDERMAL GEL</b> .....	388
<b>UBRELVY ORAL TABLET 100 MG, 50 MG</b> .....	407	<b>VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP</b> .....	388
<b>ULORIC</b> .....	408	<b>VONJO</b> .....	428
<b>UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG</b> .....	306	<i>voriconazole intravenous</i> .....	429
<b>UPTRAVI ORAL TABLETS,DOSE PACK</b> .....	306	<b>VOSEVI</b> .....	430
<b>VALCHLOR</b> .....	409	<b>VOTRIENT</b> .....	431
<b>VALTOCO</b> .....	410	<b>VOWST</b> .....	119
<b>VANCOCIN ORAL CAPSULE 125 MG, 250 MG</b> .....	411	<b>VOXZOGO</b> .....	432
<i>vancomycin oral capsule 125 mg, 250 mg</i> .....	411	<b>VRAYLAR ORAL CAPSULE</b> .....	433
<b>VANFLYTA</b> .....	412	<b>VRAYLAR ORAL CAPSULE,DOSE PACK</b> .....	433
<b>VELTASSA</b> .....	413	<b>VTAMA</b> .....	434
<b>VELTIN</b> .....	400	<b>VUITY</b> .....	435
<b>VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG</b> .....	415	<b>VUMERITY</b> .....	436
<b>VENCLEXTA STARTING PACK</b> .....	415	<b>VYNDAMAX</b> .....	26
<i>venlafaxine besylate</i> .....	414	<b>VYNDAQEL</b> .....	26
<b>VENTAVIS</b> .....	306	<b>WAKIX</b> .....	437
<b>VEOZAH</b> .....	416	<b>WELIREG</b> .....	439
<b>VERKAZIA</b> .....	417	<b>WINLEVI</b> .....	400
<b>VERQUVO</b> .....	418	<b>XALKORI</b> .....	440
<b>VERZENIO</b> .....	419	<b>XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG</b> .....	296
<b>VFEND IV</b> .....	429	<b>XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG</b> .....	296
<b>VIBERZI</b> .....	420	<b>XCOPRI</b> .....	441
<b>VICTOZA 3-PAK</b> .....	140	<b>XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1)</b> .....	441
<i>vigabatrin</i> .....	337	<b>XCOPRI TITRATION PACK</b> .....	441
<b>VIGADRONE</b> .....	337	<b>XDEMVI</b> .....	442
<b>VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG</b> .....	421	<b>XELJANZ ORAL SOLUTION</b> .....	444
<b>VIMOVO</b> .....	422	<b>XELJANZ ORAL TABLET</b> .....	443
		<b>XELJANZ XR</b> .....	443
		<b>XENAZINE ORAL TABLET 12.5 MG, 25 MG</b> .....	445
		<b>XERMELO</b> .....	446
		<b>XGEVA</b> .....	447

<b>XIFAXAN ORAL TABLET 550 MG</b> .....	448	<b>ZTALMY</b> .....	470
<b>XOLAIR</b> .....	449	<b>ZTLIDO</b> .....	471
<b>XOSPATA</b> .....	451	<b>ZYDELIG</b> .....	472
<b>XPOVIO ORAL TABLET 100</b>		<b>ZYFLO</b> .....	205
<b>MG/WEEK (50 MG X 2), 40</b>		<b>ZYKADIA</b> .....	473
<b>MG/WEEK (40 MG X 1), 40MG</b>		<b>ZYTIGA ORAL TABLET 250 MG, 500</b>	
<b>TWICE WEEK (40 MG X 2), 60</b>		<b>MG</b> .....	474
<b>MG/WEEK (60 MG X 1), 60MG</b>			
<b>TWICE WEEK (120 MG/WEEK), 80</b>			
<b>MG/WEEK (40 MG X 2), 80MG</b>			
<b>TWICE WEEK (160 MG/WEEK)</b> .....	452		
<b>XTAMPZA ER</b> .....	296		
<b>XTANDI ORAL CAPSULE</b> .....	453		
<b>XTANDI ORAL TABLET 40 MG, 80</b>			
<b>MG</b> .....	453		
<b>XURIDEN</b> .....	454		
<b>XYOSTED</b> .....	388		
<b>XYREM</b> .....	455		
<b>XYWAV</b> .....	456		
<b>YONSA</b> .....	458		
<b>YUFLYMA(CF)</b> .....	6		
<b>YUFLYMA(CF) AUTOINJECTOR</b>			
<b>SUBCUTANEOUS AUTO-INJECTOR,</b>			
<b>KIT 40 MG/0.4 ML</b> .....	6		
<b>YUSIMRY(CF) PEN</b> .....	6		
<i>zaleplon oral capsule 10 mg, 5 mg</i> .....	296		
<b>ZAVESCA</b> .....	459		
<b>ZAVZPRET</b> .....	460		
<b>ZEJULA ORAL CAPSULE</b> .....	461		
<b>ZEJULA ORAL TABLET</b> .....	461		
<b>ZELBORAF</b> .....	462		
<b>ZEMAIRA</b> .....	17		
<b>ZEPATIER</b> .....	463		
<b>ZEPOSIA</b> .....	464		
<b>ZEPOSIA STARTER KIT (28-DAY)</b> .....	464		
<b>ZEPOSIA STARTER PACK (7-DAY)</b> .....	464		
<b>ZIANA</b> .....	400		
<i>zileuton</i> .....	205		
<b>ZOKINVY</b> .....	465		
<b>ZOLINZA</b> .....	466		
<i>zolpidem</i> .....	296, 467		
<b>ZOMACTON</b> .....	145		
<b>ZONALON</b> .....	93		
<b>ZONISADE</b> .....	468		
<b>ZORBTIVE</b> .....	145		
<b>ZORYVE</b> .....	469		

# Advair HFA AG

---

## Products Affected

- *fluticasone propionate 115 mcg-salmeterol 21 mcg/actuation hfa inhaler*
- *fluticasone propionate 230 mcg-salmeterol 21 mcg/actuation hfa inhaler*
- *fluticasone propionate 45 mcg-salmeterol 21 mcg/actuation hfa inhaler*

## Details

---

Criteria	
	Require a 1 month trial of Advair HFA (Step 1 drug) in the last 90 days

---

# Brand ADHD

---

## Products Affected

- **ADDERALL 20 MG TABLET**
- **ADDERALL 5 MG TABLET**
- **ADDERALL 7.5 MG TABLET**
- **ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE**
- **ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **AZSTARYS 26.1 MG-5.2 MG CAPSULE**
- **AZSTARYS 39.2 MG-7.8 MG CAPSULE**
- **AZSTARYS 52.3 MG-10.4 MG CAPSULE**
- **CONCERTA 18 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 27 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 36 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 54 MG TABLET,EXTENDED RELEASE**
- **COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE**
- **DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE**
- **DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION**
- **DYANAVEL XR 20 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 5 MG TABLET,**



**EXTENDED RELEASE**

- **EVEKEO ODT 10 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 15 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 20 MG DISINTEGRATING TABLET**
- **EVEKEO ODT 5 MG DISINTEGRATING TABLET**
- **FOCALIN 10 MG TABLET**
- **FOCALIN 2.5 MG TABLET**
- **FOCALIN 5 MG TABLET**
- **FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE**
- **JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE**

**SPRINKLE**

- *lisdexamfetamine 10 mg capsule*
- *lisdexamfetamine 20 mg capsule*
- *lisdexamfetamine 30 mg capsule*
- *lisdexamfetamine 40 mg capsule*
- *lisdexamfetamine 50 mg capsule*
- *lisdexamfetamine 60 mg capsule*
- *lisdexamfetamine 70 mg capsule*
- **METHYLIN 10 MG/5 ML ORAL SOLUTION**
- **METHYLIN 5 MG/5 ML ORAL SOLUTION**
- *methylphenidate er 45 mg tablet,extended release 24 hr*
- *methylphenidate er 63 mg tablet,extended release 24 hr*
- *methylphenidate er 72 mg tablet,extended release 24 hr*
- **MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR**
- **QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET**
- **QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR**
- **RELEXXII 45 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 63 MG TABLET,EXTENDED RELEASE**
- **RELEXXII 72 MG TABLET,EXTENDED RELEASE**
- **RITALIN 10 MG TABLET**
- **RITALIN 20 MG TABLET**
- **RITALIN 5 MG TABLET**
- **RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 20 MG**

- **CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 30 MG**
- **CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 40 MG**
- **CAPSULE,EXTENDED RELEASE**
- **STRATTERA 10 MG CAPSULE**
- **STRATTERA 100 MG CAPSULE**
- **STRATTERA 18 MG CAPSULE**
- **STRATTERA 25 MG CAPSULE**
- **STRATTERA 40 MG CAPSULE**
- **STRATTERA 60 MG CAPSULE**
- **STRATTERA 80 MG CAPSULE**
- **VYVANSE 10 MG CAPSULE**
- **VYVANSE 10 MG CHEWABLE**
- **TABLET**
- **VYVANSE 20 MG CAPSULE**
- **VYVANSE 20 MG CHEWABLE**
- **TABLET**
- **VYVANSE 30 MG CAPSULE**
- **VYVANSE 30 MG CHEWABLE**

- **TABLET**
- **VYVANSE 40 MG CAPSULE**
- **VYVANSE 40 MG CHEWABLE**
- **TABLET**
- **VYVANSE 50 MG CAPSULE**
- **VYVANSE 50 MG CHEWABLE**
- **TABLET**
- **VYVANSE 60 MG CAPSULE**
- **VYVANSE 60 MG CHEWABLE**
- **TABLET**
- **VYVANSE 70 MG CAPSULE**
- **XELSTRYM 13.5 MG/9 HOUR**
- **TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 18 MG/9 HOUR**
- **TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 4.5 MG/9 HOUR**
- **TRANSDERMAL 24 HOUR PATCH**
- **XELSTRYM 9 MG/9 HOUR**
- **TRANSDERMAL 24 HOUR PATCH**

**Details**

<b>Criteria</b>	Require a 1 month trial of 2 of the following generic ADHD medications (Step 1 drug) when being utilized for the same medically accepted indication: methylphenidate, atomoxetine, dextroamphetamine/amphetamine or dexamethylphenidate in the last 180 days
-----------------	--

# Brand Albuterol

---

## Products Affected

- *albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983)*
- **PROAIR RESPICLICK 90 MCG/ACTUATION BREATH**
- **ACTIVATED PROVENTIL HFA 90 MCG/ACTUATION AEROSOL INHALER**

## Details

---

<b>Criteria</b>	Require a 1 month trial of albuterol (generic Proair HFA) in the last 90 days
-----------------	---

---

# Brand Epinephrine

---

## Products Affected

- **AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR**
- **AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS)**
- **AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR**

## Details

---

<b>Criteria</b>	Require a trial of 2 of the following (Step 1 drug): generic epinephrine injection, Epipen or Symjepi in the last 180 days
-----------------	--

---

# Brand Glaucoma

---

## Products Affected

- **IYUZEH 0.005 % EYE DROPS IN A DROPPERETTE**
- **RHOPRESSA 0.02 % EYE DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE DROPS**
- **VYZULTA 0.024 % EYE DROPS**

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic latanoprost (Step 1 drug) plus one other preferred generic formulary glaucoma drug (Step 1 drug) in the last 180 days
-----------------	--

---

# Brand Levalbuterol

---

## Products Affected

- **XOPENEX HFA 45 MCG/ACTUATION  
AEROSOL INHALER**

## Details

---

<b>Criteria</b>	Require a 1 month trial of albuterol (generic Proair HFA) and generic levalbuterol in the last 180 days
-----------------	---

---

# Breo Ellipta AG

---

## Products Affected

- *fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder*
- *fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder*

## Details

---

Criteria	Require a 1 month trial of Breo Ellipta (Step 1 drug) in the last 90 days
----------	---

---

# Celecoxib

---

## Products Affected

- **CELEBREX 100 MG CAPSULE**
  - **CELEBREX 200 MG CAPSULE**
  - **CELEBREX 400 MG CAPSULE**
  - **CELEBREX 50 MG CAPSULE**
- *celecoxib 100 mg capsule*
  - *celecoxib 200 mg capsule*
  - *celecoxib 400 mg capsule*
  - *celecoxib 50 mg capsule*

## Details

---

<b>Criteria</b>	Require a 1 month trial of 2 formulary generic NSAIDs (Step 1 drug) in the last 180 days
-----------------	--

---



# Conjupri

---

## Products Affected

- **CONJUPRI 2.5 MG TABLET**
  - **CONJUPRI 5 MG TABLET**
- *levamlodipine 2.5 mg tablet*
  - *levamlodipine 5 mg tablet*

## Details

---

<b>Criteria</b>	Require a trial of 2 of the following generic medications (Step 1 drug): amlodipine tablet, felodipine extended-release tablet, or nifedipine 24hr extended-release tablet in the last 180 days
-----------------	---

---

# DPP4 Agents

---

## Products Affected

- *alogliptin 12.5 mg tablet*
- *alogliptin 12.5 mg-metformin 1,000 mg tablet*
- *alogliptin 12.5 mg-metformin 500 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 30 mg tablet*
- *alogliptin 25 mg tablet*
- *alogliptin 25 mg-pioglitazone 15 mg tablet*
- *alogliptin 25 mg-pioglitazone 30 mg tablet*
- *alogliptin 25 mg-pioglitazone 45 mg tablet*
- *alogliptin 6.25 mg tablet*
- **KAZANO 12.5 MG-1,000 MG TABLET**
- **KAZANO 12.5 MG-500 MG TABLET**
- **KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE**
- **NESINA 12.5 MG TABLET**
- **NESINA 25 MG TABLET**
- **NESINA 6.25 MG TABLET**
- **ONGLYZA 2.5 MG TABLET**
- **ONGLYZA 5 MG TABLET**
- **OSENI 12.5 MG-30 MG TABLET**
- **OSENI 25 MG-15 MG TABLET**
- **OSENI 25 MG-30 MG TABLET**
- **OSENI 25 MG-45 MG TABLET**
- *saxagliptin 2.5 mg tablet*
- *saxagliptin 2.5 mg-metformin er 1,000 mg tablet,extend release 24hr mp*
- *saxagliptin 5 mg tablet*
- *saxagliptin 5 mg-metformin er 1,000 mg tablet,extend release 24hr mp*
- *saxagliptin 5 mg-metformin er 500 mg tablet,extend release 24hr mp*

## Details

<b>Criteria</b>	Require a 1 month trial of a preferred linagliptin and sitagliptin product in the last 180 days
-----------------	---

# DPP4-SGLT2 Combo

---

## Products Affected

- QTERN 10 MG-5 MG TABLET
- QTERN 5 MG-5 MG TABLET
- STEGLUJAN 15 MG-100 MG TABLET
- STEGLUJAN 5 MG-100 MG TABLET

## Details

---

<b>Criteria</b>	Require a 1 month trial of Glyxambi and Trijardy the last 180 days
-----------------	--

---

# Dry Eye

---

## Products Affected

- **CEQUA 0.09 % EYE DROPS IN A DROPPERETTE**
- **MIEBO 100 % EYE DROPS**
- **TYRVAYA 0.03 MG/SPRAY NASAL SPRAY**

## Details

---

<b>Criteria</b>	Require a 1 month trial of Xiidra and one of the following: Restasis or cyclosporine eye drop (i.e. generic Restasis), in the last 180 days
-----------------	---

---

# Dymista

---

## Products Affected

- **DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY**
- **RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY**

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic azelastine/fluticasone spray in the last 90 days
-----------------	---

---

# Flovent HFA AG

---

## Products Affected

- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*

## Details

---

Criteria	Require a 1 month trial of Flovent HFA (Step 1 drug) in the last 90 days
----------	--

---

# Fortamet

---

## Products Affected

- *metformin er 1,000 mg tablet, extended release 24hr*
- *metformin er 500 mg tablet, extended release 24hr*

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days
-----------------	--

# Glumetza

---

## Products Affected

- **GLUMETZA 1,000 MG  
TABLET,EXTENDED RELEASE**
  - **GLUMETZA 500 MG  
TABLET,EXTENDED RELEASE**
- *metformin er 1,000 mg 24 hr tablet,extended release*
  - *metformin er 500 mg 24 hr tablet,extended release*

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days
-----------------	--

---



# GnRH Agonists

---

## Products Affected

- *leuprolide 22.5 mg (3 month) intramuscular suspension*
- **LUPRON DEPOT 11.25 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT**
- **TRELSTAR 11.25 MG IM SUSPENSION**
- **TRELSTAR 22.5 MG IM SUSPENSION**
- **TRELSTAR 3.75 MG IM SUSPENSION**

## Details

---

Criteria	Require a trial of Eligard (Step 1 drug) in the last 180 days when being utilized for the same medically accepted indication
----------	--

---

# Herpetic Keratitis

---

## Products Affected

- ZIRGAN 0.15 % EYE GEL

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days
-----------------	---

---

# Lactulose

---

## Products Affected

- **KRISTALOSE 10 GRAM ORAL PACKET**
  - **KRISTALOSE 20 GRAM ORAL PACKET**
- *lactulose 10 gram oral packet*

## Details

---

<b>Criteria</b>	Require a 1 month trial of lactulose solution (Step 1 drug) in the last 90 days
-----------------	---

---

# Mupirocin

---

## Products Affected

- *mupirocin calcium 2 % topical cream*

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic mupirocin ointment (Step 1 drug) in the last 90 days
-----------------	---

---

# Riomet

---

## Products Affected

- *metformin 500 mg/5 ml oral solution*

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic metformin IR tablets in the last 90 days -OR- documentation supporting the inability to swallow or difficulty swallowing tablets containing metformin
-----------------	---

---

# Rytary

---

## Products Affected

- **DHIVY 25 MG-100 MG TABLET**
- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

## Details

---

<b>Criteria</b>	Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days
-----------------	---

---

## SGLT2 Agents

---

### Products Affected

- FARXIGA 10 MG TABLET
- FARXIGA 5 MG TABLET
- INPEFA 200 MG TABLET
- SEGLUROMET 2.5 MG-1,000 MG TABLET
- SEGLUROMET 2.5 MG-500 MG TABLET
- SEGLUROMET 7.5 MG-1,000 MG TABLET
- SEGLUROMET 7.5 MG-500 MG TABLET
- STEGLATRO 15 MG TABLET
- STEGLATRO 5 MG TABLET
- XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE
- XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE
- XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE

### Details

<b>Criteria</b>	Require a 1 month trial of a preferred canagliflozin product and empagliflozin product in the last 180 days, when being utilized for the same medically accepted indication
-----------------	---

# Sleeper Meds

---

## Products Affected

- **BELSOMRA 10 MG TABLET**
- **BELSOMRA 15 MG TABLET**
- **BELSOMRA 20 MG TABLET**
- **BELSOMRA 5 MG TABLET**
- **DAYVIGO 10 MG TABLET**
- **DAYVIGO 5 MG TABLET**
- **QUVIVIQ 25 MG TABLET**
- **QUVIVIQ 50 MG TABLET**

## Details

---

<b>Criteria</b>	Require a trial of 2 of the following (Step 1 drug): generic zolpidem tablet/zolpidem ER tablet, zaleplon or eszopiclone in the last 180 days
-----------------	---

---



# Soanz

---

## Products Affected

- SOAANZ 20 MG TABLET
- SOAANZ 40 MG TABLET
- SOAANZ 60 MG TABLET

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic furosemide tablets and generic torsemide tablets in the last 180 days
-----------------	--

---

# Suboxone

---

## Products Affected

- **SUBOXONE 12 MG-3 MG SUBLINGUAL FILM**
- **SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM**
- **SUBOXONE 4 MG-1 MG SUBLINGUAL FILM**
- **SUBOXONE 8 MG-2 MG SUBLINGUAL FILM**

## Details

---

<b>Criteria</b>	Require a 1 month trial of Zubsolv (Step 1 drug) in the last 90 days
-----------------	--

---

# Topical Antifungals

---

## Products Affected

- **ERTACZO 2 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL SOLUTION**
- **KETODAN 2 % TOPICAL FOAM**
- *naftifine 1 % topical cream*
- *naftifine 2 % topical cream*
- *naftifine 2 % topical gel*
- **NAFTIN 1 % TOPICAL GEL**
- **NAFTIN 2 % TOPICAL GEL**
- *oxiconazole 1 % topical cream*
- **OXISTAT 1 % LOTION**
- **OXISTAT 1 % TOPICAL CREAM**

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic econazole cream and one of the following: generic ketoconazole cream or ketoconazole shampoo (Step 1 drugs), when being utilized for the same medically accepted indication, in the last 180 days
-----------------	--

---

# Topical Psoriasis

---

## Products Affected

- *calcipotriene 0.005 % topical foam*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical ointment*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical suspension*
- *calcitriol 3 mcg/gram topical ointment*
- **ENSTILAR 0.005 %-0.064 % TOPICAL FOAM**
- **SORILUX 0.005 % TOPICAL FOAM**
- **TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT**
- **TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION**
- **VECTICAL 3 MCG/GRAM TOPICAL OINTMENT**

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic calcipotriene cream, ointment or solution (Step 1 drug) in the last 90 days
-----------------	--

---

# Ursodiol

---

## Products Affected

- **RELTONE 200 MG CAPSULE**
- **RELTONE 400 MG CAPSULE**
- **URSO 250 250 MG TABLET**
- **URSO FORTE 500 MG TABLET**
- *ursodiol 200 mg capsule*
- *ursodiol 400 mg capsule*

## Details

---

<b>Criteria</b>	Require a 1 month trial of generic ursodiol 250mg tablet, 300mg capsule or 500mg tablet (step 1 drug) in the last 90 days
-----------------	---

---



**Index of Drugs**

<b>ADDERALL 20 MG TABLET</b> .....2	<i>alogliptin 6.25 mg tablet</i> .....12
<b>ADDERALL 5 MG TABLET</b> .....2	<b>APTENSIO XR 10 MG</b>
<b>ADDERALL 7.5 MG TABLET</b> .....2	<b>CAPSULE,EXTENDED RELEASE</b>
<b>ADDERALL XR 10 MG</b>	<b>SPRINKLE</b> .....2
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>APTENSIO XR 15 MG</b>
<b>ADDERALL XR 15 MG</b>	<b>CAPSULE,EXTENDED RELEASE</b>
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>SPRINKLE</b> .....2
<b>ADDERALL XR 20 MG</b>	<b>APTENSIO XR 20 MG</b>
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>CAPSULE,EXTENDED RELEASE</b>
<b>ADDERALL XR 25 MG</b>	<b>SPRINKLE</b> .....2
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>APTENSIO XR 30 MG</b>
<b>ADDERALL XR 30 MG</b>	<b>CAPSULE,EXTENDED RELEASE</b>
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>SPRINKLE</b> .....2
<b>ADDERALL XR 5 MG</b>	<b>APTENSIO XR 40 MG</b>
<b>CAPSULE,EXTENDED RELEASE</b> .....2	<b>CAPSULE,EXTENDED RELEASE</b>
<b>ADZENYS XR-ODT 12.5 MG</b>	<b>SPRINKLE</b> .....2
<b>EXTENDED RELEASE</b>	<b>APTENSIO XR 50 MG</b>
<b>DISINTEGRATING TABLET</b> ..... 2	<b>CAPSULE,EXTENDED RELEASE</b>
<b>ADZENYS XR-ODT 15.7 MG</b>	<b>SPRINKLE</b> .....2
<b>EXTENDED RELEASE</b>	<b>APTENSIO XR 60 MG</b>
<b>DISINTEGRATING TABLET</b> ..... 2	<b>CAPSULE,EXTENDED RELEASE</b>
<b>ADZENYS XR-ODT 18.8 MG</b>	<b>SPRINKLE</b> .....2
<b>EXTENDED RELEASE</b>	<b>AUVI-Q 0.1 MG/0.1 ML</b>
<b>DISINTEGRATING TABLET</b> ..... 2	<b>INJECTION,AUTO-INJECTOR</b> ..... 6
<b>ADZENYS XR-ODT 3.1 MG</b>	<b>AUVI-Q 0.15 MG/0.15 ML AUTO-</b>
<b>EXTENDED RELEASE</b>	<b>INJECTOR (FOR 33 LB TO 66 LB</b>
<b>DISINTEGRATING TABLET</b> ..... 2	<b>PATIENTS)</b> .....6
<b>ADZENYS XR-ODT 6.3 MG</b>	<b>AUVI-Q 0.3 MG/0.3 ML INJECTION,</b>
<b>EXTENDED RELEASE</b>	<b>AUTO-INJECTOR</b> .....6
<b>DISINTEGRATING TABLET</b> ..... 2	<b>AZSTARYS 26.1 MG-5.2 MG</b>
<b>ADZENYS XR-ODT 9.4 MG</b>	<b>CAPSULE</b> ..... 2
<b>EXTENDED RELEASE</b>	<b>AZSTARYS 39.2 MG-7.8 MG</b>
<b>DISINTEGRATING TABLET</b> ..... 2	<b>CAPSULE</b> ..... 2
<i>albuterol sulfate hfa 90 mcg/actuation</i>	<b>AZSTARYS 52.3 MG-10.4 MG</b>
<i>aerosol inhaler (nda020983)</i> .....5	<b>CAPSULE</b> ..... 2
<i>alogliptin 12.5 mg tablet</i> .....12	<b>BELSOMRA 10 MG TABLET</b> ..... 26
<i>alogliptin 12.5 mg-metformin 1,000 mg</i>	<b>BELSOMRA 15 MG TABLET</b> ..... 26
<i>tablet</i> ..... 12	<b>BELSOMRA 20 MG TABLET</b> ..... 26
<i>alogliptin 12.5 mg-metformin 500 mg</i>	<b>BELSOMRA 5 MG TABLET</b> ..... 26
<i>tablet</i> ..... 12	<i>calcipotriene 0.005 % topical foam</i> .....30
<i>alogliptin 12.5 mg-pioglitazone 30 mg</i>	<i>calcipotriene-betamethasone 0.005 %-</i>
<i>tablet</i> ..... 12	<i>0.064 % topical ointment</i> .....30
<i>alogliptin 25 mg tablet</i> .....12	<i>calcipotriene-betamethasone 0.005 %-</i>
<i>alogliptin 25 mg-pioglitazone 15 mg tablet</i> ..12	<i>0.064 % topical suspension</i> ..... 30
<i>alogliptin 25 mg-pioglitazone 30 mg tablet</i> ..12	<i>calcitriol 3 mcg/gram topical ointment</i> ..... 30
<i>alogliptin 25 mg-pioglitazone 45 mg tablet</i> ..12	<b>CELEBREX 100 MG CAPSULE</b> .....10

<b>CELEBREX 200 MG CAPSULE</b> .....	10	<b>DYMISTA 137 MCG-50 MCG/SPRAY</b>	
<b>CELEBREX 400 MG CAPSULE</b> .....	10	<b>NASAL SPRAY</b> .....	15
<b>CELEBREX 50 MG CAPSULE</b> .....	10	<b>ENSTILAR 0.005 %-0.064 %</b>	
<i>celecoxib 100 mg capsule</i> .....	10	<b>TOPICAL FOAM</b> .....	30
<i>celecoxib 200 mg capsule</i> .....	10	<b>ERTACZO 2 % TOPICAL CREAM</b> .....	29
<i>celecoxib 400 mg capsule</i> .....	10	<b>EVEKEO ODT 10 MG</b>	
<i>celecoxib 50 mg capsule</i> .....	10	<b>DISINTEGRATING TABLET</b> .....	2
<b>CEQUA 0.09 % EYE DROPS IN A</b>		<b>EVEKEO ODT 15 MG</b>	
<b>DROPPERETTE</b> .....	14	<b>DISINTEGRATING TABLET</b> .....	2
<b>CONCERTA 18 MG</b>		<b>EVEKEO ODT 20 MG</b>	
<b>TABLET,EXTENDED RELEASE</b> .....	2	<b>DISINTEGRATING TABLET</b> .....	2
<b>CONCERTA 27 MG</b>		<b>EVEKEO ODT 5 MG</b>	
<b>TABLET,EXTENDED RELEASE</b> .....	2	<b>DISINTEGRATING TABLET</b> .....	2
<b>CONCERTA 36 MG</b>		<b>EXELDERM 1 % TOPICAL CREAM</b> ....	29
<b>TABLET,EXTENDED RELEASE</b> .....	2	<b>EXELDERM 1 % TOPICAL</b>	
<b>CONCERTA 54 MG</b>		<b>SOLUTION</b> .....	29
<b>TABLET,EXTENDED RELEASE</b> .....	2	<b>FARXIGA 10 MG TABLET</b> .....	25
<b>CONJUPRI 2.5 MG TABLET</b> .....	11	<b>FARXIGA 5 MG TABLET</b> .....	25
<b>CONJUPRI 5 MG TABLET</b> .....	11	<i>fluticasone furoate 100 mcg-vilanterol 25</i>	
<b>COTEMPLA XR-ODT 17.3 MG</b>		<i>mcg/dose inhalation powder</i> .....	9
<b>EXTENDED RELEASE</b>		<i>fluticasone furoate 200 mcg-vilanterol 25</i>	
<b>DISINTEGRATING TABLET</b> .....	2	<i>mcg/dose inhalation powder</i> .....	9
<b>COTEMPLA XR-ODT 25.9 MG</b>		<i>fluticasone propionate 110 mcg/actuation</i>	
<b>EXTENDED RELEASE</b>		<i>hfa aerosol inhaler</i> .....	16
<b>DISINTEGRATING TABLET</b> .....	2	<i>fluticasone propionate 115 mcg-salmeterol</i>	
<b>COTEMPLA XR-ODT 8.6 MG</b>		<i>21 mcg/actuation hfa inhaler</i> .....	1
<b>EXTENDED RELEASE</b>		<i>fluticasone propionate 220 mcg/actuation</i>	
<b>DISINTEGRATING TABLET</b> .....	2	<i>hfa aerosol inhaler</i> .....	16
<b>DAYVIGO 10 MG TABLET</b> .....	26	<i>fluticasone propionate 230 mcg-salmeterol</i>	
<b>DAYVIGO 5 MG TABLET</b> .....	26	<i>21 mcg/actuation hfa inhaler</i> .....	1
<b>DEXEDRINE SPANSULE 10 MG</b>		<i>fluticasone propionate 44 mcg/actuation</i>	
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<i>hfa aerosol inhaler</i> .....	16
<b>DEXEDRINE SPANSULE 15 MG</b>		<i>fluticasone propionate 45 mcg-salmeterol</i>	
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<i>21 mcg/actuation hfa inhaler</i> .....	1
<b>DHIVY 25 MG-100 MG TABLET</b> .....	24	<b>FOCALIN 10 MG TABLET</b> .....	2
<b>DYANAVAL XR 10 MG TABLET,</b>		<b>FOCALIN 2.5 MG TABLET</b> .....	2
<b>EXTENDED RELEASE</b> .....	2	<b>FOCALIN 5 MG TABLET</b> .....	2
<b>DYANAVAL XR 15 MG TABLET,</b>		<b>FOCALIN XR 10 MG</b>	
<b>EXTENDED RELEASE</b> .....	2	<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>DYANAVAL XR 2.5 MG/ML ORAL 24</b>		<b>FOCALIN XR 15 MG</b>	
<b>HR EXTENDED RELEASE</b>		<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>SUSPENSION</b> .....	2	<b>FOCALIN XR 20 MG</b>	
<b>DYANAVAL XR 20 MG TABLET,</b>		<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>EXTENDED RELEASE</b> .....	2	<b>FOCALIN XR 25 MG</b>	
<b>DYANAVAL XR 5 MG TABLET,</b>		<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>EXTENDED RELEASE</b> .....	2		



<b>FOCALIN XR 30 MG</b>		<b>KRISTALOSE 20 GRAM ORAL</b>	
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<b>PACKET</b> .....	21
<b>FOCALIN XR 35 MG</b>		<i>lactulose 10 gram oral packet</i> .....	21
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<i>leuprolide 22.5 mg (3 month)</i>	
<b>FOCALIN XR 40 MG</b>		<i>intramuscular suspension</i> .....	19
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<i>levamlodipine 2.5 mg tablet</i> .....	11
<b>FOCALIN XR 5 MG</b>		<i>levamlodipine 5 mg tablet</i> .....	11
<b>CAPSULE,EXTENDED RELEASE</b> .....	2	<i>lisdexamfetamine 10 mg capsule</i> .....	2
<b>GLUMETZA 1,000 MG</b>		<i>lisdexamfetamine 20 mg capsule</i> .....	2
<b>TABLET,EXTENDED RELEASE</b> .....	18	<i>lisdexamfetamine 30 mg capsule</i> .....	2
<b>GLUMETZA 500 MG</b>		<i>lisdexamfetamine 40 mg capsule</i> .....	2
<b>TABLET,EXTENDED RELEASE</b> .....	18	<i>lisdexamfetamine 50 mg capsule</i> .....	2
<b>INPEFA 200 MG TABLET</b> .....	25	<i>lisdexamfetamine 60 mg capsule</i> .....	2
<b>IYUZEH 0.005 % EYE DROPS IN A</b>		<i>lisdexamfetamine 70 mg capsule</i> .....	2
<b>DROPPERETTE</b> .....	7	<b>LUPRON DEPOT 11.25 MG (3</b>	
<b>JORNAY PM 100 MG</b>		<b>MONTH) INTRAMUSCULAR</b>	
<b>CAPSULE,DELAYED</b>		<b>SYRINGE KIT</b> .....	19
<b>RELEASE,EXTENDED RELEASE</b>		<b>LUPRON DEPOT 22.5 MG (3 MONTH)</b>	
<b>SPRINKLE</b> .....	2	<b>INTRAMUSCULAR SYRINGE KIT</b> .....	19
<b>JORNAY PM 20 MG</b>		<b>LUPRON DEPOT 3.75 MG</b>	
<b>CAPSULE,DELAYED</b>		<b>INTRAMUSCULAR SYRINGE KIT</b> .....	19
<b>RELEASE,EXTENDED RELEASE</b>		<b>LUPRON DEPOT 30 MG (4 MONTH)</b>	
<b>SPRINKLE</b> .....	2	<b>INTRAMUSCULAR SYRINGE KIT</b> .....	19
<b>JORNAY PM 40 MG</b>		<b>LUPRON DEPOT 45 MG (6 MONTH)</b>	
<b>CAPSULE,DELAYED</b>		<b>INTRAMUSCULAR SYRINGE KIT</b> .....	19
<b>RELEASE,EXTENDED RELEASE</b>		<b>LUPRON DEPOT 7.5 MG</b>	
<b>SPRINKLE</b> .....	2	<b>INTRAMUSCULAR SYRINGE KIT</b> .....	19
<b>JORNAY PM 60 MG</b>		<i>metformin 500 mg/5 ml oral solution</i> .....	23
<b>CAPSULE,DELAYED</b>		<i>metformin er 1,000 mg 24 hr</i>	
<b>RELEASE,EXTENDED RELEASE</b>		<i>tablet,extended release</i> .....	18
<b>SPRINKLE</b> .....	2	<i>metformin er 1,000 mg tablet,extended</i>	
<b>JORNAY PM 80 MG</b>		<i>release 24hr</i> .....	17
<b>CAPSULE,DELAYED</b>		<i>metformin er 500 mg 24 hr tablet,extended</i>	
<b>RELEASE,EXTENDED RELEASE</b>		<i>release</i> .....	18
<b>SPRINKLE</b> .....	2	<i>metformin er 500 mg tablet,extended</i>	
<b>KAZANO 12.5 MG-1,000 MG TABLET</b> .	12	<i>release 24hr</i> .....	17
<b>KAZANO 12.5 MG-500 MG TABLET</b> ...	12	<b>METHYLIN 10 MG/5 ML ORAL</b>	
<b>KETODAN 2 % TOPICAL FOAM</b> .....	29	<b>SOLUTION</b> .....	2
<b>KOMBIGLYZE XR 2.5 MG-1,000 MG</b>		<b>METHYLIN 5 MG/5 ML ORAL</b>	
<b>TABLET,EXTENDED RELEASE</b> .....	12	<b>SOLUTION</b> .....	2
<b>KOMBIGLYZE XR 5 MG-1,000 MG</b>		<i>methylphenidate er 45 mg tablet,extended</i>	
<b>TABLET,EXTENDED RELEASE</b> .....	12	<i>release 24 hr</i> .....	2
<b>KOMBIGLYZE XR 5 MG-500 MG</b>		<i>methylphenidate er 63 mg tablet,extended</i>	
<b>TABLET,EXTENDED RELEASE</b> .....	12	<i>release 24 hr</i> .....	2
<b>KRISTALOSE 10 GRAM ORAL</b>		<i>methylphenidate er 72 mg tablet,extended</i>	
<b>PACKET</b> .....	21	<i>release 24 hr</i> .....	2

<b>MIEBO 100 % EYE DROPS</b> .....	14	<b>QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND</b>	
<i>mupirocin calcium 2 % topical cream</i> .....	22	<b>RELEASE 24HR</b> .....	2
<b>MYDAYIS 12.5 MG CAPSULE</b>		<b>QUVIVIQ 25 MG TABLET</b> .....	26
<b>EXTENDED RELEASE 24 HR</b> .....	2	<b>QUVIVIQ 50 MG TABLET</b> .....	26
<b>MYDAYIS 25 MG CAPSULE</b>		<b>RELEXXII 45 MG</b>	
<b>EXTENDED RELEASE 24 HR</b> .....	2	<b>TABLET,EXTENDED RELEASE</b> .....	2
<b>MYDAYIS 37.5 MG CAPSULE</b>		<b>RELEXXII 63 MG</b>	
<b>EXTENDED RELEASE 24 HR</b> .....	2	<b>TABLET,EXTENDED RELEASE</b> .....	2
<b>MYDAYIS 50 MG CAPSULE</b>		<b>RELEXXII 72 MG</b>	
<b>EXTENDED RELEASE 24 HR</b> .....	2	<b>TABLET,EXTENDED RELEASE</b> .....	2
<i>naftifine 1 % topical cream</i> .....	29	<b>RELTONE 200 MG CAPSULE</b> .....	31
<i>naftifine 2 % topical cream</i> .....	29	<b>RELTONE 400 MG CAPSULE</b> .....	31
<i>naftifine 2 % topical gel</i> .....	29	<b>RHOPRESSA 0.02 % EYE DROPS</b> .....	7
<b>NAFTIN 1 % TOPICAL GEL</b> .....	29	<b>RITALIN 10 MG TABLET</b> .....	2
<b>NAFTIN 2 % TOPICAL GEL</b> .....	29	<b>RITALIN 20 MG TABLET</b> .....	2
<b>NESINA 12.5 MG TABLET</b> .....	12	<b>RITALIN 5 MG TABLET</b> .....	2
<b>NESINA 25 MG TABLET</b> .....	12	<b>RITALIN LA 10 MG</b>	
<b>NESINA 6.25 MG TABLET</b> .....	12	<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>ONGLYZA 2.5 MG TABLET</b> .....	12	<b>RITALIN LA 20 MG</b>	
<b>ONGLYZA 5 MG TABLET</b> .....	12	<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>OSENI 12.5 MG-30 MG TABLET</b> .....	12	<b>RITALIN LA 30 MG</b>	
<b>OSENI 25 MG-15 MG TABLET</b> .....	12	<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<b>OSENI 25 MG-30 MG TABLET</b> .....	12	<b>RITALIN LA 40 MG</b>	
<b>OSENI 25 MG-45 MG TABLET</b> .....	12	<b>CAPSULE,EXTENDED RELEASE</b> .....	2
<i>oxiconazole 1 % topical cream</i> .....	29	<b>ROCKLATAN 0.02 %-0.005 % EYE</b>	
<b>OXISTAT 1 % LOTION</b> .....	29	<b>DROPS</b> .....	7
<b>OXISTAT 1 % TOPICAL CREAM</b> .....	29	<b>RYALTRIS 665 MCG-25 MCG/SPRAY</b>	
<b>PROAIR RESPICLICK 90</b>		<b>NASAL SPRAY</b> .....	15
<b>MCG/ACTUATION BREATH</b>		<b>RYTARY 23.75 MG-95 MG</b>	
<b>ACTIVATED</b> .....	5	<b>CAPSULE,EXTENDED RELEASE</b> .....	24
<b>PROVENTIL HFA 90</b>		<b>RYTARY 36.25 MG-145 MG</b>	
<b>MCG/ACTUATION AEROSOL</b>		<b>CAPSULE,EXTENDED RELEASE</b> .....	24
<b>INHALER</b> .....	5	<b>RYTARY 48.75 MG-195 MG</b>	
<b>QTERN 10 MG-5 MG TABLET</b> .....	13	<b>CAPSULE,EXTENDED RELEASE</b> .....	24
<b>QTERN 5 MG-5 MG TABLET</b> .....	13	<b>RYTARY 61.25 MG-245 MG</b>	
<b>QUILLICHEW ER 20 MG</b>		<b>CAPSULE,EXTENDED RELEASE</b> .....	24
<b>CHEWABLE TABLET, EXTENDED</b>		<i>saxagliptin 2.5 mg tablet</i> .....	12
<b>RELEASE</b> .....	2	<i>saxagliptin 2.5 mg-metformin er 1,000 mg</i>	
<b>QUILLICHEW ER 30 MG</b>		<i>tablet,extend release 24hr mp</i> .....	12
<b>CHEWABLE TABLET, EXTENDED</b>		<i>saxagliptin 5 mg tablet</i> .....	12
<b>RELEASE</b> .....	2	<i>saxagliptin 5 mg-metformin er 1,000 mg</i>	
<b>QUILLICHEW ER 40 MG</b>		<i>tablet,extend release 24hr mp</i> .....	12
<b>CHEWABLE, EXTENDED RELEASE</b>		<i>saxagliptin 5 mg-metformin er 500 mg</i>	
<b>TABLET</b> .....	2	<i>tablet,extend release 24hr mp</i> .....	12

<b>SEGLUROMET 2.5 MG-1,000 MG TABLET</b> .....	25	<b>VECTICAL 3 MCG/GRAM TOPICAL OINTMENT</b> .....	30
<b>SEGLUROMET 2.5 MG-500 MG TABLET</b> .....	25	<b>VYVANSE 10 MG CAPSULE</b> .....	2
<b>SEGLUROMET 7.5 MG-1,000 MG TABLET</b> .....	25	<b>VYVANSE 10 MG CHEWABLE TABLET</b> .....	2
<b>SEGLUROMET 7.5 MG-500 MG TABLET</b> .....	25	<b>VYVANSE 20 MG CAPSULE</b> .....	2
<b>SOAANZ 20 MG TABLET</b> .....	27	<b>VYVANSE 20 MG CHEWABLE TABLET</b> .....	2
<b>SOAANZ 40 MG TABLET</b> .....	27	<b>VYVANSE 30 MG CAPSULE</b> .....	2
<b>SOAANZ 60 MG TABLET</b> .....	27	<b>VYVANSE 30 MG CHEWABLE TABLET</b> .....	2
<b>SORILUX 0.005 % TOPICAL FOAM</b> ....	30	<b>VYVANSE 40 MG CAPSULE</b> .....	2
<b>STEGLATRO 15 MG TABLET</b> .....	25	<b>VYVANSE 40 MG CHEWABLE TABLET</b> .....	2
<b>STEGLATRO 5 MG TABLET</b> .....	25	<b>VYVANSE 50 MG CAPSULE</b> .....	2
<b>STEGLUJAN 15 MG-100 MG TABLET</b> ..	13	<b>VYVANSE 50 MG CHEWABLE TABLET</b> .....	2
<b>STEGLUJAN 5 MG-100 MG TABLET</b> ..	13	<b>VYVANSE 60 MG CAPSULE</b> .....	2
<b>STRATTERA 10 MG CAPSULE</b> .....	2	<b>VYVANSE 60 MG CHEWABLE TABLET</b> .....	2
<b>STRATTERA 100 MG CAPSULE</b> .....	2	<b>VYVANSE 70 MG CAPSULE</b> .....	2
<b>STRATTERA 18 MG CAPSULE</b> .....	2	<b>VYZULTA 0.024 % EYE DROPS</b> .....	7
<b>STRATTERA 25 MG CAPSULE</b> .....	2	<b>XELSTRYM 13.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH</b> .....	2
<b>STRATTERA 40 MG CAPSULE</b> .....	2	<b>XELSTRYM 18 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH</b> .....	2
<b>STRATTERA 60 MG CAPSULE</b> .....	2	<b>XELSTRYM 4.5 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH</b> .....	2
<b>STRATTERA 80 MG CAPSULE</b> .....	2	<b>XELSTRYM 9 MG/9 HOUR TRANSDERMAL 24 HOUR PATCH</b> .....	2
<b>SUBOXONE 12 MG-3 MG SUBLINGUAL FILM</b> .....	28	<b>XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE</b> .....	25
<b>SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM</b> .....	28	<b>XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE</b> .....	25
<b>SUBOXONE 4 MG-1 MG SUBLINGUAL FILM</b> .....	28	<b>XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE</b> .....	25
<b>SUBOXONE 8 MG-2 MG SUBLINGUAL FILM</b> .....	28	<b>XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE</b> .....	25
<b>TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT</b> .....	30	<b>XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE</b> .....	25
<b>TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION</b> .....	30	<b>XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER</b> .....	8
<b>TRELSTAR 11.25 MG IM SUSPENSION</b> .....	19	<b>ZIRGAN 0.15 % EYE GEL</b> .....	20
<b>TRELSTAR 22.5 MG IM SUSPENSION</b>	19		
<b>TRELSTAR 3.75 MG IM SUSPENSION</b>	19		
<b>TYRVAYA 0.03 MG/SPRAY NASAL SPRAY</b> .....	14		
<b>URSO 250 250 MG TABLET</b> .....	31		
<b>URSO FORTE 500 MG TABLET</b> .....	31		
<i>ursodiol 200 mg capsule</i> .....	31		
<i>ursodiol 400 mg capsule</i> .....	31		